THERAPEUTIC AGENT FOR TAUOPATHIES

Abstract

The present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav). The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.

Description

TECHNICAL FIELD

The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.

BACKGROUND OF THE INVENTION

Nav1.1 is one of voltage-gated sodium channels (VGSC; Nav), which is expressed in, for example, parvalbumin-positive GABA neurons (PV-GABA neurons). It is known that Nav1.1 is important for the neuronal firing function in the neurons (Non-patent literature 1).

It has been suggested that patients suffering from a central nervous system disease such as schizophrenia, autism spectrum disorder (ASD), and attention deficit hyperactivity disorder (ADHD) have dysfunctions in GABAergic neurons which express Nav1.1 (Non-patent literatures 2 and 3).

It has also been reported that heterozygous loss-of-function mutation in SCN1A (Nav1.1) gene leads to epileptic syndromes such as Dravet syndrome (severe myoclonic epilepsy of infancy) and generalized epilepsy with febrile seizure plus (GEFS+) (Non-patent literature 2).

Tauopathy is a general term for a disease whose important pathogenic mechanism is thought to be as follows, tau which is one of microtubule-associated proteins is phosphorylated to be insoluble, and the phosphorylated tau is abnormally accumulated in cells. The typical tauopathy includes Alzheimer's disease (AD) and frontotemporal lobar degeneration (for example, Pick disease, progressive supranuclear palsy and corticobasal degeneration, etc.). In these diseases, the abnormal accumulated of the phosphorylated tau is thought to cause neuronopathy. The mutation of tau gene may cause familial frontotemporal dementia parkinsonism linked to chromosome 17 which is familial tauopathy (Non-patent literature 4), and thus the abnormality of tau is a sufficient condition for neurodegeneration, but the detailed mechanism how the abnormal tau accumulation causes neurodegeneration has not been particularly known.

The decrease of Nav1.1 expression may occur in AD patients or AD model mice. And, AD patients and AD model mice may present with epileptiform hyperexcitation, but the defect of tau may release the hyperexcitation in AD model mice or Nav1.1 heterozygous epilepsy model mice. Thus, it is thought that tau plays a main role in the disorder of interneuron which may cause the Nav1.1 decrease. In addition, it has been reported that the operation of increasing the expression of Nav1.1 in an AD model mouse can improve the cognitive function and can improve the mortality caused by convulsive seizure (Non-patent literature 5), but it has never been reported that the activation of the voltage-gated sodium channel such as Nav1.1 can decrease the aggregation/accumulation of phosphorylated tau or can inhibit the cerebral atrophy.

PRIOR ART

Non-Patent Literature

• [Non-patent literature 1] J. Neurosci., 2007, 27, 5903.
• [Non-patent literature 2] Trends in Pharmacological Sciences 2014, 35, 113.
• [Non-patent literature 3] Curr. Med. Chem. 2015, 22, 1850.
• [Non-patent literature 4] Annu. Rev. Pathol. Mech. Dis. 2019, 14, 239.
• [Non-patent literature 5] Cell 2012, 149, 708.
• [Non-patent literature 6] Journal of Alzheimer's Disease, vol. 71, no. 4, pp. 1163-1174, 2019.

SUMMARY OF INVENTION

Technical Problem

One of the purposes of the present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav).

Solution to Problem

The present inventors have extensively studied to reach the above purpose, and then have found that a Nav activator may be useful for treating and/or preventing tauopathy. Based upon the findings, the present invention has been completed.

Accordingly, the present invention is described as follows:

(Item 1)

A medicament for treating and/or preventing tauopathy, comprising a Nav activator.

(Item 2)

The medicament of Item 1, wherein the Nav activator is an activator for at least one Nav subtype selected from the group consisting of Nav1.1, Nav1.2, Nav1.3, and Nav1.6.

(Item 3)

The medicament of Item 1, wherein the Nav activator is Nav1.1 activator.

(Item 4)

The medicament of Item 3, wherein the Nav1.1 activator is a small molecule compound.

(Item 5)

The medicament of Item 3, wherein the Nav1.1 activator is a compound of formula (1):

or a pharmaceutically acceptable salt thereofwherein

M¹ is

(1-1) saturated or partially-unsaturated C_4-12 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(e) amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(f) amino-carbonyl wherein the amino may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(1-2) 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(e) C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(f) amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(g) amino-carbonyl wherein the amino may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(1-3) C_6-10 aryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(g) amino-carbonyl wherein the amino may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(1-4) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(g) amino-carbonyl wherein the amino may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(1-5) C_1-10 alkoxy which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of

(a) halogen atom,

(b) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(c) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, and

(d) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(1-6) C_6-10 aryloxy which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(e) amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(f) amino-carbonyl wherein the amino may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(1-7) 5- to 10-membered heteroaryloxy which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and

(g) amino-carbonyl wherein the amino may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(1-8) C_1-10 alkyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, and

(d) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(1-9) C_2-10 alkenyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, and

(d) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(1-10) C_2-10 alkynyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, and

(d) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(1-11) —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom and C_2-10 alkynyl,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, C_1-6 alkoxy-C_1-6 alkyl, and C_3-6 cycloalkyl,

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(e) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(f) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy;

M² is

(2-1) a group of the following formula (2a) or (2b):

wherein

X^1a, X^1b, X^1c, X⁵, X⁶, X⁷, and X⁸ are independently N or CR³,

X², X³, and X⁴ are independently CR³, O, S, N, or NR⁴,

A¹ and A² are independently N or C,

wherein X^1a, X^1b, X^1c, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, A¹, and A² are selected so that the ring comprising them can be a 9- or 10-membered bicyclic heteroaromatic ring;

R³ is

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) hydroxy,

(e) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, C_1-6 alkoxy, 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(f) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(g) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(h) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(i) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, and C_1-6 alkyl,

(j) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy, or

(k) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

R⁴ is

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(c) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

provided that when there are plural R³ or R⁴, each R³ or each R⁴ may be the same or different,

(2-2) a group of the following formula (2c):

wherein

R⁵, R⁶, and R⁷ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_1-6 alkoxy,

(e) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

(f) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(g) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl,

(h) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, and C_1-6 alkyl,

(i) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

(j) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

(k) C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, or

(l) C_2-7 alkoxycarbonyl which may be optionally substituted with the same or different 1 to 3 halogen atom,

wherein R⁵ and R⁶ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, oxo, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

i is 0, 1, or 2, and

the substitutable carbon atom on the ring of formula (2c) may have one fluorine atom as a substituent,

(2-3) a group of the following formula (2d), (2e), (2f), (2g), (2h), (2i), or (2j)

wherein

R⁸, R⁹, and R¹⁰ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; saturated or partially-unsaturated C_3-7 carbocyclyl; C_1-6 alkoxy which may be optionally substituted with hydroxy or C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy or C_1-6 alkyl; 5- or 6-membered heteroaryl which may be optionally substituted with C_1-6 alkyl; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy),

(e) C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(f) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(g) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(h) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(i) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

(j) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl; C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; and oxo,

(k) 4- to 7-membered saturated or partially-unsaturated heterocyclyloxy which may be optionally substituted with the same or different 1 to 4 C_1-6 alkyl,

(l) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

(m) —C(O)OR^z, wherein R^z is C_1-6 alkyl, or

(n) ethenyl which may be substituted with one 6-membered saturated heterocyclyl,

wherein R⁸ and R⁹ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl, and

the substitutable carbon atom on the ring of formula (2d), (2e), (2f), (2g), (2h), (2i), or (2j) may have one fluorine atom as a substituent,

(2-4) a group of the following formula (2k):

wherein

R⁸, R⁹, and R¹⁰ are as defined in the above (2-3),

n is 0, 1, or 2,

X⁹ is CH₂ or O, and

the substitutable carbon atom on the ring of formula (2k) may have one fluorine atom as a substituent,

(2-5) a group of the following formula (2l), (2m), or (2n):

wherein

X¹⁰, X¹¹, X¹², and X¹³ are independently N or CR¹¹, wherein X¹⁰, X¹¹, X¹², and X¹³ are selected so that the 6-membered ring comprising them can be a heteroaromatic ring,

X¹⁴ is CR¹⁵, CHR¹⁵, NR¹⁶, or O,

provided that when X¹⁴ is CR¹⁵, the bond having a broken line in formula (2m) is a double bond, or when X¹⁴ is CHR¹⁵, NR¹⁶, or O, the bond having a broken line in formula (2m) is a single bond,

X¹⁵ is NR¹⁷ or O,

R¹¹ is independently

(a) hydrogen atom,

(b) halogen atom,

(c) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(d) 5- or 6-membered heteroaryl-methyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(e) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of C_1-6 alkyl, C_1-6 alkoxy, C_2-7 alkylcarbonyl, and C_2-7 alkoxycarbonyl,

provided that there are plural R¹¹, each R¹¹ may be the same or different,

R¹², R¹³, and R¹⁴ are independently

(a) hydrogen atom, or

(b) C_1-6 alkyl,

wherein R¹² and R¹⁴, or R¹³ and R¹⁴ may be taken together with the carbon atoms to which they attach to form a bridged structure,

R¹⁵ is

(a) phenyl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(b) benzyl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(c) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(d) hydroxy,

(e) phenyloxy which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(f) phenylamino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

R¹⁶ is

(a) phenyl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(b) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl which may be optionally substituted with 1 to 3 fluorine atoms, and C_1-6 alkoxy which may be optionally substituted with 1 to 3 fluorine atoms,

(c) 5- or 6-membered heteroarylmethyl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

(d) 5- or 6-membered saturated or partially-unsaturated carbocyclyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, or

(e) 5- or 6-membered saturated heterocyclyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

R¹⁷ is

(a) pyridyl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(b) 5- or 6-membered saturated heterocyclyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

k is 0, 1, or 2, and

j¹, j², j³, and ja are independently 0 or 1,

(2-6) a group of the following formula (20):

or

(2-7) a group of the following formula (2p) or (2q):

wherein

R¹⁸ is

(a) phenyl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(b) benzyl which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy,

k¹ and k² are independently 0 or 1, wherein the nitrogen-containing saturated ring in formula (2p) may be optionally substituted with oxo; and

Ring Cy is an optionally-substituted 5- to 10-membered heteroarylene.

(Item 6)

The medicament of Item 5, wherein

Ring Cy is a group of formula (a):

wherein* is binding point to M¹, and ** is binding point to CH₂C(═O)M²,

R^1a and R^2a are independently

(3-1) hydrogen atom,

(3-2) halogen atom,

(3-3) cyano,

(3-4) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) saturated or partially-unsaturated C_3-7 carbocyclyl,

(d) C_1-6 alkoxy, and

(e) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl,

(3-5) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

(3-6) C_2-6 alkenyl which may be optionally substituted with the same or different 1 to 4 halogen atoms,

(3-7) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_1-6 alkoxy, or

(3-8) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_2-7 alkylcarbonyl; or

R^1a and R^2a may be taken together with the carbon atoms to which they are attached to form

(4-1) 5- to 7-membered saturated or partially-unsaturated carbon ring which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, and

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(4-2) 5- to 7-membered saturated or partially-unsaturated hetero ring which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of the above (a)-(d) in (4-1), or a group of formula (b):

wherein* is binding point to M¹, and ** is binding point to CH₂C(═O)M²,

Y¹, Y², and Y³ are independently N or CR^2b.

R^1b is hydrogen atom, halogen atom, cyano, C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 halogen atoms, or amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl;

R^2b is, independently if there are plural R^2b, hydrogen atom, halogen atom, cyano, C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 halogen atoms, or amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl, provided that when there are plural R^2b, each R^2b may be the same or different.

(Item 7)

The medicament of Item 5 or 6, wherein

M² is

(1) a group of any one of the following formulae (2a-1)-(2a-23) and (2b-1)-(2b-11):

wherein X^1a, X^1b, R³, and R⁴ are as defined in the above Item 5,

(2) a group of the following (2c′):

wherein

R⁵ and R⁶ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl,

(e) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, and C_1-6 alkyl,

(f) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy, or

(g) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring, or

R⁵ and R⁶ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, oxo, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

the substitutable carbon atom on the ring of formula (2c′) may have one fluorine atom as a substituent,

(3) a group of the following formula (2d), (2f), (2g), or (2h):

wherein

R⁸, R⁹, and R¹⁰ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; C_1-6 alkoxy which may be optionally substituted with hydroxy or C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with C_1-6 alkyl or C_1-6 alkoxy; 5- or 6-membered heteroaryl which may be optionally substituted with C_1-6 alkyl; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy),

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(g) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

(h) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl; C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; and oxo,

(i) 4- to 7-membered saturated or partially-unsaturated heterocyclyloxy which may be optionally substituted with the same or different 1 to 4 C_1-6 alkyl,

(j) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

(k) —C(O)OR^z, wherein R^z is C_1-6 alkyl, or

(l) ethenyl which may be substituted with one 6-membered saturated heterocyclyl,

wherein R⁸ and R⁹ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl, and

the substitutable carbon atom on the ring of formula (2d), (2f), (2g), or (2h) may have one fluorine atom as a substituent, or

(4) a group of formula (2k′):

wherein R⁸, R⁹, and R¹⁰ are as defined in the above (3).

(Item 8)

The medicament of Item 5 or 6, wherein

M² is a group of

(1) a group of the following formulae (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10):

wherein X^1a, X^1b, and R³ are as defined in the above Item 5,

(2) a group of the following formula (2c′):

wherein

R⁵ and R⁶ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano, or

(d) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl,

the substitutable carbon atom on the ring of formula (2c′) may have one fluorine atom as a substituent,

(3) a group of the following formula (2d) or (2f):

wherein R⁸, R⁹, and R¹⁰ are as defined in the above Item 7,

the substitutable carbon atom on the ring of formula (2d) or (2f) may have one fluorine atom as a substituent, or

(4) a group of the following formula (2k″):

wherein R⁸ and R⁹ are as defined in the above Item 7.

(Item 9)

The medicament of any one of Items 5 to 8, wherein

M¹ is

(1) saturated or partially-unsaturated C_4-12 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom; and C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(2) 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom; and C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(3) —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(d) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(e) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(f) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy.

(Item 10)

The medicament of any one of Items 5 to 9, wherein

M² is a group of the following formula (2a-20), (2a-21), (2b-3), (2b-4), or (2b-7):

wherein

X^1a and X^1b are independently N or CR³;

R³ is independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) hydroxy,

(e) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, C_1-6 alkoxy, 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(f) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(g) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl, or

(h) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

provided that when there are plural R³, each R³ may be the same or different.

(Item 11)

The medicament of any one of Items 5 to 9, wherein

M² is a group of the following formula (2a′-20), (2a′-21), (2b′-3), (2b′-4), or (2b′-7):

wherein

R³ is independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, C_1-6 alkoxy, 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl,

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkoxy, and amino which may be optionally substituted with the same or different 1 to 2 C_1-6 alkyl, or

(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

provided that when there are plural R³, each R³ may be the same or different.

(Item 12)

The medicament of any one of Items 5 to 9, wherein

M² is a group of the following formula (2d) or (2f):

wherein

R⁸, R⁹, and R¹⁰ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; C_1-6 alkoxy which may be optionally substituted with hydroxy or C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with C_1-6 alkyl or C_1-6 alkoxy; 5- or 6-membered heteroaryl which may be optionally substituted with C_1-6 alkyl; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy),

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(g) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

(h) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl; C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; and oxo,

(i) 4- to 7-membered saturated or partially-unsaturated heterocyclyloxy which may be optionally substituted with the same or different 1 to 4 C_1-6 alkyl,

(j) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

(k) —C(O)OR^z, wherein R^z is C_1-6 alkyl, or

(l) ethenyl which may be substituted with one 6-membered saturated heterocyclyl, wherein R⁸ and R⁹ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl.

(Item 13)

The medicament of Item 12, wherein

R⁸, R⁹, and R¹⁰ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; C_1-6 alkoxy which may be optionally substituted with hydroxy or C_1-6 alkoxy; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy.

(Item 14)

The medicament of any one of Items 5 to 13, wherein

M¹ is a group of the following formula (3):

wherein

X¹⁶ is N, C, or CH,

the bond having a broken line is a single bond or a double bond,

m is 0, 1, 2, or 3,

R^a and R^b are independently

(1-1) hydrogen atom,

(1-2) halogen atom, or

(1-3) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

R^a and R^b may be taken together with the carbon atom(s) to which they are attached to form 3- to 6-membered saturated carbocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, and

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy.

(Item 15)

The medicament of Item 14, wherein X¹⁶ is C, and the bond having a broken line is a double bond.

(Item 16)

The medicament of Item 14, wherein X¹⁶ is CH, and the bond having a broken line is a single bond.

(Item 17)

The medicament of Item 14, wherein X¹⁶ is N, and the bond having a broken line is a single bond.

(Item 18)

The medicament of any one of Items 5 to 13, wherein

M¹ is —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(e) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(f) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy.

(Item 19)

The medicament of any one of Items 5 to 13, wherein

M¹ is —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl, or

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl.

(Item 20)

The medicament of any one of Items 5 to 13, wherein

M¹ is —NR^eR^f, wherein

R^e is methyl, and

R^f is

(a) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(b) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl, or

(c) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl.

(Item 21)

The medicament of any one of Items 5 to 13, wherein

M¹ is a group of any one of the following formulae (3a-1)-(3a-4):

(Item 22)

The medicament of any one of Items 5 to 13, wherein

M¹ is a group of any one of the following formulae (3c-1)-(3c-6):

(Item 23)

The medicament of any one of Items 5 to 13, wherein

M is a group of any one of the following formulae (3d-1)-(3d-12):

(Item 24)

The medicament of any one of Items 6 to 23, wherein Ring Cy is formula (a).

(Item 25)

The medicament of Item 24, wherein R^1a and R^2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy.

(Item 26)

The medicament of Item 24, wherein R^1a and R^2a are hydrogen atom.

(Item 27)

The medicament of any one of Items 6 to 23, wherein Ring Cy is formula (b).

(Item 28)

The medicament of Item 27, wherein Y¹ is N, and Y² and Y³ are independently CR^2b.

(Item 29)

The medicament of Item 27, wherein Y¹ and Y² are N, and Y³ is CR^2b.

(Item 30)

The medicament of Item 27, wherein Y¹ and Y³ are N, and Y² is CR^2b.

(Item 31)

The medicament of any one of Items 27 to 30, wherein

R^1b and R^2b are independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, C_3-6 cycloalkyl, or C_1-6 alkoxy, provided that when there are plural R^2b, each R^2b may be the same or different.

(Item 32)

The medicament of any one of Items 27 to 30, wherein R^1b and R^2b are hydrogen atom.

(Item 33)

The medicament of Item 5, wherein the Nav1.1 activator is any one compound selected from the group consisting of the following compounds:

• N-(4-cyanophenyl)-2-[3-(4-methylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide (Example 1),
• N-(1,3-benzoxazol-5-yl)-2-[3-(4-methylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide (Example 50),
• 2-[3-(6-azaspiro[3.4]octan-6-yl)-6-oxopyridazin-1(6H)-yl]-N-(quinazolin-7-yl)acetamide (Example 236),
• N-[2-(dimethylamino)-1,3-benzoxazol-5-yl]-2-[3-(4-methylcyclohex-1-ene)-6-oxopyridazin-1(6H)-yl]acetamide (Example 244),
• N-(2,6-dimethylpyridin-4-yl)-2-[3-(4-methylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide (Example 364),
• 6-(4-methylcyclohex-1-en-1-yl)-2-{2-[4-(2-methylpyridin-3-yl) piperazin-1-yl]-2-oxoethyl}pyridazin-3 (2H)-one (Example 410),
• 2-[3-(4,4-dimethylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide (Example 428),
• 2-[3-(4,4-dimethylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 429),
• N-(1,3-benzoxazol-5-yl)-2-[3-(4,4-dimethylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide (Example 445),
• 2-[6-oxo-3-(spiro[2.5]oct-5-en-6-yl)pyridazin-1(6H)-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 512),
• 2-{2-oxo-2-[4-(pyridazin-4-yl)-2,3-dihydro-1H-indol-1-yl] ethyl}-6-(spiro[2.5]oct-5-en-6-yl) pyridazin-3(2H)-one (Example 526),
• N-(1,3-benzoxazol-5-yl)-2-[3-(4-methylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide (Example 531),
• 2-{3-[(4S)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 537),
• 2-{3-[(4R)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 538),
• 2-{3-[(4S)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide (Example 539),
• 2-{3-[(4R)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide (Example 540),
• N-(6-cyanopyridin-3-yl)-2-[3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-6-oxopyridazin-1(6H)-yl]acetamide (Example 560), and
• 6-[cyclopentyl(methyl)amino]-2-{2-[4-(morpholin-4-yl)-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}pyridazin-3(2H)-one (Example 565).

(Item 34)

The medicament of Item 5, wherein the Nav1.1 activator is any one compound selected from the group consisting of the following compounds:

• 2-{6-[cyclopentyl(methyl)amino]-1H-pyrazolo[3,4-b]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 593),
• 2-[6-(4-methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 577),
• 2-[6-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 609),
• 2-{6-[methyl(spiro[2.3]hexan-5-yl)amino]-1H-pyrazolo[3,4-b]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 630),
• 2-{6-[(3,3-dimethylcyclobutyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 632),
• 2-{6-[(3,3-dimethylcyclobutyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide (Example 668),
• N-(6-cyanopyridin-3-yl)-2-[6-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]acetamide (Example 746),
• N-(6-cyanopyridin-3-yl)-2-{6-[methyl(spiro[2.3]hexan-5-yl)amino]-1H-pyrazolo[3,4-b]pyrazin-1-yl}acetamide (Example 753),
• 2-{6-[cyclopentyl(methyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 795),
• 2-{6-[(cyclobutylmethyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide (Example 819),
• 2-{6-[(3,3-dimethylcyclobutyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide (Example 821), and
• an optically active form of 2-[6-(4-methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide (Example 895 or 896).

(Item 35)

The medicament of any one of Items 1 to 34, wherein

the tauopathy is Alzheimer's disease, Alzheimer-type dementia, diffuse neurofibrillary tangles with calcification, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam island, amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, frontotemporal lobar degeneration (including Pick's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, globular glial tauopathy, and frontotemporal dementia and parkinsonism linked to chromosome 17), senile dementia of the neurofibrillary tangle type, Down syndrome, chronic traumatic encephalopathy, myotonic dystrophy, Niemann-Pick disease type C, static encephalopathy of childhood with neurodegeneration in adulthood, PLA2G6-associated neurodegeneration, Gerstmann-Straussler-Scheinker disease, familial British dementia, familial Danish dementia, post-encephalitic Parkinsonism, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, or a combination of any two or more of these diseases.

(Item 36)

The medicament of any one of Items 1 to 34, wherein the tauopathy is diffuse neurofibrillary tangles with calcification, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam island, amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, frontotemporal lobar degeneration (including Pick's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, globular glial tauopathy, and frontotemporal dementia and parkinsonism linked to chromosome 17), senile dementia of the neurofibrillary tangle type, Down syndrome, chronic traumatic encephalopathy, myotonic dystrophy, Niemann-Pick disease type C, static encephalopathy of childhood with neurodegeneration in adulthood, PLA2G6-associated neurodegeneration, Gerstmann-Straussler-Scheinker disease, familial British dementia, familial Danish dementia, post-encephalitic Parkinsonism, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, or a combination of any two or more of these diseases.

(Item 37)

The medicament of any one of Items 1 to 36, which can decrease phosphorylated tau aggregation and/or inhibit cerebral atrophy.

(Item 38)

A method for decreasing phosphorylated tau aggregation and/or inhibiting cerebral atrophy, comprising administering a Nav activator.

(Item 39)

A method for treating and/or preventing tauopathy, comprising administering a therapeutically effective amount of a Nav activator to a patient in need thereof.

(Item 40) Use of a Nav activator in the manufacture of a medicament for treating and/or preventing tauopathy.

(Item 41)

A Nav activator in use for treating and/or preventing tauopathy.

(Item 42)

A combination of the medicament of any one of Items 1 to 37, and at least one medicament selected from another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, antiparkinsonian agent, antihypertensive drug, anti-inflammatory agent, antidiabetic drug, antihyperlipidemic drug, anti-obesity agent, antiemetic drug, a medicament for treating dysphagia, a medicament for treating dysuria, and cathartic drug.

(Item 43)

The medicament of any one of Items 1 to 37, which is used in combination with at least one medicament selected from another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, antiparkinsonian agent, antihypertensive drug, anti-inflammatory agent, antidiabetic drug, antihyperlipidemic drug, anti-obesity agent, antiemetic drug, a medicament for treating dysphagia, a medicament for treating dysuria, and cathartic drug.

(Item 44)

A method for treating and/or preventing tauopathy, comprising administering a therapeutically effective amount of the medicament of any one of Items 1 to 37 in combination with at least one medicament selected from another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, antiparkinsonian agent, antihypertensive drug, anti-inflammatory agent, antidiabetic drug, antihyperlipidemic drug, anti-obesity agent, antiemetic drug, a medicament for treating dysphagia, a medicament for treating dysuria, and cathartic drug, to a patient in need thereof.

Effect of the Invention

The present invention can decrease the phosphorylated tau aggregation and/or inhibit the cerebral atrophy, by activating the voltage-gated sodium channel. Thereby, the present invention can provide a medicament for treating and/or preventing tauopathy accompanied with various symptoms including cognitive dysfunction, comprising a Nav activator as an active ingredient.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the evaluation results of tau PET in rTg4510 mice when the compound of Example 1 was administered in Test 5, and shows SUVR average images and typical T2-weighted images of a corresponding positions.

FIG. 2 shows the evaluation results of the volume change in each brain region when the compound of Example 1 was administered in Test 5.

FIG. 3 shows the evaluation results of SUVR in each brain region when the compound of Example 1 was administered in Test 5.

FIG. 4 shows the evaluation results of tau PET in rTg4510 mice when the compound of Example 795 was administered in Test 5, and shows SUVR average images at each evaluation time point corresponding to the brain region shown by the T2-weighted image.

FIG. 5 shows the evaluation results of SUVR in each brain region when the compound of Example 795 was administered in Test 5.

FIG. 6 shows the evaluation results of tau PET in rTg4510 mice when the compound of Example 560 was administered in Test 5, and shows SUVR average images at each evaluation time point corresponding to the brain region shown by the T2-weighted image.

FIG. 7 shows the evaluation results of SUVR in each brain region when the compound of Example 560 was administered in Test 5.

DESCRIPTION OF EMBODIMENTS

Hereinafter, the present invention is explained in detail.

The “Nav activator” used herein is a medicament for activating the function of voltage-gated sodium channels, which means a medicament that acts on voltage-gated sodium channels and increases the amount of sodium current resulting from them. The “Nav activator” may be an agent that can activate any of Nav1.1-Nav1.9 which are nine subtypes of voltage-gated sodium channels. In an embodiment, the “Nav activator” is a substance that can activate Nav expressed in the brain. It includes, for example, Nav1.1 activator, Nav1.2 activator, Nav1.3 activator, and Nav1.6 activator. And, the “Nav activator” also includes selective Nav activators that selectively activate one Nav subtype (e.g., selective Nav1.1 activators, selective Nav1.2 activators and selective Nav1.6 activators, etc.), dual activators that activate two Nav subtypes (e.g., Nav1.1/Nav1.2 activators and Nav1.1/Nav1.6 activators, etc.), triple activators that activate three Nav subtypes (e.g., Nav1.1/Nav1.2/Nav1.6 activators, etc.), and multiple activators that activate four or more Nav subtypes. Examples of the “Nav activator” include medicaments that increase the amount of sodium current resulting from any subtype of Nav by 50%, preferably at 10 μM, and more preferably at 1 μM. The amount of sodium current resulting from each subtype can be measured according to the method described in Example 1.

The “Nav1.1 activator” means a medicament for activating Nav1.1, which includes a medicament for selectively activating Nav1.1 and a medicament for activating both of Nav1.1 and other Nav subtypes. When activating both Nav1.1 and other Nav subtypes, it is not necessary to activate Nav1.1 the most strongly, and medicaments that activate other Nav subtypes more strongly are also included in the “Nav1.1 activator”. The “Nav1.1 activator” includes, for example, selective Nav1.1 activators, Nav1.1/Nav1.2 dual activators, Nav1.1/Nav1.3 dual activators, Nav1.1/Nav1.6 dual activators, and Nav1.1/Nav1.2/Nav1.6 triple activators, but should not be limited thereto. The “Nav1.1 activator” can activate the function of Nav1.1 by acting on Nav1.1, and increase the sodium current resulting from Nav1.1. As a result, the nerve firing ability of cells expressing Nav1.1 is increased, and the function of GABAergic neurons is enhanced. Examples of the “Nav1.1 activator” include medicaments that increase the amount of sodium current resulting from Nav1.1 by 50%, preferably at 10 μM, and more preferably at 1 μM. The amount of sodium current resulting from Nav1.1 can be measured according to the method described in Example 1.

The “Nav activator” or “Nav1.1 activator” includes modality such as small molecule compounds, peptides and antibodies. The “Nav activator” or “Nav1.1 activator” includes preferably small molecule compounds and peptides, more preferably small molecule compounds.

The “small molecule compound” used herein means an organic compound whose molecular weight is 1000 or less. Examples of the atoms constituting the “small molecule compound” include carbon atom, hydrogen atom, oxygen atom, nitrogen atom, sulfur atom and halogen atom, but are not limited thereto. It is hopeful that the “small molecule compound” has one or more aromatic hetero ring comprising one of more functional group and/or atom, wherein said functional group is represented by alcohol, ether, ketone, carboxylic acid, ester, amine, amide, imide, carbamate, urea, thiol, sulfide, sulfoxide, sulfonic acid, sulfone, sulfone amide and the like, and said atom is oxygen atom, nitrogen atom, or sulfur atom. The “small molecule compound” includes, preferably an organic compound having one or more functional group selected from the group consisting of alcohol, ether, ester, amine, amide, imide, carbamate, urea, sulfone, and sulfonamide, and more preferably an organic compound having one or more aromatic hetero ring comprising one of more functional group selected from the group consisting of alcohol, ether, ester, amine, amide, imide, carbamate, urea, sulfone, and sulfonamide; and one or more nitrogen atom. And, the “small molecule compound” includes preferably an organic compound having a molecular weight of 100 to 800, more preferably 150 to 600, still more preferably 150 to 500, and particularly preferably 200 to 500.

The “small molecule compound” can be identified by various physical characteristic parameters, besides the above-mentioned parameters. In an embodiment, the “small molecule compound” is identified by the lipophilicity (Log P) expressed by the partition coefficient of octanol/water. For example, the Log P of the “small molecule compound” includes preferably −10 to 10, more preferably −8 to 8, even more preferably −5 to 5, and particularly preferably −2 to 5. In another embodiment, the “small molecule compound” is also identified by the number of hydrogen bond acceptor (HBA) or hydrogen bond donor (HBD) contained within the molecule. For example, the number of HBA contained within the molecule in the “small molecule compound” includes preferably 20 or less, more preferably 15 or less, and even more preferably 10 or less; and the number of HBD contained within the molecule in the “small molecule compound” includes preferably 10 or less, more preferably 8 or less, and even more preferably 5 or less. In further another embodiment, the “small molecule compound” is also identified by the acid dissociation constant (pKa) which represents the acid strength of the compound. The pKa of the “small molecule compound” includes preferably −5 to 10, more preferably −2 to 8, and even more preferably 0 to 5. In further another embodiment, the “small molecule compound” is also identified by the number of rotatable bond (RB) contained within the molecule. The number of RB of the “small molecule compound” includes preferably 30 or less, more preferably 20 or less, even more preferably 10 or less. In a preferred embodiment, any two or more of these physical characteristic parameters may be combined. The “small molecule compound” having one or more of these physical characteristic parameters has physical characteristics suitable for development as a pharmaceutical, and the high druggability thereof can be expected.

The “Peptide” used herein means a compound in which two or more amino acids are linked via an amide bond, which should not be limited by the number of amino acids. The “peptide” includes preferably a peptide consisting of 2 to 200 amino acids, more preferably a peptide consisting of 5 to 100 amino acids, and further preferably a peptide consisting of 5 to 50 amino acids. The amino acid may be a natural amino acid or an unnatural amino acid. And, the “peptide” also includes derivatives obtained by chemically modifying a “peptide”.

The “antibody” used herein is not limited as long as it is an antibody that specifically binds to a voltage-gated sodium channel, and it may be a human antibody, a mouse antibody, or a chimeric antibody. And, the “antibody” also includes a small molecule antibody such as one consisting of a Fab region and one consisting of a Fab region and a hinge portion.

The present specification may denote the number of carbon atoms in definitions of “substituents” in formula (1) as, for example, “C_1-6”. Specifically, the term “C_1-6 alkyl” is synonymous with alkyl having 1 to 6 carbon atoms.

The “halogen atom” includes, for example, fluorine atom, chlorine atom, bromine atom, and iodine atom.

The “C_1-6 alkyl” means a straight- or branched-chain saturated hydrocarbon group having 1 to 6 carbon atoms. It is preferably “C_1-4 alkyl”. The “C_1-6 alkyl” includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl.

The “C_1-10 alkyl” means a straight- or branched-chain saturated hydrocarbon group having 1 to 10 carbon atoms. It is preferably “C_1-6 alkyl”. The “C_1-10 alkyl” includes, for example, heptyl, 2-methyl-3,3-dimethylbutyl, octyl, 2,4-dimethylhexyl, nonyl, decyl, and 4-ethyl-2-methylheptyl, besides the examples listed in the said “C_1-6 alkyl”.

The “C_2-7 alkylcarbonyl” means a carbonyl group substituted with the above “C_1-6 alkyl”. It is preferably “C_2-4 alkylcarbonyl”. The “C_2-7 alkylcarbonyl” includes, for example, methylcarbonyl, ethylcarbonyl, normal-propylcarbonyl, and isopropylcarbonyl.

The “C_1-6 alkoxy” means oxy group substituted with the above-mentioned “C_1-6 alkyl”, and the “C_1-6 alkyl” part in “C_1-6 alkoxy” is as defined in the above-mentioned “C_1-6 alkyl”. It is preferably “C_1-4 alkoxy”. The “C_1-6 alkoxy” includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy.

The “C_1-10 alkoxy” means oxy group substituted with the above-mentioned “C_1-10 alkyl”, and the “C_1-10 alkyl” part in “C_1-10 alkoxy” is as defined in the above-mentioned “C_1-10 alkyl”. It is preferably “C_1-6 alkoxy”. The “C_1-10 alkoxy” includes, for example, heptyloxy, 2-methyl-3,3-dimethylbutoxy, octyloxy, 2,4-dimethylhexyloxy, nonyloxy, decyloxy, and 4-ethyl-2-methylheptyloxy, besides the examples listed in the said “C_1-6 alkoxy”.

The “C_2-7 alkoxycarbonyl” means carbonyl group substituted with the above-mentioned “C_1-6 alkoxy”. It is preferably “C_2-5 alkoxycarbonyl”. The “C_2-7 alkoxycarbonyl” includes, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, and tert-butoxycarbonyl.

The “C_2-10 alkenyl” means a straight- or branched-chain unsaturated hydrocarbon group having 1 to 3 carbon-carbon double bonds and 2 to 10 carbon atoms. It is preferably “C_2-6 alkenyl”. The “C_2-6 alkenyl” includes, for example, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

The “C_2-10 alkynyl” means a straight- or branched-chain unsaturated hydrocarbon group having 1 to 3 carbon-carbon triple bonds and 2 to 10 carbon atoms. It is preferably “C_2-6 alkynyl”. The “C_2-10 alkynyl” includes, for example, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

The “C_3-10 cycloalkyl” means cyclic saturated or partially-unsaturated hydrocarbon group having 3 to 10 carbon atoms, which may have a bridged structure or a spiro structure. The “C_3-10 cycloalkyl” includes preferably “C_3-6 cycloalkyl”. The “C_3-6 cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The “C_3-10 cycloalkyl” includes, for example, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, and adamanthyl, besides the examples listed in the said “C_3-6 cycloalkyl”.

The “saturated or partially-unsaturated C_3-7 carbocyclyl” means a 3- to 7-membered monocyclic or polycyclic saturated or partially-unsaturated hydrocarbon group. It is preferably “saturated or partially-unsaturated C_5-7 carbocyclyl”. The “saturated or partially-unsaturated C_3-7 carbocyclyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, and cyclohexenyl.

The “saturated or partially-unsaturated C_4-12 carbocyclyl” means a 4- to 12-membered monocyclic or polycyclic saturated or partially-unsaturated hydrocarbon group. It is preferably “saturated or partially-unsaturated C_4-6 carbocyclyl”. The “saturated or partially-unsaturated C_4-12 carbocyclyl” includes, for example, cyclooctyl, cyclodecyl, and cyclododecyl, besides those listed as examples of the above “saturated or partially-unsaturated C_3-7 carbocyclyl”.

The above “saturated or partially-unsaturated C_4-12 carbocyclyl” also includes fused or bridged, saturated or partially-unsaturated bicyclic groups and saturated or partially-unsaturated spiro groups. Examples thereof include groups of the following formulae:

The term “5- or 6-membered saturated or partially-unsaturated carbocyclyl” means a 5- or 6-membered monocyclic saturated or partially-unsaturated hydrocarbon group. The “5- or 6-membered saturated or partially-unsaturated carbocyclyl” includes, for example, cyclopentyl, cyclohexyl, cyclopentenyl, and cyclohexenyl.

The “5- to 7-membered saturated or partially-unsaturated carbocycle” means a monocyclic or bicyclic saturated or partially-unsaturated hydrocarbon group having 5 to 7 carbon atoms, and includes structures having partially-unsaturated bond(s), structures having fused ring(s), structures having bridged structure(s), and structures forming spiro ring(s). The “5- to 7-membered saturated or partially-unsaturated carbocycle” includes, for example, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclohexadiene, and cycloheptadiene.

The term “3- to 6-membered saturated carbocyclic ring” means a saturated hydrocarbon ring having 3 to 6 carbon atoms, and also includes structures forming spiro ring(s). The “3- to 6-membered saturated carbocyclic ring” includes, for example, cyclopropane, cyclobutane, cyclopentane, and cyclohexane.

The “5- or 6-membered heteroaryl” means a 5- or 6-membered aromatic heterocyclyl which comprises the same or different one or more (for example, 1 to 4) heteroatoms selected from nitrogen atom, sulfur atom, and oxygen atom, and which may be optionally substituted with oxo. The “5- or 6-membered heteroaryl” include groups of the following formulae:

It is preferably imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl; and it is more preferably imidazolyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl.

The “C_6-10 aryl” means aromatic hydrocarboncyclyl having 6 to 10 carbon atoms. The “C_6-10 aryl” includes, for example, phenyl, 1-naphthyl, and 2-naphthyl. It includes preferably phenyl.

The “C_6-10 aryl” also encompasses bicyclic compounds, i.e., C_6-10 aryl fused with C_4-6 cycloalkyl or 5- or 6-membered saturated heterocyclyl. The bicyclic “C_6-10 aryl” includes, for example, the following groups:

The “C_6-10 aryloxy” means oxy group substituted with the above-mentioned “C_6-10 aryl”. The “C_6-10 aryl” includes, for example, phenyloxy and naphthyloxy, and preferably phenyloxy.

The term “5- to 10-membered heteroaryl” includes, for example, a 5- to 10-membered monocyclic or 9- or 10-membered bicyclic aromatic heterocyclyl. The “5- to 10-membered heteroaryl” group comprises the same or different one or more (for example, 1 to 4) heteroatoms selected from nitrogen atom, sulfur atom, and oxygen atom, and may be optionally substituted with oxo. The bicyclic heteroaryl group also includes fused structures of the above monocyclic heteroaryl with an aromatic ring (such as benzene and pyridine) or a non-aromatic ring (such as cyclohexane and piperidine). The “5- to 10-membered heteroaryl” includes, for example, groups of the following formulae:

The “5- to 10-membered heteroarylene” means a divalent group of the “5- to 10-membered heteroaryl”, which has the same or different one or more (for example, 1 to 4) heteroatom and may be optionally substituted with oxo. In case of 9- or 10-membered bicyclic aromatic heterocyclyl, the bond may be attached to either ring if it is substitutable. The “5- to 10-membered heteroarylene” includes, for example, groups of the following formulae:

The “5- to 10-membered heteroaryloxy” means an oxy group substituted with the above “5- to 10-membered heteroaryl”. The “5- to 10-membered heteroaryloxy” includes, for example, pyridyloxy, imidazolyloxy, and furyloxy, and preferably pyridyloxy.

In the present specification, a bond across a ring means that a “group” having the bond is attached at a substitutable position of the ring. For example, a heteroaryl group of the following formula:

denotes 2-pyridyl, 3-pyridyl, or 4-pyridyl.

When a bond crossing a ring is drawn from a fused ring in the present description, the bond may be attached to at any substitutable site of either ring. For example, the heteroaryl of the following formula:

means any one group of the following groups:

The term “4- to 7-membered saturated or partially-unsaturated heterocyclyl” includes, for example, a 4- to 7-membered monocyclic or polycyclic saturated or partially-unsaturated heterocyclyl comprising the same or different 1 to 2 atoms selected from nitrogen atom, oxygen atom, and sulfur atom. It is preferably “5- to 7-membered saturated or partially-unsaturated heterocyclyl”. The “5- to 7-membered saturated or partially-unsaturated heterocyclyl” includes, for example, pyranyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuryl, dihydropyrrolyl, dihydrofuranyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, dioxanyl, azepanyl, morpholinyl, and thiomorpholinyl. The “4- to 7-membered saturated or partially-unsaturated heterocyclyl” includes, for example, azetidinyl and oxetanyl, besides those listed as examples of the above “5- to 7-membered saturated or partially-unsaturated heterocyclyl”. Among them, the “4- to 7-membered saturated heterocyclyl” includes, for example, azetidinyl, oxetanyl, tetrahydropyranyl, tetrahydrofuryl, pyrrolidinyl, imidazolidinyl, piperazinyl, dioxanyl, azepanyl, morpholinyl, and thiomorpholinyl. Each group may be attached to a group via any of carbon atom(s) and nitrogen atom(s) that constitute a ring.

The term “4- to 12-membered saturated or partially-unsaturated heterocyclyl” includes, for example, a 4- to 12-membered monocyclic or polycyclic saturated or partially-unsaturated heterocyclyl comprising the same or different 1 to 3 atoms selected from nitrogen atom, oxygen atom, and sulfur atom. It is preferably a 4- to 10-membered saturated or partially-unsaturated heterocyclyl. The “4- to 12-membered saturated or partially-unsaturated heterocyclyl” includes, for example, azocanyl, 1,4-oxazocanyl, 1,5-oxazocanyl, 1,4-diazocanyl, 1,5-diazocanyl, besides those listed as examples of the above “4- to 7-membered saturated or partially-unsaturated heterocyclyl”. Each group may be attached to a group via any of carbon atom(s) and nitrogen atom(s) that constitute a ring.

The term “4- to 7-membered saturated or partially-unsaturated heterocyclyl” or “4- to 12-membered saturated or partially-unsaturated heterocyclyl” includes a fused or bridged, saturated or partially-unsaturated bicyclic group and a saturated or partially-unsaturated spiro group. The “4- to 7-membered saturated or partially-unsaturated heterocyclyl” includes, for example, groups of the following formulae:

The “4- to 12-membered saturated or partially-unsaturated heterocyclyl” includes, for example, groups of the following formulae:

The term “nitrogen-containing saturated ring” means a saturated heterocyclic ring comprising one or more nitrogen atoms as ring components. The “nitrogen-containing saturated ring” includes, for example, azetidine, pyrrolidine, and piperidine.

The term “9- or 10-membered bicyclic heteroaromatic ring” means a bicyclic aromatic heterocyclic ring which consists of 9 or 10 atoms and comprises the same or different 1 to 3 heteroatoms selected from the group consisting of oxygen atom, nitrogen atom, and sulfur atom, and which may be optionally substituted with oxo. The oxygen atom (═O) and sulfur atom (═S) of carbonyl, sulfinyl, sulfonyl, and thiocarbonyl which compose the bicyclic heteroaromatic ring is not counted as ring members (i.e., the ring size) of the 9- or 10-membered ring nor as heteroatom(s) which compose the ring. The “9- or 10-membered bicyclic heteroaromatic ring” includes, for example, quinoline, isoquinoline, naphthyridine, quinazoline, quinoxaline, benzofuran, benzothiophene, indole, benzooxazole, benzoisooxazole, benzoimidazole, benzooxadiazole, benzothiadiazole, indolizine, benzofuran, indazole, pyrazolopyridine, imidazopyridine, triazolopyridine, imidazopyrimidine, imidazopyridazine, thiazolopyridine, pyrazolopyrimidine, triazolopyridazine, and furopyridine.

The term “3- to 6-membered saturated heterocyclic ring” means a monocyclic or bicyclic saturated heterocyclic ring which consists of 3 to 6 atoms and comprises the same or different 1 or 2 heteroatoms selected from the group consisting of oxygen atom, nitrogen atom, and sulfur atom. The saturated heterocyclic ring may be optionally substituted with oxo, and may comprise 1 or 2 carbonyl, thiocarbonyl, sulfinyl, or sulfonyl groups. The oxygen atom (═O) of carbonyl, sulfinyl, and sulfonyl is not counted as ring members (i.e., the ring size) of the 3- to 6-membered ring or as heteroatom(s) which compose the ring, and the sulfur atom (═S) of thiocarbonyl is not counted as ring members (i.e., the ring size) of the 3- to 6-membered ring or as heteroatom(s) which compose the ring. Preferably, the “3- to 6-membered saturated heterocyclic ring” includes “5- or 6-membered saturated heterocyclic ring”. Examples of the “5- or 6-membered saturated heterocyclic ring” include, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydrofuran, and tetrahydropyran. The “3- to 6-membered saturated heterocyclic ring” includes, for example, aziridine and azetidine, besides those listed as examples of the above “5- or 6-membered saturated heterocyclic ring”. Among them, the “6-membered saturated heterocyclic ring” includes, for example, piperidine, morpholine, and tetrahydropyran.

The “4- to 7-membered saturated or partially-unsaturated heterocyclyloxy” means an oxy group substituted with the above “4- to 7-membered saturated or partially-unsaturated heterocyclyl”.

Examples of the group of formula (2c) comprising a 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring which is formed by taking R⁵ and R⁶ together with the carbon atoms to which they attach, include groups of the following formulae:

Examples of the group of formula (3) comprising a 3- to 6-membered saturated carbocyclic ring or 3- to 6-membered saturated heterocyclic ring which is formed by taking R^a and R^b together with the carbon atoms to which they attach, include groups of the following formulae:

Examples of the group of formula (2a) or (2b) comprising a 9- or 10-membered bicyclic heteroaromatic ring include groups of the following formulae:

Among the present compounds of formula (1), specific embodiments of Ring Cy, R^1a, R^2a, Y¹, Y², Y³, R^1b, R^2b, M¹, and M² are shown below, but the technical scope of the present invention shall not be limited to the scope of the following exemplary embodiments. The specific embodiments shown below may be optionally combined with each other as long as they do not contradict.

Ring Cy includes preferably 5- or 6-membered heteroarylene and 9- or 10-membered heteroarylene, more preferably a group of formula (a) or formula (b). An embodiment of Ring Cy includes 5- or 6-membered heteroarylene, and another embodiment thereof includes 9- or 10-membered heteroarylene. And, another embodiment of Ring Cy includes a group of formula (a), and further another embodiment includes a group of formula (b).

R^1a and R^2a preferably include, independently,

(1) hydrogen atom,

(2) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_1-6 alkoxy,

(3) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(4) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_2-7 alkylcarbonyl.

Another preferred embodiment of R^1a and R^2a includes the case when they are taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbon ring.

Preferably, Y¹, Y², and Y³ include, independently N and CR^2b. More preferably, Y¹ is N, and Y² and Y³ are independently N or CR^2b. In another embodiment, Y¹ is N, and Y² and Y³ are CR^2b. In further another embodiment, Y¹ and Y² are N, and Y³ is CR^2b. In another embodiment, Y¹ and Y³ is N, and Y² is CR^2b. In further another embodiment, Y¹, Y², and Y³ are CR^2b. In further another embodiment, Y¹, Y², and Y³ are N.

Preferably, R^1b includes hydrogen atom, halogen atom, cyano, C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, more preferably hydrogen atom, halogen atom, cyano, C_1-6 alkyl, and C_3-6 cycloalkyl. More preferably, R^1b includes hydrogen atom, halogen atom, and C_1-3 alkyl, especially preferably hydrogen atom and halogen atom, the most preferably hydrogen atom.

Preferably, R^2b includes hydrogen atom, halogen atom, cyano, C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and C_3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, more preferably hydrogen atom, halogen atom, cyano, C_1-6 alkyl, and C_3-6 cycloalkyl. More preferably, R^2b includes hydrogen atom, halogen atom, and C_1-3 alkyl, especially preferably hydrogen atom and halogen atom, the most preferably hydrogen atom.

Preferably, M¹ includes

(1) saturated or partially-unsaturated C_4-12 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,(2) 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, and(3) —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(e) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(f) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy.

More preferably, M¹ includes

(1) saturated or partially-unsaturated C_4-2 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,(2) 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, and(3) —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl, or

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl.

An embodiment of M¹ includes a group of the following formula (3′):

wherein

X¹⁶ is N, C, or CH,

the bond having a broken line is a single bond or a double bond,

m is 0, 1, 2, or 3,

R^a, R^b, R^c, and R^d are independently

(1-1) hydrogen atom,

(1-2) halogen atom,

(1-3) hydroxy,

(1-4) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(1-5) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(1-6) amino-carbonyl which may be substituted with C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

wherein R^a and R^b may be taken together with the carbon atom(s) to which they are attached to form

(2-1) 3- to 6-membered saturated carbocyclyl, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, and

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(2-2) 3- to 6-membered saturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of the above (a)-(d) in (2-1).

Another embodiment of M¹ includes a group of formula (3′) wherein X¹⁶ is C or N; m is 1 or 2; R^a and R^b are independently hydrogen atom, halogen atom, or C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; and R^c and R^d are hydrogen atom.

Another embodiment of M¹ includes a group of following formula (3a):

wherein

m is 0, 1, 2, or 3,

R^a, R^b, R^c, and R^d are independently (1-1) hydrogen atom,

(1-2) halogen atom,

(1-3) hydroxy,

(1-4) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(1-5) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(1-6) amino-carbonyl which may be substituted with C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

wherein R^a and R^b may be taken together with the carbon atom(s) to which they are attached to form

(2-1) 3- to 6-membered saturated carbocyclyl, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, and

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(2-2) 3- to 6-membered saturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of the above (a)-(d) in (2-1)

Another embodiment of M¹ includes a group of formula (3b):

wherein

m is 0, 1, 2, or 3,

R^a, R^b, R^c, and R^d are independently

(1-1) hydrogen atom,

(1-2) halogen atom,

(1-3) hydroxy,

(1-4) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(1-5) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(1-6) amino-carbonyl which may be substituted with C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

wherein R^a and R^b may be taken together with the carbon atom(s) to which they are attached to form

(2-1) 3- to 6-membered saturated carbocyclyl, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, and

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(2-2) 3- to 6-membered saturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of the above (a)-(d) in (2-1).

Another embodiment of M¹ includes a group of formula (3c):

m is 0, 1, 2, or 3,

R^a, R^b, R^c, and R^d are independently

(1-1) hydrogen atom,

(1-2) halogen atom,

(1-3) hydroxy,

(1-4) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(1-5) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(1-6) amino-carbonyl which may be substituted with C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

wherein R^a and R^b may be taken together with the carbon atom(s) to which they are attached to form

(2-1) 3- to 6-membered saturated carbocyclyl, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of

(a) halogen atom,

(b) hydroxy,

(c) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, and

(d) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(2-2) 3- to 6-membered saturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of the above (a)-(d) in (2-1).

Further embodiment of M¹ includes —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

(e) C_6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy, or

(f) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, and C_1-6 alkoxy.

Another preferred embodiment of M¹ includes a group of the following formula (3a-1), (3a-2), (3a-3), (3a-4), (3a-5), (3a-6), (3b-1), (3b-2), (3b-3), (3b-4), (3c-1), (3c-2), (3c-3), (3c-4), (3c-5), (3c-6), (3c-7), (3d-1), (3d-2), (3d-3), (3d-4), (3d-5), (3d-6), (3d-7), (3d-8), (3d-9), (3d-10), (3d-11), (3d-12). (3d-13), or (3d-14):

Further preferably, it includes a group of formula (3a-1), (3a-2), (3a-3), (3a-4), (3c-2), (3c-3), (3c-4), (3d-1), (3d-2), (3d-3), (3d-4), (3d-5), (3d-6), or (3d-7).

Preferably, M² includes any group of

(1) the following formulae (2a-1)-(2a-23) and (2b-1)-(2b-11):

wherein

X^1a and X^1b are independently N or CR³,

R³ is

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) hydroxy,

(e) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_1-6 alkoxy,

(f) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

(g) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(h) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_2-7 alkylcarbonyl,

(i) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, and C_1-6 alkyl,

(j) saturated 5- or 6-membered heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy, or

(k) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

provided that when there are plural R³, each R³ may be the same or different,

R⁴ is

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(c) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

(2) the following formula (2c′):

wherein

R⁵ and R⁶ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl,

(e) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, and C_1-6 alkyl,

(f) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy, or

(g) —C(O)NR^xR^y, wherein R^x and R^Y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring, or

R⁵ and R⁶ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, oxo, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl, and

the substitutable carbon atom on the ring of formula (2c′) may have one fluorine atom as a substituent, or

(3) the following formula (2d), (2f), (2g), or (2h):

wherein

R⁸, R⁹, and R¹⁰ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; C_1-6 alkoxy which may be optionally substituted with hydroxy or C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with C_1-6 alkyl or C_1-6 alkoxy; 5- or 6-membered heteroaryl which may be optionally substituted with C_1-6 alkyl; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy),

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(g) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

(h) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl; C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; and oxo,

(i) 4- to 7-membered saturated or partially-unsaturated heterocyclyloxy which may be optionally substituted with the same or different 1 to 4 C_1-6 alkyl,

(j) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

(k) —C(O)OR^z, wherein R^z is C_1-6 alkyl, or

(l) ethenyl which may be substituted with one 6-membered saturated heterocyclyl,

wherein R⁸ and R⁹ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl, and

the substitutable carbon atom on the ring of formula (2d), (2f), (2g), or (2h) may have one fluorine atom as a substituent.

An embodiment of M² includes a group of the following formula (2a′) or (2b′):

X², X⁵, X⁶, X⁷, and X⁸ are independently N, CR²¹, or O,

A¹ and A² are independently N or C,

wherein X², X⁵, X⁶, X⁷, X⁸, A¹, and A² are chosen so that the ring composed thereof can be 9- or 10-membered bicyclic heteroaromatic ring, and

R²¹ and R²² are independently

(1) hydrogen atom,

(2) halogen atom,

(3) cyano,

(4) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_1-6 alkoxy,

(5) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

(6) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(7) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_2-7 alkylcarbonyl.

Another embodiment of M² includes a group of any one of the following formulae (2a-1)-(2a-23) and (2b-1)-(2b-11):

wherein

X^1a and X^1b are independently N or CR³,

R³ is

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) hydroxy,

(e) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_1-6 alkoxy,

(f) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy,

(g) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(h) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms, saturated or partially-unsaturated C_3-7 carbocyclyl, and C_2-7 alkylcarbonyl,

(i) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, and C_1-6 alkyl,

(j) 5- or 6-membered saturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy, or

(k) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

provided that when there are plural R³, each R³ may be the same or different, and

R⁴ is

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy, or

(c) saturated or partially-unsaturated C_3-7 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy.

Another embodiment of M² includes a group of the following formula (2c′):

wherein

R⁵ and R⁶ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl,

(e) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, and C_1-6 alkyl,

(f) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, hydroxy, C_1-6 alkyl, and C_1-6 alkoxy, or

(g) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring, or

R⁵ and R⁶ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, oxo, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl, and

the substitutable carbon atom on the ring of formula (2c′) may have one fluorine atom as a substituent.

Another embodiment of M² includes a group of the following formula (2d), (2f), (2g), or (2h):

wherein

R⁸, R⁹, and R¹⁰ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; C_1-6 alkoxy which may be optionally substituted with hydroxy or C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with C_1-6 alkyl or C_1-6 alkoxy; 5- or 6-membered heteroaryl which may be optionally substituted with C_1-6 alkyl; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy),

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(g) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

(h) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl; C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; and oxo,

(i) 4- to 7-membered saturated or partially-unsaturated heterocyclyloxy which may be optionally substituted with the same or different 1 to 4 C_1-6 alkyl,

(j) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

(k) —C(O)OR^z, wherein R^z is C_1-6 alkyl, or

(l) ethenyl which may be substituted with one 6-membered saturated heterocyclyl,

wherein R⁸ and R⁹ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl, and

the substitutable carbon atom on the ring of formula (2d), (2f), (2g), or (2h) may have one fluorine atom as a substituent.

Further embodiment of M² includes a group of the following formula (2k′):

wherein

R⁸, R⁹, and R¹⁰ are independently

(a) hydrogen atom,

(b) halogen atom,

(c) cyano,

(d) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; C_1-6 alkoxy which may be optionally substituted with hydroxy or C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with C_1-6 alkyl or C_1-6 alkoxy; 5- or 6-membered heteroaryl which may be optionally substituted with C_1-6 alkyl; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; saturated or partially-unsaturated C_3-7 carbocyclyl; 4- to 7-membered saturated heterocyclyl which may be optionally substituted with C_1-6 alkoxy; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy),

(e) C_1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with halogen atom; saturated or partially-unsaturated C_3-7 carbocyclyl; and C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy,

(g) 5- or 6-membered heteroaryl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom, cyano, C_1-6 alkyl, C_1-6 alkoxy, and C_2-7 alkoxycarbonyl,

(h) 4- to 7-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; C_1-6 alkoxy; 4- to 7-membered saturated or partially-unsaturated heterocyclyl; C_2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C_1-6 alkoxy; and oxo,

(i) 4- to 7-membered saturated or partially-unsaturated heterocyclyloxy which may be optionally substituted with the same or different 1 to 4 C_1-6 alkyl,

(j) —C(O)NR^xR^y, wherein R^x and R^y are independently hydrogen atom, C_1-6 alkyl, or saturated or partially-unsaturated C_3-7 carbocyclyl; or R^x and R^y may be taken together with the nitrogen atom to which they are attached to form 4- to 7-membered saturated heterocyclic ring,

(k) —C(O)OR^z, wherein R^z is C_1-6 alkyl, or

(l) ethenyl which may be substituted with one 6-membered saturated heterocyclyl, or

wherein R⁸ and R⁹ may be taken together with the carbon atoms to which they are attached to form 5- to 7-membered saturated or partially-unsaturated carbocyclic ring or heterocyclic ring, wherein the ring may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl.

In an embodiment, the present compound of formula (1) includes the following (A).

(A)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (a),

R^1a and R^2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy,

M¹ is saturated or partially-unsaturated C₄12 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10),

X^1a and X^1b are independently N or CR³, and

R³ is independently hydrogen atom, halogen atom, cyano, hydroxy, C_1-6 alkyl, or C_1-6 alkoxy, provided that when there are plural R³, each R³ may be the same or different.

Another embodiment of the present compound of formula (1) includes the following (B):

(B)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (a),

R^1a and R^2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy,

M¹ is 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10),

X^1a and X^1b are independently N or CR³, and

R³ is independently hydrogen atom, halogen atom, cyano, hydroxy, C_1-6 alkyl, or C_1-6 alkoxy, provided that when there are plural R³, each R³ may be the same or different.

Another embodiment of the present compound of formula (1) includes the following (C):

(C)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (a),

R^1a and R^2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy,

M¹ is —NR^eR^f,

R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl, or

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

M² is a group of formula (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10),

X^1a and X^1b are independently N or CR³, and

R³ is independently hydrogen atom, halogen atom, cyano, hydroxy, C_1-6 alkyl, or C_1-6 alkoxy, provided that when there are plural R³, each R³ may be the same or different.

Another embodiment of the present compound of formula (1) includes the following (D):

(D)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (a),

R^1a and R^2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy,

M¹ is saturated or partially-unsaturated C_4-12 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2d) or (2f), and

R⁸, R⁹, and R¹⁰ are independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_1-6 alkoxy.

Another embodiment of the present compound of formula (1) includes the following (E):

(E)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (a),

R^1a and R^2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy,

M¹ is 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2d) or (2f), and

R⁸, R⁹, and R¹⁰ are independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_1-6 alkoxy.

Another embodiment of the present compound of formula (1) includes the following (F):

(F)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (a),

R^1a and R^2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy,

M¹ is —NR^eR^f,

R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl, or

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

M² is a group of formula (2d) or (2f), and

R⁸, R⁹, and R¹⁰ are independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_1-6 alkoxy.

Another embodiment of the present compound of formula (1) includes the following (G):

(G)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (b),

Y² and Y³ are independently N or CR²,

R^1b is hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl,

R^2b is independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl, provided that when there are plural R^2b, each R^2b may be the same or different,

M¹ is saturated or partially-unsaturated C_4-12 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10),

X^1a and X^1b are independently N or CR³, and

R³ is independently hydrogen atom, halogen atom, cyano, hydroxy, C_1-6 alkyl, or C_1-6 alkoxy, provided that when there are plural R³, each R³ may be the same or different.

Another embodiment of the present compound of formula (1) includes the following (H):

(H)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (b),

Y² and Y³ are independently N or CR²,

R^1b is hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl,

R^2b is independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl, provided that when there are plural R^2b, each R^2b may be the same or different,

M¹ is 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10),

X^1a and X^1b are independently N or CR³, and

R³ is independently hydrogen atom, halogen atom, cyano, hydroxy, C_1-6 alkyl, or C_1-6 alkoxy, provided that when there are plural R³, each R³ may be the same or different.

Another embodiment of the present compound of formula (1) includes the following (I):

(I)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (b),

Y² and Y³ are independently N or CR²,

R^1b is hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl,

R^2b is independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl, provided that when there are plural R^2b, each R^2b may be the same or different,

M¹ is —NR^eR^f,

R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl, or

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

M² is a group of formula (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10),

X^1a and X^1b are independently N or CR³, and

R³ is independently hydrogen atom, halogen atom, cyano, hydroxy, C_1-6 alkyl, or C_1-6 alkoxy, provided that when there are plural R³, each R³ may be the same or different.

Another embodiment of the present compound of formula (1) includes the following (J):

(J)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (b),

Y² and Y³ are independently N or CR²,

R^1b is hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl,

R^2b is independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl, provided that when there are plural R^2b, each R^2b may be the same or different,

M¹ is saturated or partially-unsaturated C_4-12 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2d) or (2f), and

R⁸, R⁹, and R¹⁰ are independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_1-6 alkoxy.

Another embodiment of the present compound of formula (1) includes the following (K):

(K)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (b),

Y² and Y³ are independently N or CR²,

R^1b is hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl,

R^2b is independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl, provided that when there are plural R^2b, each R^2b may be the same or different,

M¹ is 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom and C_1-6 alkyl,

M² is a group of formula (2d) or (2f), and

R⁸, R⁹, and R¹⁰ are independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_1-6 alkoxy.

Another embodiment of the present compound of formula (1) includes the following (L):

(L)

A compound of formula (1) or pharmaceutically acceptable salt thereof, wherein

Ring Cy is a group of formula (b),

Y² and Y³ are independently N or CR²,

R^1b is hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl,

R^2b is independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_3-6 cycloalkyl, provided that when there are plural R^2b, each R^2b may be the same or different,

M¹ is —NR^eR^f, wherein R^e and R^f are independently

(a) hydrogen atom,

(b) C_1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,

(c) C_3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl, or

(d) C_3-10 cycloalkyl-C_1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C_1-6 alkyl, and C_3-6 cycloalkyl,

M² is a group of formula (2d) or (2f), and

R⁸, R⁹, and R¹¹ are independently hydrogen atom, halogen atom, cyano, C_1-6 alkyl, or C_1-6 alkoxy.

The “pharmaceutically acceptable salt” includes acid addition salts, base addition salts, and amino acid salts. For example, the acid addition salt includes inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, and phosphate; or organic acid salts such as citrate, oxalate, phthalate, fumarate, maleate, succinate, malate, acetate, formate, propionate, benzoate, trifluoroacetate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, and camphorsulfonate. The base addition salt includes inorganic base salts such as sodium salts, potassium salts, calcium salts, magnesium salts, barium salts, and aluminum salts; and organic base salts such as trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, tromethamine[tris(hydroxymethyl)methylamine], tert-butylamine, cyclohexylamine, dicyclohexylamine, and N,N-dibenzylethylamine. The amino acid salt includes amino acid salts of basic or acidic amino acids such as arginine, lysine, ornithine, aspartate, and glutamate.

In addition, the present compound (1) encompasses any crystalline forms thereof.

A compound of Formula (1) may have at least one asymmetric carbon atom. Thus, the present compound encompasses racemates of a compound of Formula (1), as well as optical isomers thereof. A compound of Formula (1) encompasses deuterated compounds in which any one or more 1H in the compound are replaced with ²H (D).

Some compounds of formula (1) may have isomers including tautomers such as keto-enol forms, regioisomers, geometric isomers, or optical isomers. All possible isomers including them, and mixtures of such isomers in any ratio, are also encompassed in the present invention. And, the compound of formula (1) may exist in a form of hydrate or solvate (e.g., ethanolate) with various types of solvents such as water and ethanol, and such hydrates and solvents are also encompassed in the present invention.

Hereinafter, methods for preparing a compound of Formula (1) in the present invention are exemplified, but the present invention is not limited to such examples.

Preparation

The present compound (1) may be prepared by the following processes and methods which are combined with common synthetic methods.

Compounds in the reaction schemes include ones in the salt form, and such salts include, for example, what are described in the above “pharmaceutically acceptable salt”. It should be noted that these reactions are merely illustrative, and other methods may be optionally applied for preparing the present compound based on the knowledge of a person skilled in synthetic organic chemistry.

In each of the preparation process described below, when there is a functional group that needs protection, the functional group may be protected as necessary and deprotected after the completion of a reaction or a series of reactions to afford a targeted product, even if the use of the protective group is not specifically indicated.

The protective groups used herein include common protective groups, which include, for example, the protective groups described in the literatures (T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, 3rd Ed., John Wiley and Sons, inc., New York (1999) etc.). More specifically, protective groups for amino group include, for example, tert-butoxycarbonyl, benzyloxycarbonyl, p-toluenesulfonyl, o-nitrobenzenesulfonyl, and tetrahydropyranyl. Protective groups for hydroxy group include, for example, trialkylsilyl, acetyl, benzyl, tetrahydropyranyl, and methoxymethyl. Protective groups for aldehyde group include, for example, dialkylacetal and cyclic alkylacetal. Protective groups for carboxyl group include, for example, tert-butyl ester, orthoester, and amide.

The introduction and deprotection of protective groups can be done by methods commonly used in organic synthetic chemistry (for example, the methods described in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, 3rd Ed., John Wiley and Sons, inc., New York (1999) etc.) or corresponding methods thereof.

A compound of Formula (1) is prepared by forming bonds at the positions of a, b, and c:

wherein ring Cy, M¹, and M² are as defined in the above (Item 5).

Processes for forming bonds at the positions a, b, and c are illustrated in the following Preparations, but the sequence of forming bonds may be optionally modified.

The present compound wherein Ring Cy is a group of formula (a) may be prepared in the manners of Preparations 1a-5a.

Preparation 1a

Among compounds of Formula (1), a compound of formula (1a) is prepared, for example, by the following process:

wherein R^1a and R^2a are the same as those defined in the above (Item 6); M¹ and M² are the same as those defined in the above (Item 5); R is C_1-6 alkyl; and LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl)).

Step 1a-1: Preparation Step of Compound (1a)

A compound of Formula (1a) is prepared by reacting Compound (1a-1) with Compound (1a-2) in the presence of a base in an appropriate inert solvent. As Compound (1a-1), a product synthesized in Preparation 4a or 5a described below, or a commercial product may be used. As Compound (1a-2), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the base used herein include inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; metal alkoxides such as sodium methoxide and potassium tert-butoxide; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.

Examples of the inert solvent used herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of −10° C. to 200° C., preferably the range of 0° C. to 40° C. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

Step 1a-2: Preparation Step of Compound (1a-4)

Compound (1a-4) is prepared by reacting Compound (1a-1) with Compound (1a-3) according to the method described in Step 1a-1. As Compound (1a-3), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Step 1a-3: Preparation Step of Compound (1a-5)

Compound (1a-5) is prepared by hydrolyzing Compound (1a-4) by common methods (for example, Protective Groups in Organic Synthesis 3^rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, R. C. Laroque et al, VCH publisher Inc., 1989 etc.) or corresponding methods thereof.

Step 1a-4: Preparation Step of Compound (1a)

A compound of formula (1a) is also prepared by reacting Compound (1a-5) with Compound (1a-6) in the presence or absence of a base in an appropriate inert solvent using a condensing agent. As Compound (1-6), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the condensing agent include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (WSC), benzotriazol-1-yl-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), diphenylphosphoryl azide (DPPA), N,N-carbonyldiimidazole (CDI), benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), and 7-azabenzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU). If necessary, additives such as N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), and 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOOBt) may be added to the reaction.

Examples of the base used herein include organic bases such as triethylamine, diisopropylethylamine, and pyridine; inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.

Examples of the inert solvent used herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range from −10° C. to 200° C., preferably the range from 0° C. to 40° C. Reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

The present step can also be proceeded, for example, by activating a carbonyl group with an acid anhydride, a mixed acid anhydride, or an acid halide, and then reacting with Compound (1a-6).

Preparation 2a

Among compounds of Formula (1), a compound of formula (2a-4) is prepared, for example, by the following process:

wherein R^1a and R^2a are the same as those defined in the above (Item 6); and M² is the same as those defined in the above (Item 5); LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl)); R^g and R^h are each independently the same as the definition of R^e or R^f defined in the above (Item 5); or alternatively, R^g and R^h may be taken together with the nitrogen atom to which they attach to form an optionally-substituted 4- to 12-membered saturated heterocyclic ring.Step 2a-1: Preparation Step of Compound (2a-2)

Compound (2a-2) is prepared from Compound (2a-1) and Compound (1a-2) according to the method described in Step 1a-1. For Compound (2a-1), a product synthesized by common methods (for example, those described in Tetrahedron, 2015, 71, 4859, Bioorganic & Medicinal Chemistry Letters, 2015, 25, 1030, etc.) or corresponding methods thereof, or a commercial product may be used.

Step 2a-2: Preparation Step of Compound (2a-4)

Compound (2a-4) can be prepared by reacting Compound (2a-2) with Compound (2a-3) in the presence of a base in an appropriate inert solvent. As Compound (2a-3), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the base used herein include organic bases such as triethylamine, diisopropylethylamine, and pyridine; inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium hydrogen phosphate, potassium phosphate, disodium hydrogen phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.

Examples of the inert solvent used herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of 20° C. to 200° C., preferably the range of 50° C. to 170° C. The present step may be conducted under microwave irradiation, if necessary. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

Preparation 3a

Among compounds of Formula (1), compounds of formulae (3a-2) and (3a-3) are prepared, for example, by the following process:

wherein R^1a and R^2a are the same as those described in the above (Item 6); M² is the same as those described in the above (Item 5); LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl)); A is boronic acid, boronate, BF₃K, or BF₃Na; Q² is optionally-substituted 4- to 12-membered partially-unsaturated heterocyclyl or saturated or partially-unsaturated C_4-12 carbocyclyl; and Q³ is optionally-substituted saturated or partially-unsaturated C_4-12 carbocyclyl, or optionally-substituted 4- to 12-membered saturated heterocyclyl.Step 3a-1: Preparation Step of Compound (3a-2)

Compound (3a-2) is prepared by reacting Compound (2a-2) with Compound (3a-1) in the presence of a palladium catalyst, a phosphine ligand, and a base in an appropriate inert solvent. As Compound (3a-1), a commercial product, or a product synthesized by common methods or corresponding methods may be used.

Examples of the palladium catalyst herein include tetrakis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), bis(tri-tert-butylphosphine)palladium(0), palladium(0) acetate, [1,1-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II).

Phosphine ligands include, for example, o-tolylphosphine, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (S-Phos), 2-(dicyclohexylphosphino)-2′,4′,6′-triisopropylbiphenyl (X-Phos), 1,1′-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane (DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis(2-(diphenylphosphino)phenyl) ether (DPE-Phos).

Examples of the base used herein include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, and potassium hydroxide.

Examples of the inert solvent used herein include 1,4-dioxane, THF, 1,2-dimethoxyethane, water, and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of 50° C. to 200° C., preferably the range of 80° C. to 150° C. The present step can be conducted under microwave irradiation, if necessary. Reaction time is usually 30 minutes to 48 hours.

Step 3a-2: Preparation Step of Compound (3a-3)

Compound (3a-3) is prepared by catalytic reduction of Compound (3a-2) with a metal catalyst in an appropriate inert solvent under hydrogen atmosphere.

Examples of the metal catalyst used herein include palladium/carbon, palladium hydroxide/carbon, Raney nickel, platinum oxide/carbon, and rhodium/carbon. The amount of a metal catalyst is usually 0.1% to 1000% by weight to Compound (3a-2), and preferably 1% to 100% by weight.

Examples of the inert solvent used herein include ethers such as tetrahydrofuran; and esters such as ethyl acetate.

The hydrogen pressure is usually 1 to 100 atm, and preferably 1 to 5 atm.

The reaction temperature is selected from, but not limited to, usually the range of 0° C. to 120° C., preferably the range of 20° C. to 80° C. Reaction time is usually 30 minutes to 72 hours.

Preparation 4a

Among compounds of formula (1a-1), a compound of formula (4a-3) is prepared, for example, by the following process:

wherein R^1a and R^2a are the same as those defined in the above (Item 6); LG¹ and LG² are each independently a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyl (such as methanesulfonyl and p-toluenesulfonyl)); R^g and R^h are each independently the same as the definition of R^e or R^f defined in the above (Item 5); or alternatively, R^g and R^h may be taken together with the nitrogen atom to which they attach to form an optionally-substituted 4- to 12-membered saturated heterocyclic ring.Step 4a-1: Preparation Step of Compound (4a-2)

Compound (4a-2) is prepared from Compound (4a-1) and Compound (2a-3) according to the method described in Step 2a-2. As Compound (4a-1) and Compound (2a-3), a commercial product or a product synthesized by common methods (for example, WO 2004/006922, ACS Medicinal Chemistry Letters, 2012, 3, 903. etc.) or corresponding methods thereof may be used. The amount of Compound (2a-3) used herein is usually 1.0 equivalent to 1.5 equivalent, and preferably 1.05 equivalent to 1.2 equivalent, to the amount of Compound (4a-2).

Step 4a-2: Preparation Step of Compound (4a-3)

Compound (4a-3) is prepared from Compound (4a-2) according to common methods (for example, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 2007., WO 2012/114268, etc.) or corresponding methods thereof.

Preparation 5a

Among compounds of Formula (1a-1), a compound of formula (5a-4) is prepared, for example, by the following process:

wherein R^1a and R^2a are the same as those defined in the above (Item 6); Q³ is optionally-substituted saturated or partially-unsaturated C_4-12 carbocyclyl or optionally-substituted 4- to 12-membered saturated heterocyclyl; G is a metallic species such as magnesium and zinc; and X is halogen atom.Step 5a-1: Preparation Step of Compound (5a-3)

Compound (5a-3) is prepared by reacting Compound (5a-1) with a organometallic compound (5a-2) such as Grignard reagent according to a known method (for example, Organic Letters, 2015, 17, 5517., Organic & Biomolecular Chemistry, 2014, 12, 2049. etc.). As Compound (5a-1) and Compound (5a-2), a commercial product or a product synthesized by common methods (for example, Organic Letters, 2008, 10, 4815., Journal of Organic Chemistry, 2015, 80, 12182., etc.) or corresponding methods thereof may be used.

Step 5a-2: Preparation Step of Compound (5a-4)

Compound (5a-4) is prepared by reacting Compound (5a-3) with hydrazine according to a known method (for example, Journal of Medicinal Chemistry, 1993, 36, 4052., WO 2007/020343).

The present compound wherein Ring Cy is a group of formula (b) may be prepared in the manners of Preparations 1b-6b.

Preparation 1b

Among compounds of Formula (1), a compound of formula (1b) is prepared, for example, by the following process:

wherein M¹ and M² are the same as those defined in the above (Item 5); R^1b, Y¹, Y², and Y³ are the same as those defined in the above (Item 6); R is C_1-6 alkyl; X is halogen atom; LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyloxy (such as methanesulfonyloxy and p-toluenesulfonyloxy)); and Z is boronic acid, boronate, BF₃K, BF₃Na, trialkyltin, zinc halide, or hydrogen atom.Step 1b-1: Preparation Step of Compound (1b-3)

Compound (1b-3) can be prepared by reacting Compound (1b-1) with Compound (1b-2) in the presence of a base in an appropriate inert solvent. As Compound (1b-1), a product synthesized by common methods (for example, US 2005/0277655 A, WO 2018/081091, WO 2017/009798 A) or corresponding methods thereof, or a commercial product may be used. As Compound (1b-2), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the base used herein include inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; metal alkoxides such as sodium methoxide and potassium tert-butoxide; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.

Examples of the inert solvent used herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of −10° C. to 200° C., preferably the range of 0° C. to 40° C. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

Step 1b-2: Preparation Step of Compound (1b-5)

Among Compound (1b-5), the compound wherein M¹ is optionally-substituted partially-unsaturated C_4-12 carbocyclyl, optionally-substituted 4- to 12-membered partially-unsaturated heterocyclyl, optionally-substituted C_6-10 aryl, optionally-substituted 5- to 10-membered heteroaryl, or optionally-substituted C_2-10 alkenyl can be prepared by reacting Compound (1b-3) with Compound (1b-4) wherein Z is boronic acid, boronate, BF₃K, BF₃Na, trialkyltin, or zinc halide, in a suitable inert solvent, in the presence of a palladium catalyst and a phosphine ligand, optionally in the presence of a base. As Compound (1b-4), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the palladium catalyst used herein include tetrakis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), bis(tri-tert-butylphosphine)palladium(0), palladium(0) acetate, [1,1-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II).

Phosphine ligands include, for example, o-tolylphosphine, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (S-Phos), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos), 1,1′-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane (DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis(2-(diphenylphosphino)phenyl) ether (DPE-Phos).

Examples of the base used herein include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, and potassium hydroxide.

Examples of the inert solvent include 1,4-dioxane, THF, 1,2-dimethoxyethane, acetonitrile, water, and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of 50° C. to 200° C., preferably the range of 80° C. to 150° C. The present step can be conducted under microwave irradiation, if necessary. Reaction time is usually 30 minutes to 48 hours.

Among Compound (1b-5), the compound wherein M¹ is optionally-substituted C_1-10 alkoxy, optionally-substituted C_6-10 aryloxy, optionally-substituted 5- to 10-membered heteroaryloxy, or —NR^eR^f wherein R^e and R^f are the same as those defined in the above (Item 5) can be prepared by reacting Compound (1b-3) with Compound (1b-4) wherein Z is hydrogen atom, in a suitable inert solvent. Among Compound (1b-5), the compound wherein M¹ is —NR^eR^f wherein R^e and R^f are the same as those defined in the above (Item 5) can be also prepared by reacting Compound (1b-3) with Compound (1b-4) wherein Z is hydrogen atom, in a suitable inert solvent, in the presence of a palladium catalyst, a phosphine ligand, and a base. As Compound (1b-4), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the base used herein include organic bases such as triethylamine, diisopropylethylamine, and pyridine; inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.

Examples of the inert solvent used herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.

Examples of the palladium catalyst herein include tetrakis(triphenylphosphine) palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), bis(tri-tert-butylphosphine)palladium(0), palladium(0) acetate, [1,1-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II).

Phosphine ligands include, for example, o-tolylphosphine, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (S-Phos), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos), 1,1′-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane (DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis(2-(diphenylphosphino)phenyl) ether (DPE-Phos).

The reaction temperature is selected from, but not limited to, usually the range of 20° C. to 200° C., preferably the range of 50° C. to 170° C. The present step can be conducted under microwave irradiation, if necessary. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

In addition, the present step may be done by replacing X with another leaving group such as alkyl sulfonyl group, followed by reacting with Compound (1b-4), according to known methods.

Step 1b-3: Preparation Step of Compound (1b-6)

Compound (1b-6) is prepared by hydrolyzing or hydrogenating Compound (1b-5) according to a known method (for example, Protective Groups in Organic Synthesis 3^rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, R. C. Laroque et al, VCH publisher Inc., 1989, etc.).

Step 1b-4: Preparation Step of Compound (1b)

The compound of formula (1b) is prepared by reacting Compound (1b-6) with Compound (1b-7) in the presence or absence of a base in an appropriate inert solvent using a condensing agent. As Compound (1b-7), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the condensing agent include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (WSC), benzotriazol-1-yl-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), diphenylphosphoryl azide (DPPA), N,N-carbonyldiimidazole (CDI), benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), 7-azabenzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU). If necessary, additives such as N-hydroxysuccinimide (HOSu), 1-hydroxybenzotriazole (HOBt), and 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOOBt) may be added to the reaction.

Examples of the base used herein include organic bases such as triethylamine, diisopropylethylamine, pyridine, and 4-(dimethylamino)pyridine; inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.

Examples of the inert solvent herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of −10° C. to 200° C., preferably the range of 0° C. to 40° C. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

In addition, the present step may be done by activating the carboxyl group in Compound (1b-6) to transform an acid anhydride, mixed acid anhydride, or acid halide thereof, followed by reacting with Compound (1b-7), according to known methods.

Step 1b-5: Preparation Step of Compound (1b-8)

Compound (1b-8) is prepared from Compound (1b-3) according to the method described in Step 1b-3.

Step 1b-6: Preparation Step of Compound (1b-9)

Compound (1b-9) is prepared from Compound (1b-8) and Compound (1b-7) according to the method described in Step 1b-4.

Step 1b-7: Preparation Step of Compound (1b)

Compound (1b) is prepared from Compound (1b-9) and Compound (1b-4) according to the method described in Step 1b-2.

Preparation 2b

A compound of formula (1b-3) is prepared, for example, by the following process:

wherein R^1b, Y¹, Y², and Y³ are the same as those defined in the above (Item 6); R is C_1-6 alkyl; X is halogen atom; LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyloxy (such as methanesulfonyloxy and p-toluenesulfonyloxy)).Step 2b-1: Preparation Step of Compound (1b-3)

Compound (1b-3) is prepared by reacting Compound (2b-1) with Compound (2b-2) in a suitable inert solvent.

Examples of the inert solvent herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene and toluene; alcohol solvents such as methanol, ethanol, 2-propanol, tert-butanol, and 1-butanol, and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of −10° C. to 200° C., preferably the range of 20° C. to 150° C. The reaction time herein is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

Preparation 3b

A compound of formula (1b-3) is prepared, for example, by the following process:

wherein Y¹, Y², and Y³ are the same as those defined in the above (Item 6); R^1b is cyano, optionally-substituted C_1-6 alkyl, or optionally-substituted C_3-6 cycloalkyl; R is C_1-6 alkyl; X is halogen atom; X^a is iodine atom or bromine atom; Z is boronic acid, boronate, BF₃K, BF₃Na, or zinc cyanide.Step 3b-1: Preparation Step of Compound (1b-3)

Compound (1b-3) is prepared by reacting Compound (3b-1) with Compound (3b-2) in the presence of a palladium catalyst and a phosphine ligand, optionally in the presence of a base in a suitable inert solvent. Compound (3b-1) is prepared according to the method described in Step 1b-1. As Compound (3b-2), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the palladium catalyst herein include tetrakis(triphenylphosphine)palladium(0), bis(dibenzylideneacetone)palladium(0), tris(dibenzylideneacetone)dipalladium(0), bis(tri-tert-butylphosphine)palladium(0), palladium(0) acetate, [1,1-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II).

Phosphine ligands include, for example, o-tolylphosphine, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (S-Phos), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos), 1,1′-bis(diphenylphosphino)ferrocene (DPPF), 1,2-bis(diphenylphosphino)ethane (DPPE), 1,3-bis(diphenylphosphino)propane (DPPP), 1,4-bis(diphenylphosphino)butane (DPPB), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis(2-(diphenylphosphino)phenyl) ether (DPE-Phos).

Examples of the base used herein include sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, and potassium hydroxide.

Examples of the inert solvent used herein include 1,4-dioxane, THF, 1,2-dimethoxyethane, acetonitrile, dimethylformamide, water, and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of 50° C. to 200° C., preferably the range of 80° C. to 150° C. The present step can be conducted under microwave irradiation, if necessary. Reaction time is usually 30 minutes to 48 hours.

Preparation 4b

Among compounds of Formula (1), a compound of formula (4b-2) is prepared, for example, by the following process:

wherein M² is the same as those defined in the above (Item 5); R^1b, Y¹, Y², and Y³ are the same as those defined in the above (Item 6); Q¹ is optionally-substituted 4- to 12-membered partially-unsaturated heterocyclyl, or partially-unsaturated C_4-12 carbocyclyl; Q² is optionally-substituted 4- to 12-membered saturated heterocyclyl, or saturated C_4-12 carbocyclyl.Step 4b-1: Preparation Step of Compound (4b-2)

Compound (4b-2) is prepared by catalytic reduction of Compound (4b-1) with a metal catalyst in a suitable inert solvent under hydrogen atmosphere. Compound (4b-1) is prepared, for example, according to the method described in Preparation 1b.

Examples of the metal catalyst used herein include palladium/carbon, palladium hydroxide/carbon, Raney nickel, platinum oxide/carbon, and rhodium/carbon. The amount of a metal catalyst is usually 0.1% to 1000% by weight to Compound (4-1), and preferably 1% to 100% by weight.

Examples of the inert solvent used herein include ethers such as tetrahydrofuran; esters such as ethyl acetate; and alcohols such as methanol.

The hydrogen pressure is usually 1 to 100 atm, and preferably 1 to 5 atm. Or, the present process can be done using ammonium formate or other reagents, instead of hydrogen atmosphere.

The reaction temperature is selected from, but not limited to, usually the range of 0° C. to 120° C., preferably the range of 20° C. to 80° C. Reaction time is usually 30 minutes to 72 hours.

Preparation 5b

A compound of formula (1b-9) is prepared, for example, by the following process:

wherein M² is the same as those defined in the above (Item 5); R^1b, Y¹, Y², and Y³ are the same as those defined in the above (Item 6); X is halogen atom; LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyloxy (such as methanesulfonyloxy and p-toluenesulfonyloxy)).Step 5b-1: Preparation Step of Compound (1b-9)

Compound (1b-9) is prepared from Compound (1b-1) and Compound (5b-1) according to the method described in Step 1b-1. As Compound (5b-1), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Preparation 6b

Among compounds of Formula (1), a compound of formula (6b-4) wherein M¹ is —NR^eR^f is also prepared, for example, by the following process:

wherein R^1b, Y¹, Y², and Y³ are the same as those defined in the above (Item 6); R^e and R^f are the same as those defined in the above (Item 5); X is halogen atom; R is C_1-6 alkyl; LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyloxy (such as methanesulfonyloxy and p-toluenesulfonyloxy)).Step 6b-1: Preparation Step of Compound (6b-2)

Compound (6b-2) is also prepared from Compound (1b-3) and Compound (6b-1) according to the method described in Step 1b-2. As Compound (6b-1), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Step 6b-2: Preparation Step of Compound (6b-4)

Compound (6b-4) is prepared by reacting Compound (6b-2) with Compound (6b-3) in the presence of a base in a suitable inert solvent.

Examples of the base used herein include inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; metal alkoxides such as sodium methoxide and potassium tert-butoxide; and organic bases such as triethylamine, diisopropylethylamine, and pyridine.

Examples of the inert solvent used herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of −78° C. to 200° C., preferably the range of 0° C. to 180° C. The present step can be conducted under microwave irradiation, if necessary. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

Among groups of M², when a corresponding reagent is not commercially available, the amine can be prepared, for example, according to the method of Preparation 7 or 8.

Preparation 7

A compound of formula (7-4) is prepared, for example, by the following process:

wherein P is a protective group for amino group; LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyloxy (such as methanesulfonyloxy and p-toluenesulfonyloxy)); R⁸ is optionally-substituted partially-unsaturated C_3-7 carbocyclyl, optionally-substituted amino, optionally-substituted 5- or 6-membered heteroaryl, or optionally-substituted 4- to 7-membered partially-unsaturated heterocyclic ring; and Z is boronic acid, boronate, BF₃K, BF₃Na, or hydrogen atom.

Step 7-1: Preparation Step of Compound (7-3)

Compound (7-3) is prepared from Compound (7-1) and Compound (7-2) according to the method described in Step 1b-2. As Compound (7-1) and Compound (7-2), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Step 7-2: Preparation Step of Compound (7-4)

Compound (7-4) is prepared from Compound (7-3) by deprotection according to a known method (for example, Protective Groups in Organic Synthesis 3^rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, R. C. Laroque et al, VCH publisher Inc., 1989, etc.).

Preparation 8

A compound of formula (8-7) is prepared, for example, by the following process:

wherein R³ is the same as those defined in the above (Item 5); LG is a leaving group (for example, iodine atom, bromine atom, chlorine atom, and substituted sulfonyloxy (such as methanesulfonyloxy and p-toluenesulfonyloxy)); and P is a protective group for amino group.

Step 8-1: Preparation Step of Compound (8-3)

Compound (8-3) is prepared by reacting Compound (8-1) with Compound (8-2) in an inert solvent. As Compound (8-1) and compound (8-2), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the inert solvent include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; and mixed solvents thereof. Or, the reaction may be done without a solvent.

The reaction temperature is selected from, but not limited to, usually the range of 0° C. to 200° C., preferably the range of 40° C. to 150° C. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

Step 8-2: Preparation Step of Compound (8-5)

Compound (8-5) is prepared by reacting Compound (8-3) with Compound (8-4) in the presence of a base in a suitable inert solvent. As Compound (8-4), a commercial product or a product synthesized by common methods or corresponding methods thereof may be used.

Examples of the base used herein include organic bases such as triethylamine, diisopropylethylamine, pyridine, and 4-(dimethylamino)pyridine; inorganic bases such as potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, dipotassium phosphate, potassium phosphate, disodium phosphate, sodium phosphate, potassium hydroxide, sodium hydroxide, and sodium hydride; and metal alkoxides such as sodium methoxide and potassium tert-butoxide.

Examples of the inert solvent used herein include aprotic polar solvents such as dimethylformamide, N-methyl-2-pyrrolidinone, dimethylsulfoxide, acetonitrile, acetone, and methyl ethyl ketone; ether solvents such as diethyl ether, tetrahydrofuran, and 1,4-dioxane; halogenated hydrocarbon solvents such as chloroform and dichloromethane; aromatic hydrocarbon solvents such as benzene and toluene; alcohol solvents such as methanol, ethanol, 2-propanol, and tert-butanol; and mixed solvents thereof.

The reaction temperature is selected from, but not limited to, usually the range of −10° C. to 200° C., preferably the range of 0° C. to 40° C. The reaction time is usually 10 minutes to 48 hours, but it depends on conditions including reaction temperature, materials, and solvents which are used.

And, the present Step may also be done according to a known method (for example, European Journal of Organic Chemistry 2005, 3761.).

Step 8-3: Preparation Step of Compound (8-6)

Compound (8-6) is prepared from Compound (8-5) according to the method described in Step 1b-2.

Step 8-4: Preparation Step of Compound (8-7)

Compound (8-7) is prepared from Compound (8-6) by deprotection according to a known method (for example, Protective Groups in Organic Synthesis 3^rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, R. C. Laroque et al, VCH publisher Inc., 1989, etc.).

The compound of formula (1) having desired substituent(s) at desired positon(s) can be prepared by suitably combining the above-mentioned Preparations.

The intermediates and the desired compounds in the preparations described above can be isolated and purified by a method commonly-used in organic synthetic chemistry, for example, filtration, extraction, washing, drying, enrichment, crystallization, various chromatography, and the like, or a combination thereof. In addition, intermediates may be used in next reaction without further purification.

Starting compounds or intermediates described in the above-mentioned Preparations may be in salt form such as hydrochloride, depending on each reaction condition. In such case, they may be used in salt form itself or in free form. If starting compounds or intermediates are in salt form, and the salt form should be transformed to free form, it can be transformed to free form by dissolving or suspending it in an appropriate solvent and then neutralizing it with a base such as aqueous sodium bicarbonate.

The optical isomers can also be separated by common separation processes such as methods using an optically active column or fractional crystallization at an appropriate step of the above preparation processes. An optically active material can be used as a starting material.

In the case where a salt of a compound of formula (1) is needed, when the compound of formula (1) is obtained in a salt form, the salt can be obtained by purification of the obtained salt, and when the compound of formula (1) is obtained in a free form, the salt can be formed by dissolving or suspending the compound of formula (1) in an appropriate solvent, followed by addition of an acid or base.

The “tauopathy” used herein is a general term for a sporadic or familial pathology that tau protein is abnormally phosphorylated to be insoluble, and the phosphorylated tau is abnormally accumulated in cells. The “tauopathy” includes, for example, Alzheimer's disease (AD), Alzheimer-type dementia (ATD), dementia of Alzheimer's type (DAT), dementia in Alzheimer disease, major neurocognitive disorder due to Alzheimer's disease, diffuse neurofibrillary tangles with calcification (DNTC), amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam island (Guam ALS/PDC), amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula (Kii ALS/PDC), frontotemporal lobar degeneration (FTLD; such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain dementia (AGD), globular glial tauopathy (GGT) and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)), senile dementia of the neurofibrillary tangle type (SD-NFT), Down syndrome (DS), chronic traumatic encephalopathy (CTE), myotonic dystrophy (DM), Niemann-Pick disease type C (NPC), static encephalopathy of childhood with neurodegeneration in adulthood (SENDA), PLA2G6-associated neurodegeneration (PLAN), Gerstmann-Straussler-Scheinker disease (GSS), familial British dementia (FBD), familial Danish dementia (FDD), post-encephalitic Parkinsonism (PEP), subacute sclerosing panencephalitis (SSPE), and SLC9A6-related mental retardation, but should not be limited thereto. For example, when phosphorylated tau is abnormally accumulated in brain, the pathology may be within “tauopathy”. It may be determined that any two or more of these diseases are applicable at the same time, depending on the differences of Patient's condition and diagnostic method. And, a pathological condition in which two or more of these diseases coexist, that is, a combination of any two or more diseases of the above-mentioned diseases is also included in “tauopathy”. Characteristic inclusion bodies may be formed for each disease, and there are differences in the types of cells that accumulate, the isoforms of tau that accumulate, and the phosphorylation sites of tau. In neurodegenerative diseases associated with “tauopathy”, the accumulation of abnormally phosphorylated tau protein is thought to cause cerebral atrophy, cerebral dysfunction, etc.

The action of a compound on cognitive dysfunction of tauopathy can be evaluated by the method described in Test 3 described later. And, the effect of a compound on the accumulation of tau in tauopathy can be evaluated by the method described in Test 4 described later, and the effect of a compound on the accumulation of tau in tauopathy and cerebral atrophy can be evaluated by the method described in Test 5. A compound that is effective in any of Tests 3 to 5 can be expected to have a therapeutic and/or preventive effect on tauopathy.

The “Nav activator” and “Nav1.1 activator” can be used in combination with other drugs (hereinafter, optionally referred to as “concomitant drug”) prescribed for the purpose of enhancing the effect and/or reducing side effects and for various symptoms of various diseases. The concomitant drug includes, for example, another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, antiparkinsonian agent, antihypertensive drug, anti-inflammatory agent, antidiabetic drug, antihyperlipidemic drug, anti-obesity agent, antiemetic drug, a medicament for treating dysphagia, and a medicament for treating dysuria, cathartic drug. More preferably, it includes another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, and antiparkinsonian agent. The “another medicament for treating tauopathy” means any tauopathy therapeutic agent that is different from the Nav activator used.

The concomitant drug includes, for example, acetylcholinesterase inhibitors such as donepezil, NMDA inhibitors such as memantine, GABA signal enhancers such as valproic acid, SV2A ligands such as levetiracetam, and medicaments for treating partial seizure such as carbamazepine. And, the concomitant drug may include one or more medicament selected from the group consisting of atypical antipsychotic agent for behavioral and psychological symptoms of dementia (BPSD) such as quetiapine, risperidone, clozapine, and aripiprazole; selective serotonin reuptake inhibitor (SSRI) such as paroxetine, sertraline, and citalopram; serotonin antagonist reuptake inhibitor (SARI) such as trazodone; noradrenergic and specific serotonergic antidepressant (NaSSA) such as mirtazapine; serotonin 1A receptor agonist such as tandospirone; Chinese herbal drug such as yokukansan; and Parkinson's disease drug such as levodopa.

In an embodiment, the Nav activator may exhibit selective pharmacological action on some Nav subtypes, for example, one or more Nav subtypes selected from the group consisting of Nav1.1, Nav1.2, Nav1.3 and Nav1.6, and it may have a weak effect on other Nav subtypes such as Nav1.5. It can be expected that the Nav activator having a reduced action on Nav1.5 is highly safe with less concern about cardiotoxicity.

The “preventing” used herein means the act of administering a drug or a medicament to a healthy person who has not developed a disease, and is intended, for example, to prevent the onset or development of a disease. The “treating” used herein means the act of administering a drug or a medicament to a person, i.e., a patient who has been diagnosed by a doctor as being affected with a disease to improve the symptom, release the symptom, or inhibit the progress of disease.

The “therapeutically effective amount” used herein means the amount of a drug or medicament that elicits a biological or pharmaceutical response required by a researcher or physician in a tissue, system, animal or human.

A Nav activator may be administered directly via an appropriate route of administration, or administered in an appropriate dosage form after formulation.

As a route of administration, it is preferable to use the most effective route for treatment, which may vary depending on the embodiment of a Nav activator such as a small molecule compound, a peptide, and an antibody. The route of administration includes, for example, oral; and parenteral administration such as intravenous administration, application, inhalation, and eye drop. The route of administration is preferably oral administration.

The dosage form used herein may suitably vary depending on the embodiment of a Nav activator, which includes, for example, a tablet, a capsule, a powder, a granule, a liquid, a suspension, an injection, a patch, and a poultice. The dosage form is preferably a tablet.

The formulation into a dosage form or a pharmaceutical composition can be carried out according to common methods using pharmaceutically acceptable additives.

As a pharmaceutically acceptable additive, an excipient, a disintegrant, a binder, a fluidizer, a lubricant, a coating, a solubilizer, a solubilizing adjuvant, a thickener, a dispersant, a stabilizing agent, a sweetening agent, a flavor, and the like can be used, depending on a purpose. Specifically, examples of the pharmaceutically acceptable additive herein include lactose, mannitol, crystalline cellulose, low-substituted hydroxypropylcellulose, corn starch, partially-pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, and talc.

The amount and the frequency of administration of the dosage form or pharmaceutical composition comprising a Nav activator can be optionally determined depending on an embodiment of a Nav activator, a mode of administration, a disease of a patient or symptoms thereof, the age or weight of a patient, and the like. When the Nav activator is a small molecule compound, the amount of the active ingredient (herein, also referred to as “therapeutically effective amount”) per day can be usually administered to an adult in several portions in a day, preferably in one to three portions in a day, wherein the amount ranges from about 0.0001 to about 5000 mg, more preferably from about 0.001 to about 1000 mg, further preferably from about 0.1 to about 500 mg, especially preferably from about 1 to about 300 mg.

The timing to administer a Nav activator and a concomitant drug is not limited, and they may be administered to a subject needed in treatment concurrently or with a time lag. A Nav activator may be formulated as a combination medicament with a concomitant drug. The dose or mixing ratio of the concomitant drug can be optionally selected depending on an embodiment of a Nav activator, a subject to be administered, a route of administration, a targeted disease, symptoms, and combination thereof, on the basis of the doses in the clinical use. For example, when the subject for administration is a human and the Nav activator is a small molecule compound, the concomitant drug for combination use may be used in 0.01 to 100 parts by weight to 1 part by weight of the Nav activator.

EXAMPLES

The present invention is explained in more detail in the following by referring to Reference examples, Examples, and Tests; however, the present invention is not limited thereto. The names of compounds in the following Reference examples and Examples do not necessarily conform to the IUPAC nomenclature.

In the present specification, the abbreviations shown below may be used.

• CDCl₃: deuterated chloroform
• DMSO-d₆: deuterated dimethylsulfoxide
• Rt: retention time
• min: minute(s)
• HATU: O-(7-aza-1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
• THF: tetrahydrofuran
• TFA: trifluoroacetic acid
• DMF: N,N-dimethylformamide
• Boc: tert-butoxycarbonyl
• Tf: trifluoromethanesulfonyl
• Cbz: benzyloxycarbonyl
• Ph: phenyl
• WSC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

Physicochemical data of each compound in Examples and Reference examples were obtained with the following apparatus:

¹H-NMR: JEOL JNM-AL400; JEOL JNM-ECS400; Brucker AVANCE 400 Spectrometer

Symbols used in NMR are defined as follows: s for singlet, d for doublet, dd for doublet of doublets, t for triplet, td for triplet of doublets, dt for doublet of triplets, q for quartet, m for multiplet, br for broad singlet or multiplet, and J for coupling constant.

LC/MS data of each compound in Examples and Reference examples were obtained with any one of the following apparatuses:

Method A

Detection apparatus: ACQUITY™ SQ deteceter (Waters Corporation)

HPLC: ACQUITY™ UPLC SYSTEM

Column: Waters ACQUITY™ UPLC BEH C18 (1.7 μm, 2.1 mm×30 mm)

Method B

Detection apparatus: Shimadzu LCMS-2020Column: Phenomenex Kinetex (C18, 1.7 μm, 2.1 mm×50 mm)

Method C

Detection apparatus: Agilent 6110 Quadropole LC/MSHPLC: Agilent 1200 seriesColumn: XBridge C18 (3.5 μm, 4.6 mm×50 mm)

Method D

Detection apparatus: ACQUITY™ SQ detector (Waters

Corporation)

HPLC: ACQUITY™ UPLC SYSTEM

Column: Waters ACQUITY™ UPLC BEH C18 (1.7 μm, 2.1 mm×30 mm)

High performance liquid chromatograph-mass spectrometer; Measurement conditions for LC/MS are shown below, observed values of mass spectrometry [MS(m/z)] are shown in MH⁺, and retention times are shown in Rt (minutes). In each observed value, measurement conditions used for the measurement are described as any one of A to D.

Method A

Solvents: Solution A; 0.06% formic acid/H₂O, Solution B; 0.06% formic acid/acetonitrileGradient condition: 0.0 to 1.3 minutes (linear gradient of B from 2% to 96%)Flow rate: 0.8 mL/min; Detection UV: 220 nm and 254 nm;

Temperature: 40° C.

Method B

Solvents: Solution A; 0.05% TFA/H₂O, Solution B; acetonitrileGradient condition: 0.0 to 1.7 minutes (linear gradient of B from 10% to 99%)Flow rate: 0.5 mL/min; Detection UV: 220 nm; Temperature: 40° C.

Method C

Solvents: Solution A; 10 mM NH₄HCO₃/H₂O, Solution B; acetonitrileGradient condition: 0.0 to 0.2 minutes (5% B), 0.2 to 1.5 minutes (linear gradient of B from 5% to 95%), 1.5 to 2.8 minutes (95% B)Flow rate: 1.8 mL/min; Detection UV: 214 nm and 254 nm; Temperature 50° C.

Method D

Solvents: Solution A; 0.05% formic acid/H₂O, Solution B; acetonitrileGradient condition: 0.0 to 1.3 minutes (linear gradient of B from 10% to 95%), 1.3 to 1.5 minutes (10% B)Flow rate: 0.8 mL/min; Detection UV: 220 nm and 254 nm;

Temperature: 40° C.

Reference Example 1

2-Chloro-N-(4-cyanophenyl) acetamide

To a suspension of 4-aminobenzonitrile (25.2 g) and potassium carbonate (35.4 g) in acetone (200 ml) was added dropwise 2-chloroacetyl chloride (28.9 g) at 0° C., and the mixture was heated under reflux for 2 hours. After cooling to room temperature, the reaction mixture was poured slowly into water (400 ml), resulting in precipitation of a solid. The precipitated solid was filtered, washed with water, and dried under reduced pressure to obtain the titled compound (35.0 g).

¹H-NMR (400 MHz, DMSO-d₆) δ: 10.71 (s, 1H), 7.80 (d, J=9.2 Hz, 2H), 7.76 (d, J=9.2 Hz, 2H), 4.30 (s, 2H).

Reference Example 2

6-(4-Methylpiperidin-1-yl)pyridazin-3(2H)-one

To a solution of 3,6-dichloropyridazine (34.3 g) in dimethylformamide (288 mL) were added 4-methylpiperidine (27.4 g) and triethylamine (48.1 mL). The reaction mixture was stirred at 80° C. for 8 hours, and concentrated under reduced pressure. After the addition of saturated aqueous sodium bicarbonate (200 mL) and water (200 mL) thereto, the mixture was extracted twice with ethyl acetate. The obtained organic layers were combined, dried over sodium sulfate, and concentrated. The residue was dissolved in acetic acid (460 mL), and the mixture was heated under reflux for 37 hours. The reaction mixture was cooled to room temperature, and then concentrated under reduced pressure. To the residue were added 10% aqueous sodium hydroxide (300 mL) and diethyl ether (150 mL), resulting in precipitation of a solid. The precipitated solid was filtered, washed sequentially with water, diethyl ether, and ethyl acetate, and dried under reduced pressure to obtain the titled compound (31.6 g).

¹H-NMR (400 MHz, CDCl₃) δ: 7.17 (d, J=10.5 Hz, 1H), 6.83 (d, J=10.1 Hz, 1H), 3.73 (dt, J=12.9, 2.4 Hz, 2H), 2.71 (td, J=12.6, 2.6 Hz, 2H), 1.72-1.65 (m, 2H), 1.59-1.47 (m, 1H), 1.25 (dd, J=12.3, 4.1 Hz, 1H), 1.19 (dd, J=12.1, 4.3 Hz, 1H), 0.95 (d, J=6.4 Hz, 3H).

Reference Example 3

2-(3-Chloro-6-oxopyridazin-1(6H)-yl)-N-(4-cyanophenyl)acetamide

To a solution of the compound of Reference example 1 (16.7 g) in dimethylformamide (240 mL) were added potassium carbonate (23.7 g) and 6-chloropyridazin-3(2H)-one (14.8 g). After stirring at room temperature for 6 hours, water (360 mL) was added to the mixture, resulting in precipitation of a solid, and the precipitated solid was filtered. After washing with water, the solid was dried under reduced pressure to obtain the titled compound (18.4 g).

¹H-NMR (400 MHz, DMSO-d₆) δ: 10.78 (s, 1H), 7.79 (dt, J=8.8, 2.1 Hz, 2H), 7.73 (dt, J=9.0, 2.1 Hz, 2H), 7.64 (d, J=9.6 Hz, 1H), 7.11 (d, J=10.1 Hz, 1H), 4.90 (s, 2H).

Reference Example 4

2-(4,4-Difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

a) To a solution of 4,4-difluorocyclohexanone (25.0 g) in 1,2-dichloroethane (373 mL) were added 2-chloropyridine (26.5 g) and trifluoromethanesulfonic anhydride (63.1 g), and the mixture was stirred at 50° C. for 6 hours. After cooling to 0° C., hexane (750 mL) was added thereto, resulting in precipitation of a solid, and the precipitated solid was filtered out. The filtrate was concentrated under reduced pressure to obtain Compound 1A (46.1 g).

¹H-NMR (400 MHz, CDCl₃) δ: 5.67-5.63 (m, 1H), 2.69 (td, J=13.5, 2.9 Hz, 2H), 2.60-2.55 m, 2H), 2.24-2.14 (m, 2H).

b) To a solution of Compound 1A (46.1 g) and bis(pinacolato)diboron (52.8 g) in 1,4-dioxane (577 mL) were added potassium acetate (42.5 g) and 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride (6.34 g), and the mixture was heated under reflux for 2 hours. After cooling to room temperature, the mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. After the addition of ethyl acetate (1.5 L), the organic layer was washed with water (300 mL) and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; hexane:ethyl acetate=100:0, then 90:10) to obtain the titled compound (39.8 g).

¹H-NMR (400 MHz, CDCl₃) δ: 6.37-6.35 (m, 1H), 2.60-2.50 (m, 2H), 2.41-2.36 (m, 2H), 2.00-1.89 (m, 2H), 1.24 (s, 12H).

Reference Example 5

6-(4,4-Dimethylcyclohexyl)pyridazin-3 (2H)-one

a) 6-Chloropyridazin-3 (2H)-one (497 mg), 2-(4,4-dimethylcyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (900 mg), and 2 mol/L aqueous sodium carbonate (4.76 mL) were suspended in 1,2-dimethoxyethane (17 mL). To the mixture was added 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride (279 mg). The mixture was stirred under nitrogen atmosphere at 80° C. for 6 hours. After cooling to room temperature, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform:methanol=99:1, then 93:7) to obtain Compound 2A (88 mg).

¹H-NMR (400 MHz, DMSO-d₆) δ: 7.80 (d, J=10.1 Hz, 1H), 6.80 (d, J=9.6 Hz, 1H), 6.43-6.40 (m, 1H), 2.35-2.30 (m, 2H), 1.98 (dt, J=4.1, 1.8 Hz, 2H), 1.42 (t, J=6.4 Hz, 2H), 0.91 (s, 6H).

b) A suspension of Compound 2A (88 mg) and 10% palladium/carbon (20 mg) in methanol (20 mL) was stirred under hydrogen atmosphere at room temperature for 10 hours. Pd/C was filtered through Celite, and the filtrate was washed with methanol. The filtrate was concentrated to obtain the titled compound (89 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 10.66 (s, 1H), 7.19 (d, J=10.1 Hz, 1H), 6.89 (d, J=9.6 Hz, 1H), 2.42 (tt, J=11.8, 4.0 Hz, 1H), 1.71-1.67 (m, 2H), 1.63-1.55 (m, 2H), 1.52-1.45 (m, 2H), 1.27 (td, J=12.3, 4.0 Hz, 2H), 0.93 (s, 3H), 0.92 (s, 3H).

Reference Example 6

[3-(4-Methylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl]acetic acid

a) The compound of Reference example 2 (2.5 g), methyl bromoacetate (2.8 g), and potassium carbonate (3.6 g) in dimethylformamide (26 mL) were stirred at room temperature for 2.5 hours. After the addition of saturated aqueous ammonium chloride, the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=30:70) to obtain Compound 3A (3.2 g).

¹H-NMR (400 MHz, CDCl₃) δ: 7.16 (d, J=10.1 Hz, 1H), 6.84 (d, J=10.1 Hz, 1H), 4.75 (s, 2H), 3.77-3.74 (m, 2H), 3.76 (s, 3H), 2.71 (td, J=12.5, 2.4 Hz, 2H), 1.69 (d, J=12.5 Hz, 2H), 1.59-1.48 (m, 1H), 1.28-1.18 (m, 2H), 0.96 (d, J=6.4 Hz, 3H).

b) Compound 3A (3.2 g) was dissolved in a mixed solvent of methanol (20 mL) and THF (20 mL), and 2 mol/L aqueous sodium hydroxide (30 mL) was added thereto with ice cooling. Then, the mixture was stirred at room temperature for 30 minutes. The organic solvent of the reaction solution was removed under reduced pressure, and to the resulting aqueous layer was added 1 mol/L hydrochloric acid to adjust pH to 3, resulting in precipitation of a solid. The precipitated solid was filtered, washed with water, and dried under reduced pressure to obtain the titled compound (3.0 g).

¹H-NMR (400 MHz, CD₃OD) δ: 7.50 (d, J=10.1 Hz, 1H), 6.86 (d, J=10.1 Hz, 1H), 4.72 (s, 2H), 3.92-3.88 (br, 2H), 2.76 (td, J=12.7, 2.6 Hz, 2H), 1.73-1.68 (br, 2H), 1.64-1.51 (m, 1H), 1.23 (ddd, J=24.4, 12.7, 3.9 Hz, 2H), 0.97 (d, J=6.4 Hz, 3H).

Reference Example 7

4-(4-Methylphenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one

a) To a solution of 4,5,6,7-tetrahydroisobenzofuran-1,3-dione (5.0 g) in tetrahydrofuran (329 mL) was added dropwise a solution of p-tolylmagnesium bromide in tetrahydrofuran (32.9 mL), and the mixture was stirred at room temperature for 23 hours. To the reaction mixture was added 1 mol/L hydrochloric acid, resulting in precipitation of a solid, and the precipitated solid was filtered and washed with water. The resulting solid was purified by silica gel column chromatography (solvent; chloroform:methanol=9:1) to obtain Compound 4A (10.7 g).

¹H-NMR (400 MHz, CDCl₃) δ: 7.40-7.31 (m, 2H), 7.15 (d, J=8.5 Hz, 2H), 2.42-2.20 (m, 6H), 1.98-1.43 (m, 5H).

b) To a solution of Compound 4A (7.61 g) in ethanol (156 mL) was added hydrazine monohydrate (3.03 mL), and the mixture was heated under reflux for 5 hours. After cooling to room temperature, saturated aqueous sodium bicarbonate was added thereto, and the ethanol was removed by concentration under reduced pressure, resulting in precipitation of a solid. The precipitated solid was filtered, washed with water, and dried under reduced pressure to obtain the titled compound (6.22 g).

¹H-NMR (400 MHz, CDCl₃) δ: 10.42 (s, 1H), 7.26-7.25 (m, 2H), 7.23-7.21 (m, 2H), 2.64-2.62 (m, 2H), 2.40-2.37 (m, 5H), 1.79-1.77 (m, 2H), 1.68-1.65 (m, 2H).

Reference Example 8

6-(2-Azaspiro[4.4]nonan-2-yl)-4-methylpyridazin-3 (2H)-one

Reference Example 9

6-(2-Azaspiro[4.4]nonan-2-yl)-5-methylpyridazin-3 (2H)-one

a) To a solution of 3,6-dichloro-4-methylpyridazine (0.40 g) in dimethylformamide (4 mL) was added 2-azaspiro[4.4]nonane (0.31 g) and triethylamine (1.03 mL). The reaction mixture was stirred at 80° C. for 6 hours. After the addition of saturated aqueous sodium bicarbonate (20 mL) and water (20 mL), the mixture was extracted twice with ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=90:10, and then 30:70) to obtain Compound 5A (250 mg) and Compound 5B (260 mg).

b) Compound 5A was dissolved in acetic acid (3 mL), and the reaction mixture was subjected to microwave irradiation and stirred at 200° C. for 2 hours. The reaction mixture was cooled to room temperature, and toluene was added thereto. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography (solvent; chloroform:methanol=100:0, then 98:2) to obtain 6-(2-azaspiro[4.4]nonan-2-yl)-4-methylpyridazin-3(2H)-one (220 mg).

LC-MS: [M+H]⁺/Rt (min) 234.2/0.832 (Method A)

Similarly, 6-(2-azaspiro[4.4]nonan-2-yl)-5-methylpyridazin-3(2H)-one (195 mg) was obtained from Compound 5B.

LC-MS: [M+H]⁺/Rt (min) 234.2/0.839 (Method A)

Reference Example 10

6-(6-Azaspiro[3.4]octan-6-yl)-4-methoxypyridazin-3 (2H)-one

a) To a solution of 6-chloro-3,4-dimethoxypyridazine (0.25 g) in toluene (2.5 mL) were added 6-azaspiro[3.4]octane (0.23 g), potassium tert-butoxide (0.14 g), and 2,2′-bis(biphenylphosphino)-1,1′-binaphthalene (6.4 mg). The reaction mixture was subjected to microwave irradiation, and stirred at 80° C. for one hour. After the reaction mixture was cooled to room temperature, water (20 mL) was added thereto, and the mixture was extracted twice with ethyl acetate. The combined organic layer was dried over sodium sulfate, and then concentrated. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=90:10, then 15:85) to obtain Compound 6A (44 mg). LC-MS: [M+H]⁺/Rt (min) 250.2/0.506 (Method A)

b) Compound 6A (80 mg) was dissolved in dioxane (500 μL) and concentrated hydrochloric acid (2 mL). The reaction mixture was subjected to microwave irradiation, and stirred at 100° C. for 2 hours. The reaction mixture was cooled to room temperature, and then concentrated under reduced pressure. The residue was poured into water, resulting in precipitation of a solid, and the precipitated solid was filtered to obtain the titled compound (53 mg).

LC-MS: [M+H]⁺/Rt (min) 236.2/0.527 (Method A)

Reference Example 11

1,1-Difluoro-4,4-dimethyl-6-azaspiro[2.5]octane hydrochloride

a) To a solution of tert-butyl 3,3-dimethyl-4-methylidenepiperidine-1-carboxylate (4.6 g) in tetrahydrofuran (29.2 mL) were added (trifluoromethyl)trimethylsilane (10.54 ml) and sodium iodide (1.53 g), and the mixture was heated under reflux for 33 hours. To the reaction mixture was added heptane (10 ml), and the mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate. The organic layer was washed with water, saturated aqueous sodium thiosulfate, and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=95:5, and then 75:25) to obtain Compound 7A (4.2 g).

¹H-NMR (400 MHz, CDCl₃) δ: 3.87 (br s, 1H), 3.43 (br s, 1H), 3.06-2.99 (m, 1H), 2.87-2.83 (m, 1H), 1.97-1.90 (m, 1H), 1.46 (s, 9H), 1.44-1.40 (m, 1H), 1.31-1.23 (m, 1H), 1.06 (s, 3H), 0.92-0.86 (m, 4H).

b) Compound 7A (4.2 g) was dissolved in cyclopentyl methyl ether (10 ml). To the mixture was added a solution of hydrogen chloride in cyclopentyl methyl ether (18.5 mL), and the mixture was stirred for 5 hours, resulting in precipitation of a solid. The precipitated solid was filtered, and dried to obtain the titled compound (3.71 g).

¹H-NMR (400 MHz, DMSO-d₆) δ: 9.59 (s, 1H), 8.96 (s, 1H), 3.16-3.12 (m, 1H), 2.94-2.91 (m, 1H), 2.88-2.70 (m, 2H), 2.09-2.02 (m, 1H), 1.70-1.64 (m, 1H), 1.46-1.40 (m, 1H), 1.32-1.26 (m, 1H), 1.17 (s, 3H), 0.89 (s, 3H).

Reference Example 12

7-Chloro-2-methyl-1,3-benzoxazole-5-amine

a) To a solution of 2-amino-6-chloro-4-nitrophenol (0.5 g) in DMF (15 mL) were added triethyl orthoacetate (1.72 g) and p-toluenesulfonic acid (0.23 g), and the mixture was stirred at 70° C. for 4 hours. To the reaction mixture was added saturated aqueous sodium bicarbonate, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvents; hexane:ethyl acetate=80:20) to obtain Compound 8A (0.37 g).

¹H-NMR (400 MHz, CDCl₃) δ: 8.46 (d, J=1.8 Hz, 1H), 8.30 (d, J=2.4 Hz, 1H), 2.75 (s, 3H).

b) Compound 8A (62.5 mg) was dissolved in a mixed solvent of methanol (4 ml) and water (1 ml), and reduced iron (164 mg) and ammonium chloride (157 mg) were added thereto. The mixture was stirred at 70° C. for 2 hours. Insoluble substances were filtered out through Celite, and the organic layer was concentrated. The residue was dissolved again in ethyl acetate. The mixture was washed with water and brine, and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the titled compound (43.7 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 6.81 (d, J=2.1 Hz, 1H), 6.66 (d, J=1.8 Hz, 1H), 3.69 (br s, 2H), 2.61 (s, 3H).

Reference Example 13

[1,2,4]Triazolo[1,5-a]pyridine-7-amine dihydrochloride

a) A solution of 7-bromo[1,2,4]triazolo[1,5-a]pyridine (975 mg), tert-butyl carbamate (865 mg), sodium t-butoxide (710 mg), [(2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (196 mg) in toluene (33 mL) was stirred at 100° C. for 2 hours. To the reaction mixture was added water, and the mixture was extracted with a mixed solvent of chloroform and ethanol (3:1). The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by amino silica gel column chromatography (solvent; hexane:ethyl acetate=75:25, and then ethyl acetate) to obtain the titled compound 9A (780 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 8.43 (d, J=7.3 Hz, 1H), 8.23 (s, 1H), 7.70 (d, J=2.4 Hz, 1H), 7.18 (dd, J=7.3, 2.4 Hz, 1H), 6.79 (s, 1H), 1.52 (s, 9H).

b) Compound 9A (780 mg) was suspended in ethyl acetate (3 ml), and a solution of hydrogen chloride in dioxane (16 ml) was added thereto. The mixture was stirred at 40° C. for 3 hours. The reaction mixture was concentrated under reduced pressure, and the following steps were repeated twice: toluene was added thereto, and the mixture was concentrated under reduced pressure. To the residue was added ethyl acetate, and the mixture was stirred, and then filtered to obtain the titled compound (499 mg).

¹H-NMR (400 MHz, CD₃OD) δ: 8.71 (s, 1H), 8.54 (d, J=7.3 Hz, 1H), 6.90 (dd, J=7.3, 2.1 Hz, 1H), 6.71 (d, J=2.1 Hz, 1H).

Reference Example 14

4-(Morpholin-4-yl)-2,3-dihydro-1H-indole dihydrochloride

a) A solution of tert-butyl 4-bromo-2,3-dihydro-1H-indole-1-carboxylate (1.55 g), morpholine (1.81 g), tris(dibenzylideneacetone)dipalladium(0) (0.48 g), (R)-(+)-2,2′-bis(diphenylphosphino)-1,1-binaphthyl (0.324 g), and sodium t-butoxide (0.999 g) in toluene (17.3 mL) was stirred at 100° C. for 2 hours. Insoluble substances were filtered out through Celite, and the organic layer was concentrated. To the residue was added saturated aqueous ammonium chloride, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=80:20) to obtain Compound 10A (1.07 g).

LC-MS: [M+H]⁺/Rt (min) 305.2/1.984 (Method B)

b) Compound 10A (1.07 g) was dissolved in ethyl acetate (15 ml), and a solution of hydrogen chloride in ethyl acetate (15 ml) was added thereto. The mixture was stirred at room temperature for 20 hours, and concentrated under reduced pressure. To the residue was added ethyl acetate, and the mixture was filtered to obtain the titled compound (0.92 g).

¹H-NMR (400 MHz, CD₃OD) δ: 7.48 (t, J=8.2 Hz, 1H), 7.27 (t, J=7.9 Hz, 2H), 3.94-3.92 (m, 4H), 3.87 (t, J=7.6 Hz, 2H), 3.41 (t, J=7.3 Hz, 2H), 3.26-3.24 (m, 4H).

Reference Example 15

4-(Pyridazin-4-yl)-2,3-dihydro-1H-indole hydrochloride

a) A solution of tert-butyl 4-bromo-2,3-dihydro-1H-indole-1-carboxylate (2.62 g), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridazine (2.17 g), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (0.62 g), 2 mol/L aqueous potassium acetate (13 ml) in acetonitrile (35 mL) was stirred at 90° C. for 4 hours. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate, and then ethyl acetate:methanol=95:5) to obtain Compound 11A (2.30 g).

LC-MS: [M+H]⁺/Rt (min) 298.2/0.891 (Method A)

b) Compound 11A (2.30 g) was dissolved in chloroform (35 ml). After the addition of a solution of hydrogen chloride in ethyl acetate (4 mol/L, 35 ml), the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, and the following steps were repeated twice: toluene was added to the mixture, and the mixture was concentrated under reduced pressure to obtain the titled compound (1.8 g).

LC-MS: [M+H]⁺/Rt (min) 198.2/0.333 (Method A)

Reference Example 16

[3-(4-Methylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl] acetic acid

a) According to the method of a) in Reference example 6, Compound 12A (49.4 g) was obtained using 6-chloropyridazin-3(2H)-one (44.0 g).

¹H-NMR (400 MHz, DMSO-d₆) δ: 7.64 (d, J=9.8 Hz, 1H), 7.13 (d, J=9.8 Hz, 1H), 4.85 (s, 2H), 3.69 (s, 3H).

b) A solution of Compound 12A (2.15 g), 4,4,5,5-tetramethyl-2-(4-methylcyclohex-1-en-1-yl)-1,3,2-dioxaborolane (3.06 g) and 2 mol/L aqueous potassium acetate (15.92 mL) was suspended in acetonitrile (140 mL), and bis(di-tert-butyl (4-dimethylaminophenyl)phosphine)dichloropalladium(II) (301 mg) was added thereto. The mixture was stirred under a nitrogen atmosphere at 90° C. for 5 hours. After cooling to room temperature, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=90:10, and then 70:30) to obtain Compound 12B (2.40 g).

LC-MS: [M+H]⁺/Rt (min) 263.2/0.935 (Method A)

c) According to the method of b) in Reference example 6, the titled compound (1.5 g) was obtained using Compound 12B (2.40 g).

LC-MS: [M+H]⁺/Rt (min) 249.2/0.835 (Method A)

Reference Example 17

2-(Trifluoromethyl)imidazo[1,2-a]pyridine-7-amine

Pyridine-2,4-diamine (300 mg) and sodium bicarbonate (462 mg) was suspended in ethanol (9.1 mL), and 3-chloro-1,1,1-trifluoropropan-2-one was added thereto. The mixture was heated under reflux for 4 hours. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted with a mixed solvent of chloroform and ethanol (3:1). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by amino silica gel column chromatography (solvent; hexane:ethyl acetate=50:50, and then ethyl acetate) to obtain the titled compound (250 mg).

LC-MS: [M+H]⁺/Rt (min) 202.1/0.344 (Method A)

Reference Example 18

7-Fluoro-1,3-benzoxazole-5-amine

a) 2-Amino-6-fluoro-4-nitrophenol (507 mg) and triethoxymethane (0.98 mL) were dissolved in chloroform (14.7 mL) and acetic acid (0.68 mL). The mixture was heated under reflux for 5 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=83:17, and then 75:25) to obtain Compound 13A (330 mg).

LC-MS: [M+H]⁺/Rt (min) 183.0/0.749 (Method A)

b) Compound 13A (330 mg) was dissolved in methanol (9.0 mL) and palladium/carbon (96 mg) was added thereto. The mixture was stirred at room temperature for 3 hours. Insoluble substances were filtered through Celite, and the organic layer was concentrated to obtain the titled compound (268 mg).

LC-MS: [M+H]⁺/Rt (min) 153.0/0.445 (Method A)

Reference Example 19

2-(Difluoromethyl)-1,3-benzoxazole-5-amine

a) 2-Amino-4-nitrophenol (300 mg), triethylamine (1.36 mL), triphenylphosphine (1.28 g), and difluoroacetic acid (0.12 mL) were dissolved in carbon tetrachloride (6.5 mL), and the mixture was heated under reflux for 3 hours. After cooling to room temperature, to the reaction mixture was added water, and the mixture was extracted with a mixed solvent of chloroform and methanol (10:1). The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvate; hexane:ethyl acetate=75:25, and then ethyl acetate) to obtain Compound 14A (331 mg).

LC-MS: [M+H]⁺/Rt (min) 215.1/0.850 (Method A)

b) According to the method of b) in Reference example 18, the titled compound (268 mg) was obtained using Compound 14A (330 mg).

LC-MS: [M+H]⁺/Rt (min) 185.1/0.505 (Method A)

Reference Example 20

7-Fluoro-2-methoxy-1,3-benzoxazole-5-amine

a) According to the method of a) in Reference example 18, Compound 15A (318 mg) was obtained by using 2-amino-6-fluoro-4-nitrophenol (303 mg) and tetramethyl orthocarbonate (0.47 mL).

LC-MS: [M+H]⁺/Rt (min) 213.1/0.843 (Method A)

b) According to the method of b) in Reference example 18, the titled compound (248 mg) was obtained by using Compound 120A (318 mg).

LC-MS: [M+H]⁺/Rt (min) 183.0/0.517 (Method A)

Reference Example 21

2-Methyl[1,3]thiazolo[5,4-b]pyridine-6-amine

a) 2-Chloro-3,5-dinitropyridine (300 mg) was dissolved in sulfolane (9.8 mL), and thioacetamide (1.48 g) was added thereto. The mixture was heated under reflux at 110° C. for 3 hours. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=90:10, and then 75:25) to obtain Compound 16A (0.23 g).

LC-MS: [M+H]⁺/Rt (min) 196.1/0.667 (Method A)

b) Compound 16A (177 mg) was dissolved in ethanol (3.8 mL), and water (1.3 mL), ammonium chloride (485 mg), and reduced iron (253 mg) were added thereto. The mixture was heated under reflux for 3 hours. Insoluble substances were filtered through Celite, and the organic layer was concentrated under reduced pressure. To the residue was added saturated aqueous sodium bicarbonate, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the titled compound (97 mg).

LC-MS: [M+H]⁺/Rt (min) 166.0/0.423 (Method A)

Reference Example 22

2-(5-Amino-1,3-benzoxazol-2-yl)propan-2-ol

Methyl 5-amino-1,3-benzoxazole-2-carboxylate (200 mg) and cerium(III) chloride (1.03 g) were dissolved in tetrahydrofuran (6.9 mL). While stirring at 0° C., 3 mol/L methylmagnesium bromide (1.39 ml) was added thereto, and the mixture was stirred at 0° C. for 2 hours. To the reaction mixture was added saturated aqueous ammonium chloride, and the mixture was extracted with chloroform. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate, and then ethyl acetate:methanol=96:4) to obtain the titled compound (10.0 mg).

LC-MS: [M+H]⁺/Rt (min) 193.1/0.317 (Method A)

Reference Example 23

1-(5-Methoxy-2-methylpyridin-3-yl)piperazine trihydrochloride

a) 1-Boc-piperazine (277 mg), tris(dibenzylidene-acetone)dipalladium(0) (91 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (172 mg), and sodium t-butoxide (190 mg) were suspended in toluene (10 ml). 3-Bromo-5-methoxy-2-methylpyridine (200 mg) was added thereto, and the mixture was stirred at 70° C. for one hour. After cooling to room temperature, ethyl acetate was added to the reaction mixture. Insoluble substances were filtered through Celite, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=70:30, and then 50:50) to obtain Compound 17A (296 g).

¹H-NMR (400 MHz, CDCl₃) δ: 7.94 (d, J=2.4 Hz, 1H), 6.86 (d, J=2.4 Hz, 1H), 3.84 (s, 3H), 3.60-3.57 (m, 4H), 2.86-2.84 (m, 4H), 2.48 (s, 3H), 1.49 (s, 9H).

b) Compound 17A (296 mg) was dissolved in methanol (5 mL), and 2 mol/L solution of hydrogen chloride in methanol (9.6 mL) was added thereto while stirring at 0° C. The mixture was stirred at 50° C. for 3 hours. After cooling to room temperature, the precipitated solid was filtered, and the resulting solid was dried under reduced pressure to obtain the titled compound (271.7 mg).

¹H-NMR (400 MHz, CD₃OD) δ: 8.16 (d, J=2.4 Hz, 1H), 7.83 (d, J=2.4 Hz, 1H), 4.03 (s, 3H), 3.47-3.45 (m, 4H), 3.37-3.35 (m, 4H), 2.68 (s, 3H).

Reference Example 24

(2R,6S)-2,6-Dimethyl-1-(pyridin-3-yl)piperazine trihydrochloride

a) 0.5 mol/L Potassium hexamethyldisilazide (2.57 ml), tert-butyl (3R,5S)-3,5-dimethylpiperazine-1-carboxylate (250 mg), and 3-bromopyridine (184 mg) were suspended in 1,4-dioxane (10 ml), and the mixture was stirred at 100° C. for 8 hours. After cooling to room temperature, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=80:20, and then 40:60) to obtain Compound 18A (114 mg).

LC-MS: [M+H]⁺/Rt (min) 292.0/0.689 (Method A)

b) According to the method of b) in Reference example 15, the titled compound (75 mg) was obtained by using Compound 18A (114 mg).

LC-MS: [M+H]⁺/Rt (min) 192.2/0.149 (Method A)

Reference Example 25

4-[(Morpholin-4-yl)methyl]-2,3-dihydro-1H-indole

a) 2,3-Dihydro-1H-indole-4-carbaldehyde (147 mg) was dissolved in dichloromethane (2 ml), and morpholine (88 mg) and sodium triacetoxyborohydride (322 mg) were added thereto. The mixture was stirred at room temperature for 4 hours. To the reaction mixture was added saturated aqueous sodium bicarbonate, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to obtain Compound 19A (209 mg).

LC-MS: [M+H]⁺/Rt (min) 217.2/0.292 (Method A)

b) Compound 19A (209 mg) were dissolved in acetic acid (3 ml), and sodium cyanoborohydride (182 mg) was added thereto, and the mixture was stirred at room temperature for 4 hours. The mixture was concentrated under reduced pressure, and the following steps were repeated twice: toluene was added thereto, and the mixture was concentrated under reduced pressure. To the residue was added saturated aqueous sodium bicarbonate, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to obtain the titled compound (256 mg).

LC-MS: [M+H]⁺/Rt (min) 219.2/0.131 (Method A)

Reference Example 26

4-[(¹H-Imidazol-1-yl)methyl]-2,3-dihydro-1H-indole hydrochloride

a) (2,3-Dihydro-1H-indol-4-yl)methanol (0.92 g) was dissolved in tetrahydrofuran (2 ml), and di-tert-butyl dicarbonate (1.48 g) was added thereto. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, resulting in precipitation of a solid, and the resulting residue was purified by silica gel column chromatography (solvent; hexane, and then hexane:ethyl acetate=70:30) to obtain Compound 20A (1.54 g).

LC-MS: [M+H-tBu]⁺/Rt (min) 194.1/0.866 (Method A)

b) Compound 20A (1.54 g) was dissolved in dichloromethane (20 ml), and thionyl chloride (0.57 ml) was added thereto while stirring at 0° C. The mixture was warmed to room temperature, and stirred overnight. The reaction mixture was concentrated under reduced pressure, and the following steps were repeated twice: toluene was added thereto, and the mixture was concentrated under reduced pressure to obtain Compound 20B (1.65 g).

LC-MS: [M+H-tBu]⁺/Rt (min) 212.1/1.169 (Method A)

c) Compound 20B (200 mg) was dissolved in dimethylformamide (3 ml), and imidazole (2.5 g) was added thereto. The mixture was stirred at 80° C. for 2 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate, and then ethyl acetate:methanol=95:5) to obtain Compound 20C (80 mg).

LC-MS: [M+H]⁺/Rt (min) 300.3/0.683 (Method A)

d) Compound 20C (80 mg) were dissolved in chloroform (3 ml), and a solution of hydrogen chloride in ethyl acetate (0.54 mL) were added thereto. The reaction mixture was stirred at room temperature for one hour, and concentrated under reduced pressure. The following steps were repeated twice: to the residue was added toluene, and the mixture was concentrated to obtain the titled compound (53 mg).

LC-MS: [M+H]⁺/Rt (min) 200.1/0.115 (Method A)

Reference Example 27

Methyl (3-chloro-5-methyl-6-oxopyridazin-1(6H)-yl)acetate

Reference Example 28

Methyl (3-chloro-4-methyl-6-oxopyridazin-1(6H)-yl)acetate

3,6-Dichloro-4-methylpyridazine (650 mg) was dissolved in acetic acid (6 mL), and the reaction mixture was subjected to microwave irradiation, and stirred at 200° C. for 2 hours. After cooling to room temperature, the following steps were repeated three times: toluene was added thereto, and the mixture was concentrated under reduced pressure. The residue was dissolved in dimethylformamide (3 mL), and methyl bromoacetate (855 mg) and potassium carbonate (1.10 g) were added thereto. The mixture was stirred at room temperature overnight. After the addition of saturated aqueous ammonium chloride, the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=90:10, and then 25:75) to obtain the compound of Reference example 27 (374 mg) and the compound of Reference example 28 (190 mg), respectively.

Reference example 27 LC-MS: [M+H]⁺/Rt (min) 217.1/0.610 (Method A)

Reference example 28 LC-MS: [M+H]⁺/Rt (min) 217.1/0.598 (Method A)

Reference Example 29

4,4,5,5-Tetramethyl-2-(4-methylcyclopent-1-en-1-yl)-1,3,2-dioxaborolane

a) A solution of 4,4-dimethyl-2-cyclopenten-1-one (750 mg) in tetrahydrofuran (40 mL) was stirred at −78° C., and 1 mol/L solution of lithium tri-sec-butylborohydride in tetrahydrofuran (7.8 ml) was added thereto. The mixture was stirred at −78° C. for one hour. To the reaction mixture was added a solution of 2-[N,N-bis(trifluoromethylsulfonyl)amino]pyridine (2.80 g) in tetrahydrofuran (10 ml), and the mixture was stirred at room temperature for one hour. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with 2 mol/L aqueous sodium hydroxide (30 mL) and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=99:1) to obtain Compound 21A (310 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 5.57-5.55 (m, 1H), 2.78-2.70 (m, 1H), 2.63-2.49 (m, 2H), 2.22-2.15 (m, 1H), 2.02-1.95 (m, 1H), 1.11 (d, J=6.8 Hz, 3H).

b) According to the method of b) in Reference example 4, the titled compound (150 mg) was obtained by using Compound 21A (300 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 6.48-6.43 (1H, m), 2.67-2.52 (2H, m), 2.42-2.28 (1H, m), 2.08-1.95 (2H, m), 1.33-1.21 (12H, m), 1.04-0.99 (3H, m).

Reference Example 30

2-(1,1-Difluorospiro[2.5]oct-5-en-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

a) To a suspension of methyltriphenylphosphonium bromide (121.0 g) in toluene (570 mL) was added potassium tert-butoxide (37.9 g), and the mixture was stirred at room temperature for one hour. To the reaction mixture was added a solution of 1,4-dioxaspiro[4.5]decan-8-one (24.0 g) in toluene (1000 ml), and the mixture was stirred at room temperature for 2 hours. To the reaction mixture was added sandy magnesium chloride (64.4 g), and the mixture was stirred at 60° C. for 2 hours. To the reaction mixture was added acetone (13.54 ml), and the mixture was stirred at 60° C. for 2 hours, and then at room temperature overnight. The reaction mixture was filtered, and the solid was washed with heptane (400 ml). The filtrate was concentrated under reduced pressure. To the residue was added hexane, and the mixture was stirred for a while. Insoluble substances were filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvate; hexane, and then hexane:ethyl acetate=85:15) to obtain Compound 22A (20.8 g).

¹H-NMR (400 MHz, CDCl₃) δ: 4.65 (s, 2H), 3.96 (s, 4H), 2.27 (t, J=6.5 Hz, 4H), 1.69 (t, J=6.5 Hz, 4H).

b) According to the method of a) in Reference example 11, Compound 22B (24.0 g) was obtained by using Compound 22A (20.8 g).

¹H-NMR (400 MHz, CDCl₃) δ: 3.96 (s, 4H), 1.74-1.66 (m, 8H), 1.05 (t, J=8.2 Hz, 2H).

c) Compound 22B (23.8 g) was dissolved in a mixed solvent of acetone (180 ml) and water (120 ml). p-Toluenesulfonic acid monohydrate (2.22 g) was added thereto, and the mixture was heated under reflux for 4 hours. After cooling to room temperature, saturated aqueous sodium bicarbonate was added thereto, and the acetone layer was removed under reduced pressure. The aqueous layer was extracted twice with ethyl acetate. The combined organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=90:10, and then hexane:ethyl acetate=75:25) to obtain Compound 22C (15.2 g).

¹H-NMR (400 MHz, CDCl₃) δ: 2.48-2.37 (m, 4H), 1.98-1.89 (m, 4H), 1.25-1.21 (m, 2H).

d) A solution of Compound 22C (4.77 g) and 2,6-lutidine in dichloromethane (48 ml) was stirred at 0° C., and trifluoromethanesulfonic anhydride (10.57 ml) was added thereto. The mixture was warmed, and heated under reflux for 3 hours. After cooling to room temperature, saturated aqueous sodium bicarbonate was added thereto, and the dichloromethane layer was removed under reduced pressure. The aqueous layer was extracted twice with ethyl acetate. The combined organic layer was washed sequentially with 1 mol/l aqueous hydrochloric acid, water, and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=95:5, and then hexane:ethyl acetate=77:23) to obtain Compound 22D (6.61 g).

¹H-NMR (400 MHz, CDCl₃) δ: 5.78 (t, J=3.7 Hz, 1H), 2.45-2.35 (m, 3H), 2.19-2.14 (m, 1H), 1.86-1.81 (m, 2H), 1.21-1.11 (m, 2H).

e) To a solution of Compound 22D (6.61 g), triphenylphosphine (593 mg), potassium phenoxide (2.99 g), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (6.03 g) in toluene (113 ml) was added bis(triphenylphosphine)palladium(II) dichloride (794 mg), and the mixture was stirred at 50° C. for 4 hours. To the reaction mixture were added potassium phenoxide (1.14 g) and tetrakis(triphenylphosphine)palladium(0) (784 mg), and the mixture was stirred at 50° C. for 1.5 hours. After cooling to room temperature, water and ethyl acetate were added thereto, and the mixture was filtered through Celite. The organic layer was washed with 1 M aqueous sodium carbonate and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane, and then hexane:ethyl acetate=80:20), and purified again by silica gel column chromatography (solvent; hexane:toluene=50:50, and then hexane:toluene:ethyl acetate=45:50:5) to obtain the titled compound (3.72 g).

¹H-NMR (400 MHz, CDCl₃) δ: 6.53-6.50 (m, 1H), 2.36-2.14 (m, 3H), 2.05-2.00 (m, 1H), 1.67-1.55 (m, 2H), 1.25 (s, 12H), 1.09-0.97 (m, 2H).

Reference Example 31

8-Fluoro-[1,2,4]triazolo[1,5-a]pyridine-7-amine

a) A solution of 2-chloro-3-fluoro-4-iodopyridine (3.1 g), benzyl carbamate (2.28 g), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.74 g), and tris(dibenzylidene-acetone)dipalladium (1.32 g) in toluene (80 mL) was stirred at 100° C. for 8 hours. After cooling to room temperature, water and ethyl acetate were added thereto, and the mixture was filtered through Celite. The aqueous layer was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=87:13, and then hexane:ethyl acetate=67:33) to obtain Compound 23A (1.8 g).

LC-MS: [M+H]⁺/Rt (min) 281.1/0.948 (Method A)

b) A solution of Compound 23A (1.25 g), benzophenone imine (1.12 mL), sodium t-butoxide (642 mg), and [(2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (354 mg) in toluene (18 ml) was stirred at 150° C. for 5 hours under microwave irradiation. After cooling to room temperature, water and ethyl acetate were added thereto, and the mixture was filtered through Celite. The aqueous layer was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by amino silica gel column chromatography (solvent; hexane:ethyl acetate=87:13, and then hexane:ethyl acetate=67:33) to obtain Compound 23B (490 mg).

LC-MS: [M+H]⁺/Rt (min) 426.3/1.117 (Method A)

c) Compound 23B (780 mg) was dissolved in tetrahydrofuran (5.3 ml), and 1 mol/L aqueous hydrochloric acid (5.3 ml) was added thereto. The mixture was stirred at room temperature for 4 hours. To the reaction mixture was added saturated sodium bicarbonate, and the mixture was extracted with a mixed solvent of chloroform and ethanol (3:1). The organic layer was dried oved anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by amino silica gel column chromatography (solvent; hexane:ethyl acetate=87:13, and then ethyl acetate) to obtain Compound 23C (179 mg).

LC-MS: [M+H]⁺/Rt (min) 262.1/0.542 (Method A)

d) Compound 23C (179 mg) was dissolved in 2-propanol (2.7 ml), and N,N-dimethylformamide dimethyl acetal (0.119 ml) was added thereto. The mixture was stirred at 100° C. for 3 hours. To the reaction mixture was added toluene (2.7 mL), and the mixture was concentrated under reduced pressure to obtain Compound 23D (212 mg).

LC-MS: [M+H]⁺/Rt (min) 317.2/0.598 (Method A)

e) Compound 23D (178 mg) was dissolved in 2-propanol (2.7 ml), and 50% aqueous hydroxyamine (0.05 ml) was added thereto. The mixture was stirred at 60° C. for 6 hours. To the reaction mixture was added water, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=67:33, and then hexane:ethyl acetate=30:70) to obtain Compound 23E (146 mg).

LC-MS: [M+H]⁺/Rt (min) 305.2/0.782 (Method A)

f) Compound 23E (171 mg) was dissolved in tetrahydrofuran (5.6 ml), and trifluoroacetic anhydride (0.119 ml) was added thereto. The mixture was stirred at room temperature for 21 hours. To the reaction mixture was added saturated sodium bicarbonate, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=83:17, and then hexane:ethyl acetate=50:50) to obtain Compound 23F (82 mg).

LC-MS: [M+H]⁺/Rt (min) 287.2/0.742 (Method A)

g) Compound 23F (90 mg) was dissolved in methanol (1.6 ml), and 10% palladium/carbon (17 mg) was added thereto. The mixture was stirred under hydrogen atmosphere at room temperature for 4 hours. The palladium/carbon was filtered through Celite, and washed with methanol. The filtrate was concentrated to obtain the titled compound (47 mg).

LC-MS: [M+H]⁺/Rt (min) 153.0/0.294 (Method A)

Reference Example 32

[6-(4,4-Dimethylpiperidin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]acetic acid hydrochloride

a) To a solution of 6-chloro-1H-pyrazolo{3,4-b}pyrazine (2.50 g) in dimethylformamide (65 mL) were added cesium carbonate (7.38 g) and tert-butyl bromoacetate (3.08 mL), and the mixture was stirred at room temperature for 4 hours. After the addition of saturated aqueous ammonium chloride, the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=83:17, then 0:100) to obtain Compound 32A (2.26 g).

LC-MS: [M+H]⁺/Rt (min) 268.9/0.945 (Method A)

b) To a solution of Compound 32A (200 mg) in N-methylpyrrolidone (2 mL) were added potassium carbonate (309 mg) and 4,4-dimethylpiperidine hydrochloride (134 mg), and the mixture was stirred at 50° C. for 2 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; hexane:ethyl acetate=90:10, and then 20:80) to obtain Compound 32B (246 mg).

LC-MS: [M+H]⁺/Rt (min) 346.0/1.146 (Method A)

c) To Compound 32B (246 mg) was added 4 mol/L hydrogen chloride in dioxane (5 mL), and the mixture was stirred at 55° C. for 8 hours. The reaction mixture was concentrated under reduced pressure, and the following steps were repeated twice: toluene was added thereto, and the mixture was concentrated under reduced pressure to obtain the titled compound (200 mg).

LC-MS: [M+H]⁺/Rt (min) 290.0/0.801 (Method A)

Reference Example 33

[6-(4-Methylpiperidin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl] acetic acid hydrochloride

a) To a solution of Compound 32A (330 mg) in toluene (5 mL) were added sodium tert-butoxide (236 mg), 4-methylpiperidine (0.30 mL), and [(2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (98 mg), and the mixture was stirred at 120° C. for 6 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; hexane:ethyl acetate=90:10, and then 0:100) to obtain Compound 33A (161 mg).

LC-MS: [M+H]⁺/Rt (min) 332.3/2.14 (Method B)

b) According to the method of c) in Reference example 32, the titled compound (150 mg) was obtained by using Compound 33A (161 mg).

LC-MS: [M+H]⁺/Rt (min) 276.3/1.93 (Method B)

Reference Example 34

[6-(4-Methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl] acetic acid

a) According to the method of a) in Reference example 32, Compound 34A (12.5 g) was obtained by using 6-chloro-1H-pyrazolo{3,4-b}pyrazine (15.0 g) and ethyl chloroacetate (11.6 mL).

LC-MS: [M+H]⁺/Rt (min) 240.9/0.766 (Method A)

b) To a solution of Compound 34A (11.3 g) in acetonitrile (200 mL) were added 2-(4-methylcyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (12.6 g), 2 mol/L aqueous potassium acetate (65.9 mL), and bis[di-tert-butyl(4-dimethylaminophenyl)phosphine]dichloropalladium(II) (3.7 g), and the mixture was stirred at 100° C. for 5 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; hexane:ethyl acetate=90:10, and then 75:25) to obtain Compound 34B (14.0 g).

LC-MS: [M+H]⁺/Rt (min) 302.0/1.108 (Method A)

c) To a solution of Compound 34B (14.0 g) in ethanol (400 mL) was added 4 mol/L aqueous sodium hydroxide (117 mL), and the mixture was stirred at room temperature for 2 hours. To the reaction solution was added 2 mol/L hydrochloric acid to adjust pH to 3. The solution was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. To the residue were added ethyl acetate, and the mixture was stirred for one hour, resulting in precipitation of a solid. The precipitated solid was filtered to obtain the titled compound (10.1 g).

LC-MS: [M+H]⁺/Rt (min) 272.9/0.863 (Method A)

Reference Example 35

2-(6-Chloro-1H-pyrazolo[3,4-b]pyrazin-1-yl)-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl) acetamide

a) According to the method of c) in Reference example 32, Compound 35A (333 mg) was obtained using Compound 32A (560 mg).

LC-MS: [M+H]⁺/Rt (min) 212.8/0.486 (Method A)

b) To a solution of Compound 35A (518 mg) in dichloromethane (15 mL) were added [1,2,4]triazolo[1,5-a]pyridine-7-amine dihydrochloride (517 mg), WSC (518 mg), and N,N-dimethyl-4-aminopyridine (1270 mg), and the mixture was stirred at room temperature for 3 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; hexane:ethyl acetate=100:0, and then 96:4) to obtain the titled compound (180 mg).

LC-MS: [M+H]⁺/Rt (min) 328.9/0.566 (Method A)

Reference Example 36

[6-(4-Methylcyclohexyl)-1H-pyrazolo[3,4-b]pyrazin-1-yl] acetic acid hydrochloride

a) According to the method of b) in Reference example 34, Compound 36A (1150 mg) was obtained by using Compound 32A (940 mg).

LC-MS: [M+H]⁺/Rt (min) 329.0/1.236 (Method A)

b) To a solution of Compound 36A (350 mg) in methanol (5 mL) was added 10% palladium/carbon (100 mg), and the mixture was stirred under hydrogen atmosphere at room temperature for 5 hours. The palladium/carbon was filtered through Celite, and washed with methanol. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; hexane:ethyl acetate=90:10) to obtain Compound 36B (310 mg).

LC-MS: [M+H]⁺/Rt (min) 331.0/1.237 (Method A)

c) According to the method of c) in Reference example 32, the titled compound (257 mg) was obtained by using Compound 36B (310 mg).

LC-MS: [M+H]⁺/Rt (min) 275.0/0.861 (Method A)

Reference Example 37

2-(6-Chloro-1H-pyrazolo[3,4-b]pyrazin-1-yl)-N-(4-cyanophenyl) acetamide

a) According to the method of a) in Reference example 32, the titled compound (21.0 mg) was obtained by using 6-chloro-1H-pyrazolo{3,4-b}pyrazine (20.0 mg) and the compound of Reference example 1 (27.7 mg).

LC-MS: [M+H]⁺/Rt (min) 313.1/0.784 (Method A)

Reference Example 38

2-[6-(Methanesulfonyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide

a) To a solution of 6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine (866 mg) in dimethylformamide (5.2 mL) were added tert-butyl 2-bromoacetate (0.917 mL) and potassium carbonate (1080 mg), and the mixture was stirred at room temperature for 16 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; hexane:ethyl acetate=75:25, and then 50:50) to obtain Compound 38A (772 mg).

LC-MS: [M+H]⁺/Rt (min) 280.9/0.911 (Method A)

b) According to the method of c) in Reference example 32, Compound 38B (620 mg) was obtained by using Compound 38A (772 mg).

LC-MS: [M+H]⁺/Rt (min) 224.9/0.504 (Method A)

c) According to the method of b) in Reference example 35, Compound 38C (177 mg) was obtained by using Compound 38B (200 mg).

LC-MS: [M+H]⁺/Rt (min) 340.9/0.548 (Method A)

d) To a solution of Compound 38C (78 mg) in tetrahydrofuran (2.3 mL) was added meta-chloroperbenzoic acid (169 mg), and the mixture was stirred at room temperature for 16 hours. To the reaction solution were assed saturated aqueous sodium bicarbonate and saturated aqueous sodium thiosulfate, and the mixture was extracted with chloroform. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (solvent; chloroform:methanol=99:1, then 90:10) to obtain the titled compound (100 mg).

LC-MS: [M+H]⁺/Rt (min) 372.9/0.430 (Method A)

Reference Example 39

[6-(4-Methylpiperidin-1-yl)-1H-pyrazolo[3,4-b]pyrimidin-1-yl] acetic acid hydrochloride

a) According to the method of a) in Reference example 32, Compound 39A (1.25 g) was obtained by using 6-chloro-1H-pyrazolo{3,4-b}pyrimidine (1.24 g) and tert-butyl bromoacetate (12.0 mL).

LC-MS: [M+H]⁺/Rt (min) 269.2/0.859 (Method A)

b) According to the method of b) in Reference example 32, Compound 39B (133 mg) was obtained by using Compound 39A (300 mg) and 4-methylpiperidine (0.79 mL).

LC-MS: [M+H]⁺/Rt (min) 332.2/1.185 (Method A)

c) According to the method of c) in Reference example 32, the titled compound (109 mg) was obtained by using Compound 39B (133 mg).

LC-MS: [M+H]⁺/Rt (min) 276.1/0.728 (Method D)

Reference Example 40

[6-(4-Methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyrimidin-1-yl] acetic acid hydrochloride

a) According to the method of b) in Reference example 34, Compound 40A (290 mg) was obtained by using Compound 39A (400 mg).

LC-MS: [M+H]⁺/Rt (min) 329.4/1.184 (Method D)

b) According to the method of c) in Reference example 32, the titled compound (240 mg) was obtained by using Compound 40A (290 mg).

LC-MS: [M+H]⁺/Rt (min) 273.1/0.758 (Method D)

Reference Example 41

2-(6-Chloro-1H-pyrazolo[3,4-b]pyrimidin-1-yl)-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl) acetamide

a) According to the method of c) in Reference example 32, Compound 41A (820 mg) was obtained by using Compound 39A (1.0 g).

LC-MS: [M+H]⁺/Rt (min) 212.9/0.403 (Method A)

b) According to the method of b) in Reference example 35, the titled compound (57 mg) was obtained by using Compound 41A (50 mg).

LC-MS: [M+H]⁺/Rt (min) 328.9/0.566 (Method A)

Reference Example 42

[6-(4-Methylpiperidin-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl] acetic acid hydrochloride

a) According to the method of a) in Reference example 32, Compound 42A (0.96 g) was obtained by using 6-chloro-1H-pyrazolo{3,4-b}pyridine (1.0 g) and tert-butyl bromoacetate (1.43 mL).

LC-MS: [M+H]⁺/Rt (min) 269.2/0.859 (Method A)

b) According to the method of b) in Reference example 32, Compound 42B (1.19 g) was obtained by using Compound 42A (0.96 g) and 4-methylpiperidine (2.54 mL).

LC-MS: [M+H]⁺/Rt (min) 331.3/1.206 (Method A)

c) According to the method of c) in Reference example 32, the titled compound (0.86 g) was obtained by using Compound 42B (1.19 g).

LC-MS: [M+H]⁺/Rt (min) 275.2/0.865 (Method A)

Reference Example 43

[6-(4-Methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl] acetic acid hydrochloride

a) According to the method of b) in Reference example 34, Compound 43A (1030 mg) was obtained by using Compound 42A (922 mg).

LC-MS: [M+H]⁺/Rt (min) 328.3/1.252 (Method A)

b) According to the method of c) in Reference example 32, the titled compound (840 mg) was obtained by using Compound 43A (1030 mg).

LC-MS: [M+H]⁺/Rt (min) 272.1/0.941 (Method A)

Reference Example 44

2-(6-Chloro-1H-pyrazolo[3,4-b]pyridin-1-yl)-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide

a) According to the method of c) in Reference example 32, Compound 44A (1.06 g) was obtained by using Compound 42A (1.82 g).

LC-MS: [M+H]⁺/Rt (min) 211.9/0.559 (Method A)

b) According to the method of b) in Reference example 35, the titled compound (763 mg) was obtained by using Compound 44A (550 mg).

LC-MS: [M+H]⁺/Rt (min) 327.9/0.621 (Method A)

Reference Example 45

[6-(4-Methylcyclohex-1-en-1-yl)-1H-indazol-1-yl] acetic acid hydrochloride

a) According to the method of a) in Reference example 32, Compound 45A (1.1 g) was obtained by using 6-bromo-1H-indazole (1.0 g) and tert-butyl bromoacetate (0.89 mL).

LC-MS: [M+H]⁺/Rt (min) 313.1/1.025 (Method A)

b) According to the method of b) in Reference example 34, Compound 45B (503 mg) was obtained by using Compound 45A (500 mg).

LC-MS: [M+H]⁺/Rt (min) 328.3/1.252 (Method A)

c) According to the method of c) in Reference example 32, the titled compound (390 mg) was obtained by using Compound 45B (503 mg).

LC-MS: [M+H]⁺/Rt (min) 271.2/0.980 (Method A)

Example 1

N-(4-Cyanophenyl)-2-[3-(4-methylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide

To a solution of the compound of Reference example 2 (1.0 g) in dimethylformamide (14 mL) were added potassium carbonate (1.43 g) and the compound of Reference example 1 (1.0 g). After stirring at room temperature for 24 hours, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=2:3, and then ethyl acetate) to obtain the titled compound (1.21 g).

¹H-NMR (400 MHz, CDCl₃) δ: 9.79 (s, 1H), 7.63 (dt, J=9.0, 2.0 Hz, 2H), 7.55 (dt, J=8.5, 1.8 Hz, 2H), 7.24 (d, J=9.8 Hz, 1H), 6.93 (d, J=10.4 Hz, 1H), 4.84 (s, 2H), 3.84 (d, J=13.4 Hz, 2H), 2.77 (td, J=12.8, 2.4 Hz, 2H), 1.75-1.68 (m, 2H), 1.58-1.53 (m, 1H), 1.25 (dd, J=12.5, 4.0 Hz, 1H), 1.19 (dd, J=12.2, 4.3 Hz, 1H), 0.97 (d, J=6.7 Hz, 3H).

Example 2

N-(4-Cyanophenyl)-2-[3-(4,4-dimethylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide

A solution of the compound of Reference example 3 (60 mg), 4,4-dimethylpiperidine hydrochloride (93 mg), and diisopropylethylamine (1 mL) in dimethylacetamide (0.5 mL) was stirred at 150° C. for 11 hours. After the completion of the reaction, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase HPLC (eluent; 0.035% trifluoroacetic acid in acetonitrile/water), and then by amino silica gel column chromatography (solvent; chloroform:methanol=99:1, and then 93:7) to obtain the titled compound (22 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 9.78 (s, 1H), 7.65 (d, J=8.5 Hz, 2H), 7.57 (d, J=8.5 Hz, 2H), 7.25 (d, J=9.8 Hz, 1H), 6.94 (d, J=10.4 Hz, 1H), 4.84 (s, 2H), 3.32-3.28 (m, 4H), 1.46-1.42 (m, 4H), 0.98 (s, 6H).

Examples 3-36

According to the method of Example 1 or 2 and common reaction conditions, the compounds of Examples 3 to 36 were obtained by using each corresponding material compound.

				LC-MS:
				[M + H]+/Rt
				(min)
Example	M1	R1	R2	(Method)
3		H	H	338.3/0.810 (Method A)
4		H	H	324.2/0.730 (Method A)
5		H	H	374.2/0.778 (Method A)
6		H	H	394.4/1.05 (Method A)
7		H	H	354.3/0.586 (Method A)
8		H	H	381.3/0.552 (Method A)
9		H	H	368.3/0.689 (Method A)
10		H	H	406.3/0.864 (Method A)
11		H	H	352.3/0.860 (Method A)
12		H	H	366.4/0.872 (Method A)
13		H	H	352.3/0.874 (Method A)
14		H	H	366.3/0.945 (Method A)
15		H	H	366.4/0.951 (Method A)
16		H	H	406.3/0.875 (Method A)
17		H	H	364.3/0.885 (Method A)
18		H	H	336.2/0.795 (Method A)
19		H	H	338.2/0.836 (Method A)
20		H	H	364.3/0.907 (Method A)
21		H	H	352.3/0.895 (Method A)
22		H	H	366.3/0.970 (Method A)
23		H	H	406.4/1.079 (Method A)
24		H	H	378.3/0.979 (Method A)
25		H	H	350.2/0.938 (Method A)
26		H	H	378.3/1.001 (Method A)
27		H	H	380.3/0.698 (Method A)
28		H	H	380.3/1.029 (Method A)
29		H	H	394.3/0.790 (Method A)
30		H	H	340.3/0.890 (Method A)
31		H	H	392.3/1.033 (Method A)
32		H	H	414.3/0.908 (Method A)
33		H	H	378.3/1.004 (Method A)
34		H	H	364.3/0.938 (Method A)
35		Me	Me	380.3/1.05 (Method A)
36		—(CH2)4—	406.3/1.14 (Method A)

Example 37

N-(4-Cyanophenyl)-2-[3-(4,4-difluorocyclohex-1-en-1-yl)-6-oxopyridazin-10 (6H)-yl]acetamide

The compound of Reference example 3 (1.58 g), the compound of Reference example 4 (1.74 g), and 2 mol/L aqueous sodium carbonate (6.85 mL) were suspended in 1,2-dimethoxyethane (25 mL), and 1,1′-bis(diphenylphosphino)ferrocene palladium dichloride (401 mg) was added thereto. The mixture was stirred under a nitrogen atmosphere at 80° C. for 4 hours. After cooling to room temperature, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform:methanol=99:1, and then 93:7), and recrystallized with ethanol (60 mL)-acetonitrile (20 mL) to obtain the titled compound (1.64 g).

¹H-NMR (400 MHz, CDCl₃) δ: 9.37 (s, 1H), 7.65-7.58 (m, 3H), 7.54 (d, J=8.7 Hz, 2H), 7.04 (d, J=9.6 Hz, 1H), 6.22 (s, 1H), 4.99 (s, 2H), 2.82-2.71 (m, 4H), 2.20-2.10 (m, 2H).

Example 38

N-(4-Cyanophenyl)-2-[3-(4,4-dimethylcyclohexyl)-6-oxopyridazin-1(6H)-yl] acetamide

To a solution of the compound of Reference example 5 (40 mg) in dimethylformamide (2 mL) were added potassium carbonate (54 mg) and the compound of Reference example 1 (45 mg). After stirring the mixture at room temperature for 6 hours, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; hexane:ethyl acetate=1:1, and then 1:4) to obtain the titled compound (60 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 9.54 (s, 1H), 7.62 (dt, J=9.0, 2.2 Hz, 2H), 7.54 (dt, J=9.1, 2.0 Hz, 2H), 7.27 (d, J=9.5 Hz, 1H), 7.00 (d, J=9.6 Hz, 1H), 4.95 (s, 2H), 2.48 (tt, J=11.9, 3.7 Hz, 1H), 1.73-1.69 (m, 2H), 1.64-1.57 (td, J=12.8, 3.63 Hz, 2H), 1.55-1.46 (m, 2H), 1.28 (td, J=13.2, 4.1 Hz, 2H), 0.94 (s, 3H), 0.93 (s, 3H).

Examples 39-49

According to the method of Example 37 or 38 and common reaction conditions, the compounds of Examples 39 to 49 were obtained by using each corresponding material compound.

		LC-MS:
		[M + H]+/Rt (min)
Example	M1	(Method)
39		335.2/0.901 (Method A)
40		337.2/0.920 (Method A)
41		349.3/0.978 (Method A)
42		363.3/1.03 (Method A)
43		351.2/0.968 (Method A)
44		351.2/0.985 (Method A)
45		363.3/1.046 (Method A)
46		365.3/1.058 (Method A)
47		373.2/0.858 (Method A)
48		337.2/0.777 (Method A)
49		365.2/0.817 (Method A)

Example 50

N-(1,3-Benzooxazol-5-yl)-2-[3-(methylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide

To a suspension of the compound of Reference example 6 (50 mg), 1,3-benzoxazole-5-amine (32 mg), and HATU (91 mg) in acetonitrile (1.5 mL) was added N,N-diisopropylethylamine (0.34 mL), and the mixture was stirred at room temperature for 2 hours. After the addition of saturated aqueous ammonium chloride, the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate:methanol=100:0, and then 92:8) to obtain the titled compound (38 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 9.35 (s, 1H), 8.09 (s, 1H), 8.06 (s, 1H), 7.48 (s, 2H), 7.23 (d, J=9.8 Hz, 1H), 6.94 (d, J=9.8 Hz, 1H), 4.86 (s, 2H), 3.86-3.83 (m, 2H), 2.80-2.74 (m, 2H), 1.73-1.70 (i, 2H), 1.61-1.53 (i, 1H), 1.28-1.18 (m, 2H), 0.97 (d, J=6.4 Hz, 3H).

Examples 51-99

According to the method of Example 50 and common reaction conditions, the compounds of Examples 51 to 99 were obtained by using each corresponding material compound.

Example	M2	Analytical data
51		1H-NMR (400 MHz, CDCl3) δ: 10.14 (br, 1H), 8.63 (s, 1H), 8.29 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.28-7.25 (m, 1H), 6.95 (d, J = 10.1 Hz, 1H), 4.87 (s, 2H), 3.87-3.84 (m, 2H),
		2.82-2.75 (m, 2H), 1.74-1.71 (m,
		2H), 1.60-1.54 (m, 1H), 1.28-
		1.17 (m, 2H), 0.97 (d, J = 6.4
		Hz, 3H).
52		1H-NMR (400 MHz, CDCl3) δ: 10.21 (s, 1H), 8.50 (d, J = 5.5 Hz, 1H), 7.83 (s, 1H), 7.60 (d, J = 5.9 Hz, 1H), 7.26 (d, J = 10.0 Hz, 1H), 6.95 (d, J = 9.6 Hz, 1H), 4.87 (s, 2H), 3.82 (d, J =
		12.8 Hz, 2H), 2.76 (td, J = 12.7,
		2.3 Hz, 2H), 1.70 (d, J = 12.3
		Hz, 2H), 1.59-1.50 (m, 1H), 1.24
		(dd, J = 12.1, 3.4 Hz, 1H), 1.18
		(dd, J = 12.1, 3.4 Hz, 1H), 0.95
		(d, J = 6.4 Hz, 3H).
53		1H-NMR (400 MHz, DMSO-d6) δ: 11.01 (s, 1H), 8.59 (d, J = 5.5 Hz, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.76 (dd, J = 5.8, 2.1 Hz, 1H), 7.57 (d, J = 10.4 Hz, 1H), 6.85 (d, J = 9.8 Hz, 1H), 4.75
		(s, 2H), 3.81 (d, J = 12.8 Hz,
		2H), 2.66 (t, J = 11.3 Hz, 2H),
		1.63 (d, J = 12.2 Hz, 2H), 1.55-
		1.46 (m, 1H), 1.15 (dd, J = 11.9,
		4.0 Hz, 1H), 1.09 (dd, J = 12.5,
		3.4 Hz, 1H), 0.90 (d, J = 6.1
		Hz, 3H).
54		1H-NMR (400 MHz, CDCl3) δ: 7.34 (s, 2H), 7.26 (d, J = 10.3 Hz, 1H), 7.16 (br, 1H), 6.90 (d, J = 10.4 Hz, 1H), 4.91 (s, 2H), 3.81 (d, J = 13.4 Hz, 2H), 2.75 (td, J = 12.8, 2.4 Hz, 2H), 2.54 (s, 6H), 1.70 (d, J = 12.8 Hz, 2H), 1.58-1.51 (m, 1H), 1.23 (dd, J =
		12.2, 3.7 Hz, 1H), 1.17 (dd, J =
		12.5, 3.4 Hz, 1H), 0.95 (d, J =
		6.1 Hz, 3H).
55		LC-MS: [M + H]+/Rt (min) 352.2/1.83 (Method B)
56		LC-MS: [M + H]+/Rt (min) 329.2/1.60 (Method B)
57		LC-MS: [M + H]+/Rt (min) 371.2/1.55 (Method B)
58		LC-MS: [M + H]+/Rt (min) 346.2/1.74 (Method B)
59		1H-NMR (400 MHz, CDCl3) δ: 9.95 (br, 1H), 8.64 (s, 1H), 8.30- 8.28 (m, 1H), 7.60-7.56 (m, 1H), 7.26 (d, J = 10.1 Hz, 1H), 6.95 (d, J = 10.1, 1H), 4.87 (s, 2H), 3.86-3.83 (m, 2H), 2.80-2.75 (m,
		2H), 1.72 (d, J = 12.3 Hz, 2H),
		1.58-1.53 (m, 1H), 1.28-1.17 (m,
		2H), 0.97 (d, J = 6.4 Hz, 3H).
60		1H-NMR (400 MHz, CDCl3) δ: 10.06 (br, 1H), 8.70 (d, J = 2.1 Hz, 1H), 8.56 (d, J = 2.1 Hz, 1H), 8.52 (t, J = 2.1 Hz, 1H), 7.26 (d, J = 9.6 Hz, 1H), 6.95 (d, J = 9.6 Hz, 1H), 4.86 (s, 2H), 3.85
		(d, J = 12.8 Hz, 2H), 2.78 (t, J =
		12.8 Hz, 2H), 1.72 (d, J = 12.3
		Hz, 2H), 1.60-1.55 (m, 1H),
		1.28-1.18 (m, 2H), 0.97 (d, J =
		6.4 Hz, 3H).
61		1H-NMR (400 MHz, CDCl3) δ: 9.88 (br, 1H), 8.74 (s, 1H), 8.56 (s, 1H), 8.40 (s, 1H), 7.24 (d, J = 9.9 Hz, 1H), 6.94 (d, J = 9.9 Hz, 1H), 4.85 (s, 2H), 3.85-3.82 (m, 2H), 2.80-2.73 (m, 2H),
		1.73-1.69 (m, 2H), 1.58-1.53 (m,
		1H), 1.26-1.15 (m, 2H), 0.95 (d,
		J = 6.4 Hz, 3H).
62		LC-MS: [M + H]+/Rt (min) 358.2/1.73 (Method B)
63		1H-NMR (400 MHz, CDCl3) δ: 9.76 (br, 1H), 8.41 (d, J = 1.8 Hz, 1H), 8.25 (d, J = 1.8 Hz, 1H), 8.22 (d, J = 1.8 Hz, 1H), 7.25 (d, J = 9.8 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 4.85 (s, 2H),
		3.86-3.82 (m, 2H), 2.81-2.74 (m,
		2H), 1.73-1.70 (m, 2H), 1.61-
		1.53 (m, 1H), 1.27-1.17 (m, 2H),
		0.97 (d, J = 6.7 Hz, 3H).
64		LC-MS: [M + H]+/Rt (min) 358.2/1.55 (Method B)
65		LC-MS: [M + H]+/Rt (min) 346.2/1.73 (Method B)
66		1H-NMR (400 MHz, CDCl3) δ: 9.37 (br, 1H), 8.04 (d, J = 5.5 Hz, 1H), 7.23 (d, J = 9.8 Hz, 1H), 7.08 (d, J = 1.5 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.63 (dd, J = 5.5, 1.5 Hz, 1H), 4.81 (s, 2H), 3.85-3.78 (m, 6H), 3.49-3.47 (m, 4H), 2.80-2.73 (m, 2H), 1.73-
		1.70 (m, 2H), 1.58-1.53 (m, 1H),
		1.27-1.17 (m, 2H), 0.97 (d, J =
		6.7 Hz, 3H).
67		1H-NMR (400 MHz, CDCl3) δ: 9.57 (br, 1H), 7.84-7.82 (m, 2H), 7.36-7.34 (m, 2H), 7.26 (d, J = 2.7 Hz, 1H), 7.24 (d, J = 10.1 Hz, 1H), 7.18 (s, 1H), 7.10-7.06 (m, 1H), 6.94 (d, J = 10.1 Hz, 1H), 4.85 (s, 2H), 3.86-3.83 (m, 2H), 2.81-2.74 (m, 2H), 1.73- 1.70 (m, 2H), 1.62-1.54 (m, 1H), 1.30-1.18 (m, 2H), 0.97 (d, J = 6.4 Hz, 3H).
68		1H-NMR (400 MHz, CDCl3) δ: 9.39 (br, 1H), 8.10 (d, J = 2.0 Hz, 1H), 7.50 (d, J = 8.6 Hz, 1H), 7.23 (d, J = 10.1 Hz, 1H), 7.12 (dd, J = 8.6, 2.0 Hz, 1H), 6.93 (d, J = 10.1 Hz, 1H), 4.85 (s,
		2H), 3.86-3.83 (m, 2H), 2.81-
		2.74 (m, 2H), 2.61 (s, 3H), 1.73-
		1.70 (m, 2H), 1.60-1.52 (m, 1H),
		1.28-1.18 (m, 2H), 0.97 (d, J =
		6.4 Hz, 3H).
69		1H-NMR (400 MHz, CDCl3) δ: 9.23 (br, 1H), 7.90 (s, 1H), 7.40- 7.34 (m, 2H), 7.22 (d, J = 9.9 Hz, 1H), 6.93 (d, J = 9.9 Hz, 1H), 4.85 (s, 2H), 3.86-3.83 (m, 2H), 2.80-2.74 (m, 2H), 2.61 (s,
		3H), 1.73-1.70 (m, 2H), 1.60-
		1.52 (m, 1H), 1.28-1.18 (m, 2H),
		0.97 (d, J = 6.4 Hz, 3H).
70		1H-NMR (400 MHz, CDCl3) δ: 9.50 (br, 1H), 8.08 (s, 1H), 7.43- 7.42 (m, 2H), 7.24 (d, J = 10.1 Hz, 1H), 6.94 (d, J = 10.1 Hz, 1H), 4.87 (s, 2H), 3.87-3.83 (m, 2H), 2.781-2.74 (m, 2H), 2.53 (s, 3H), 1.74-1.70 (m, 2H),
		1.60-1.53 (m, 1H), 1.28-1.18 (m,
		2H), 0.97 (d, J = 6.4 Hz, 3H).
71		1H-NMR (400 MHz, CDCl3) δ: 9.59 (br, 1H), 8.32 (d, J = 7.8 Hz, 1H), 7.99 (d, J = 1.8 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.24 (d, J = 10.3 Hz, 1H), 6.94 (d, J = 10.3 Hz, 1H), 6.72 (dd, J =
		7.8, 2.3 Hz, 1H), 6.38 (d, J =
		1.8 Hz, 1H), 4.85 (s, 2H), 3.87-
		3.83 (m, 2H), 2.81-2.74 (m, 2H),
		1.74-1.70 (m, 2H), 1.61-1.53 (m,
		1H), 1.28-1.18 (m, 2H), 0.97 (d,
		J = 6.9 Hz, 3H).
72		1H-NMR (400 MHz, CDCl3) δ: 9.72 (br, 1H), 7.95 (d, J = 7.3 Hz, 1H), 7.87 (br, 1H), 7.52 (br s, 1H), 7.43 (s, 1H), 7.23 (d, J = 10.1 Hz, 1H), 6.99 (dd, J = 7.3, 2.4 Hz, 1H), 6.92 (d, J = 10.1
		Hz, 1H), 4.86 (s, 2H), 3.85-3.82
		(m, 2H), 2.80-2.73 (m, 2H),
		1.73-1.70 (m, 2H), 1.61-1.52 (m,
		1H), 1.27-1.17 (m, 2H), 0.96 (d,
		J = 6.7 Hz, 3H).
73		1H-NMR (400 MHz, CDCl3) δ: 9.52 (br, 1H), 8.24 (d, J = 1.8 Hz, 1H), 8.04 (s, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.23 (d, J = 10.4 Hz, 1H), 7.19 (dd, J = 8.5, 1.8 Hz, 1H), 6.94 (d, J = 10.4 Hz,
		1H), 4.85 (s, 2H), 3.87-3.83 (m,
		2H), 2.81-2.74 (m, 2H), 1.73-
		1.71 (m, 2H), 1.61-1.52 (m, 1H),
		1.28-1.19 (m, 2H), 0.97 (d, J =
		6.7 Hz, 3H).
74		LC-MS: [M + H]+/Rt (min) 358.2/1.59 (Method B)
75		LC-MS: [M + H]+/Rt (min) 407.2/1.57 (Method B)
76		LC-MS: [M + H]+/Rt (min) 393.2/1.55 (Method B)
77		LC-MS: [M + H]+/Rt (min) 394.2/1.83 (Method B)
78		LC-MS: [M + H]+/Rt (min) 394.2/1.85 (Method B)
79		1H-NMR (400 MHz, CDCl3) δ: 9.36 (br, 1H), 7.55 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 10.1 Hz, 1H), 6.92 (d, J = 10.1 Hz, 1H), 4.83 (s, 2H), 3.85-3.82 (m, 2H), 3.63- 3.60 (m, 2H), 3.44-3.41 (m, 2H), 2.79-2.73 (m, 2H), 1.95-1.90 (m,
		2H), 1.88-1.84 (m, 2H), 1.73-
		1.69 (br m, 2H), 1.60-1.51 (br
		m, 1H), 1.27-1.18 (m, 2H), 0.96
		(d, J = 6.4 Hz, 3H).
80		1H-NMR (400 MHz, CDCl3) δ: 9.21 (br, 1H), 8.06-8.06 (m, 1H), 7.85-7.84 (m, 1H), 7.72-7.68 (m, 2H), 7.40-7.36 (m, 1H), 7.33 (d, J = 3.1 Hz, 1H), 7.23 (d, J = 9.8 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 4.85 (s, 2H), 3.86-3.83 (m, 2H), 2.81-2.74 (m, 2H), 1.73-1.71 (m, 2H), 1.62-1.52 (m, 1H), 1.28-1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
81		1H-NMR (400 MHz, CDCl3) δ: 9.40 (br, 1H), 7.63 (d, J = 2.1 Hz, 1H), 7.24 (d, J = 10.1 Hz, 1H), 7.07 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 10.1 Hz, 1H), 6.92 (dd, J = 8.5, 2.1 Hz, 1H), 4.84 (s, 2H), 3.86-3.83 (m, 2H), 3.37 (s,
		3H), 2.81-2.74 (m, 2H), 1.73-
		1.71 (br, 2H), 1.62-1.53 (m,
		1H), 1.28-1.17 (m, 2H), 0.97 (d,
		J = 6.7 Hz, 3H).
82		1H-NMR (400 MHz, CD3OD) δ: 7.60 (br, 1H), 7.52 (d, J = 10.1 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 7.10 (d, J = 8.7 Hz, 1H), 6.89 (d, J = 10.1 Hz, 1H), 4.82 (s, 2H), 3.93-3.90 (m, 2H), 2.81-
		2.73 (m, 2H), 1.71-1.70 (m, 2H),
		1.56 (br, 1H), 1.28-1.18 (m,
		2H), 0.96 (d, J = 6.4 Hz, 3H).
83		1H-NMR (400 MHz, CDCl3) δ: 9.43 (br, 1H), 8.09 (s, 1H), 7.87 (s, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.23 (d, J = 10.1 Hz, 1H), 6.94 (d, J = 10.1 Hz, 1H), 6.89 (dd, J = 8.5, 1.2 Hz, 1H), 4.87 (s,
		2H), 4.02 (s, 3H), 3.86-3.83 (m,
		2H), 2.81-2.74 (m, 2H), 1.73-
		1.70 (m, 2H), 1.62-1.52 (m, 1H),
		1.28-1.18 (m, 2H), 0.97 (d, J =
		6.7 Hz, 3H).
84		1H-NMR (400 MHz, CDCl3) δ: 9.71 (br, 1H), 8.08 (s, 1H), 7.74 (d, J = 8.7 Hz, 1H), 7.24 (d, J = 10.3 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 10.3 Hz, 1H), 4.86 (s, 1H), 3.86-3.83 (m, 2H), 2.81-2.74 (m, 2H), 2.53 (s,
		3H), 1.73-1.70 (m, 2H), 1.60-
		1.53 (m, 1H), 1.28-1.17 (m, 2H),
		0.97 (d, J = 6.4 Hz, 3H).
85		1H-NMR (400 MHz, CDCl3) δ: 9.37 (br, 1H), 8.08 (s, 1H), 7.77- 7.75 (br, 1H), 7.65-7.62 (m, 1H), 7.23 (d, J = 10.1 Hz, 1H), 6.99-6.97 (br, 1H), 6.94 (d, J = 10.1 Hz, 1H), 4.88 (s, 2H), 3.86-
		3.83 (m, 2H), 3.76 (br, 3H),
		2.80-2.74 (m, 2H), 1.73-1.70
		(br, 2H), 1.60-1.52 (m, 1H),
		1.28-1.18 (m, 2H), 0.97 (d, J =
		6.9 Hz, 3H).
86		1H-NMR (400 MHz, CD3OD) δ: 7.52 (d, J = 10.1 Hz, 1H), 7.39 (d, J = 1.8 Hz, 1H), 7.17 (d, J = 7.9 Hz, 1H), 7.03 (dd, J = 7.9, 1.8 Hz, 1H), 6.89 (d, J = 10.1 Hz, 1H), 4.82 (s, 2H), 3.93-3.90 (m,
		2H), 3.47 (s, 2H), 2.80-2.73 (m,
		2H), 1.72-1.69 (m, 2H), 1.61-
		1.52 (m, 1H), 1.28-1.18 (m, 2H),
		0.96 (d, J = 6.1 Hz, 3H).
87		1H-NMR (400 MHz, CDCl3) δ: 9.43 (br, 1H), 8.98 (s, 1H), 8.38 (d, J = 1.8 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.61 (dd, J = 8.5, 1.8 Hz, 1H), 7.23 (d, J = 10.1 Hz, 1H), 6.95 (d, J = 10.1 Hz,
		1H), 4.88 (s, 2H), 3.87-3.38 (m,
		2H), 2.81-2.74 (m, 2H), 1.73-
		1.70 (m, 2H), 1.62-1.53 (m, 1H),
		1.28-1.18 (m, 2H), 0.97 (d, J =
		6.1 Hz, 3H).
88		1H-NMR (400 MHz, CDCl3) δ: 9.30 (br, 1H), 8.18 (d, J = 1.8 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H), 7.51 (dd, J = 8.6, 1.8 Hz, 1H), 7.22 (d, J = 10.1 Hz, 1H), 6.93 (d, J = 10.1 Hz, 1H), 4.86 (s,
		2H), 3.86-3.83 (m, 2H), 2.81 (s,
		3H), 2.80-2.73 (m, 2H), 1.73-
		1.70 (m, 2H), 1.61-1.52 (m, 1H),
		1.28-1.18 (m, 2H), 0.96 (d, J =
		6.7 Hz, 3H).
89		1H-NMR (DMSO-d6) δ: 7.83 (d, J = 9.2 Hz, 1H), 7.56 (d, J = 9.8 Hz, 1H), 6.89 (s, 1H), 6.85 (d, J = 9.8 Hz, 1H), 6.73 (dd, J = 8.5, 2.4 Hz, 1H), 4.82 (s, 2H), 4.18-4.10 (m, 2H), 3.83-3.77 (m, 2H), 3.74-3.68 (m, 4H), 3.33- 3.27 (m, 1H), 3.19-3.10 (m, 2H),
		3.07-3.00 (m, 4H), 2.70-2.60 (m,
		2H), 1.68-1.59 (m, 2H), 1.56-
		1.45 (br, 1H), 1.20-1.08 (m,
		2H), 0.91 (3H, d, J = 6.7 Hz.)
90		1H-NMR (400 MHz, CD3OD) δ: 9.21 (s, 1H), 7.89 (s, 1H), 7.62-7.53 (m, 3H), 7.35 (d, J = 9.5 Hz, 1H), 6.90 (d, J = 9.5 Hz, 1H), 4.87 (s, 2H), 3.94-3.90 (m, 2H), 2.80-2.74 (m, 2H), 1.72-1.68 (m,
		2H), 1.57 (s, 1H), 1.28-1.17 (m,
		2H), 0.96 (d, J = 6.7 Hz, 3H).
91		1H-NMR (400 MHz, CDCl3) δ: (br, 1H), 7.52 (s, 1H), 7.20 (d, J = 9.8 Hz, 1H), 7.14-7.14 (br, 2H), 6.91 (d, J = 9.8 Hz, 1H), 4.83 (s, 2H), 3.85-3.82 (m, 2H), 3.18 (s, 6H), 2.79-2.72 (m, 2H),
		1.72-1.69 (m, 2H), 1.61-1.51 (m,
		1H), 1.28-1.18 (m, 2H), 0.97 (d,
		J = 6.7 Hz, 3H).
92		1H-NMR (400 MHz, CDCl3) δ: (br, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.42 (dd, J = 8.5, 2.4 Hz, 1H), 7.24 (d, J = 10.1 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 10.1 Hz, 1H), 4.82 (s,
		2H), 3.86-3.83 (m, 2H), 3.28 (s,
		3H), 2.81-2.74 (m, 2H), 2.46 (s,
		3H), 1.73-1.70 (m, 2H), 1.61-
		1.52 (m, 1H), 1.28-1.18 (m, 2H),
		0.97 (d, J = 6.1 Hz, 3H).
93		1H-NMR (400 MHz, CDCl3) δ: (br, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 1.8 Hz, 1H), 7.31 (dd, J = 8.5, 1.8 Hz, 1H), 7.23 (d, J = 9.9 Hz, 1H), 6.93 (d, J = 9.9 Hz, 1H), 5.77 (s, 1H), 4.83 (s, 2H), 3.86-3.82 (m, 2H), 3.55-3.51 (m, 2H), 2.98-
		2.95 (m, 2H), 2.81-2.74 (m, 2H),
		1.73-1.71 (m, 2H), 1.61-1.54 (m,
		1H), 1.28-1.17 (m, 2H), 0.97 (d,
		J = 6.9 Hz, 3H).
94		1H-NMR (400 MHz, CDCl3) δ: (br, 1H), 8.09 (s, 1H), 7.95 (d, J = 1.8 Hz, 1H), 7.62 (d, J = 1.8 Hz, 1H), 7.24 (d, J = 10.1 Hz, 1H), 6.95 (d, J = 10.1 Hz, 1H), 4.85 (s, 2H), 3.87-3.83 (m, 2H), 2.81-2.74 (m, 2H), 1.74- 1.71 (m, 2H), 1.62-1.50 (m, 1H),
		1.28-1.18 (m, 2H), 0.97 (d, J =
		6.9 Hz, 3H).
95		1H-NMR (CDCl3) δ: 9.80 (s, 1H), 8.50 (d, J = 2.0 Hz, 1H), 7.88 (d, J = 9.9 Hz, 1H), 7.50 (dd, J = 9.1, 2.0 Hz, 1H), 7.25 (d, J = 9.1 Hz, 1H), 6.96 (d, J = 9.9 Hz, 1H), 4.89 (s, 2H), 3.87-3.84
		(m, 2H), 2.82-2.75 (m, 2H),
		1.74-1.71 (m, 2H), 1.61-1.53 (m,
		1H), 1.28-1.18 (m, 2H), 0.97 (d,
		J = 6.9 Hz, 3H).
96		1H-NMR (400 MHz, CDCl3) δ: 9.25 (br, 1H), 8.04 (s, 1H), 7.89 (s, 1H), 7.28 (br, 1H), 7.22 (d, J = 10.1 Hz, 1H), 6.94 (d, J = 10.1 Hz, 1H), 4.85 (s, 2H), 3.86-3.83 (m, 2H), 2.81-2.74 (m, 2H), 2.49 (s, 3H), 1.73-1.70 (br, 2H), 1.61-1.53 (m, 1H), 1.28-1.18 (m,
		2H), 0.97 (d, J = 6.7 Hz, 3H).
97		1H-NMR (400 MHz, CDCl3) δ: 9.20 (br, 1H), 7.92 (d, J = 1.2 Hz, 1H), 7.40-7.35 (m, 2H), 7.22 (d, J = 10.4 Hz, 1H), 6.93 (d, J = 10.4 Hz, 1H), 4.85 (s, 2H), 3.86- 3.83 (br, 2H), 2.94 (q, J = 7.7
		Hz, 2H), 2.80-2.74 (m, 2H),
		1.73-1.70 (br, 2H), 1.58-1.53
		(m, 1H), 1.43 (t, J = 7.7 Hz,
		3H), 1.28-1.18 (m, 2H), 0.97 (d,
		J = 6.7 Hz, 3H).
98		1H-NMR (400 MHz, CDCl3) δ: 9.08 (s, 1H), 7.93 (s, 1H), 7.83 (s, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.29-7.26 (m, 1H), 7.20 (d, J = 9.8 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 4.86 (s, 2H), 3.85-3.82 (m, 2H), 3.80 (s, 2H), 2.79-2.73 (m, 2H), 1.73-1.70 (m, 2H),
		1.60-1.51 (m, 1H), 1.28-1.18 (m,
		2H), 0.96 (d, J = 6.7 Hz, 3H).
99		1H-NMR (400 MHz, CDCl3) δ: 9.19 (br, 1H), 7.79 (s, 1H), 7.24 (s, 1H), 7.23 (s, 1H), 7.22 (d, J = 10.4 Hz, 1H), 6.92 (d, J = 10.4 Hz, 1H), 4.84 (s, 2H), 4.20 (s, 3H), 3.85-3.82 (m, 2H), 2.80-
		2.73 (m, 2H), 1.73-1.70 (m, 2H),
		1.61-1.52 (m, 1H), 1.28-1.17 (m,
		2H), 0.97 (d, J = 6.7 Hz, 3H).

Examples 100 to 135

According to the method of Example 2, 37, 38, or 50 and corresponding reaction conditions, the compounds of Examples 100 to 135 were obtained by using each corresponding material compound.

Example	Chemical structure	Analytical data
100		1H-NMR (DMSO-d6) δ: 10.97 (br, 1H), 8.85 (d, J = 2.7 Hz, 1H), 8.22 (dd, J = 8.5, 2.5 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 4.81 (s, 2H), 3.20-3.13 (m, 2H), 2.59- 2.52 (m, 2H), 2.14 (3H, s), 2.03 (3H, s), 1.72-1.64 (m, 2H), 1.53-1.41 (br, 1H), 1.31-1.19 (m, 2H), 0.94 (3H, d, J = 6.4 Hz).
101		LC-MS: [M + H]+/Rt (min) 339.2/0.638 (Method A)
102		LC-MS: [M + H]+/Rt (min) 375.3/0.595 (Method A)
103		1H-NMR (400 MHz, CDCl3) δ: 9.51 (s, 1H), 8.60 (d, J = 2.3 Hz, 1H), 8.26 (dd, J = 8.7, 2.3 Hz, 1H), 7.63 (d, J = 10.1 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.03 (d, J = 9.6 Hz, 1H), 6.21 (br, 1H), 5.00 (s, 2H), 2.79- 2.68 (m, 4H), 2.19-2.06 (m, 2H).
104		LC-MS: [M + H]+/Rt (min) 382.2/0.860 (Method A)
105		LC-MS: [M + H]+/Rt (min) 382.2/0.771 (Method A)
106		LC-MS: [M + H]+/Rt (min) 349.2/0.734 (Method A)
107		1H-NMR (400 MHz, CDCl3) δ: 9.59 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.54 (d, J = 1.8 Hz, 1H), 8.44 (t, J = 2.1 Hz, 1H), 7.64 (d, J = 9.8 Hz, 1H), 7.04 (d, J = 9.8 Hz, 1H), 6.22 (1H, bs), 5.00 (s, 2H), 2.79-2.70 (m, 4H), 2.19-2.09 (m, 2H).
108		LC-MS: [M + H]+/Rt (min) 339.2/0.713 (Method A)
109		1H-NMR (400 MHz, DMSO-d6) δ: 11.03 (s, 1H), 8.85 (d, J = 2.7 Hz, 1H), 8.21 (dd, J = 8.7, 1.8 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.93 (d, J = 10.1 Hz, 1H), 6.97 (d, J = 9.6 Hz, 1H), 6.45 (br, 1H), 4.94 (s, 2H), 2.78 (t, J = 13.7 Hz, 2H), 2.63-2.57 (m, 2H), 2.18- 2.07 (m, 2H).
110		LC-MS: [M + H]+/Rt (min) 339.2/0.743 (Method A)
111		LC-MS: [M + H]+/Rt (min) 382.3/0.840 (Method A)
112		1H-NMR (400 MHz, CDCl3) δ: 9.45 (s, 1H), 8.64 (s, 1H), 8.49 (s, 1H), 8.31 (s, 1H), 7.58 (dd, J = 10.1, 2.1 Hz, 1H), 6.99 (dd, J = 9.8, 1.8 Hz, 1H), 6.17 (br, 1H), 4.96 (s, 2H), 2.74-2.64 (m, 4H), 2.13-2.03 (m, 2H).
113		LC-MS: [M + H]+/Rt (min) 382.3/0.845 (Method A)
114		1H-NMR (400 MHz, CDCl3) δ: 9.66 (s, 1H), 8.51 (d, J = 5.9 Hz, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.64 (d, J = 9.6 Hz, 1H), 7.57 (dd, J = 5.3, 2.1 Hz, 1H), 7.04 (d, J = 9.6 Hz, 1H), 6.22 (br, 1H), 4.99 (s, 2H), 2.79- 2.70 (m, 4H), 2.18-2.08 (m, 2H).
115		1H-NMR (400 MHz, DMSO-d6) δ: 11.12 (s, 1H), 8.60 (d, J = 5.9 Hz, 1H), 8.08 (d, J = 2.3 Hz, 1H), 7.94 (d, J = 10.1 Hz, 1H), 7.76 (dd, J = 5.5, 2.3 Hz, 1H), 6.99 (d, J = 10.1 Hz, 1H), 6.45 (br, 1H), 4.94 (s, 2H), 2.78 (t, J = 13.7 Hz, 2H), 2.63-2.57 (m, 2H), 2.18- 2.08 (m, 2H).
116		LC-MS: [M + H]+/Rt (min) 339.2/0.743 (Method A)
117		LC-MS: [M + H]+/Rt (min) 344.3/0.721 (Method A)
118		LC-MS: [M + H]+/Rt (min) 368.3/0.747 (Method A)
119		1H-NMR (400 MHz, CDCl3) δ: 10.29 (s, 1H), 8.64 (d, J = 1.8 Hz, 1H), 8.28 (dd, J = 8.7, 2.7 Hz, 1H), 7.59 (d, J = 8.7 Hz, 1H), 7.15 (d, J = 10.1 Hz, 1H), 6.95 (d, J = 10.1 Hz, 1H), 4.87 (s, 2H), 3.47 (t, J = 5.9 Hz, 4H), 1.73 (br, 4H), 1.56-1.53 (m, 4H).
120		1H-NMR (400 MHz, CDCl3) δ: 10.31 (s, 1H), 8.54 (d, J = 5.5 Hz, 1H), 7.85 (d, J = 1.8 Hz, 1H), 7.66 (dd, J = 5.5, 1.8 Hz, 1H), 7.15 (d, J = 10.1 Hz, 1H), 6.95 (d, J = 10.1 Hz, 1H), 4.86 (s, 2H), 3.47 (t, J = 5.9 Hz, 4H), 1.73 (br, 4H), 1.56-1.53 (m, 4H).
121		1H-NMR (400 MHz, DMSO-d6) δ: 10.91 (s, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.22 (dd, J = 9.5, 2.4 Hz, 1H), 7.99 (d, J = 9.2 Hz, 1H), 7.26 (d, J = 9.8 Hz, 1H), 6.85 (d, J = 10.4 Hz, 1H), 4.75 (s, 2H), 3.36 (t, J = 6.7 Hz, 2H), 3.16 (s, 2H), 1.80 (t, J = 6.7 Hz, 2H), 1.68- 1.48 (m, 8H).
122		1H-NMR (400 MHz, DMSO-d6) δ: 10.35 (s, 1H), 8.70 (s, 1H), 8.12 (d, J = 2.4 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.51 (dd, J = 8.9, 2.1 Hz, 1H), 7.25 (d, J = 9.8 Hz, 1H), 6.85 (d, J = 9.8 Hz, 1H), 4.71 (s, 2H), 3.40-3.34 (m, 2H), 3.17 (s, 2H), 1.80 (t, J = 7.0 Hz, 2H), 1.68-1.49 (m, 8H).
123		1H-NMR (400 MHz, DMSO-d6) δ: 10.43 (s, 1H), 8.14 (s, 1H), 7.89 (s, 1H), 7.62 (s, 1H), 7.49-7.44 (m, 2H), 7.35-7.31 (m, 1H), 7.24 (d, J = 9.6 Hz, 1H), 7.11 (s, 1H), 6.85 (d, J = 10.1 Hz, 1H), 4.71 (s, 2H), 3.38-3.34 (m, 2H), 3.16 (s, 2H), 1.80 (t, J = 6.9 Hz, 2H), 1.64-1.53 (m, 8H).
124		1H-NMR (400 MHz, DMSO-d6) δ: 10.92 (s, 1H), 8.85 (d, J = 2.3 Hz, 1H), 8.22 (dd, J = 8.2, 2.3 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.58 (d, J = 10.1 Hz, 1H), 6.85 (d, J = 10.1 Hz, 1H), 4.76 (s, 2H), 3.17-3.15 (m, 4H), 1.88-1.82 (m, 2H), 1.76-1.72 (m, 4H), 1.59- 1.56 (m, 4H).
125		1H-NMR (400 MHz, DMSO-d6) δ: 10.45 (s, 1H), 8.14 (s, 1H), 7.89 (s, 1H), 7.62 (s, 1H), 7.57 (d, J = 10.1 Hz, 1H), 7.49-7.44 (m, 2H), 7.34-7.31 (m, 1H), 7.10 (s, 1H), 6.85 (d, J = 10.1 Hz, 1H), 4.72 (s, 2H), 3.16 (m, 4H), 1.89-1.82 (m, 2H), 1.77-1.72 (m, 4H), 1.58 (m, 4H).
126		1H-NMR (400 MHz, DMSO-d6) δ: 10.37 (s, 1H), 8.71 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 9.8 Hz, 1H), 7.51 (dd, J = 8.9, 2.1 Hz, 1H), 6.85 (d, J = 9.8 Hz, 1H), 4.72 (s, 2H), 3.18-3.15 (m, 4H), 1.90- 1.82 (m, 2H), 1.77-1.72 (m, 4H), 1.60-1.56 (m, 4H).
127		1H-NMR (400 MHz, DMSO-d6) δ: 10.45 (s, 1H), 9.37 (s, 1H), 8.44 (d, J = 1.8 Hz, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.61-7.56 (m, 2H), 6.86 (d, J = 10.4 Hz, 1H), 4.75 (s, 2H), 3.19-3.14 (m, 4H), 1.90-1.82 (m, 2H), 1.77-1.72 (m, 4H), 1.60-1.56 (m, 4H).
128		1H-NMR (400 MHz, DMSO-d6) δ: 10.43 (s, 1H), 9.37 (s, 1H), 8.45 (d, J = 1.8 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.60 (dd, J = 8.7, 1.8 Hz, 1H), 7.26 (d, J = 10.1 Hz, 1H), 6.86 (d, J = 9.6 Hz, 1H), 4.74 (s, 2H), 3.40-3.36 (m, 2H), 3.18 (s, 2H), 1.83-1.78 (m, 2H), 1.66-1.52 (m, 8H).
129		1H-NMR (400 MHz, DMSO-d6) δ: 10.47 (s, 1H), 8.70 (s, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.89 (d, J = 9.8 Hz, 1H), 7.72 (d, J = 9.2 Hz, 1H), 7.51 (dd, J = 9.2, 1.8 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.56-6.52 (m, 1H), 4.88 (s, 2H), 2.27- 2.20 (m, 2H), 2.14 (s, 2H), 0.92 (s, 6H).
130		1H-NMR (400 MHz, DMSO-d6) δ: 10.36 (s, 1H), 8.69 (s, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.61 (d, J = 10.6 Hz, 1H), 7.51 (dd, J = 9.2, 1.8 Hz, 1H), 6.84 (d, J = 9.8 Hz, 1H), 4.72 (s, 2H), 3.15-3.10 (m, 5H), 1.94- 1.46 (m, 11H).
131		1H-NMR (400 MHz, DMSO-d6) δ: 10.33 (s, 1H), 8.70 (d, J = 1.2 Hz, 1H), 8.11 (s, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.51 (d, J = 9.1 Hz, 1H), 7.23 (d, J = 10.1 Hz, 1H), 6.84 (d, J = 10.1 Hz, 1H), 4.70 (s, 2H), 3.33- 3.26 (m, 3H), 2.03-1.80 (m, 9H).
132		1H-NMR (400 MHz, DMSO-d6) δ: 10.37 (s, 1H), 8.71 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 10.1 Hz, 1H), 7.52 (dd, J = 8.9, 1.8 Hz, 1H), 6.84 (d, J = 10.1 Hz, 1H), 4.72 (s, 2H), 3.21-3.18 (m, 2H), 3.00 (s, 2H), 1.63-1.52 (m, 6H), 1.49-1.43 (m, 4H), 1.33-1.27 (m, 2H).
133		1H-NMR (400 MHz, CDCl3) δ: 9.42 (br, 1H), 8.98 (s, 1H), 8.39 (d, J = 2.0 Hz, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.62 (dd, J = 8.7, 2.0 Hz, 1H), 7.26 (d, J = 9.8 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 4.89 (s, 2H), 3.21 (br s, 2H), 3.18 (s, 2H), 1.94-1.88 (m, 2H), 1.79- 1.73 (m, 4H), 1.60-1.59 (m, 4H).
134		LC-MS: [M + H]+/Rt (min) 436.2/2.00 (Method B)
135		1H-NMR (400 MHz, DMSO-d6) δ: 10.38 (s, 1H), 8.71 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 10.4 Hz, 1H), 7.52 (dd, J = 8.5, 1.8 Hz, 1H), 6.86 (d, J = 10.4 Hz, 1H), 4.73 (s, 2H), 3.25-3.21 (m, 4H), 1.60- 1.56 (m, 4H), 1.48-1.40 (m, 8H).

Examples 136-159

According to the method of Example 37 or 50 and common reaction conditions, the compounds of Examples 136 to 159 were obtained by using each corresponding material compound.

Example	M2	R1	R2	Analytical data
136		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
137		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
138		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
139		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
140		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
141		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
142		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
143		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
144		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
145		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
146		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
147		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
148		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
149		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
150		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
151		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
152		H	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
153		Me	Me	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
154		Me	H	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
155		—(CH2)4—	LC-MS: [M + H]+/Rt (min) 322.2/0.613 (Method A)
156		Me	Me	LC-MS: [M + H]+/Rt (min) 388.2/1.584 (Method B)
157		H	H	LC-MS: [M + H]+/Rt (min) 346.2/0.966 (Method A)
158		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 8.09 (d, J = 9.8 Hz, 1H), 7.83-7.78 (m, 3H), 7.31 (d, J = 7.9 Hz, 2H), 7.10 (d, J = 9.8 Hz, 1H), 6.91 (d, J = 1.8 Hz, 1H), 6.73 (dd, J = 8.5, 2.4 Hz, 1H), 5.13 (s, 2H),
				4.22 (t, J = 8.2 Hz, 2H),
				3.72 (t, J = 4.6 Hz, 4H),
				3.18 (t, J = 8.2 Hz, 2H),
				3.04 (t, J = 4.9 Hz, 4H),
				2.36 (s, 3H).
159		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 8.43 (s, 1H), 8.32 (d, J = 4.9 Hz, 1H), 8.11 (d, J = 9.8 Hz, 1H), 7.81-7.78 (m, 3H), 7.31 (d, J = 8.5 Hz, 2H), 7.12
				(d, J = 9.8 Hz, 1H), 5.21
				(s, 2H), 4.32 (t, J = 8.5
				Hz, 2H), 3.31-3.25 (m,
				2H), 2.36 (s, 3H).

Examples 160-192

According to the method of Example 1, 2, or 50 and common reaction conditions, the compounds of Examples 160 to 192 were obtained by using each corresponding material compound.

Example	Chemical structure	Analytical data
160		1H-NMR (400 MHz, CDCl3) δ: 9.50 (br s, 1H), 8.98 (s, 1H), 8.38 (d, J = 2.3 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.62 (dd, J = 8.7, 2.3 Hz, 1H), 6.99 (d, J = 9.9 Hz, 1H), 6.95 (d, J = 9.9 Hz, 1H), 4.88 (s, 2H), 3.39 (t, J = 6.9 Hz, 2H), 3.35 (s, 2H), 2.07-1.91 (m, 8H).
161		1H-NMR (400 MHz, CDCl3) δ: 9.35 (s, 1H), 8.06-8.00 (m, 2H), 7.43-7.37 (m, 2 H), 7.13 (d, J = 10.0 Hz, 1H), 6.93 (d, J = 10.0 Hz, 1H), 4.85 (s, 2H), 3.81 (dd, J = 14.4, 7.0 Hz, 1H), 3.48-2.40 (m, 1H), 3.28- 3.12 (m, 2H), 2.00-1.92 (m, 1H), 1.86-1.68 (m, 3H).
162		1H-NMR (400 MHz, CDCl3) δ: 9.52 (s, 1H), 8.01 (d, J = 12.2 Hz, 2H), 7.42-7.35 (m, 2H), 6.92 (s, 2H), 4.85 (s, 2H), 3.75-3.58 (m, 4H), 2.37 (d, J = 11.6 Hz, 2H).
163		1H-NMR (400 MHz, CDCl3) δ: 9.27 (br s, 1H), 8.04 (br s, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 7.22 (d, J = 9.8 Hz, 1H), 7.14 (dd, J = 8.5, 1.8 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.70-6.69 (br m, 1H), 4.85 (s, 2H), 3.86- 3.83 (m, 2H), 2.80-2.73 (m, 2H), 1.73-1.70 (m, 2H), 1.59-1.51 (m, 1H), 1.28- 1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
164		LC-MS: [M + H]+/Rt (min) 438.4/0.858 (Method A)
165		1H-NMR (400 MHz, DMSO-d6) δ: 10.36 (s, 1H), 8.70 (s, 1H), 8.11 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.50 (dd, J = 8.9, 2.1 Hz, 1H), 4.72 (s, 2H), 3.32-3.28 (m, 2H), 3.06 (s, 2H), 2.16 (s, 3H), 2.04 (s, 3H), 1.73 (t, J = 7.0 Hz, 2H), 1.63-1.46 (m, 8H).
166		1H-NMR (400 MHz, DMSO-d6) δ: 10.44 (s, 1H), 8.44 (d, J = 7.3 Hz, 1H), 7.90 (s, 1H), 7.81 (s, 1H), 7.44 (d, J = 1.2 Hz, 1H), 6.94 (dd, J = 7.3, 1.8 Hz, 1H), 4.73 (s, 2H), 3.32-3.29 (m, 2H), 3.07 (s, 2H), 2.16 (s, 3H), 2.04 (s, 3H), 1.73 (t, J = 7.0 Hz, 2H), 1.63-1.46 (m, 8H).
167		1H-NMR (400 MHz, CDCl3) δ: 9.67 (s, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.86 (d, J = 1.8 Hz, 1H), 7.55 (s, 1H), 7.47 (s, 1H), 7.04 (dd, J = 7.3, 1.8 Hz, 1H), 7.00 (d, J = 10.1 Hz, 1H), 6.95 (d, J = 10.1 Hz, 1H), 4.85 (s, 2H), 3.44 (t, J = 6.9 Hz, 2H), 3.23 (s, 2H), 1.87 (t, J = 6.9 Hz, 2H), 1.71-1.56 (m, 8H).
168		1H-NMR (400 MHz, CDCl3) δ: 9.54 (br s, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.86 (d, J = 1.8 Hz, 1H), 7.56 (s, 1H), 7.47 (s, 1H), 7.24 (d, J = 10.1 Hz, 1H), 7.02 (dd, J = 7.3, 1.8 Hz, 1H), 6.93 (d, J = 10.1 Hz, 1H), 4.85 (s, 2H), 3.25-3.23 (m, 4H), 1.94-1.88 (m, 2H), 1.81- 1.78 (m, 4H), 1.66-1.64 (m, 4H).
169		1H-NMR (400 MHz, CDCl3) δ: 9.69 (br s, 1H), 8.32 (d, J = 7.5 Hz, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.00 (d, J = 10.1 Hz, 1H), 6.95 (d, J = 10.1 Hz, 1H), 6.72 (dd, J = 7.5, 2.3 Hz, 1H), 6.39 (d, J = 2.4 Hz, 1H), 4.84 (s, 2H), 3.44 (t, J = 7.0 Hz, 2H), 3.22 (s, 2H), 1.87 (t, J = 7.0 Hz, 2H), 1.71-1.66 (m, 4H), 1.62-1.56 (m, 4H).
170		1H-NMR (400 MHz, CDCl3) δ: 8.99 (br s, 1H), 7.20 (d, J = 9.8 Hz, 1H), 7.10-7.10 (br m, 1H), 7.07 (d, J = 7.9 Hz, 1H), 6.92-6.89 (m, 2H), 4.80 (s, 2H), 4.55 (t, J = 8.7 Hz, 2H), 3.84-3.81 (m, 2H), 3.14 (t, J = 8.7 Hz, 2H), 2.79-2.72 (m, 2H), 1.72-1.69 (m, 2H), 1.58- 1.53 (m, 1H), 1.28-1.17 (m, 2H), 0.96 (d, J = 6.7 Hz, 3H).
171		1H-NMR (400 MHz, CDCl3) δ: 7.67 (s, 1H), 7.63 (br s, 1H), 7.46-7.44 (br m, 1H), 7.37 (br s, 1H), 7.28 (s, 1H), 7.24 (br s, 1H), 7.22 (d, J = 9.8 Hz, 1H), 6.91 (d, J = 9.8 Hz, 1H), 4.88 (s, 2H), 3.85-3.83 (br m, 2H), 2.81-2.74 (m, 2H), 1.73-1.70 (m, 2H), 1.66- 1.49 (m, 1H), 1.29-1.19 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
172		1H-NMR (400 MHz, CDCl3) δ: 9.08 (br s, 1H), 7.10 (d, J = 1.2 Hz, 1H), 7.06 (d, J = 7.9 Hz, 1H), 6.97-6.90 (m, 3H), 4.80 (s, 2H), 4.55 (t, J = 8.7 Hz, 2H), 3.37 (t, J = 6.7 Hz, 2H), 3.34 (s, 2H), 3.13 (t, J = 8.7 Hz, 2H), 2.04-1.91 (m, 8H).
173		1H-NMR (400 MHz, CDCl3) δ: 9.74 (br s, 1H), 7.95-7.93 (m, 2H), 7.51 (s, 1H), 7.25 (d, J = 10.1 Hz, 1H), 7.08 (dd, J = 7.9, 1.8 Hz, 1H), 6.94 (d, J = 10.1 Hz, 1H), 4.86 (s, 2H), 3.87-3.83 (m, 2H), 2.81-2.74 (m, 2H), 1.73-1.70 (m, 2H), 1.62- 1.54 (m, 1H), 1.28-1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
174		1H-NMR (400 MHz, CDCl3) δ: 9.46 (br s, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.72 (d, J = 2.4 Hz, 1H), 7.23 (d, J = 10.4 Hz, 1H), 7.21 (br s, 1H), 6.99-6.96 (m, 1H), 6.93 (d, J = 10.4 Hz, 1H), 4.84 (s, 2H), 3.86-3.83 (m, 2H), 2.81-2.74 (m, 2H), 2.41 (s, 3H), 1.73-1.70 (m, 2H), 1.63-1.53 (m, 1H), 1.28-1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
175		1H-NMR (400 MHz, CDCl3) δ: 9.04 (br s, 1H), 7.78 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 7.21 (d, J = 9.8 Hz, 1H), 7.18 (dd, J = 8.5, 2.1 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.31 (s, 1H), 4.84 (s, 2H), 3.85- 3.82 (m, 2H), 2.80-2.73 (m, 2H), 2.42 (s, 3H), 1.73- 1.69 (m, 2H), 1.61-1.53 (m, 1H), 1.28-1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
176		1H-NMR (400 MHz, CD3OD) δ: 9.05 (s, 1H), 8.43 (d, J = 7.3 Hz, 1H), 8.20 (d, J = 1.8 Hz, 1H), 7.54 (d, J = 9.8 Hz, 1H), 7.10 (dd, J = 7.3, 1.8 Hz, 1H), 6.90 (d, J = 9.8 Hz, 1H), 4.87 (s, 2H), 3.29-3.26 (m, 4H), 1.97-1.89 (m, 2H), 1.84- 1.79 (m, 4H), 1.67-1.65 (m, 4H).
177		1H-NMR (400 MHz, CDCl3) δ: 9.62 (br s, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.85-7.84 (br m, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.47 (s, 1H), 7.03 (dd, J = 7.3, 1.5 Hz, 1H), 6.99 (d, J = 9.8 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 4.85 (s, 2H), 3.39 (t, J = 6.7 Hz, 2H), 3.35 (s, 2H), 2.06-1.91 (m, 8H).
178		LC-MS: [M + H]+/Rt (min) 409.3/1.71 (Method B)
179		LC-MS: [M + H]+/Rt (min) 393.4/0.628 (Method A)
180		LC-MS: [M + H]+/Rt (min) 397.1/0.609 (Method A)
181		1H-NMR (400 MHz, CDCl3) δ: 9.26 (br s, 1H), 7.50 (s, 1H), 7.25 (d, J = 2.0 Hz, 1H), 7.22 (d, J = 9.8 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.92 (dd, J = 8.1, 2.0 Hz, 1H), 4.82 (s, 2H), 3.85-3.82 (m, 2H), 2.91- 2.89 (m, 2H), 2.76 (td, J = 12.8, 2.4 Hz, 2H), 2.61- 2.58 (m, 2H), 1.73-1.69 (m, 2H), 1.60-1.53 (m, 1H), 1.27-1.17 (m, 2H), 0.97 (d, J = 6.1 Hz, 3H).
182		LC-MS: [M + H]+/Rt (min) 386.2/1.695 (Method B)
183		1H-NMR (400 MHz, CDCl3) δ: 8.11 (d, J = 8.5 Hz, 1H), 7.18 (d, J = 9.8 Hz, 1H), 6.87 (d, J = 9.8 Hz, 1H), 6.75 (br s, 1H), 6.70-6.68 (br m, 1H), 4.88 (s, 2H), 4.17-4.13 (m, 2H), 3.77 (s, 3H), 3.77-3.75 (m, 2H), 3.25-3.20 (m, 2H), 2.75- 2.68 (m, 2H), 1.70-1.67 (m, 2H), 1.56-1.49 (m, 1H), 1.28-1.18 (m, 2H), 0.95 (d, J = 6.7 Hz, 3H).
184		1H-NMR (400 MHz, CDCl3) δ: 8.10 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.88 (d, J = 9.8 Hz, 1H), 6.78 (br s, 1H), 6.74-6.71 (br m, 1H), 4.88 (s, 2H), 4.16-4.11 (m, 2H), 3.86- 3.83 (m, 4H), 3.37-3.33 (m, 2H), 3.30 (s, 2H), 3.24- 3.20 (m, 2H), 3.10-3.08 (m, 4H), 2.04-1.86 (m, 8H).
185		1H-NMR (400 MHz, CDCl3) δ: 8.41 (s, 1H), 8.38 (d, J = 5.5 Hz, 1H), 8.00 (br s, 1H), 7.21-7.19 (m, 1H), 6.88 (d, J = 9.8 Hz, 1H), 4.89 (br s, 2H), 4.21 (t, J = 8.5 Hz, 2H), 3.33-3.29 (m, 2H), 3.19-3.16 (m, 4H), 1.92-1.87 (m, 2H), 1.80- 1.76 (m, 4H), 1.65-1.62 (m, 4H).
186		1H-NMR (400 MHz, CDCl3) δ: 7.82 (d, J = 8.5 Hz, 1H), 7.19-7.12 (m, 2H), 6.88 (d, J = 9.8 Hz, 1H), 6.58 (d, J = 8.5 Hz, 1H), 4.88 (s, 2H), 4.17 (t, J = 8.5 Hz, 2H), 3.84 (s, 3H), 3.25- 3.22 (m, 4H), 3.17 (t, J = 8.5 Hz, 2H), 1.44-1.42 (m, 4H), 0.96 (s, 6H).
187		1H-NMR (400 MHz, CDCl3) δ: 8.12 (d, J = 8.9 Hz, 1H), 6.94 (d, J = 10.1 Hz, 1H), 6.89 (d, J = 10.1 Hz, 1H), 6.75-6.75 (br m, 1H), 6.69 (dd, J = 8.9, 2.4 Hz, 1H), 4.88 (s, 2H), 4.15 (t, J = 8.5 Hz, 2H), 3.77 (s, 3H), 3.35 (t, J = 6.7 Hz, 2H), 3.31 (s, 2H), 3.23 (t, J = 8.5 Hz, 2H), 2.05-1.88 (m, 8H).
188		1H-NMR (400 MHz, CDCl3) δ: 7.31-7.28 (m, 2H), 6.94- 6.89 (m, 4H), 6.86 (d, J = 10.4 Hz, 1H), 4.88 (s, 2H), 3.82-3.79 (m, 2H), 3.67- 3.65 (m, 2H), 3.35 (t, J = 6.7 Hz, 2H), 3.30 (s, 2H), 3.23-3.18 (m, 4H), 2.04- 1.88 (m, 8H).
189		1H-NMR (400 MHz, CDCl3) δ: 8.28-8.26 (br m, 1H), 7.45- 7.43 (m, 2H), 7.20 (d, J = 10.4 Hz, 1H), 6.88 (d, J = 10.4 Hz, 1H), 4.91 (s, 2H), 4.25-4.21 (m, 2H), 3.78- 3.75 (m, 2H), 3.33-3.29 (m, 2H), 2.76-2.69 (m, 2H), 1.71-1.67 (m, 2H), 1.57- 1.48 (m, 1H), 1.28-1.18 (m, 2H), 0.96 (d, J = 6.7 Hz, 3H).
190		1H-NMR (400 MHz, CDCl3) δ: 9.23 (br s, 1H), 7.57 (s, 1H), 7.29-7.26 (m, 1H), 7.22 (d, J = 9.8 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 5.05 (s, 4H), 4.82 (s, 2H), 3.24-3.21 (m, 4H), 1.96- 1.88 (m, 2H), 1.81-1.77 (m, 4H), 1.66-1.63 (m, 4H).
191		1H-NMR (400 MHz, CDCl3) δ: 8.96 (s, 1H), 7.18 (d, J = 2.4 Hz, 1H), 7.00-6.88 (m, 3H), 6.76 (d, J = 8.5 Hz, 1H), 4.79 (s, 2H), 4.23- 4.20 (m, 4H), 3.37 (t, J = 7.0 Hz, 2H), 3.33 (s, 2H), 2.07-1.90 (m, 8H).
192		1H-NMR (400 MHz, CDCl3) δ: 9.62 (br s, 1H), 8.02 (d, J = 7.3 Hz, 1H), 7.90 (s, 1H), 7.54 (s, 1H), 7.51 (s, 1H), 7.27-7.24 (m, 1H), 7.04 (d, J = 6.1 Hz, 1H), 6.94 (d, J = 10.4 Hz, 1H), 4.87 (s, 2H), 3.32-3.29 (m, 4H), 1.46-1.43 (m, 4H), 0.98 (s, 6H).

Examples 193-238

According to the method of Example 1, 2, or 50 and common reaction conditions, the compounds of Examples 193 to 238 were obtained by using each corresponding material compound.

Example	Chemical structure	Analytical data
193		1H-NMR (400 MHz, DMSO-d6) δ: 10.33 (s, 1H), 8.70 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.51 (dd, J = 8.8, 2.1 Hz, 1H), 7.16 (d, J = 1.2 Hz, 1H), 4.71 (s, 2H), 3.35 (t, J = 6.7 Hz, 2H), 3.16 (s, 2H), 2.08 (s, 3H), 1.80 (t, J = 7.0 Hz, 2H), 1.65-1.52 (m, 8H).
194		1H-NMR (400 MHz, DMSO-d6) δ: 10.34 (s, 1H), 8.70 (s, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.50 (dd, J = 8.6, 1.8 Hz, 1H), 6.71 (d, J = 1.2 Hz, 1H), 4.70 (s, 2H), 3.39 (t, J = 6.7 Hz, 2H), 3.14 (s, 2H), 2.25 (s, 3H), 1.74 (t, J = 7.0 Hz, 2H), 1.63-1.46 (m, 8H).
195		1H-NMR (400 MHz, DMSO-d6) δ: 10.31 (s, 1H), 8.70 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.51 (dd, J = 8.7, 1.8 Hz, 1H), 6.20 (s, 1H), 4.66 (s, 2H), 3.83 (s, 3H), 3.45 (t, J = 7.1 Hz, 2H), 3.20 (s, 2H), 1.71 (t, J = 7.1 Hz, 2H), 1.63-1.48 (m, 8H).
196		1H-NMR (400 MHz, DMSO-d6) δ: 10.29 (s, 1H), 8.70 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.51 (dd, J = 8.8, 2.1 Hz, 1H), 5.83 (s, 1H), 4.66 (s, 2H), 3.35-3.31 (m, 2H), 3.14 (s, 2H), 3.04 (s, 6H), 1.77 (t, J = 6.7 Hz, 2H), 1.65- 1.49 (m, 8H).
197		1H-NMR (400 MHz, DMSO-d6) δ: 10.35 (s, 1H), 8.70 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.51 (dd, J = 8.8, 2.1 Hz, 1H), 5.98 (s, 1H), 4.67 (s, 2H), 3.24 (t, J = 7.3 Hz, 2H), 3.04 (s, 2H), 2.79 (s, 6H), 1.73 (t, J = 7.0 Hz, 2H), 1.63-1.47 (m, 8H).
198		1H-NMR (400 MHz, DMSO-d6) δ: 10.36 (s, 1H), 7.21 (s, 2H), 7.16-7.14 (m, 1H), 4.68 (s, 2H), 3.35-3.31 (m, 2H), 3.14 (s, 2H), 2.35 (s, 6H), 2.06 (s, 3H), 1.79 (t, J = 6.7 Hz, 2H), 1.66-1.49 (m, 8H).
199		1H-NMR (400 MHz, DMSO-d6) δ: 10.38 (s, 1H), 7.20 (s, 2H), 6.70 (d, J = 1.2 Hz, 1H), 4.68 (s, 2H), 3.38 (t, J = 7.0 Hz, 2H), 3.13 (s, 2H), 2.35 (s, 6H), 2.25 (s, 3H), 1.74 (t, J = 7.0 Hz, 2H), 1.63-1.47 (m, 8H).
200		1H-NMR (400 MHz, DMSO-d6) δ: 10.35 (s, 1H), 8.70 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.53-7.47 (m, 2H), 4.73 (s, 2H), 3.81 (d, J = 13.4 Hz, 2H), 2.68-2.61 (m, 2H), 2.07 (s, 3H), 1.64 (d, J = 12.2 Hz, 2H), 1.57-1.45 (m, 1H), 1.19-1.09 (m, 2H), 0.91 (d, J = 6.2 Hz, 3H).
201		1H-NMR (400 MHz, DMSO-d6) δ: 10.39 (s, 1H), 8.71 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 9.2 Hz, 1H), 7.51 (dd, J = 8.9, 2.1 Hz, 1H), 6.78 (d, J = 1.2 Hz, 1H), 4.75 (s, 2H), 3.23 (d, J = 12.8 Hz, 2H), 2.63-2.52 (m, 2H), 2.20 (s, 3H), 1.67 (d, J = 10.4 Hz, 2H), 1.55- 1.43 (m, 1H), 1.29-1.19 (m, 2H), 0.94 (d, J = 6.7 Hz, 3H).
202		1H-NMR (400 MHz, CDCl3) δ: 9.11 (br s, 1H), 7.08-7.05 (br m, 2H), 6.93 (dd, J = 8.2, 2.0 Hz, 1H), 6.81 (d, J = 2.0 Hz, 1H), 4.80 (s, 2H), 4.55 (t, J = 8.7 Hz, 2H), 3.36 (t, J = 6.7 Hz, 2H), 3.32 (s, 2H), 3.13 (t, J = 8.7 Hz, 2H), 2.23 (d, J = 1.2 Hz, 3H), 2.06-1.90 (m, 8H).
203		1H-NMR (400 MHz, CDCl3) δ: 9.17 (br s, 1H), 7.11 (br s, 1H), 7.07-7.05 (br m, 1H), 6.90 (dd, J = 7.9, 1.8 Hz, 1H), 6.71 (br s, 1H), 4.78 (s, 2H), 4.55 (t, J = 8.7 Hz, 2H), 3.38 (t, J = 6.7 Hz, 2H), 3.33 (s, 2H), 3.13 (t, J = 8.7 Hz, 2H), 2.28 (d, J = 1.2 Hz, 3H), 2.06- 1.86 (m, 8H).
204		1H-NMR (400 MHz, DMSO-d6) δ: 10.34 (s, 1H), 8.71 (s, 1H), 8.12 (d, J = 2.4 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 8.9, 2.1 Hz, 1H), 7.15 (d, J = 1.2 Hz, 1H), 4.72 (s, 2H), 3.31-3.28 (m, 4H), 2.08 (d, J = 1.2 Hz, 3H), 2.03-1.80 (m, 8H).
205		1H-NMR (400 MHz, DMSO-d6) δ: 10.35 (s, 1H), 8.71 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.51 (dd, J = 8.9, 2.1 Hz, 1H), 6.71 (s, 1H), 4.70 (s, 2H), 3.35-3.28 (m, 4H), 2.25 (s, 3H), 2.03-1.76 (m, 8H).
206		1H-NMR (400 MHz, DMSO-d6) δ: 10.33 (s, 1H), 8.71 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.51 (dd, J = 8.5, 1.8 Hz, 1H), 5.78 (s, 1H), 4.67 (s, 2H), 3.29-3.25 (m, 4H), 3.10 (t, J = 7.3 Hz, 2H), 2.95 (s, 2H), 1.91-1.87 (m, 4H), 1.75 (t, J = 7.3 Hz, 2H), 1.61-1.51 (m, 8H).
207		1H-NMR (400 MHz, DMSO-d6) δ: 10.28 (s, 1H), 8.70 (s, 1H), 8.13 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.51 (dd, J = 8.9, 2.1 Hz, 1H), 5.52 (s, 1H), 4.63 (s, 2H), 3.57 (s, 4H), 3.29-3.23 (m, 4H), 2.01-1.79 (m, 12H).
208		1H-NMR (400 MHz, DMSO-d6) δ: 10.33 (s, 1H), 8.70 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.51 (dd, J = 8.9, 2.1 Hz, 1H), 5.78 (s, 1H), 4.66 (s, 2H), 3.26-3.22 (m, 4H), 3.08 (s, 2H), 3.04 (t, J = 7.2 Hz, 2H), 2.03-1.76 (m, 12H).
209		1H-NMR (400 MHz, DMSO-d6) δ: 10.45 (s, 1H), 8.45 (d, J = 7.3 Hz, 1H), 7.91 (d, J = 1.2 Hz, 1H), 7.82 (s, 1H), 7.45 (d, J = 1.2 Hz, 1H), 6.95 (dd, J = 7.3, 1.8 Hz, 1H), 4.74 (s, 2H), 3.26-3.21 (m, 4H), 2.16 (s, 3H), 2.05 (s, 3H), 2.01-1.78 (m, 8H).
210		LC-MS: [M + H]+/Rt (min) 422.4/0.695 (Method A)
211		1H-NMR (400 MHz, CDCl3) δ: 9.42 (br s, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.71 (br m, 1H), 7.55 (br m, 1H), 7.46 (s, 1H), 7.16 (dd, J = 7.3, 1.8 Hz, 1H), 5.99 (s, 1H), 4.83 (s, 2H), 3.27-3.24 (m, 4H), 3.13 (s, 6H), 1.46-1.43 (m, 4H), 0.97 (s, 6H).
212		LC-MS: [M + H]+/Rt (min) 411.4/0.618 (Method A)
213		LC-MS: [M + H]+/Rt (min) 409.4/0.608 (Method A)
214		1H-NMR (400 MHz, CDCl3) δ: 9.37 (s, 1H), 8.04 (d, J = 9.2 Hz, 2H), 7.42 (s, 2H), 7.20 (d, J = 10.0 Hz, 1H), 6.94 (d, J = 10.0 Hz, 1H) 4.85 (s, 2H), 3.70-3.65 (m, 1H), 3.21 (d, J = 12.6 Hz, 1H), 3.00-2.95 (m, 1H), 2.84 (d, J = 12.6 Hz, 1H), 2.08- 2.04 (m, 1H), 1.48-1.32 (m, 2H), 1.11 (s, 3H), 0.96-0.84 (m, 1H), 0.92 (s, 3H).
215		1H-NMR (400 MHz, CDCl3) δ: 9.41 (br s, 1H), 7.76 (d, J = 1.8 Hz, 1H), 7.53 (d, J = 1.8 Hz, 1H), 7.23 (d, J = 10.1 Hz, 1H), 6.94 (d, J = 10.1 Hz, 1H), 4.84 (s, 2H), 3.84 (d, J = 12.8 Hz, 2H), 2.81-2.74 (m, 2H), 2.65 (s, 3H), 1.74-1.70 (m, 2H), 1.59-1.53 (m, 1H), 1.30- 1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
216		1H-NMR (400 MHz, CDCl3) δ: 9.53 (br s, 1H), 8.07 (s, 1H), 7.75 (d, J = 1.4 Hz, 1H), 7.53-7.50 (m, 1H), 7.24 (d, J = 10.4 Hz, 1H), 6.94 (d, J = 10.4 Hz, 1H), 4.85 (s, 2H), 3.87-3.83 (m, 2H), 2.80-2.74 (m, 2H), 1.74- 1.70 9m, 2H), 1.61-1.50 (m, 1H), 1.31-1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
217		1H-NMR (400 MHz, CDCl3) δ: 9.65 (s, 1H), 8.64 (d, J = 2.7 Hz, 1H), 8.10 (dd, J = 8.5, 2.7 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.25 (d, J = 10.4 Hz, 1H), 6.95 (d, J = 10.4 Hz, 1H), 4.86 (s, 2H), 3.87-3.83 (m, 2H), 3.78-3.74 (m, 2H), 3.68- 3.65 (m, 2H), 2.81-2.74 (m, 2H), 1.93-1.89 (m, 4H), 1.74-1.70 (m, 2H), 1.58- 1.53 (m, 1H), 1.28-1.18 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H).
218		1H-NMR (400 MHz, CDCl3) δ: 7.94-7.92 (br m, 1H), 7.19- 7.14 (m, 2H), 6.87 (d, J = 9.8 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.89 (s, 2H), 4.17-4.13 (m, 2H), 3.85- 3.83 (m, 4H), 3.77-3.74 (m, 2H), 3.19-3.15 (m, 2H), 2.99-2.97 (m, 4H), 2.75- 2.68 (m, 2H), 1.70-1.67 (m, 2H), 1.60-1.49 (m, 1H), 1.28-1.18 (m, 2H), 0.95 (d, J = 6.1 Hz, 3H).
219		1H-NMR (400 MHz, CDCl3) δ: 8.15 (d, J = 9.0 Hz, 1H), 7.79 (s, 1H), 7.18 (d, J = 10.1 Hz, 1H), 7.09 (dd, J = 9.0, 2.1 Hz, 1H), 6.88 (d, J = 10.1 Hz, 1H), 4.89 (s, 2H), 4.19-4.14 (m, 2H), 3.86-3.82 (m, 2H), 3.76 (br m, 2H), 3.29-3.25 (br m, 2H), 2.75-2.68 (br m, 2H), 2.62-2.58 (m, 2H), 2.18- 2.11 (m, 2H), 1.70-1.67 (m, 2H), 1.56-1.49 (m, 1H), 1.28-1.18 (m, 2H), 0.96 (d, J = 6.7 Hz, 3H).
220		1H-NMR (400 MHz, CDCl3) δ: 8.07 (d, J = 9.1 Hz, 1H), 7.17 (d, J = 10.1 Hz, 1H), 6.87 (d, J = 10.1 Hz, 1H), 6.79 (br s, 1H), 6.75 (d, J = 8.4 Hz, 1H), 4.87 (s, 2H), 4.13 (t, J = 8.4 Hz, 2H), 3.77-3.74 (br m, 2H), 3.21 (t, J = 8.2 Hz, 2H), 3.16- 3.14 (m, 4H), 2.74-2.68 (m, 2H), 2.58 (d, J = 9.8 Hz, 4H), 2.35 (s, 3H), 1.71-1.66 (m, 2H), 1.57-1.47 (m, 1H), 1.27-1.17 (m, 2H), 0.95 (d, J = 6.1 Hz, 3H).
221		1H-NMR (400 MHz, CDCl3) δ: 7.93 (d, J = 7.9 Hz, 1H), 7.20-7.14 (m, 2H), 6.88 (d, J = 9.8 Hz, 1H), 6.69 (d, J = 7.9 Hz, 1H), 4.89 (s, 2H), 4.18-4.13 (m, 2H), 3.85- 3.83 (m, 4H), 3.25-3.20 (m, 4H), 3.19-3.15 (m, 2H), 2.99-2.97 (m, 4H), 1.44- 1.41 (m, 4H), 0.96 (s, 6H).
222		LC-MS: [M + H]+/Rt (min) 493.4/1.077 (Method A)
223		1H-NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 7.9 Hz, 1H), 7.18 (d, J = 10.1 Hz, 1H), 7.14 (t, J = 7.9 Hz, 1H), 6.88 (d, J = 10.1 Hz, 1H), 6.69 (d, J = 7.9 Hz, 1H), 4.89 (s, 2H), 4.14 (t, J = 8.2 Hz, 2H), 3.24-3.22 (m, 4H), 3.16 (t, J = 8.2 Hz, 2H), 3.03-3.00 (m, 4H), 2.57 (br s, 4H), 2.36 (s, 3H), 1.44-1.41 (br m, 4H), 0.96 (s, 6H).
224		1H-NMR (400 MHz, DMSO-d6) δ: 7.67 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 6.74 (s, 1H), 6.67 (d, J = 7.6 Hz, 1H), 4.84 (s, 2H), 4.18-4.14 (m, 2H), 3.82 (s, 3H), 3.73-3.71 (m, 4H), 3.24-3.21 (m, 4H), 3.12- 3.07 (m, 2H), 2.93-2.90 (m, 4H), 1.38-1.35 (m, 4H), 0.93 (s, 6H).
225		1H-NMR (400 MHz, CDCl3) δ: 7.89 (d, J = 7.9 Hz, 1H), 7.13-7.09 (m, 1H), 6.82 (br s, 1H), 6.66 (d, J = 7.9 Hz, 1H), 4.89 (s, 2H), 4.17-4.12 (m, 2H), 3.34 (t, J = 6.7 Hz, 2H), 3.30 (s, 2H), 3.12- 3.08 (m, 2H), 3.02 (br s, 4H), 2.77 (br s, 4H), 2.51 (br s, 3H), 2.21 (d, J = 1.2 Hz, 3H), 2.05-1.86 (m, 8H).
226		1H-NMR (400 MHz, DMSO-d6) δ: 7.68 (d, J = 7.9 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 4.86 (s, 2H), 4.18 (t, J = 8.2 Hz, 2H), 3.73 (t, J = 4.6 Hz, 4H), 3.25-3.20 (m, 4H), 3.11 (t, J = 8.2 Hz, 2H), 2.92 (t, J = 4.3 Hz, 4H), 2.16 (s, 3H), 2.05 (s, 3H), 2.00-1.78 (m, 8H).
227		1H-NMR (400 MHz, DMSO-d6) δ: 7.67 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 8.0 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 6.39 (s, 1H), 4.82 (s, 2H), 4.18-4.14 (m, 2H), 3.83 (s, 3H), 3.73-3.71 (m, 4H), 3.30-3.28 (m, 2H), 3.12- 3.07 (m, 2H), 2.93-2.90 (m, 5H), 2.00-1.84 (m, 9H).
228		1H-NMR (400 MHz, CDCl3) δ: 10.26 (s, 1H), 8.39 (d, J = 7.3 Hz, 1H), 8.25 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.28-7.25 (m, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 4.91 (s, 2H), 3.35-3.25 (m, 4H), 1.48- 1.38 (m, 4H), 0.98 (s, 6H).
229		1H-NMR (400 MHz, CDCl3) δ: 10.01 (s, 1H), 8.42 (d, J = 7.3 Hz, 1H), 8.24 (s, 1H), 8.11 (d, J = 2.4 Hz, 1H), 7.35-7.21 (m, 1H), 7.12 (dd, J = 7.6, 2.1 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 4.87 (s, 2H), 3.85 (d, J = 13.4 Hz, 2H), 2.78 (td, J = 12.8, 2.4 Hz, 2H), 1.72 (d, J = 12.8 Hz, 2H), 1.27-1.17 (m, 3H), 0.97 (d, J = 6.1 Hz, 3H).
230		1H-NMR (400 MHz, CDCl3) δ: 10.11 (s, 1H), 8.44 (d, J = 7.3 Hz, 1H), 8.26 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.15 (dd, J = 7.3, 2.4 Hz, 1H), 7.05 (d, J = 10.4 Hz, 1H), 6.95 (d, J = 10.4 Hz, 1H), 4.89 (s, 2H), 3.40 (t, J = 7.0 Hz, 2H, 3.36 (s, 2H), 2.10-1.90 (m, 8H).
231		1H-NMR (400 MHz, CDCl3) δ: 10.07 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.24 (s, 1H), 8.10 (d, J = 1.2 Hz, 1H), 7.30-7.24 (m, 1H), 7.15-7.11 (m, 1H), 6.95 (d, J = 9.8 Hz, 1H), 4.89 (s, 2H), 3.27- 3.24 (m, 4H), 1.98-1.89 (m, 2H), 1.85-1.77 (m, 4H), 1.68-1.65 (m, 4H).
232		LC-MS: [M + H]+/Rt (min) 381.2/1.54 (Method B)
233		1H-NMR (400 MHz, CDCl3) δ: 8.87 (s, 1H), 7.20 (d, J = 10.1 Hz, 1H), 7.05 (d, J = 1.8 Hz, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.90 (d, J = 10.1 Hz, 1H), 6.64 (dd, J = 7.6, 1.8 Hz, 1H), 4.79 (s, 2H), 3.84-3.77 (m, 3H), 3.54 (t, J = 8.2 Hz, 2H), 2.95 (t, J = 8.2 Hz, 2H), 2.79- 2.72 (m, 2H), 1.72-1.69 (m, 2H), 1.58-1.51 (m, 1H), 1.27-1.17 (m, 2H), 0.96 (d, J = 6.7 Hz, 3H).
234		1H-NMR (400 MHz, DMSO-d6) δ: 8.72 (s, 1H), 8.60 (d, J = 4.9 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.59 (d, J = 9.8 Hz, 1H), 7.51 (dd, J = 7.9, 4.9 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 7.3 Hz, 1H), 6.87 (d, J = 9.8 Hz, 1H), 4.89 (s, 2H), 4.21 (t, J = 8.2 Hz, 2H), 3.29-3.23 (m, 6H), 1.39- 1.36 (m, 4H), 0.94 (s, 6H).
235		1H-NMR (400 MHz, DMSO-d6) δ: 9.45 (dd, J = 2.4, 1.2 Hz, 1H), 9.32 (dd, J = 5.5, 1.2 Hz, 1H), 8.15 (d, J = 7.9 Hz, 1H), 7.87 (dd, J = 4.9, 2.4 Hz, 1H), 7.59 (d, J = 10.4 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.28-7.25 (m, 1H), 6.87 (d, J = 10.4 Hz, 1H), 4.91 (s, 2H), 4.23 (t, J = 8.2 Hz, 2H), 3.36 (t, J = 8.2 Hz, 2H), 3.26-3.23 (m, 4H), 1.37 (t, J = 5.8 Hz, 4H), 0.94 (s, 6H).
236		1H-NMR (400 MHz, CDCl3) δ: 10.18 (s, 1H), 9.15 (s, 2H), 8.23 (s, 1H), 7.75-7.65 (m, 2H), 7.01-6.92 (m, 2H), 4.93 (s, 2H), 3.41-3.35 (m, 2H), 2.08-1.87 (m, 10H).
237		1H-NMR (400 MHz, CD3OD) δ: 8.32 (s, 1H), 7.97 (s, 1H), 7.70 (s, 1H), 7.52-7.37 (m, 2H), 7.06 (s, 1H), 6.89 (s, 1H), 4.95-4.85 (m, 2H), 4.27 (s, 2H), 2.15-1.90 (m, 3H), 1.90-1.70 (m, 3H), 1.55- 1.40 (m, 3H), 1.24 (d, J = 6.0 Hz, 3H).
238		1H-NMR (400 MHz, CDCl3) δ: 7.98 (d, J = 7.3 Hz, 1H), 7.18 (t, J = 8.2 Hz, 1H), 7.06 (d, J = 9.8 Hz, 1H), 6.88 (d, J = 9.8 Hz, 1H), 6.74 (d, J = 7.3 Hz, 1H), 4.90 (s, 2H), 4.19-4.09 (m, 4H), 3.89 (t, J = 25.6 Hz, 4H), 3.24 (s, 2H), 3.04 (s, 4H), 2.05-1.90 (m, 2H), 1.78-1.70 (m, 2H), 1.30- 1.22 (m, 3H), 0.90-0.85 (m, 2H), 0.83 (d, J = 6.7 Hz, 3H).

Examples 239-243

According to the method of Example 1, 37, or 50 and common reaction conditions, the compounds of Examples 239 to 243 were obtained by using each corresponding material compound.

Example	M2	Analytical data
239		1H-NMR (400 MHz, CDCl3) δ: 8.87 (s, 1H), 7.76 (s, 1H), 7.60 (d, J = 9.8 Hz, 1H), 7.24 (br s, 2H), 6.98 (d, J = 9.8 Hz, 1H), 6.37 (br s, 1H), 4.97 (s, 2H), 4.21 (s, 3H), 2.65-2.62 (br m, 1H), 2.37-2.30
		(br m, 2H), 1.89-1.81 (br m, 2H),
		1.76-1.67 (br m, 1H), 1.34-1.24
		(m, 1H), 1.01 (d, J = 6.1 Hz, 3H).
240		1H-NMR (400 MHz, CDCl3) δ: 9.18 (s, 1H), 8.02-7.99 (m, H1), 7.59 (d, J = 9.8 Hz, 1H), 7.48 (d, J = 8.6 Hz, 1H), 7.26-7.22 (m, H1), 6.98 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H), 4.98 (s, 2H), 2.68-2.59 (m, 1H), 2.52 (s, 3H), 2.43-2.31 (m,
		2H), 1.92-1.82 (m, 2H), 1.8-1.70
		(m, 1H), 1.39-1.27 (m, 1H), 1.02
		(d, J = 6.1 Hz, 3H).
241		1H-NMR (400 MHz, CDCl3) δ: 9.28 (s, 1H), 8.06 (s, 1H), 7.71 (s, 1H), 7.62 (d, J = 9.8 Hz, 1H), 7.50 (d, J = 11.6 Hz, 1H), 6.99 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H), 4.99 (s, 2H), 2.73-2.57 (m, 1H), 2.38-2.27 (m, 2H), 1.90-1.78 (m, 2H), 1.75- 1.57 (m, 2H), 1.01 (d, J = 6.7 Hz,
		3H).
242		1H-NMR (400 MHz, CDCl3) δ: 9.38 (s, 1H), 8.33 (d, J = 7.3 Hz, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.68 (d, J = 1.2 Hz, 1H), 7.59 (d, J = 9.8 Hz, 1H), 7.44 (d, J = 1.2 Hz, 1H), 6.97 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H),
		5.14 (s, 2H), 2.65-2.55 (m, 1H),
		2.37-2.25 (m, 2H), 1.91-1.80 (m,
		2H), 1.78-1.65 (m, 1H), 1.35-1.20
		(m, 1H), 1.00 (d, J = 6.1 Hz, 3H).
243		1H-NMR (400 MHz, CDCl3) δ: 9.34 (s, 1H), 8.11 (s, 1H), 7.62 (d, J = 9.8 Hz, 1H), 7.48-7.42 (m, 2H), 6.99 (d, J = 9.8 Hz, 1H), 6.76 (t, J = 52.4 Hz, 1H), 6.38 (s, 1H), 5.02 (s, 2H), 2.68-2.53 (m, 1H),
		2.40-2.28 (m, 2H), 1.90-1.79 (m,
		2H), 1.48-1.42 (m, 1H), 1.35-1.24
		(m, 1H), 1.01 (d, J = 6.1 Hz, 3H).

Example 244

N-[2-(Dimethylamino)-1,3-benzooxazol-5-yl]-2-[3-(4-methylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide

To a suspension of the compound of Reference example 16 (45 mg), N²,N²-dimethyl-1,3-benzoxazole-2,5-diamine (39 mg), and HATU (90 mg) in acetonitrile (1.8 mL) was added N,N-diisopropylethylamine (0.13 mL), and the mixture was stirred at room temperature for 2 hours. After the addition of saturated aqueous ammonium chloride, the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate:methanol=100:0, and then 96:4) to obtain the titled compound (75 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 8.68 (s, 1H), 7.60 (d, J=9.8 Hz, 1H), 7.50 (s, 1H), 7.21-7.14 (m, 2H), 6.98 (d, J=9.8 Hz, 1H), 6.38 (s, 1H), 4.97 (s, 2H), 3.20 (s, 6H), 2.70-2.60 (m, 1H), 2.41-2.30 (m, 2H), 1.92-1.82 (m, 2H), 1.80-1.67 (m, 1H), 1.35-1.25 (m, 1H), 1.03 (d, J=6.1 Hz, 3H).

Examples 245-424

According to the method of Example 1, 37, or 50 and common reaction conditions, the compounds of Examples 245 to 424 were obtained by using each corresponding material compound.

Example	M2	Analytical data
245		1H-NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 9.8 Hz, 1H), 7.16 (t, J = 8.2 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.69 (d, J = 7.9 Hz, 1H), 6.33-6.32 (br m, 1H), 5.01 (d, J = 3.7 Hz, 2H), 4.19 (t, J = 8.2 Hz, 2H), 3.87-
		3.84 (m, 4H), 3.19 (t, J =
		8.2 Hz, 2H), 2.99-2.97 (m,
		4H), 2.61-2.56 (m, 1H),
		2.34-2.25 (m, 2H), 1.88-
		1.78 (m, 2H), 1.74-1.65 (m,
		1H), 1.32-1.22 (m, 1H),
		0.99 (d, J = 6.1 Hz, 3H).
246		LC-MS: [M + H]+/Rt (min) 435.4/1.308 (Method A)
247		LC-MS: [M + H]+/Rt (min) 385.3/1.019 (Method A)
248		1H-NMR (400 MHz, DMSO-d6) δ: 8.73 (d, J = 1.8 Hz, 1H), 8.60 (d, J = 4.9 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.90 (d, J = 10.4 Hz, 1H), 7.51 (dd, J = 7.9, 4.9 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.3
		Hz, 1H), 6.96 (d, J = 9.8
		Hz, 1H), 6.55 (s, 1H), 5.07
		(s, 2H), 4.25 (t, J = 8.5
		Hz, 2H), 3.32-3.27 (m, 2H),
		2.67-2.54 (m, 2H), 2.37-
		2.19 (m, 2H), 1.87-1.62 (m,
		3H), 0.98 (d, J = 6.7 Hz,
		3H).
249		1H-NMR (400 MHz, DMSO-d6) δ: 8.79 (s, 2H), 8.05 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 10.4 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.15 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.56-6.52 (m, 1H), 5.06 (s, 2H), 4.25 (t, J = 8.2 Hz, 2H), 3.98 (s, 3H), 3.34-3.29 (m, 2H),
		2.56-2.51 (m, 1H), 2.36-
		2.18 (m, 2H), 1.87-1.60 (m,
		3H), 1.29-1.19 (m, 1H),
		0.97 (d, J = 6.7 Hz, 3H).
250		1H-NMR (400 MHz, DMSO-d6) δ: 8.67-8.65 (m, 2H), 8.09 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 9.8 Hz, 1H), 7.55- 7.53 (m, 2H), 7.33 (t, J = 7.9 Hz, 1H), 7.17 (d, J = 6.7 Hz, 1H), 6.96 (d, J = 10.4 Hz, 1H), 6.56-6.53 (m, 1H), 5.07 (s, 2H), 4.25 (t,
		J = 8.2 Hz, 2H), 3.35-3.31
		(m, 1H), 2.56-2.51 (m, 1H),
		2.37-2.18 (m, 2H), 1.87-
		1.61 (m, 3H), 1.29-1.18 (m,
		1H), 1.16-1.12 (m, 1H),
		0.97 (d, J = 6.1 Hz, 3H).
251		LC-MS: [M + H]+/Rt (min) 430.2/0.965 (Method A)
252		1H-NMR (400 MHz, DMSO-d6) δ: 7.95 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 9.8 Hz, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.20 (t, J = 7.9 Hz, 1H), 6.95 (d, J = 10.4 Hz, 1H), 6.67 (d, J = 2.4 Hz,
		1H), 6.55-6.53 (m, 1H),
		5.05 (s, 2H), 4.27 (t, J =
		8.2 Hz, 2H), 3.91 (s, 3H),
		3.46 (t, J = 8.5 Hz, 2H),
		2.58-2.51 (m, 1H), 2.37-
		2.18 (m, 2H), 1.88-1.62 (m,
		3H), 1.29-1.18 (m, 1H),
		0.97 (d, J = 5.8 Hz, 3H).
253		1H-NMR (400 MHz, CDCl3) δ: 9.32-9.26 (m, 2H), 8.34 (d, J = 8.5 Hz, 1H), 7.58-7.52 (m, 2H), 7.35 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 7.7 Hz, 1H), 6.93 (d, J = 9.5 Hz, 1H), 6.35-6.33 (m, 1H), 5.09-5.00 (m, 2H), 4.25 (t, J = 8.2 Hz, 2H), 3.36 (t,
		J = 8.2 Hz, 2H), 2.62-2.54
		(m, 1H), 2.37-2.25 (m, 2H),
		2.02-1.64 (m, 4H), 1.00 (d,
		J = 6.5 Hz, 3H).
254		LC-MS: [M + H]+/Rt (min) 416.3/0.933 (Method A)
255		1H-NMR (400 MHz, CDCl3) δ: 10.20 (s, 1H), 7.72 (s, 1H), 7.66 (t, J = 4.0 Hz, 2H), 7.45 (t, J = 9.1 Hz, 2H), 7.22 (dd, J = 8.8, 7.6 Hz, 1H), 7.08 (d, J = 9.8 Hz, 1H), 6.41 (s, 1H), 5.09
		(s, 2H), 2.68-2.59 (m, 1H),
		2.40-2.28 (m, 2H), 1.91-
		1.80 (m, 2H), 1.79-1.65 (m,
		1H), 1.39-1.22 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
256		LC-MS: [M + H]+/Rt (min) 392.2/2.01 (Method B)
257		1H-NMR (400 MHz, CDCl3) δ: 7.53 (d, J = 9.8 Hz, 1H), 7.41-7.28 (m, 5H), 6.91 (d, J = 9.8 Hz, 1H), 6.31 (br s, 1H), 6.08-6.02 (br m, 1H), 5.05 (d, J = 3.7 Hz, 1H), 4.99 (d, J = 3.7 Hz, 1H), 4.27 (d, J = 2.8 Hz,
		1H), 4.20 (d, J = 2.8 Hz,
		1H), 3.87-3.84 (br m, 1H),
		3.74-3.71 (br m, 1H), 2.66-
		2.56 (m, 3H), 2.34-2.26 (m,
		2H), 1.87-1.78 (m, 2H),
		1.73-1.65 (m, 1H), 1.32-
		1.22 (m, 1H), 0.99 (d, J =
		6.7 Hz, 3H).
258		1H-NMR (400 MHz, CDCl3) δ: 7.53 (d, J = 9.8 Hz, 1H), 7.33-7.29 (m, 2H), 7.04- 6.92 (m, 3H), 6.90 (d, J = 9.8 Hz, 1H), 6.32 (br s, 1H), 5.00 (br s, 2H), 3.84- 3.72 (br m, 4H), 3.28-3.22 (br m, 4H), 2.62-2.56 (m,
		1H), 2.35-2.25 (m, 2H),
		1.87-1.79 (m, 2H), 1.74-
		1.65 (m, 1H), 1.33-1.22 (m,
		1H), 1.00 (d, J = 6.1 Hz,
		3H).
259		1H-NMR (400 MHz, CDCl3) δ: 8.60-8.56 (m, 2H), 7.54 (dd, J = 9.8, 1.2 Hz, 1H), 7.36-7.25 (br m, 2H), 6.90 (d, J = 9.8 Hz, 1H), 6.32 (br s, 1H), 5.08-5.02 (m, 1H), 4.96-4.90 (br m, 1H), 4.81-4.77 (br m, 1H), 4.01-
		3.98 (br m, 1H), 3.30-3.24
		(br m, 1H), 2.92-2.79 (br
		m, 1H), 2.77-2.71 (br m,
		1H), 2.61-2.57 (br m, 1H),
		2.35-2.29 (br m, 2H), 2.00-
		1.91 (m, 2H), 1.87-1.70 (m,
		5H), 1.33-1.24 (m, 1H),
		1.00 (d, J = 6.1 Hz, 3H).
260		1H-NMR (400 MHz, CDCl3) δ: 8.59-8.57 (m, 1H), 7.82- 7.78 (br m, 1H), 7.53 (d, J = 10.1 Hz, 1H), 7.30-7.27 (br m, 2H), 6.89 (d, J = 10.1 Hz, 1H), 6.32-6.30 (m, 1H), 5.05-4.93 (m, 2H), 4.77-4.74 (br m, 1H), 3.99-
		3.95 (br m, 1H), 3.34-3.27
		(m, 1H), 3.19-3.11 (br m,
		1H), 2.83-2.75 (m, 1H),
		2.62-2.57 (br m, 1H), 2.35-
		2.28 (m, 2H), 2.14-2.11 (br
		m, 1H), 2.03-2.00 (br m,
		1H), 1.92-1.77 (m, 4H),
		1.75-1.66 (m, 1H), 1.33-
		1.23 (br m, 1H), 1.00 (d,
		J = 6.7 Hz, 3H).
261		1H-NMR (400 MHz, CD3OD) δ: 8.17 (d, J = 7.0 Hz, 2H), 7.85 (d, J = 9.8 Hz, 1H), 7.02 (d, J = 7.0 Hz, 2H), 6.94 (d, J = 9.8 Hz, 1H), 6.52-6.50 (br m, 1H), 5.11 (s, 2H), 3.84-3.77 (br m, 4H), 3.73-3.71 (br m, 2H),
		3.66-3.63 (br m, 2H), 2.65-
		2.58 (m, 1H), 2.40-2.26 (m,
		2H), 1.91-1.81 (m, 2H),
		1.72 (br s, 1H), 1.35-1.25
		(m, 1H), 1.02 (d, J = 6.7
		Hz, 3H).
262		1H-NMR (400 MHz, CD3OD) δ: 8.62 (br s, 1H), 8.53 (br s, 1H), 8.14-8.08 (m, 1H), 7.85 (d, J = 9.8 Hz, 1H), 7.68-7.63 (m, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.52-6.50 (br m, 1H), 5.18 (dd, J = 15.9, 3.7 Hz, 1H), 5.05-
		5.00 (m, 1H), 4.68-4.64 (br
		m, 1H), 4.17-4.12 (m, 1H),
		3.38-3.30 (br m, 2H), 3.10-
		3.03 (m, 1H), 2.88-2.81 (m,
		1H), 2.66-2.60 (br m, 1H),
		2.41-2.28 (m, 2H), 2.02-
		1.83 (m, 4H), 1.78-1.67 (m,
		2H), 1.36-1.26 (m, 1H),
		1.02 (d, J = 6.7 Hz, 3H).
263		LC-MS: [M + H]+/Rt (min) 412.3/0.803 (Method A)
264		1H-NMR (400 MHz, DMSO-d6) δ: 8.87 (s, 2H), 8.08 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 9.8 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.18 (d, J = 6.7 Hz, 1H), 6.96 (d, J = 9.8 Hz, 1H), 6.54 (s, 1H), 5.07 (s, 2H), 4.25 (t,
		J = 8.2 Hz, 2H), 3.36-3.33
		(m, 2H), 2.70-2.64 (m, 4H),
		2.37-2.18 (m, 2H), 1.88-
		1.62 (m, 3H), 1.29-1.20 (m,
		1H), 0.98 (d, J = 6.7 Hz,
		3H).
265		LC-MS: [M + H]+/Rt (min) 417.4/0.728 (Method A)
266		LC-MS: [M + H]+/Rt (min) 380.4/0.892 (Method A)
267		LC-MS: [M + H]+/Rt (min) 431.4/0.793 (Method A)
268		LC-MS: [M + H]+/Rt (min) 419.5/0.767 (Method A)
269		LC-MS: [M + H]+/Rt (min) 7.88 (d, J = 9.8 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 7.9 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.54-6.52 (m, 1H),
		5.02 (s, 2H), 4.22 (t, J =
		8.5 Hz, 2H), 3.39-3.32 (m
		3H), 3.19 (t, J = 8.2 Hz,
		2H), 2.81 (t, J = 8.5 Hz,
		1H), 2.67-2.42 (m, 5H),
		2.36-2.18 (m, 3H), 1.85-
		1.61 (m, 4H), 1.28-1.17 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
270		1H-NMR (400 MHz, DMSO-d6) δ: 7.88 (d, J = 9.8 Hz, 2H), 7.12 (t, J = 7.6 Hz, 1H), 6.98-6.93 (m, 2H), 6.55-6.52 (m, 1H), 5.03 (s, 2H), 4.24 (t, J = 8.5 Hz, 2H), 3.56 (t, J = 4.3 Hz,
		4H), 3.42 (s, 2H), 3.23 (t,
		J = 8.2 Hz, 2H), 2.55-2.50
		(m, 1H), 2.38-2.16 (m, 6H),
		1.87-1.74 (m, 2H), 1.72-
		1.60 (m, 1H), 1.28-1.17 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
271		LC-MS: [M + H]+/Rt (min) 433.4/0.848 (Method A)
272		1H-NMR (400 MHz, CDCl3) δ: 8.09 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 10.4 Hz, 1H), 7.13 (t, J = 7.9 Hz, 1H), 7.00 (d, J = 7.3 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.33 (s, 1H), 5.05-4.97 (m,
		2H), 4.19 (t, J = 8.2 Hz,
		2H), 3.95-3.89 (m, 1H),
		3.59-3.52 (m, 2H), 2.76-
		2.44 (m, 5H), 2.34-2.27 (m,
		2H), 2.11-2.02 (m, 1H),
		1.87-1.62 (m, 10H), 0.99
		(d, J = 6.7 Hz, 3H).
273		1H-NMR (400 MHz, CDCl3) δ: 8.09 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 9.8 Hz, 1H), 7.15-7.11 (m, 1H), 7.02- 6.98 (m, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.32 (s, 1H), 5.06-4.97 (m, 2H), 4.19 (t,
		J = 8.2 Hz, 2H), 3.94-3.89
		(m, 1H), 3.60-3.53 (m, 3H),
		2.76-2.45 (m, 6H), 2.35-
		2.27 (m, 2H), 1.86-1.57 (m,
		9H), 0.99 (d, J = 6.7 Hz,
		3H).
274		1H-NMR (400 MHz, DMSO-d6) δ: 7.87 (t, J = 9.4 Hz, 2H), 7.11 (t, J = 7.9 Hz, 1H), 6.96-6.93 (m, 2H), 6.53 (s, 1H), 5.02 (s, 2H), 4.23 (t, J = 8.2 Hz, 2H), 4.00-3.94 (m, 1H), 3.53 (s,
		4H), 3.49-3.45 (m, 4H),
		3.20-3.15 (m, 5H), 2.87-
		2.83 (m, 2H), 2.70-2.54 (m,
		1H), 2.36-2.17 (m, 2H),
		1.88-1.74 (m, 2H), 1.70-
		1.60 (m, 1H), 1.29-1.18 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
275		1H-NMR (400 MHz, DMSO-d6) δ: 7.90-7.86 (m, 2H), 7.11 (t, J = 7.6 Hz, 1H), 6.97- 6.93 (m, 2H), 6.53 (s, 1H), 5.03 (s, 2H), 4.23 (t, J = 8.5 Hz, 2H), 3.46-3.42 (m, 4H), 3.23-3.19 (m, 5H),
		2.53-2.51 (m, 3H), 2.36-
		2.17 (m, 2H), 2.14 (s, 3H),
		1.86-1.74 (m, 2H), 1.72-
		1.60 (m, 1H), 1.28-1.17 (m,
		1H), 0.97 (d, J = 6.1 Hz,
		3H).
276		1H-NMR (400 MHz, DMSO-d6) δ: 7.91-7.87 (m, 2H), 7.13 (t, J = 7.6 Hz, 1H), 6.96 (t, J = 7.9 Hz, 2H), 6.54 (s, 1H), 5.03 (s, 2H), 4.51 (t, J = 6.4 Hz, 2H), 4.43 (t, J = 6.1 Hz, 2H), 4.25
		(t, J = 8.5 Hz, 2H), 3.61-
		3.54 (m, 1H), 3.30-3.25 (m,
		4H), 2.56-2.52 (m, 1H),
		2.36-2.18 (m, 2H), 1.95 (s,
		3H), 1.87-1.75 (m, 2H),
		1.73-1.61 (m, 1H), 1.29-
		1.17 (m, 1H), 0.97 (d, J =
		6.1 Hz, 3H).
277		1H-NMR (400 MHz, DMSO-d6) δ: 7.93-7.87 (m, 2H), 7.12- 7.07 (m, 2H), 6.94 (d, J = 10.4 Hz, 1H), 6.55-6.52 (m, 1H), 5.03 (s, 2H), 4.97 (s, 1H), 4.17 (t, J = 8.2 Hz, 2H), 3.42 (t, J = 8.5 Hz,
		2H), 2.57-2.53 (m, 1H),
		2.37-2.17 (m, 2H), 1.87-
		1.61 (m, 3H), 1.46 (s, 6H),
		1.30-1.18 (m, 1H), 0.97 (d,
		J = 6.1 Hz, 3H).
278		1H-NMR (400 MHz, DMSO-d6) δ: 7.89-7.85 (m, 2H), 7.11 (t, J = 7.6 Hz, 1H), 7.02 (d, J = 7.9 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.54 (s, 1H), 5.03 (s, 2H), 4.35 (s, 1H), 4.24 (t, J = 8.5
		Hz, 2H), 3.91 (d, J = 7.3
		Hz, 1H), 3.71-3.62 (m, 2H),
		3.53-3.51 (m, 1H), 3.41 (s,
		1H), 3.22 (t, J = 8.5 Hz,
		2H), 2.72 (d, J = 8.5 Hz,
		1H), 2.55-2.51 (m, 1H),
		2.43 (d, J = 9.8 Hz, 1H),
		2.36-2.13 (m, 2H), 1.87-
		1.74 (m, 3H), 1.71-1.56 (m,
		2H), 1.28-1.18 (m, 1H),
		0.97 (d, J = 6.7 Hz, 3H).
279		1H-NMR (400 MHz, DMSO-d6) δ: 7.88-7.83 (m, 2H), 7.10 (t, J = 7.6 Hz, 1H), 7.01 (d, J = 7.9 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.52 (s, 1H), 5.01 (s, 2H), 4.33 (s, 1H), 4.22 (t, J = 8.5
		Hz, 2H), 3.89 (d, J = 7.3
		Hz, 1H), 3.70-3.60 (m, 2H),
		3.52-3.50 (m, 1H), 3.39 (s,
		1H), 3.20 (t, J = 8.2 Hz,
		2H), 2.70 (d, J = 8.5 Hz,
		1H), 2.55-2.51 (m, 1H),
		2.41 (d, J = 9.8 Hz, 1H),
		2.35-2.16 (m, 2H), 1.84-
		1.73 (m, 3H), 1.70-1.56 (m,
		2H), 1.27-1.18 (m, 1H),
		0.96 (d, J = 6.7 Hz, 3H).
280		LC-MS: [M + H]+/Rt (min) 518.4/1.075 (Method A)
281		LC-MS: [M + H]+/Rt (min) 418.5/0.884 (Method A)
282		1H-NMR (400 MHz, DMSO-d6) δ: 7.89-7.85 (m, 2H), 7.11 (t, J = 7.6 Hz, 1H), 6.96- 6.93 (m, 2H), 6.53 (s, 1H), 5.02 (s, 2H), 4.23 (t, J = 8.2 Hz, 2H), 3.37 (s, 2H), 3.21 (t, J = 8.5 Hz, 2H),
		2.55-2.52 (m, 1H), 2.37-
		2.16 (m, 6H), 1.87-1.60 (m,
		3H), 1.51-1.34 (m, 6H),
		1.28-1.18 (m, 1H), 0.97 (d,
		J = 6.7 Hz, 3H).
283		1H-NMR (400 MHz, DMSO-d6) δ: 8.31-8.28 (m, 1H), 7.88 (d, J = 10.4 Hz, 1H), 7.73 (d, J = 4.9 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.53 (s, 1H), 6.30 (s, 1H), 5.07 (s, 2H), 4.30 (t, J = 8.2
		Hz, 2H), 3.87-3.84 (m, 2H),
		3.64-3.61 (m, 2H), 3.36-
		3.31 (m, 2H), 2.54-2.50 (m,
		1H), 2.42 (s, 3H), 2.35-
		2.16 (m, 2H), 1.86-1.73 (m,
		2H), 1.70-1.60 (m, 1H),
		1.29-1.16 (m, 1H), 0.96 (d,
		J = 6.7 Hz, 3H).
284		1H-NMR (400 MHz, DMSO-d6) δ: 8.30 (d, J = 5.5 Hz, 1H), 7.89 (d, J = 9.8 Hz, 1H), 7.76 (d, J = 5.5 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.54-6.49 (m, 2H), 5.08 (s, 2H), 5.02-4.99 (m,
		2H), 4.84-4.81 (m, 2H),
		4.33 (t, J = 8.2 Hz, 2H),
		3.40-3.34 (m, 2H), 2.35-
		2.16 (m, 2H), 1.86-1.74 (m,
		2H), 1.70-1.60 (m, 1H),
		1.28-1.16 (m, 2H), 0.96 (d,
		J = 6.1 Hz, 3H).
285		1H-NMR (400 MHz, DMSO-d6) δ: 13.15 (s, 1H), 8.30 (d, J = 5.5 Hz, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 7.88 (d, J = 9.8 Hz, 1H), 7.67 (d, J = 4.9 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.53 (s, 1H), 5.08 (s, 2H), 4.34 (t,
		J = 8.2 Hz, 2H), 3.38 (t,
		J = 8.5 Hz, 2H), 2.54-2.50
		(m, 1H), 2.36-2.15 (m, 2H),
		1.86-1.72 (m, 2H), 1.70-
		1.59 (m, 1H), 1.29-1.16 (m,
		1H), 0.96 (d, J = 6.7 Hz,
		3H).
286		1H-NMR (400 MHz, DMSO-d6) δ: 7.92-7.87 (m, 2H), 7.73 (s, 1H), 7.18-7.13 (m, 2H), 6.96-6.92 (m, 2H), 6.77 (d, J = 7.3 Hz, 1H), 6.53 (s, 1H), 5.19 (s, 2H), 5.03 (s, 2H), 4.25 (t, J = 8.2 Hz,
		2H), 3.14 (t, J = 8.2 Hz,
		2H), 2.69-2.53 (m, 1H),
		2.38-2.15 (m, 2H), 1.88-
		1.59 (m, 3H), 1.29-1.17 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
287		1H-NMR (400 MHz, CDCl3) δ: 8.26 (d, J = 7.9 Hz, 1H), 7.71 (d, J = 9.8 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.08 (d, J = 10.4 Hz, 1H), 6.49 (s, 1H), 5.95 (s, 2H),
		5.22-5.13 (m, 2H), 4.36 (t,
		J = 8.2 Hz, 2H), 3.92 (s,
		2H), 3.68-3.63 (m, 1H),
		3.47 (t, J = 8.2 Hz, 2H),
		2.79-2.70 (m, 1H), 2.52-
		2.40 (m, 2H), 2.04-1.70 (m,
		6H), 1.49-1.38 (m, 1H),
		1.16 (d, J = 6.7 Hz, 3H).
288		LC-MS: [M + H]+/Rt (min) 444.4/0.827 (Method A)
289		LC-MS: [M + H]+/Rt (min) 417.3/0.826 (Method A)
290		1H-NMR (400 MHz, DMSO-d6) δ: 12.93 (s, 1H), 8.14 (s, 1H), 7.96 (s, 1H), 7.86 (d, J = 9.8 Hz, 1H), 7.66-7.45 (m, 2H), 6.91-6.86 (m, 2H), 6.52 (s, 1H), 5.15 (s, 2H), 4.45-4.41 (m, 2H), 3.95 (s, 2H), 2.58-2.51 (m, 1H),
		2.37-2.18 (m, 2H), 1.87-
		1.61 (m, 3H), 1.29-1.16 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
291		1H-NMR (400 MHz, DMSO-d6) δ: 13.36 (s, 1H), 8.20 (s, 2H), 8.11 (d, J = 5.5 Hz, 1H), 7.88 (d, J = 10.4 Hz, 1H), 7.35 (d, J = 5.5 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.54-6.52 (m, 1H),
		5.48 (s, 2H), 4.05 (t, J =
		8.5 Hz, 2H), 2.37-2.15 (m,
		2H), 1.87-1.60 (m, 3H),
		1.30-1.15 (m, 4H), 0.97 (d,
		J = 6.7 Hz, 3H).
292		1H-NMR (400 MHz, DMSO-d6) δ: 13.07 (s, 1H), 8.07 (br s, 2H), 7.88 (d, J = 10.0 Hz, 1H), 7.37-7.33 (m, 1H), 7.10 (t, J = 9.5 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.54 (s, 1H), 5.07 (s, 2H),
		4.23 (t, J = 7.6 Hz, 2H),
		3.28-3.16 (m, 2H), 2.37-
		2.17 (m, 2H), 1.87-1.59 (m,
		3H), 1.29-1.24 (m, 2H),
		0.97 (d, J = 6.7 Hz, 3H).
293		LC-MS: [M + H]+/Rt (min) 445.5/0.864 (Method A)
294		1H-NMR (400 MHz, DMSO-d6) δ: 8.62 (s, 1H), 7.96 (s, 1H), 7.91-7.84 (m, 2H), 7.13 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.82 (d, J = 7.3 Hz, 1H), 6.51 (s, 1H), 5.38 (s, 2H),
		5.00 (s, 2H), 4.23 (t, J =
		8.5 Hz, 2H), 3.29-3.27 (m,
		1H), 3.17 (t, J = 8.5 Hz,
		2H), 2.34-2.13 (m, 2H),
		1.83-1.58 (m, 3H), 1.25-
		1.17 (m, 1H), 0.94 (d, J =
		6.7 Hz, 3H).
295		1H-NMR (400 MHz, DMSO-d6) δ: 9.40-9.37 (m, 2H), 8.09 (dd, J = 8.9, 4.6 Hz, 1H), 7.90-7.87 (m, 2H), 7.24 (t, J = 9.5 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.55-6.53 (m, 1H), 5.06 (s, 2H), 4.27 (t, J = 8.2 Hz, 2H), 3.24
		(t, J = 8.2 Hz, 2H), 2.56-
		2.52 (m, 1H), 2.37-2.18 (m,
		2H), 1.88-1.61 (m, 3H),
		1.29-1.20 (m, 1H), 0.98 (d,
		J = 6.7 Hz, 3H).
296		LC-MS: [M + H]+/Rt (min) 433.4/0.700 (Method A)
297		1H-NMR (400 MHz, CDCl3) δ: 8.99 (d, J = 1.8 Hz, 1H), 8.68 (dd, J = 4.9, 1.8 Hz, 1H), 8.54 (d, J = 5.5 Hz, 1H), 8.15-8.08 (m, 2H), 7.61 (d, J = 10.0 Hz, 1H), 7.45 (dd, J = 7.6, 4.6 Hz, 1H), 6.96 (d, J = 10.0 Hz,
		1H), 6.39-6.36 (m, 1H),
		5.07 (s, 2H), 4.31 (t, J =
		8.2 Hz, 2H), 3.52 (t, J =
		8.2 Hz, 2H), 2.63-2.58 (m,
		1H), 2.38-2.29 (m, 2H),
		1.90-1.83 (m, 2H), 1.36-
		1.26 (m, 2H), 1.03 (d, J =
		6.1 Hz, 3H).
298		1H-NMR (400 MHz, DMSO-d6) δ: 8.85 (d, J = 1.8 Hz, 1H), 8.50 (dd, J = 4.6, 1.5 Hz, 1H), 8.05-8.01 (m, 2H), 7.87 (d, J = 9.8 Hz, 1H), 7.65 (s, 1H), 7.53 (dd, J = 8.5, 1.8 Hz, 1H), 7.43 (dd, J = 7.9, 4.9 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.53-6.51 (m, 1H), 5.04 (s,
		2H), 4.27 (t, J = 8.5 Hz,
		2H), 3.29-3.24 (m, 2H),
		2.55-2.50 (m, 1H), 2.35-
		2.15 (m, 2H), 1.86-1.60 (m,
		3H), 1.27-1.18 (m, 1H),
		0.95 (d, J = 6.1 Hz, 3H).
299		LC-MS: [M + H]+/Rt (min) 405.3/0.657 (Method A)
300		LC-MS: [M + H]+/Rt (min) 419.3/0.670 (Method A)
301		LC-MS: [M + H]+/Rt (min) 461.4/0.787 (Method A)
302		1H-NMR (400 MHz, CDCl3) δ: 8.00 (d, J = 8.5 Hz, 1H), 7.48 (d, J = 9.8 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.93-6.84 (m, 2H), 6.26 (s, 1H), 4.96-4.91 (m, 2H), 4.12 (t, J = 7.9 Hz, 2H),
		3.86-3.66 (m, 3H), 3.11-
		3.01 (m, 3H), 2.55-2.46 (m,
		3H), 2.30-1.85 (m, 3H),
		1.81-1.57 (m, 3H), 1.25-
		1.15 (m, 1H), 1.00-0.92 (m,
		6H).
303		LC-MS: [M + H]+/Rt (min) 449.4/0.750 (Method A)
304		1H-NMR (400 MHz, DMSO-d6) δ: 7.85 (dd, J = 21.7, 8.9 Hz, 2H), 7.15 (t, J = 7.9 Hz, 1H), 7.01 (d, J = 7.3 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.54-6.52 (m, 1H), 5.02 (s, 2H), 4.21 (t, J = 8.5 Hz, 2H), 3.64-3.53 (m, 3H), 3.08 (t, J = 7.9 Hz,
		2H), 2.99-2.95 (m, 2H),
		2.68-2.64 (m, 1H), 2.35-
		2.21 (m, 3H), 1.86-1.75 (m,
		2H), 1.70-1.63 (m, 1H),
		1.28-1.19 (m, 1H), 0.97 (d,
		J = 6.1 Hz, 3H), 0.87 (d,
		J = 6.1 Hz, 6H).
305		LC-MS: [M + H]+/Rt (min) 475.4/0.908 (Method A)
306		1H-NMR (400 MHz, DMSO-d6) δ: 7.90-7.86 (m, 2H), 7.21 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.55- 6.52 (m, 1H), 5.12 (s, 1H), 5.03 (s, 2H), 4.78 (t, J = 8.9 Hz, 1H), 4.43-4.39 (m, 1H), 4.24 (t, J = 8.5 Hz,
		3H), 3.91-3.86 (m, 2H),
		3.15-3.10 (m, 2H), 2.36-
		2.18 (m, 2H), 1.87-1.75 (m,
		2H), 1.72-1.60 (m, 1H),
		1.31-1.21 (m, 7H), 0.97 (d,
		J = 6.7 Hz, 3H).
307		1H-NMR (400 MHz, CDCl3) δ: 7.83 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 9.8 Hz, 1H), 7.15 (t, J = 8.2 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.59 (d, J = 7.9 Hz, 1H), 6.35 (s, 1H), 5.06-4.98 (m,
		2H), 4.22 (t, J = 8.5 Hz,
		2H), 3.85 (s, 2H), 3.24 (t,
		J = 8.5 Hz, 2H), 2.65-2.56
		(m, 1H), 2.38-2.27 (m, 2H),
		2.01 (br s, 2H), 1.89-1.81
		(m, 2H), 1.76-1.67 (m, 1H),
		1.37 (s, 6H), 1.01 (d, J =
		6.1 Hz, 3H).
308		LC-MS: [M + H]+/Rt (min) 415.4/0.671 (Method A)
309		1H-NMR (400 MHz, DMSO-d6) δ: 7.94 (d, J = 5.5 Hz, 1H), 7.87 (d, J = 9.8 Hz, 1H), 7.40 (d, J = 5.5 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.52 (s, 1H), 5.02 (s, 2H), 4.22-4.18 (m, 2H), 3.69-3.63 (m, 2H), 3.39-
		3.32 (m, 1H), 3.25 (s, 3H),
		3.16 (t, J = 7.8 Hz, 2H),
		3.03-2.96 (m, 2H), 2.35-
		2.15 (m, 2H), 1.94-1.73 (m,
		4H), 1.69-1.58 (m, 1H),
		1.50-1.41 (m, 2H), 1.23-
		1.21 (m, 2H), 0.96 (d, J =
		6.7 Hz, 3H).
310		LC-MS: [M + H]+/Rt (min) 460.4/0.788 (Method A)
311		1H-NMR (400 MHz, DMSO-d6) δ: 13.19 (s, 1H), 8.94 (s, 1H), 8.54 (s, 1H), 8.22- 8.01 (m, 2H), 7.87 (d, J = 9.8 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.52 (s, 1H), 5.06 (s, 2H), 4.29 (t, J = 8.5 Hz, 2H), 3.44-3.33 (m,
		2H), 2.35-2.15 (m, 2H),
		1.86-1.57 (m, 4H), 1.29-
		1.16 (m, 1H), 0.95 (d, J =
		6.1 Hz, 3H).
312		1H-NMR (400 MHz, DMSO-d6) δ: 7.90-7.85 (m, 2H), 7.13 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.54 (s, 1H), 6.17-5.85 (m, 1H), 5.03 (s, 2H), 4.24 (t, J =
		8.2 Hz, 2H), 3.72 (s, 2H),
		3.20 (t, J = 8.2 Hz, 2H),
		2.86 (t, J = 15.9 Hz, 2H),
		2.68-2.54 (m, 2H), 2.36-
		2.15 (m, 2H), 1.88-1.60 (m,
		3H), 1.29-1.19 (m, 1H),
		0.97 (d, J = 6.1 Hz, 3H).
313		1H-NMR (400 MHz, DMSO-d6) δ: 7.90-7.84 (m, 2H), 7.11 (t, J = 7.6 Hz, 1H), 7.01- 6.93 (m, 2H), 6.54 (s, 1H), 5.03 (s, 2H), 4.58-4.54 (m, 2H), 4.31-4.22 (m, 4H), 3.92-3.82 (m, 1H), 3.58 (s,
		2H), 3.21 (t, J = 8.2 Hz,
		2H), 2.85-2.75 (m, 1H),
		2.37-2.16 (m, 2H), 1.88-
		1.58 (m, 3H), 1.30-1.17 (m,
		1H), 0.97 (d, J = 6.1 Hz,
		3H).
314		1H-NMR (400 MHz, DMSO-d6) δ: 7.90-7.83 (m, 2H), 7.12 (t, J = 7.9 Hz, 1H), 7.02 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 10.4 Hz, 1H), 6.54 (s, 1H), 5.03 (s, 2H), 4.23 (t, J = 8.5 Hz, 2H), 3.67
		(s, 2H), 3.40 (t, J = 5.8
		Hz, 2H), 3.25-3.16 (m, 5H),
		2.65 (t, J = 5.5 Hz, 2H),
		2.37-2.17 (m, 2H), 2.09-
		1.59 (m, 4H), 1.28-1.17 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
315		1H-NMR (400 MHz, DMSO-d6) δ: 7.90-7.83 (m, 2H), 7.10 (t, J = 7.9 Hz, 1H), 7.00 (d, J = 7.3 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.54 (s, 1H), 5.03 (s, 2H), 4.23 (t, J = 8.2 Hz, 2H), 3.55
		(s, 2H), 3.22-3.11 (m, 3H),
		2.36-2.04 (m, 5H), 1.85-
		1.49 (m, 7H), 1.28-1.18 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
316		1H-NMR (400 MHz, DMSO-d6) δ: 7.89-7.84 (m, 2H), 7.12 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 7.3 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.53 (s, 1H), 5.03 (s, 2H), 4.24 (t, J = 8.2 Hz, 2H), 3.78-
		3.59 (m, 5H), 3.47-3.42 (m,
		1H), 3.30-3.19 (m, 3H),
		2.36-2.11 (m, 3H), 1.97-
		1.62 (m, 5H), 1.28-1.18 (m,
		1H), 0.97 (d, J = 6.7 Hz,
		3H).
317		1H-NMR (400 MHz, DMSO-d6) δ: 7.90-7.83 (m, 2H), 7.13- 7.03 (m, 2H), 6.94 (d, J = 9.8 Hz, 1H), 6.53 (s, 1H), 5.03 (s, 2H), 4.24 (t, J = 8.2 Hz, 2H), 3.85-3.80 (m, 2H), 3.68 (s, 2H), 3.31- 3.19 (m, 4H), 2.63-2.55 (m,
		1H), 2.36-2.18 (m, 2H),
		1.96-1.62 (m, 6H), 1.33-
		1.18 (m, 3H), 0.97 (d, J =
		6.1 Hz, 3H).
318		1H-NMR (400 MHz, CDCl3) δ: 8.14-8.09 (br m, 1H), 7.56 (d, J = 9.8 Hz, 1H), 7.18- 7.16 (br m, 1H), 7.08-7.04 (br m, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.33 (br s, 1H), 5.01 (s, 2H), 4.77- 4.74 (m, 1H), 4.63-4.60 (m, 1H), 4.50-4.41 (m, 1H), 4.23-4.17 (m, 2H), 4.14- 4.10 (m, 1H), 4.03 (s, 2H),
		3.92-3.84 (m, 2H), 3.30-
		3.25 (m, 2H), 2.60-2.56 (br
		m, 1H), 2.34-2.26 (br m,
		2H), 1.87-1.79 (br m, 2H),
		1.74-1.65 (m, 1H), 1.30-
		1.24 (m, 3H), 0.99 (d, J =
		6.7 Hz, 3H).
319		1H-NMR (400 MHz, CDCl3) δ: 8.09-8.07 (br m, 1H), 7.69 (br s, 1H), 7.57 (d, J = 9.8 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.35-6.33 (br m, 1H), 5.00 (br s, 2H), 4.24-4.20 (br m, 2H), 3.83 (t, J = 4.9 Hz, 4H), 3.38-
		3.24 (br m, 6H), 2.61-2.54
		(br m, 1H), 2.36-2.26 (br
		m, 2H), 1.88-1.78 (m, 2H),
		1.75-1.66 (br m, 1H), 1.33-
		1.23 (m, 1H), 1.00 (d, J =
		6.7 Hz, 3H).
320		1H-NMR (400 MHz, CDCl3) δ: 8.09 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 9.8 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.79 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 8.6, 2.4 Hz, 1H), 6.33 (br s, 1H), 5.04- 4.96 (m, 2H), 4.19 (t, J =
		8.3 Hz, 2H), 3.76 (s, 2H),
		3.25 (t, J = 8.3 Hz, 2H),
		2.62-2.56 (br m, 1H), 2.36-
		2.27 (br m, 2H), 2.23 (s,
		1H), 1.88-1.79 (m, 2H),
		1.74-1.66 (br m, 1H), 1.33
		(s, 6H), 1.31-1.22 (m, 1H),
		1.00 (d, J = 6.7 Hz, 3H).
321		LC-MS: [M + H]+/Rt (min) 463.1/0.799 (Method A)
322		1H-NMR (400 MHz, CDCl3) δ: 8.92 (s, 1H), 8.03-7.93 (m, 1H), 7.60 (d, J = 5.1 Hz, 1H), 7.06-7.00 (m, 1H), 6.98 (d, J = 5.1 Hz, 1H), 6.86-6.75 (m, 1H), 6.42- 6.32 (m, 1H), 5.00 (d, J = 14.6 Hz, 1H), 4.95 (d, J =
		14.6 Hz, 1H), 3.93-3.85 (m,
		4H), 3.15-3.07 (m, 4H),
		2.68-2.55 (m, 1H), 2.40-
		2.25 (m, 2H), 1.92-1.80 (m,
		2H), 1.80-1.65 (m, 2H),
		1.01 (d, J = 6.1 Hz, 3H).
323		1H-NMR (400 MHz, CDCl3) δ: 9.09 (s, 1H), 8.05 (s, 1H), 7.87-7.83 (m, 1H), 7.60 (d, J = 9.8 Hz, 1H), 7.29 (s, 1H), 6.98 (d, J = 9.8 Hz, 1H), 6.37 (s, 1H), 5.00 (s, 2H), 2.70-2.58 (m, 1H), 2.46 (s, 3H), 2.36-2.30 (m,
		2H), 1.92-1.79 (m, 2H),
		1.77-1.69 (m, 2H), 1.02 (d,
		J = 6.1 Hz, 3H).
324		1H-NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 8.06 (s, 1H), 7.63 (t, J = 7.6 Hz, 1H), 7.48-7.44 (m, 2H), 7.01 (d, J = 9.8 Hz, 1H), 6.40 (s, 1H), 5.03 (s, 2H), 4.11-
		4.06 (m, 2H), 2.73-2.61 (m,
		7H), 2.38-2.26 (m, 2H),
		2.94-1.80 (m, 2H), 1.80-
		1.69 (m, 2H), 1.03 (d, J =
		6.1 Hz, 3H).
325		1H-NMR (400 MHz, CDCl3) δ: 9.17 (s, 1H), 7.98 (s, 1H), 7.60 (d, J = 10.4 Hz, 1H), 7.45-7.35 (m, 2H), 6.98 (t, J = 10.7 Hz, 1H), 6.36 (s, 1H), 5.00 (s, 2H), 4.69 (s,
		2H), 3.51 (s, 3H), 2.67-
		2.57 (m, 1H), 2.39-2.328
		(m, 2H), 1.90-1.79 (m, 2H),
		1.78-1.62 (m, 1H), 1.33-
		1.21 (m, 1H), 1.00 (d, J =
		6.7 Hz, 3H).
326		1H-NMR (400 MHz, CDCl3) δ: 9.43 (s, 1H), 8.61-8.57 (m, 2H), 7.64 (d, J = 9.8 Hz, 1H), 7.02 (d, J = 9.8 Hz, 1H), 6.40 (s, 1H), 5.05 (s, 2H), 2.84 (s, 3H), 2.82 (s,
		1H), 2.70-2.60 (m, 1H),
		2.43-2.29 (m, 1H), 1.92-
		1.83 (m, 2H), 1.65-1.75 (m,
		1H), 1.38-1.25 (m, 1H),
		1.01 (t, J = 7.3 Hz, 3H).
327		1H-NMR (400 MHz, CDCl3) δ: 9.16 (s, 1H), 7.90 (s, 1H), 7.60 (d, J = 7.0 Hz, 1H), 7.46-7.39 (m, 2H), 7.29- 7.37 (m, 1H), 6.36 (s, 1H), 5.00 (s, 2H), 2.38-2.25 (m,
		3H), 1.90-1.79 (m, 3H),
		1.75 (s, 1H), 1.73 (t, 6H),
		0.99 (t, J = 7.3 Hz, 3H).
328		1H-NMR (400 MHz, CD3OD) δ: 9.13 (s, 1H), 8.17 (s, 1H), 7.85 (d, J = 9.2 Hz, 2H), 7.53 (s, 1H), 6.95 (d, J = 9.8 Hz, 1H), 6.51 (s, 1H), 5.02 (s, 2H), 2.67-2.57 (m,
		1H), 2.42-2.28 (m, 2H),
		1.90-1.80 (m, 2H), 1.80-
		1.65 (s, 1H), 1.35-1.25 (m,
		1H), 1.01 (d, J = 6.7 Hz,
		3H).
329		1H-NMR (400 MHz, CD3OD) δ: 7.98 (d, J = 7.3 Hz, 1H), 7.85-7.80 (m, 2H), 7.09- 7.02 (m, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.53-6.45 (m, 1H), 4.97 (s, 2H), 2.67- 2.55 (m, 1H), 2.36 (s, 3H),
		2.36-2.26 (m, 2H), 2.30 (s,
		3H), 1.87-1.80 (m, 2H),
		1.73-1.68 (m, 1H), 0.98 (t,
		J = 7.0 Hz, 3H).
330		1H-NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 8.32 (d, J = 4.3 Hz, 1H), 8.23 (s, 1H), 8.01 (s, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.09 (dd, J = 7.3, 2.4 Hz, 1H), 6.98 (d,
		J = 9.8 Hz, 1H), 6.40 (s,
		1H), 5.03 (s, 2H), 2.65-
		2.55 (m, 1H), 2.40-2.25 (m,
		2H), 1.91-1.80 (m, 2H),
		1.80-1.65 (m, 1H), 1.34-
		1.20 (m, 1H), 1.00 (d, J =
		6.7 Hz, 3H).
331		1H-NMR (400 MHz, CDCl3) δ: 9.12 (s, 1H), 7.94 (s, 1H), 7.59 (d, J = 9.8 Hz, 1H), 7.41-7.34 (m, 2H), 6.97 (d, J = 9.8 Hz, 1H), 6.36 (s, 1H), 4.99 (s, 2H), 3.83 (s, 2H), 3.78-3.74 (m, 4H), 2.68-2.58 (m, 5H), 2.38-
		2.28 (m, 2H), 1.90-1.81 (m,
		2H), 1.75-1.65 (m, 1H),
		1.35-1.26 (m, 1H), 0.99 (t,
		J = 8.6 Hz, 3H).
332		1H-NMR (400 MHz, CDCl3) δ: 9.08 (s, 1H), 7.93 (s, 1H), 7.59 (d, J = 9.8 Hz, 1H), 7.41-7.33 (m, 2H), 6.98 (d, J = 7.9 Hz, 1H), 6.36 (s, 1H), 4.98 (s, 2H), 4.17- 4.05 (m, 2H), 3.92-3.88 (m, 2H), 3.85-3.76 (m, 2H), 3.24 (s, 3H), 3.21-3.11 (m, 2H), 2.68-2.57 (m, 1H),
		2.38-2.29 (m, 2H), 1.90-
		1.79 (m, 2H), 1.78-1.60 (m,
		1H), 0.98 (d, J = 6.4 Hz,
		3H).
333		1H-NMR (400 MHz, CD3OD) δ: 8.14 (d, J = 1.8 Hz, 1H), 7.84 (d, J = 9.8 Hz, 1H), 7.59 (d, J = 8.6 Hz, 1H), 7.49 (dd, J = 8.9, 2.1 Hz, 1H), 6.93 (d, J = 9.5 Hz, 1H), 6.50 (s, J = 3.1 Hz,
		1H), 4.97 (s, 2H), 4.83 (s,
		2H), 4.50-4.40 (m, 2H),
		4.40-4.29 (m, 2H), 3.32-
		3.28 (m, 5H), 2.70-2.45 (m,
		3H), 1.89-1.878 (m, 2H),
		1.35-1.26 (m, 1H), 1.00 (d,
		J = 6.7 Hz, 3H).
334		1H-NMR (400 MHz, CDCl3) δ: 10.11 (s, 1H), 7.72 (d, J = 11.3 Hz, 1H), 7.61 (s, 1H), 7.54 (d, J = 9.2 Hz, 1H), 7.11 (s, 1H), 7.06- 7.02 (m, 1H), 6.89 (d, J =
		4.9 Hz, 1H), 6.30 (s, 1H),
		4.95 (s, 2H), 2.65-2.41 (m,
		2H), 2.35-2.20 (m, 2H),
		2.00-1.91 (m, 1H), 1.86-
		1.75 (m, 2H), 1.75-1.65 (m,
		1H), 0.98 (d, J = 6.7 Hz,
		3H), 0.94-0.83 (m, 4H).
335		1H-NMR (400 MHz, CDCl3) δ: 10.06 (s, 1H), 7.97 (d, J = 7.3 Hz, 1H), 7.82 (s, 1H), 7.65-7.56 (m, 1H), 7.25-7.15 (m, 2H), 6.99- 6.93 (m, 1H), 6.35 (s, 1H), 5.05 (s, 2H), 2.65-2.56 (m, 1H), 2.50-2.22 (m, 3H), 1.90-1.60 (m, 3H), 1.34-
		1.20 (m, 1H), 0.98 (d, J =
		5.8 Hz, 3H), 1.02-0.92 (m,
		1H), 0.88 (t, J = 6.7 Hz,
		1H), 0.69-0.62 (m, 2H).
336		1H-NMR (400 MHz, CDCl3) δ: 8.93 (s, 1H), 8.04 (d, J = 1.2 Hz, 1H), 7.91 (s, 1H), 7.61 (d, J = 9.8 Hz, 1H), 7.41-7.38 (m, 1H), 7.29 (d, J = 8.5 Hz, 1H), 6.99 (d, J = 9.8 Hz, 1H), 6.38 (s,
		1H), 4.98 (s, 2H), 2.70-
		2.59 (m, 1H), 2.41-2.28 (m,
		2H), 1.93-1.79, 2H), 1.55-
		1.42 (m, 4H), 1.38-1.23 (m,
		1H), 1.01 (d, J = 6.7 Hz,
		3H).
337		1H-NMR (400 MHz, CDCl3) δ: 11.01 (s, 1H), 9.45 (s, 1H), 8.57 (s, 1H), 7.69 (s, 1H), 7.57 (d, J = 9.1 Hz, 1H), 7.43 (s, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.33 (s,
		1H), 5.14 (s, 2H), 2.63-
		2.51 (m, 1H), 2.38-2.25
		(m, 2H), 1.90-1.75 (m, 2H),
		1.75-1.60 (m, 1H), 1.30-
		1.21 (m, 1H), 0.98 (d, J =
		6.1 Hz, 3H).
338		1H-NMR (400 MHz, CDCl3) δ: 9.52 (s, 1H), 7.94 (s, 1H), 7.79 (s, 1H), 7.68 (d, J = 7.3 Hz, 1H), 7.61 (d, J = 4.9 Hz, 1H), 7.19 (s, 1H), 6.96 (d, J = 9.8 Hz, 1H),
		6.56 (dd, J = 7.6, 2.1 Hz,
		1H), 6.37 (s, 1H), 4.99 (s,
		2H), 2.67-2.56 (m, 1H),
		2.39-2.25 (m, 2H), 2.25-
		2.08 (m, 1H), 1.89-1.78 (m,
		2H), 1.35-1.21 (m, 1H),
		0.99 (d, J = 6.7 Hz, 3H).
339		1H-NMR (400 MHz, CDCl3) δ: 9.65 (s, 1H), 9.48 (s, 1H), 8.31 (s, 1H), 7.67 (dd, J = 13.7, 9.5 Hz, 2H), 7.41- 7.35 (m, 1H), 7.01 (d, J = 9.8 Hz, 1H), 6.50 (s, 1H),
		5.03 (s, 2H), 2.68-2.57 (m,
		1H), 2.40-2.31 (m, 2H),
		1.93-1.83 (m, 2H), 1.35-
		1.21 (m, 1H), 1.01 (d, J =
		6.7 Hz, 3H).
340		1H-NMR (400 MHz, CDCl3) δ: 8.99 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 7.75 (d, J = 6.7 Hz, 1H), 7.59 (d, J = 9.8 Hz, 1H), 6.98 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H),
		6.18 (s, 1H), 4.99 (s, 2H),
		2.65-2.56 (m, 1H), 2.46 (s,
		3H), 2.40-2.28 (m, 2H),
		1.89-1.80 (m, 1H), 1.78-
		1.65 (m, 2H), 1.35-1.20 (m,
		1H), 1.01 (d, J = 6.7 Hz,
		3H).
341		1H-NMR (400 MHz, CDCl3) δ: 10.90-10.70 (m, 1H), 9.48- 9.35 (m, 1H), 9.15-9.00 (m, 1H), 7.95-7.50 (m, 1H), 7.61 (d, J = 9.8 Hz, 1H), 6.98 (d, J = 9.8 Hz, 1H), 6.36
		(s, 1H), 5.12 (s, 2H),
		2.65-2.40 (m, 2H), 2.39-
		2.23 (m, 2H), 1.90-1.79 (m,
		1H), 1.75-1.65 (m, 1H),
		0.99 (d, J = 6.1 Hz, 3H).
342		1H-NMR (400 MHz, CDCl3) δ: 9.67 (s, 1H), 8.58 (d, J = 7.9 Hz, 1H), 8.19 (d, J = 1.2 Hz, 1H), 7.90 (s, 1H), 7.64 (t, J = 8.2 Hz, 1H), 7.01 (d, J = 9.8 Hz, 1H),
		6.93 (dd, J = 7.6, 2.1 Hz,
		1H), 6.40 (s, 1H), 5.01 (s,
		2H), 2.70-2.55 (m, 1H),
		2.40-2.25 (m, 2H), 1.90-
		1.64 (m, 2H), 1.35-1.26 (m,
		1H), 1.02 (t, J = 8.5 Hz,
		5H).
343		1H-NMR (400 MHz, CDCl3) δ: 9.70 (s, 1H), 9.11 (s, 1H), 7.64-7.52 (m, 3H), 7.47 (d, J = 9.2 Hz, 1H), 7.08-6.95 (m, 2H), 6.38 (s, 1H), 5.03 (s, 2H), 2.70-2.55 (m, 1H),
		2.40-2.28 (m, 1H), 2.25-
		2.10 (m, 2H), 1.93-1.78 (m,
		1H), 1.78-1.65 (m, 1H),
		1.35-1.21 (m, 1H), 1.01 (d,
		J = 6.7 Hz, 3H).
344		1H-NMR (400 MHz, CDCl3) δ: 9.96 (s, 1H), 9.02 (s, 1H), 8.49 (s, 1H), 7.60 (d, J = 9.8 Hz, 1H), 7.47 (s, 1H), 7.33 (d, J = 9.8 Hz, 1H), 6.98 (d, J = 9.5 Hz, 1H),
		6.80 (d, J = 9.2 Hz, 1H),
		6.35 (s, 1H), 5.08 (s, 2H),
		2.65-2.53 (m, 1H), 2.40-
		2.25 (m, 2H), 1.90-1.78 (m,
		2H), 1.73-1.65 (m, 1H),
		1.33-1.25 (m, 1H), 1.01 (d,
		J = 6.7 Hz, 3H).
345		1H-NMR (400 MHz, CD3OD) δ: 9.61 (s, 1H), 8.08 (s, 1H), 7.86 (d, J = 4.9 Hz, 2H), 7.32 (d, J = 7.9 Hz, 1H), 6.96 (d, J = 9.8 Hz, 1H), 6.53 (s, 1H), 5.01 (s, 2H),
		2.65-2.51 (m, 1H), 2.42-
		2.30 (m, 2H), 1.90-1.75 (m,
		2H), 1.75-1.65 (m, 1H),
		1.40-1.25 (m, 1H), 1.01 (d,
		J = 6.7 Hz, 3H).
346		1H-NMR (400 MHz, CD3OD) δ: 9.31 (s, 1H), 8.04 (d, J = 9.8 Hz, 1H), 7.91 (d, J = 9.8 Hz, 1H), 7.79 (s, 1H), 7.70 (d, J = 1.2 Hz, 1H), 7.62 (d, J = 9.8 Hz, 1H),
		7.01 (d, J = 9.8 Hz, 1H),
		6.39 (s, 1H), 5.02 (s, 2H),
		2.70-2.58 (m, 1H), 2.45-
		2.30 (m, 2H), 1.95-1.83 (m,
		2H), 1.80-1.65 (m, 1H),
		1.35-1.20 (m, 1H), 1.01 (d,
		J = 6.7 Hz, 3H).
347		1H-NMR (400 MHz, CDCl3) δ: 9.53 (s, 1H), 9.30 (s, 1H), 7.64 (d, J = 9.8 Hz, 1H), 7.46 (dd, J = 9.4, 2.7 Hz, 1H), 7.21 (d, J = 9.8 Hz, 1H), 6.99 (d, J = 9.8 Hz,
		1H), 6.39 (s, 1H), 5.01 (s,
		2H), 2.68-2.58 (m, 1H),
		2.54 (s, 3H), 2.40-2.38 (m,
		2H), 1.92-1.80 (m, 2H),
		1.80-1.65 (m, 1H), 1.35-
		1.21 (m, 1H), 1.01 (d, J =
		6.7 Hz, 3H).
348		1H-NMR (400 MHz, CDCl3) δ: 9.18 (s, 1H), 8.48 (d, J = 1.8 Hz, 1H), 8.41 (d, J = 2.4 Hz, 1H), 7.90 (s, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.00 (d, J = 9.8 Hz, 1H), 6.39 (s, 1H), 5.02 (s, 2H),
		4.11 (s, 3H), 2.70-2.59 (m,
		1H), 2.40-2.38 (m, 2H),
		1.90-1.80 (m, 2H), 1.79-
		1.63 (m, 1H), 1.36-1.24 (m,
		1H), 1.01 (d, J = 6.7 Hz,
		3H).
349		1H-NMR (400 MHz, CDCl3) δ: 9.46 (s, 1H), 9.29 (s, 1H), 8.23 (s, 1H), 7.65 (d, J = 9.8 Hz, 1H), 7.04 (s, 1H), 7.01 (d, J = 9.8 Hz, 1H), 6.40 (s, 1H), 5.01 (s, 2H), 2.68-2.58 (m, 1H), 2.56 (s, 3H), 2.40-2.38 (m, 2H),
		1.90-1.79 (m, 2H), 1.78-
		1.64 (m, 1H), 1.38-1.29 (m,
		1H), 1.01 (d, J = 6.7 Hz,
		3H).
350		1H-NMR (400 MHz, CDCl3) δ: 9.67 (s, 1H), 8.50 (d, J = 9.8 Hz, 1H), 8.41 (d, J = 15.2 Hz, 1H), 8.09 (d, J = 9.8 Hz, 1H), 7.61 (d, J = 9.8 Hz, 1H), 7.00 (d, J =
		9.8 Hz, 1H), 6.38 (d, J =
		2.4 Hz, 1H), 5.11 (s, 2H),
		2.65-2.55 (m, 1H), 2.40-
		2.25 (m, 2H), 1.93-1.81 (m,
		2H), 1.75-1.60 (m, 1H),
		1.35-1.22 (m, 1H), 1.00 (d,
		J = 6.4 Hz, 3H).
351		1H-NMR (400 MHz, CDCl3) δ: 9.52 (s, 1H), 9.15 (s, 1H), 8.23 (s, 1H), 7.61 (d, J = 9.8 Hz, 1H), 7.50 (s, 1H), 6.99 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H), 5.04 (s, 2H),
		2.68-2.57 (m, 1H), 2.40 (s,
		3H), 2.40-2.30 (m, 2H),
		1.91-1.80 (m, 2H), 1.80-
		1.65 (m, 1H), 1.35-1.25 (m,
		1H), 1.01 (d, J = 6.7 Hz,
		3H).
352		1H-NMR (400 MHz, CDCl3) δ: 9.41 (s, 1H), 8.25 (s, 1H), 7.90 (s, 1H), 7.61 (d, J = 10.4 Hz, 1H), 6.99 (d, J = 4.9 Hz, 2H), 6.38 (s, 1H), 4.99 (s, 2H), 2.73 (s, 3H), 2.68-2.58 (m, 1H), 2.43- 2.30 (m, 2H), 1.93-1.82 (m,
		2H), 1.78-1.72 (m, 1H),
		1.38-1.25 (m, 1H), 1.02 (d,
		J = 6.7 Hz, 3H).
353		1H-NMR (400 MHz, CDCl3) δ: 8.82 (s, 1H), 8.33 (s, 1H), 7.81 (d, J = 9.8 Hz, 1H), 7.63 (dd, J = 13.1, 9.4 Hz, 2H), 7.01 (d, J = 9.8 Hz, 1H), 6.40 (s, 1H), 5.05 (s, 2H), 2.73 (s, 3H), 2.68-
		2.58 (m, 1H), 2.40-2.25 (m,
		2H), 1.93-1.80 (m, 2H),
		1.79-1.65 (m, 1H), 1.34-
		1.21 (m, 1H), 1.01 (d, J =
		6.7 Hz, 3H).
354		1H-NMR (400 MHz, CDCl3) δ: 9.99 (s, 1H), 8.68 (s, 1H), 8.63 (s, 1H), 8.29 (t, J = 7.6 Hz, 1H), 7.83-7.78 (m, 2H), 7.61-7.55 (m, 1H), 7.00-6.94 (m, 1H), 6.32 (s,
		1H), 5.10 (s, 2H), 2.65-
		2.53 (m, 1H), 2.33-2.22 (m,
		2H), 1.90-1.78 (m, 2H),
		1.78-1.60 (m, 1H), 1.31-
		1.20 (m, 1H), 1.00 (d, J =
		6.5 Hz, 3H).
355		1H-NMR (400 MHz, CDCl3) δ: 10.00 (s, 1H), 9.10 (d, J = 3.7 Hz, 1H), 8.97 (t, J = 4.3 Hz, 1H), 8.22 (s, 1H), 7.77 (d, J = 6.7 Hz, 1H), 7.71-7.60 (m, 2H),
		7.02 (dd, J = 9.8, 3.7 Hz,
		1H), 6.39 (s, 1H), 5.14 (s,
		2H), 2.68-2.57 (m, 1H),
		2.40-2.31 (m, 2H), 1.95-
		1.90 (m, 2H), 1.80-1.65 (m,
		1H), 1.35-1.21 (m, 1H),
		1.02 (d, J = 6.0 Hz, 3H).
356		1H-NMR (400 MHz, CDCl3) δ: 9.59 (s, 1H), 9.27 (s, 2H), 8.28 (s, 1H), 7.85 (q, J = 6.7 Hz, 2H), 7.65 (d, J = 9.8 Hz, 1H), 7.03 (d, J = 9.8 Hz, 1H), 6.41 (s, 1H),
		5.05 (s, 2H), 2.70-2.60 (m,
		1H), 2.41-2.30 (m, 2H),
		1.95-1.83 (m, 2H), 1.80-
		1.68 (m, 1H), 1.35-1.21 (m,
		1H), 1.03 (d, J = 6.1 Hz,
		3H).
357		1H-NMR (400 MHz, CDCl3) δ: 9.65 (s, 1H), 8.93 (s, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.20 (d, J = 7.3 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.72-7.64 (m, 2H), 7.48 (s,
		1H), 7.06 (d, J = 9.8 Hz,
		1H), 6.41 (s, 1H), 5.12 (s,
		2H), 2.73-2.60 (m, 1H),
		2.43-2.30 (m, 2H), 1.93-
		1.83 (m, 2H), 1.80-1.70 (m,
		1H), 1.37-1.22 (m, 1H),
		1.05 (d, J = 6.0 Hz, 3H).
358		1H-NMR (400 MHz, DMSO-d6) δ: 10.78 (s, 1 H), 9.11 (s, 1 H), 8.54-8.44 (m, 1 H), 8.09-8.02 (m, 1 H), 7.93- 7.82 (m, 1 H), 7.01-6.89 (m, 1 H), 6.54 (s, 1 H),
		4.91 (s, 2 H), 2.35-2.16
		(m, 2 H), 1.91-1.75 (m, 2
		H), 1.70-1.60 (m, 1 H),
		1.29-1.16 (m, 1 H), 0.99
		(d, J = 8.0 Hz, 3H),
359		1H-NMR (400 MHz, CDCl3) δ: 9.16 (s, 1H), 8.60 (s, 1H), 8.49 (s, 1H), 7.71 (d, J = 1.2 Hz, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.57 (s, 1H), 7.04 (d, J = 9.8 Hz, 1H),
		6.40 (s, 1H), 5.10 (s, 2H),
		2.68-2.59 (m, 1H), 2.41-
		2.28 (m, 2H), 1.93-1.80 (m,
		2H), 1.65-1.78 (m, 1H),
		1.39-1.22 (m, 1H), 1.01 (d,
		J = 6.7 Hz, 3H).
360		1H-NMR (400 MHz, CDCl3) δ: 9.77 (s, 1H), 8.62 (d, J = 2.4 Hz, 1H), 8.29 (dd, J = 8.5, 2.4 Hz, 1H), 7.67-7.58 (m, 2H), 7.01 (d, J = 9.8 Hz, 1H), 6.40 (s, 1H), 5.01
		(s, 2H), 2.68-2.57 (m, 1H),
		2.41-2.27 (m, 2H), 1.93-
		1.80 (m, 2H), 1.80-1.65 (m,
		1H), 1.35-1.21 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
361		1H-NMR (400 MHz, CDCl3) δ: 9.42 (s, 1H), 7.69 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 9.8 Hz, 1H), 7.21 (d, J = 8.6 Hz, 2H), 7.09 (s, 1H), 7.10-6.90 (m, 2H), 6.38 (s, 1H), 5.00 (s, 2H), 2.68- 2.58 (m, 1H), 2.40-2.25 (m, 2H), 1.95-1.80 (m, 2H),
		1.80-1.60 (m, 1H), 1.31-
		1.23 (m, 1H), 1.01 (d, J =
		6.7 Hz, 3H).
362		1H-NMR (400 MHz, CDCl3) δ: 9.90 (s, 1H), 8.51 (d, J = 6.1 Hz, 1H), 7.93 (d, J = 1.8 Hz, 1H), 7.66 (d, J = 9.8 Hz, 1H), 7.60-7.56 (m, 1H), 7.01 (d, J = 9.8 Hz, 1H), 6.41 (s, 1H), 4.99 (s, 2H), 2.67-2.56 (m, 1H),
		2.41-2.28 (m, 2H), 1.93-
		1.81 (m, 2H), 1.80-1.65 (m,
		1H), 1.32-1.25 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
363		1H-NMR (400 MHz, CDCl3) δ: 9.79 (s, 1H), 8.29 (s, 1H), 7.83 (s, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.28 (s, 1H), 7.23 (s, 1H), 7.09 (d, J = 7.9 Hz, 1H), 6.97 (d, J = 9.8 Hz, 1H), 6.41-6.35 (m, 1H), 5.06 (s, 2H), 2.67- 2.56 (m, 1H), 2.41-2.28 (m,
		2H), 1.90-1.80 (m, 2H),
		1.79-1.65 (m, 1H), 1.33-
		1.23 (m, 1H), 1.00 (d, J =
		6.7 Hz, 3H).
364		1H-NMR (400 MHz, CDCl3) δ: 9.35 (s, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.18 (s, 2H), 7.00 (d, J = 9.8 Hz, 1H), 6.40 (s, 1H), 4.97 (s, 2H), 2.67-2.58 (m, 1H), 2.50 (s, 6H), 2.41-2.30 (m, 2H),
		1.93-1.83 (m, 2H), 1.79-
		1.65 (m, 1H), 1.35-1.22 (m,
		1H), 1.02 (d, J = 6.7 Hz,
		3H).
365		1H-NMR (400 MHz, CDCl3) δ: 9.20 (s, 1H), 8.61 (s, 1H), 8.25 (s, 1H), 7.99 (s, 1H), 7.60 (d, J = 9.8 Hz, 1H), 6.97 (d, J = 9.8 Hz, 1H), 6.37 (s, 1H), 4.99 (s, 2H),
		3.44 (s, 2H), 2.66-2.55 (m,
		1H), 2.38-2.28 (m, 2H),
		2.25 (s, 6H), 2.15-2.00 (m,
		1H), 1.87-1.81 (m, 1H),
		1.78-1.65 (s, 1H), 1.33-
		1.25 (m, 1H), 1.00 (d, J =
		6.7 Hz, 3H).
366		1H-NMR (400 MHz, CDCl3) δ: 9.07 (s, 1H), 8.55 (d, J = 2.4 Hz, 1H), 8.23 (d, J = 1.8 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.61 (d, J = 9.8 Hz, 1H), 6.98 (d, J =
		9.8 Hz, 1H), 6.38 (s, 1H),
		4.99 (s, 2H), 3.63-3.53 (m,
		4H), 3.25 (s, 3H), 2.97-
		2.93 (m, 2H), 2.67-2.56 (m,
		1H), 2.36-2.31 (m, 2H),
		2.15-2.00 (m, 1H), 1.90-
		1.75 (m, 1H), 1.78-1.66 (m,
		1H), 1.38-1.25 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
367		1H-NMR (400 MHz, CDCl3) δ: 9.38 (s, 1H), 8.44 (s, 1H), 8.26 (s, 1H), 8.02 (s, 1H), 7.62 (d, J = 9.8 Hz, 1H), 6.98 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H), 6.20 (s, 1H), 4.99 (s, 2H), 3.90 (s, 2H),
		3.76 (s, 2H), 2.68-2.55 (m,
		4H), 2.40-2.25 (m, 2H),
		1.91-1.80 (m, 2H), 1.75-
		1.66 (m, 1H), 1.34-1.20 (m,
		1H), 1.00 (d, J = 6.1 Hz,
		3H).
368		LC-MS: [M + H]+/Rt (min) 407.4/1.79 (Method C)
369		LC-MS: [M + H]+/Rt (min) 393.4/1.82 (Method C)
370		1H-NMR (400 MHz, CDCl3) δ: 9.44 (s, 1H), 8.36 (d, J = 5.5 Hz, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.41 (s, 1H), 7.29 (dd, J = 5.8, 2.1 Hz, 1H), 6.99 (t, J = 4.9 Hz,
		1H), 6.39 (s, 1H), 4.98 (s,
		2H), 4.67 (s, 2H), 3.75-
		3.65 (m, 1H), 2.67-2.57 (m,
		1H), 2.40-2.28 (m, 2H),
		1.93-1.78 (m, 2H), 1.77-
		1.65 (m, 1H), 1.34-1.21 (m,
		1H), 1.01 (q, J = 6.3 Hz,
		3H).
371		1H-NMR (400 MHz, CDCl3) δ: 9.49 (s, 1H), 8.35 (d, J = 5.5 Hz, 1H), 7.63 (d, J = 10.4 Hz, 1H), 7.52 (s, 1H), 7.30-7.23 (m, 1H), 6.99 (d, J = 9.8 Hz, 1H), 6.45-6.33 (m, 2H), 4.97 (s, 2H), 4.01
		(d, J = 1.8 Hz, 2H), 3.81
		(s, 2H), 2.70-2.55 (m, 4H),
		2.40-2.25 (m, 2H), 1.93-
		1.80 (m, 2H), 1.80-1.65 (m,
		1H), 1.35-1.20 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
372		LC-MS: [M + H]+/Rt (min) 379.1/1.83 (Method C)
373		1H-NMR (400 MHz, CDCl3) δ: 9.78 (s, 1H), 8.27 (d, J = 5.5 Hz, 1H), 7.61 (dd, J = 10.1, 4.6 Hz, 1H), 7.47 (d, J = 1.8 Hz, 1H), 7.22-7.18 (m, 1H), 6.95 (t, J = 7.9
		Hz, 1H), 6.35 (s, 1H), 4.97
		(q, J = 12.8 Hz, 2H), 3.70-
		3.64 (m, 4H), 3.48 (s, 2H),
		2.60-2.53 (m, 1H), 2.48-
		2.38 (m, 4H), 2.37-2.26 (m,
		2H), 1.86-1.79 (m, 2H),
		1.74-1.62 (m, 1H), 1.35-
		1.22 (m, 1H), 0.96 (d, J =
		5.8 Hz, 3H).
374		1H-NMR (400 MHz, CDCl3) δ: 9.74 (s, 1H), 8.45 (s, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.62 (dd, J = 9.5, 3.4 Hz, 1H), 7.00-6.94 (m, 2H), 6.37 (s, 1H), 6.27 (s, 1H), 4.99 (s, 2H), 4.44 (s, 2H), 4.29 (s, 2H), 2.97 (s, 3H),
		2.67-2.57 (m, 1H), 2.40-
		2.25 (m, 2H), 1.93-1.78 (m,
		2H), 1.79-1.65 (m, 1H),
		1.35-1.21 (m, 1H), 1.01 (d,
		J = 6.1 Hz, 3H).
375		1H-NMR (400 MHz, CDCl3) δ: 9.13 (s, 1H), 8.51 (d, J = 2.4 Hz, 1H), 8.04 (dd, J = 8.5, 2.4 Hz, 1H), 7.85 (d, J = 14.0 Hz, 2H), 7.62 (d, J = 9.8 Hz, 1H), 7.35 (d, J = 8.5 Hz, 1H), 6.99 (d, J = 9.8 Hz, 1H), 6.38 (s,
		1H), 4.99 (s, 2H), 3.92 (s,
		3H), 2.68-2.57 (m, 1H),
		2.40-2.30 (m, 2H), 1.91-
		1.79 (m, 2H), 1.78-1.64 (m,
		1H), 1.34-1.22 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
376		1H-NMR (400 MHz, CDCl3) δ: 9.19 (s, 1H), 8.57 (d, J = 2.4 Hz, 1H), 7.98 (d, J = 9.1 Hz, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 7.00 (t, J =
		4.9 Hz, 1H), 6.39 (s, 1H),
		4.99 (s, 2H), 4.75-4.65 (m,
		2H), 3.49 (s, 1H), 2.69-
		2.52 (m, 1H), 2.40-2.28 (m,
		2H), 1.93-1.79 (m, 2H),
		1.78-1.63 (m, 1H), 1.35-
		1.21 (m, 1H), 1.01 (d, J =
		6.1 Hz, 3H).
377		1H-NMR (400 MHz, CDCl3) δ: 9.54 (s, 1H), 8.45 (s, 1H), 8.27-8.15 (m, 2H), 7.64 (d, J = 9.8 Hz, 1H), 7.56-7.41 (m, 1H), 7.25-7.18 (m, 1H), 7.17 (s, 1H), 7.00 (d, J = 9.8 Hz, 1H), 6.39 (s, 1H), 5.01 (s, 2H), 2.68-2.57 (m,
		1H), 2.40-2.27 (m, 2H),
		1.93-1.80 (m, 2H), 1.79-
		1.62 (m, 1H), 1.35-1.21 (m,
		1H), 1.01 (d, J = 6.1 Hz,
		3H).
378		1H-NMR (400 MHz, CDCl3) δ: 9.08 (s, 1H), 8.46 (d, J = 1.8 Hz, 1H), 8.39 (d, J = 2.4 Hz, 1H), 8.23 (t, J = 2.1 Hz, 1H), 7.77 (s, 1H), 7.66 (s, 1H), 7.62 (d, J = 9.8 Hz, 1H), 7.00 (d, J = 5.2 Hz, 1H), 6.39 (s, 1H), 4.99 (s, 2H), 3.94 (s, 3H), 2.67-2.51 (m, 1H), 2.40- 2.29 (m, 2H), 1.90-1.80 (m, 2H), 1.78-1.65 (m, 1H)
		1.35-1.21 (m, 1H), 1.01 (d,
		J = 6.7 Hz, 3H).
379		1H-NMR (400 MHz, CDCl3) δ: 9.33 (s, 1H), 8.37 (d, J = 6.1 Hz, 1H), 7.91 (s, 1H), 7.85 (s, 1H), 7.68-7.60 (m, 2H), 7.21-7.17 (m, 1H), 7.00 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H), 4.98 (s, 2H), 3.92 (s, 3H), 2.67-2.56 (m, 1H), 2.40-2.26 (m, 2H), 1.90-1.80 (m, 2H), 1.75-.66 (m, 1H), 1.35- 1.21 (m, 1H), 1.01 (d, J =
		6.7 Hz, 3H).
380		1H-NMR (400 MHz, CDCl3) δ: 9.33 (s, 1H), 8.54 (s, 1H), 8.46 (s, 1H), 8.34 (s, 1H), 7.63 (d, J = 9.8 Hz, 1H), 7.27 (s, 1H), 7.00 (d, J = 9.8 Hz, 1H), 6.39 (s, 1H), 5.03 (s, 2H), 2.68-2.58 (m, 1H), 2.52 (s, 3H), 2.40- 2.28 (m, 2H), 1.91-1.80 (m, 2H), 1.78-1.65 (m, 1H), 1.35-1.21 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H).
381		1H-NMR (400 MHz, CDCl3) δ: 9.27 (s, 1H), 8.43 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 7.63 (d, J = 9.1 Hz, 1H), 6.99 (d, J = 10.4 Hz, 1H), 6.41-6.32 (m, 2H), 5.00 (s, 2H), 4.95 (d, J = 4.3 Hz, 2H), 4.84 (d, J = 4.9 Hz, 2H), 2.68-2.57 (m, 1H), 2.40-2.27 (m, 2H), 1.92- 1.80 (m, 2H), 1.79-1.65 (m,
		1H), 1.34-1.24 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
382		1H-NMR (400 MHz, CDCl3) δ: 9.55 (s, 1H), 8.35 (d, J = 2.4 Hz, 1H), 8.22 (t, J = 3.0 Hz, 1H), 7.99 (d, J = 1.8 Hz, 1H), 7.59 (d, J = 10.1, 1H), 6.97-6.91 (m, 2H), 6.35 (s, 1H), 5.00 (s, 2H), 4.03-3.97 (m, 2H), 3.00 (s, 1H), 2.65-2.53 (m, 1H), 2.38-2.25 (m, 4H), 1.99-1.78 (m, 4H), 1.75- 1.62 (m, 1H), 1.35-1.21 (m,
		1H), 0.99 (d, J = 6.0 Hz,
		3H).
383		1H-NMR (400 MHz, CDCl3) δ: 9.27 (s, 1H), 7.91 (d, J = 5.5 Hz, 1H), 7.81 (t, J = 4.9 Hz, 1H), 7.61 (d, J = 9.8 Hz, 1H), 7.00 (t, J = 4.9 Hz, 1H), 6.38 (s, 1H), 4.99 (s, 2H), 3.84-3.76 (m, 4H), 3.48-3.40 (m, 4H), 2.65-2.55 (m, 1H), 2.40- 2.27 (m, 2H), 1.92-1.80 (m, 2H), 1.80-1.65 (m, 1H), 1.34-1.26 (m, 1H), 1.01 (d,
		J = 6.7 Hz, 3H).
384		LC-MS: [M + H]+/Rt (min) 408.4/1.56 (Method C)
385		LC-MS: [M + H]+/Rt (min) 377.4/1.64 (Method C)
386		LC-MS: [M + H]+/Rt (min) 377.3/1.57 (Method C)
387		LC-MS: [M + H]+/Rt (min) 377.3/1.55 (Method C)
388		LC-MS: [M + H]+/Rt (min) 376.3/1.83 (Method C)
389		LC-MS: [M + H]+/Rt (min) 392.3/1.88 (Method C)
390		LC-MS: [M + H]+/Rt (min) 408.3/1.86 (Method C)
391		LC-MS: [M + H]+/Rt (min) 407.4/1.80 (Method C)
392		LC-MS: [M + H]+/Rt (min) 408.3/1.55 (Method C)
393		LC-MS: [M + H]+/Rt (min) 408.4/1.54 (Method C)
394		1H-NMR (400 MHz, DMSO-d6) δ: 8.14-8.12 (m, 1H), 7.83 (d, J = 10.0 Hz, 1H), 7.58- 7.53 (m, 1H), 6.89 (d, J = 9.6 Hz, 1H), 6.87-6.84 (m, 1H), 6.68-6.65 (m, 1H), 6.51-6.48 (m, 1H), 4.97 (s, 2H), 3.65-3.49 (m, 8H),
		2.68-2.64 (m, 1H), 2.34-
		2.27 (m, 1H), 2.25-2.15 (m,
		1H), 1.84-1.73 (m, 2H),
		1.71-1.60 (m, 1H), 1.28-
		1.17 (m, 1H), 0.96 (d, J =
		6.8 Hz, 3H).
395		1H-NMR (400 MHz, DMSO-d6) δ: 8.33 (d, J = 2.8 Hz, 1H), 8.03-8.02 (m, 1H), 7.83 (d, J = 10.4 Hz, 1H), 7.37-7.36 (m, 1H), 7.25- 7.21 (m, 1H), 6.89 (d, J = 10.0 Hz, 1H), 6.51-6.48 (m, 1H), 4.98 (s, 2H), 3.69-
		3.66 (m, 2H), 3.61-3.59 (m,
		2H), 3.29-3.26 (m, 2H),
		3.21-3.18 (m, 2H), 2.48-
		2.45 (m, 1H), 2.35-2.28 (m,
		1H), 2.24-2.15 (m, 1H),
		1.84-1.73 (m, 2H), 1.68-
		1.61 (m, 1H), 1.26-1.16 (m,
		1H), 0.96 (d, J = 6.0 Hz,
		3H).
396		LC-MS: [M + H]+/Rt (min) 408.4/0.643 (Method A)
397		LC-MS: [M + H]+/Rt (min) 409.3/0.932 (Method A)
398		LC-MS: [M + H]+/Rt (min) 392.4/1.239 (Method A)
399		1H-NMR (400 MHz, DMSO-d6) δ: 8.40-8.37 (m, 1H), 8.29- 8.28 (m, 1H), 7.83 (d, J = 10.0 Hz, 1H), 6.89 (d, J = 10.0 Hz, 1H), 6.65-6.63 (m, 1H), 6.51-6.48 (m, 1H), 5.02 (s, 1H), 4.96 (s, 1H), 4.31-4.28 (m, 1H), 4.15- 4.12 (m, 1H), 3.91 (s, 3H), 3.75-3.66 (m, 2H), 2.69-
		2.63 (m, 2H), 2.57-2.51 (m,
		1H), 2.34-2.14 (m, 2H),
		1.84-1.70 (m, 2H), 1.70-
		1.59 (m, 1H), 1.26-1.16
		(m, 1H), 0.95 (d, J = 6.8
		Hz, 3H).
400		1H-NMR (400 MHz, DMSO-d6) δ: 8.71 (d, J = 7.2 Hz, 2H), 7.83 (d, J = 10.0 Hz, 1H), 6.89 (d, J = 10.0 Hz, 1H), 6.51-6.48 (m, 1H), 6.30-6.26 (m, 1H), 4.98 (d, J = 22 Hz, 2H), 4.26-4.23 (m, 1H), 4.11-4.08 (m, 1H), 3.91 (s, 3H), 3.73 (t, J = 5.6 Hz, 1H), 3.68 (t, J =
		5.6 Hz, 1H), 3.40-3.33 (m,
		1H), 2.63-2.58 (m, 1H),
		2.47-2.44 (m, 1H), 2.33-
		2.26 (m, 1H), 2.24-2.14 (m,
		1H), 1.84-1.72 (m, 2H),
		1.68-1.60 (m, 1H), 1.26-
		1.15 (m, 1H), 0.95 (d, J =
		6.8 Hz, 3H).
401		LC-MS: [M + H]+/Rt (min) 462.4/1.021 (Method A)
402		1H-NMR (400 MHz, DMSO-d6) δ: 8.70-8.68 (m, 1H), 8.48- 8.47 (m, 1H), 7.87-7.82 (m, 2H), 7.39-7.36 (m, 1H), 6.90 (d, J = 10.0 Hz, 1H), 6.51-6.48 (m, 1H), 6.31- 6.29 (m, 1H), 4.99 (d, J = 23.2 Hz, 2H), 4.28-4.26 (m,
		1H), 4.13-4.10 (m, 1H),
		3.73 (t, J = 5.6 Hz, 1H),
		3.69 (t, J = 5.6 Hz, 1H),
		3.39-3.33 (m, 1H), 2.68-
		2.61 (m, 1H), 2.47-2.44 (m,
		1H), 2.34-2.26 (m, 1H),
		2.24-2.14 (m, 1H), 1.85-
		1.72 (m, 2H), 1.69-1.60 (m,
		1H), 1.26-1.16 (m, 1H),
		0.95 (d, J = 6.8 Hz, 3H).
403		1H-NMR (400 MHz, DMSO-d6) δ: 8.30-8.27 (m, 1H), 8.20- 8.19 (m, 1H), 7.84 (d, J = 10.0 Hz, 1H), 7.41-7.38 (m, 1H), 6.90 (d, J = 10.0 Hz, 1H), 6.51-6.48 (m, 1H), 6.34-6.31 (m, 1H), 4.99 (d, J = 22 Hz, 2H), 4.28-4.25
		(m, 1H), 4.13-4.10 (m, 1H),
		3.85 (s, 3H), 3.73 (t, J =
		5.6 Hz, 1H), 3.68 (t, J =
		5.6 Hz, 1H), 3.40-3.33 (m,
		1H), 2.68-2.61 (m, 1H),
		2.47-2.44 (m, 1H), 2.34-
		2.26 (m, 1H), 2.24-2.14 (m,
		1H), 1.85-1.72 (m, 2H),
		1.69-1.60 (m, 1H), 1.26-
		1.16 (m, 1H), 0.95 (d, J =
		6.8 Hz, 3H).
404		LC-MS: [M + H]+/Rt (min) 431.4/0.860 (Method A)
405		1H-NMR (400 MHz, DMSO-d6) δ: 8.24-8.22 (m, 1H), 7.90- 7.89 (m, 1H), 7.83 (d, J = 9.6 Hz, 1H), 7.18 (t, J = 2.4 Hz, 1H), 6.90 (d, J = 10.0 Hz, 1H), 6.51-6.48 (m, 1H), 4.98 (s, 2H), 3.69- 3.65 (m, 2H), 3.61-3.57 (m,
		2H), 3.39-3.34 (m, 2H),
		3.29-3.25 (m, 2H), 2.67-
		2.63 (m, 1H), 2.54-2.50 (m,
		1H), 2.35-2.30 (m, 1H),
		2.26-2.14 (m, 1H), 1.85-
		1.72 (m, 2H), 1.70-1.60 (m,
		1H), 1.27-1.17 (m, 1H),
		0.96 (d, J = 6.8 Hz, 3H).
406		LC-MS: [M + H]+/Rt (min) 399.3/0.868 (Method A)
407		LC-MS: [M + H]+/Rt (min) 424.3/0.679 (Method A)
408		LC-MS: [M + H]+/Rt (min) 401.4/0.621 (Method A)
409		LC-MS: [M + H]+/Rt (min) 442.4/0.994 (Method A)
410		LC-MS: [M + H]+/Rt (min) 408.4/0.704 (Method A)
411		LC-MS: [M + H]+/Rt (min) 401.4/0.624 (Method A)
412		LC-MS: [M + H]+/Rt (min) 397.3/0.838 (Method A)
413		LC-MS: [M + H]+/Rt (min) 441.4/0.993 (Method D)
414		1H-NMR (400 MHz, DMSO-d6) δ: 7.83 (d, J = 9.6 Hz, 1H), 7.19 (d, J = 3.6 Hz, 1H), 6.91-6.89 (m, 1H), 6.88 (s, 1H), 6.51-6.47 (m, 1H), 4.97 (s, 2H), 3.68- 3.65 (m, 2H), 3.60-3.58 (m,
		2H), 3.51-3.48 (m, 2H),
		3.41-3.39 (m, 2H), 2.48-
		2.45 (m, 1H), 2.35-2.26 (m,
		1H), 2.26-2.14 (m, 1H),
		1.85-1.73 (m, 2H), 1.69-
		1.60 (m, 1H), 1.26-1.18 (m,
		1H), 0.96 (d, J = 6.4 Hz,
		3H).
415		LC-MS: [M + H]+/Rt (min) 397.3/0.787 (Method A)
416		1H-NMR (400 MHz, DMSO-d6) δ: 8.36 (d, J = 2.8 Hz, 1H), 8.03-8.01 (m, 1H), 7.84 (d, J = 9.6 Hz, 1H), 7.39-7.36 (m, 1H), 7.25- 7.21 (m, 1H), 6.89 (d, J = 10.0 Hz, 1H), 6.52-6.49 (m, 1H), 5.01-4.90 (m, 2H),
		4.48-4.39 (m, 1H), 4.26-
		4.17 (m, 1H), 3.68-3.59 (m,
		2H), 3.34-3.32 (m, 1H),
		3.00-2.81 (m, 2H), 2.35-
		2.26 (m, 1H), 2.26-2.16 (m,
		1H), 1.86-1.74 (m, 2H),
		1.70-1.61 (m, 1H), 1.48-
		1.34 (m, 3H), 1.30-1.18 (m,
		4H), 0.96 (d, J = 6.8 Hz,
		3H).
417		LC-MS: [M + H]+/Rt (min) 422.4/0.676 (Method A)
418		1H-NMR (400 MHz, CDCl3) δ: 7.96 (d, J = 2.4 Hz, 1H), 7.54 (d, J = 9.8 Hz, 1H), 6.91-6.89 (br m, 2H), 6.32 (br s, 1H), 5.00 (d, J = 3.7 Hz, 2H), 3.86 (s, 3H), 3.83-3.80 (br m, 2H), 3.70- 3.68 (br m, 2H), 3.00-2.92
		(m, 4H), 2.62-2.60 (m, 1H),
		2.58-2.56 (m, 1H), 2.52 (s,
		3H), 1.87-1.66 (m, 4H),
		1.33-1.23 (m, 1H), 1.00 (d,
		J = 6.7 Hz, 3H).
419		1H-NMR (400 MHz, CDCl3) δ: 8.64 (d, J = 6.1 Hz, 2H), 7.59 (br s, 2H), 7.55 (d, J = 9.8 Hz, 1H), 6.90 (d, J = 9.8 Hz, 1H), 6.60-6.51 (br m, 1H), 6.33-6.31 (m, 1H), 5.05-4.98 (m, 2H), 4.40-4.34 (m, 2H), 3.92-
		3.78 (m, 1H), 2.75-2.70 (br
		m, 1H), 2.64-2.53 (br m,
		2H), 2.35-2.24 (br m, 3H),
		1.88-1.78 (br m, 2H), 1.75-
		1.65 (br m, 1H), 1.32-1.22
		(m, 1H), 0.99 (d, J = 6.1
		Hz, 3H).
420		LC-MS: [M + H]+/Rt (min) 391.2/1.62 (Method B)
421		1H-NMR (400 MHz, CDCl3) δ: 9.57 (s, 1H), 7.96 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.68 (s, 1H), 7.65 (d, J = 10.0 Hz, 1H), 7.02-6.97 (m, 2H), 6.40 (s, 1H), 5.00 (s,
		2H), 2.67-2.57 (m, 1H),
		2.40-2.25 (m, 2H), 1.90-
		1.85 (m, 2H), 1.77-1.67 (m,
		1H), 1.35-1.25 (m, 1H),
		1.01 (d, J = 6.7 Hz, 3H).
422		1H-NMR (400 MHz, CDCl3) δ: 8.73 (s, 1H), 7.84 (d, J = 2.4 Hz, 1H), 7.56 (d, J = 9.8 Hz, 1H), 7.41 (dd, J = 8.6, 2.4 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 6.96 (d,
		J = 9.8 Hz, 1H), 6.36 (s,
		1H), 4.96 (s, 2H), 2.68-
		2.60 (m, 1H), 2.60 (s, 3H),
		2.45-2.30 (m, 2H), 1.91-
		1.81 (m, 2H), 1.79-1.71 (m,
		1H), 1.37-1.27 (m, 1H),
		1.02 (d, J = 6.7 Hz, 3H).
423		1H-NMR (400 MHz, CDCl3) δ: 8.97 (s, 1H), 8.05 (s, 1H), 7.58 (d, J = 9.8 Hz, 1H), 7.43 (s, 2H), 6.98 (t, J = 6.7 Hz, 1H), 6.38 (s, 1H), 4.98 (s, 2H), 2.69-2.60 (m,
		1H), 2.53 (s, 3H), 2.43-
		2.32 (m, 2H), 1.93-1.82 (m,
		2H), 1.80-1.70 (m, 1H),
		1.39-1.25 (m, 1H), 1.03 (d,
		J = 6.7 Hz, 3H).
424		LC-MS: [M + H]+/Rt (min) 406.3/0.577 (Method D)

Examples 425-445

According to the method of Example 1, 37, or 50 and common reaction conditions, the compounds of Examples 425 to 445 were obtained by using each corresponding material compound.

Example	M2	Analytical data
425		1H-NMR (400 MHz, DMSO-d6) δ: 10.55 (s, 1H), 8.45 (d, J = 7.6 Hz, 1H), 7.88-7.91 (m, 2H), 7.82 (s, 1H), 7.45-7.44 (m, 1H), 6.93-6.96 (m, 2H), 6.49-6.52 (m, 1H), 4.89 (s, 2H), 2.32-2.38 (m, 2H), 1.99-2.03
		(m, 2H), 1.43 (t, J = 6.8 Hz, 2H),
		0.92 (s, 6H).
426		1H-NMR (400 MHz, CDCl3) δ: 8.70 (br s, 1H), 7.60 (d, J = 10.1 Hz, 1H), 7.09-7.06 (m, 2H), 6.96 (d, J = 10.1 Hz, 1H), 6.91 (dd, J = 8.2, 2.1 Hz, 1H), 6.34-6.32 (m, 1H), 4.93 (s, 2H), 4.55 (t, J = 8.7 Hz,
		2H), 3.14 (t, J = 8.7 Hz, 2H),
		2.48-2.44 (m, 2H), 2.04-2.02 (m,
		2H), 1.48 (t, J = 6.4 Hz, 2H),
		0.95 (s, 6H).
427		1H-NMR (400 MHz, CDCl3) δ: 8.34 (d, J = 7.3 Hz, 1H), 7.99 (s, 1H), 7.88 (d, J = 2.4 Hz, 1H), 7.64 (d, J = 9.8 Hz, 1H), 7.00 (d, J = 9.8 Hz, 1H), 6.73-6.71 (m, 1H), 6.40 (d, J = 2.4 Hz, 1H), 6.37-6.34 (br
		m, 1H), 4.98 (s, 2H), 2.49-2.45
		(m, 2H), 2.04-2.03 (m, 2H), 1.51-
		1.48 (br m, 2H), 0.96 (s, 6H).
428		1H-NMR (400 MHz, CDCl3) δ: 9.54 (s, 1H), 9.47 (s, 1H), 8.29 (d, J = 4.3 Hz, 1H), 7.68-7.63 (m, 2H), 7.31-7.28 (m, 1H), 7.02 (t, d = 6.7 Hz, 1H), 6.37 (s, 1H), 5.03 (s, 2H), 2.50-2.46 (m, 2H), 2.08- 2.03 (m, 2H), 1.53-1.547 (m, 2H), 0.96 (s, 6H).
429		1H-NMR (400 MHz, CDCl3) δ: 9.69 (s, 1H), 8.42 (d, J = 7.3 Hz, 1H), 8.24 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.66 (d, J = 9.8 Hz, 1H), 7.13 (dd, J = 7.6, 2.1 Hz, 1H), 7.01 (d, J = 9.8 Hz, 1H), 6.36 (s,
		1H), 5.01 (s, 2H), 2.50-2.43 (m,
		2H), 2.15-2.03 (m, 2H), 1.53-1.45
		(m, 2H), 0.95 (s, 6H).
430		1H-NMR (400 MHz, DMSO-d6) δ: 7.89- 7.84 (m, 2H), 6.93 (d, J = 10.0 Hz, 1H), 6.88-6.86 (m, 1H), 6.70 (dd, J = 2.4, 4.0 Hz, 1H), 6.50- 6.47 (m, 1H), 5.00 (s, 2H), 4.20 (t, J = 8.0 Hz, 2H), 3.71 (s, 3H), 3.17 (t, J = 8.0 Hz, 2H), 2.36-
		2.31 (m, 2H), 2.03-1.99 (m, 2H),
		1.42 (t, J = 6.8 Hz, 2H), 0.91 (s, 6H).
431		1H-NMR (400 MHz, DMSO-d6) δ: 7.88 (d, J = 10.0 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 6.93 (d, J = 9.6 Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 6.50- 6.47 (m, 1H), 5.01 (s, 2H), 4.25- 4.20 (m, 2H), 3.79 (s, 3H), 3.09-
		3.04 (m, 2H), 2.36-2.31 (m, 2H),
		2.02-1.99 (m, 2H), 1.44-1.40 (m,
		2H), 0.91 (s, 6H).
432		1H-NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 10.1 Hz, 1H), 7.16 (t, J = 8.4 Hz, 1H), 6.92 (d, J = 10.1 Hz, 1H), 6.69 (d, J = 7.3 Hz, 1H), 6.30-6.28 (m, 1H), 5.02 (s, 2H), 4.19 (t, J = 8.2 Hz, 2H), 3.86-3.83 (m, 4H), 3.19 (t, J = 8.2 Hz, 2H), 2.99-
		2.97 (m, 4H), 2.44-2.40 (m, 2H),
		2.03-2.01 (m, 2H), 1.45 (t, J =
		6.4 Hz, 2H), 0.94 (s, 6H).
433		1H-NMR (400 MHz, DMSO-d6) δ: 7.89 (d, J = 10.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.09 (t, J = 8.0 Hz, 1H), 6.93 (d, J = 9.6 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 6.51- 6.48 (m, 1H), 5.01 (s, 2H), 4.19 (t, J = 8.0 Hz, 2H), 3.09 (t, J = 8.0 Hz, 2H), 2.95-2.90 (m, 4H),
		2.47-2.43 (m, 4H), 2.36-2.30 (m,
		2H), 2.22 (s, 3H), 2.02-1.99 (m,
		2H), 1.42 (t, J = 6.8 Hz, 2H),
		0.91 (s, 6H).
434		LC-MS: [M + H]+/Rt (min) 449.2/1.098 (Method A)
435		1H-NMR (400 MHz, CDCl3) δ: 7.84 (d, 7.9 Hz, 1H), 7.56 (d, J = 9.8 Hz, 1H), 7.12 (t, J = 8.2 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.78 (d, J = 7.9 Hz, 1H), 6.30-6.28 (m, 1H), 5.20 (s, 2H), 5.01 (s, 2H), 4.21 (t, J = 8.5 Hz, 2H), 3.49 (s,
		3H), 3.23 (t, J = 8.5 Hz, 2H),
		2.42 (br s, 2H), 2.03-2.01 (m,
		2H), 1.46 (t, J = 6.4 Hz, 2H),
		0.94 (s, 6H).
436		LC-MS: [M + H]+/Rt (min) 436.4/1.054 (Method A)
437		LC-MS: [M + H]+/Rt (min) 477.4/0.895 (Method A)
438		1H-NMR (400 MHz, CDCl3) δ: 8.02 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 9.8 Hz, 1H), 7.13 (t, J = 7.9 Hz, 1H), 6.93 (d, J = 7.9 Hz, 1H), 6.85 (d, J = 9.8 Hz, 1H), 6.24-6.21 (m, 1H), 4.94 (s, 2H), 4.69 (t, J = 6.7 Hz, 2H), 4.54 (t, J = 6.1 Hz, 2H), 4.14 (t, J = 8.5 Hz, 2H), 3.86 (s, 4H), 3.33 (s, 2H), 3.07 (t, J = 8.2 Hz, 2H), 2.37-2.33 (m,
		2H), 1.96-1.94 (m, 2H), 1.39 (t,
		J = 6.4 Hz, 2H), 0.87 (s, 6H).
439		LC-MS: [M + H]+/Rt (min) 408.4/0.770 (Method A)
440		1H-NMR (400 MHz, DMSO-d6) δ: 8.33- 8.32 (m, 1H), 8.03-8.02 (m, 1H), 7.85 (d, J = 10.0 Hz, 1H), 7.37- 7.34 (m, 1H), 7.25-7.21 (m, 1H), 6.90 (d, J = 9.6 Hz, 1H), 6.48- 6.45 (m, 1H), 4.98 (s, 2H), 3.69- 3.66 (m, 2H), 3.62-3.58 (m, 2H), 3.29-3.26 (m, 2H), 3.22-3.17 (m, 2H), 2.34-2.29 (m, 2H), 2.01-1.98
		(m, 2H), 1.41 (t, J = 6.0 Hz, 2H),
		0.91 (s, 6H).
441		LC-MS: [M + H]+/Rt (min) 400.4/0.947 (Method A)
442		1H-NMR (400 MHz, DMSO-d6) δ: 8.14-8.12 (m, 1H), 7.87 (s, 1H), 7.85 (d, J = 10.0 Hz, 1H), 7.20- 7.18 (m, 1H), 6.90 (d, J = 9.6 Hz, 1H), 6.48-6.44 (m, 1H), 4.98 (s, 2H), 3.68-3.64 (m, 2H), 3.61-3.57 (m, 2H), 3.29-3.24 (m, 2H), 3.20- 3.16 (m, 2H), 2.34-2.29 (m, 2H), 2.24 (s, 3H), 2.02-1.98 (m, 2H),
		1.41 (t, J = 6.4 Hz, 2H), 0.91 (s, 6H).
443		LC-MS: [M + H]+/Rt (min) 422.4/0.754 (Method A)
444		LC-MS: [M + H]+/Rt (min) 426.4/0.858 (Method D)
445		1H-NMR (400 MHz, DMSO-d6) δ: 10.49 (s, 1H), 8.71-8.70 (m, 1H), 8.11- 8.10 (m, 1H), 7.90-7.87 (m, 1H), 7.73-7.70 (m, 1H), 7.53-7.49 (m, 1H), 6.95-6.92 (m, 1H), 6.51-6.49 (m, 1H), 4.89-4.86 (m, 2H), 2.37-
		2.31 (m, 2H), 2.03-1.99 (m, 2H),
		1.44-1.40 (m, 2H), 0.93-0.89 (m, 6H).

Examples 446-455

According to the method of Example 1, 37, or 50 and common reaction conditions, the compounds of Examples 446 to 445 were obtained by using each corresponding material compound.

Example	M1	R1	R2	Analytical data
446		H	H	1H-NMR (400 MHz, CDCl3) δ: 8.93 (s, 1H), 8.06 (s, 2H), 7.59 (d, J = 9.8 Hz, 1H), 7.51-7.44 (m, 2H), 7.01 (d, J = 9.8 Hz, 1H), 6.37-6.33 (m, 1H), 4.98 (s, 2H), 2.86-2.77 (m, 1H), 2.55-2.45 (m, 1H), 2.45-2.25 (m, 3H), 2.20-2.12 (m, 1H), 1.64-1.58 (m, 1 Hz).
447		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 8.08-8.05 (m, 2H), 7.48 (s, 2H), 6.45-6.40 (s, 1H), 6.27 (s, 1H), 4.95 (s, 2H), 3.87 (s, 3H), 2.67-2.57 (m, 1H), 2.42- 2.225 (m, 4H), 2.16-2.08 (m, 1H), 1.70-1.60 (m, 1H).
448		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 9.35 (s, 1H), 8.01 (d, J = 5.5 Hz, 2H), 7.48-7.35 (m, 2H), 6.33-6.27 (m, 2H), 6.21 (s, 1H), 4.93 (s, 2H), 3.82 (s, 3H), 2.24-2.17 (m, 2H), 2.10 (s, 2H), 1.37 (t, J = 6.4 Hz, 2H), 1.21 (s, 6H).
449		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 9.13 (s, 1H), 8.07 (s, 2H), 7.49 (s, 2H), 6.38 (s, 1H), 6.25 (s, 1H), 4.95 (s, 2H), 3.86 (s, 3H), 2.48- 2.28 (m, 3H), 1.87-1.67 (m, 2H), 1.38-1.23 (m, 2H), 1.00 (d, J = 6.1 Hz, 3H).
450		OMe	H	1H-NMR (400 MHz, CDCl3) δ: 9.07 (s, 1H), 8.07-8.06 (m, 2H), 7.48- 7.47 (m, 2H), 6.43-6.41 (m, 1H), 6.27 (s, 1H), 4.94 (s, 2H), 3.87 (s, 3H), 2.65-2.59 (m, 1H), 2.49- 2.26 (m, 4H), 2.15-2.10 (m, 1H), 1.69-1.58 (m, 1H).
451		OMe	H	1H-NMR (400 MHz, CDCl3) δ: 9.35 (s, 1H), 8.08-8.05 (m, 2H), 7.44 (s, 1H), 6.40 (s, 1H), 6.28 (s, 1H), 5.00 (s, 2H), 3.88 (s, 3H), 2.45-2.38 (m, 2H), 2.05-2.00 (m, 2H), 1.49 (t, J = 6.4 Hz, 2H), 0.98 (s, 6H).
452		H	H	1H-NMR (400 MHz, CDCl3) δ: 9.13 (s, 1H), 8.74 (s, 1H), 7.98-7.93 (m, 1H), 7.93-7.86 (m, 2H), 7.68- 7.64 (m, 1H), 7.49-7.39 (m, 1H), 7.29-7.38 (m, 1H), 7.13-7.05 (m, 1H), 6.99-6.94 (m, 1H), 4.94 (s, 2H), 2.44 (s, 3H).
453		H	H	1H-NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 8.74 (s, 1H), 8.34 (d, J = 7.9 Hz, 1H), 8.13-8.03 (m, 2H), 7.85-7.75 (m, 2H), 7.65-7.35 (m, 3H), 5.10 (s, 2H).
454		H	H	1H-NMR (400 MHz, CD3OD) δ: 8.45 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 7.99 (dd, J = 9.8, 4.9 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.60- 7.53 (m, 2H), 7.39 (d, J = 1.2 Hz, 1H), 7.09 (dd, J = 9.8, 4.3 Hz, 1H), 5.04 (s, 2H).
455		H	H	1H-NMR (400 MHz, CDCl3) δ: 8.95 (s, 1H), 8.04 (s, 2H), 7.63 (d, J = 9.8 Hz, 1H), 7.50-7.40 (m, 2H), 7.20 (q, J = 4.7 Hz, 1H), 7.06 (t, J = 11.0 Hz, 1H), 6.72 (t, J = 1.8 Hz, 1H), 5.00 (s, 2H), 7.49 (s, 3H).

Examples 456-467

According to the method of Example 1, 37, or 50 and common reaction conditions, the compounds of Examples 456 to 467 were obtained by using each corresponding material compound.

Exam-
ple	M1	R1	R2	Analytical data
456		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 8.06-7.98 (m, 1H), 7.88 (s, 1H), 7.57 (s, 1H), 7.54-7.48 (m, 1H), 7.26-7.17 (m, 1H), 6.35-6.39 (m, 1H), 6.27 (s, 1H), 5.06-5.02 (m, 2H), 3.89 (s, 3H), 2.44-2.39 (m, 2H), 2.05-1.99 (m, 2H), 1.49 (t, J = 6.4 Hz, 2H), 0.99 (s, 6H).
457		H	H	1H-NMR (400 MHz, CDCl3) δ: 10.40 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.85 (s, 1H), 7.62 (d, J = 9.6 Hz, 1H), 7.53 (s, 1H), 7.41 (s, 1H), 7.12 (dd, J = 7.6, 2.1 Hz, 1H), 6.98 (d, J =
				9.6 Hz, 1H), 6.36 (s, 1H), 5.07
				(s, 2H), 2.79-2.71 (m, 2H),
				2.64-2.57 (m, 2H), 2.04 (q, J =
				7.2 Hz, 2H).
458		H	H	1H-NMR (400 MHz, CDCl3) δ: 10.38 (s, 1H), 7.86-7.80 (m, 2H), 7.56 (d, J = 9.8 Hz, 1H), 7.46 (s, 1H), 7.34 (s, 1H), 7.05 (dd, J = 7.2, 2.0 Hz, 1H), 6.93 (d, J = 9.8H, 1 Hz), 6.36 (s, 1H), 5.02 (s, 2H), 2.40 (s, 4H),
				1.75-1.60 (m, 4H).
459		OMe	H	1H-NMR (400 MHz, CDCl3) δ: 9.58 (s, 1H), 7.97-7.83 (m, 1H), 7.81 (s, 1H), 7.49 (s, 1H), 7.39 (s, 1H), 6.98 (d, J = 6.7 Hz, 1H), 6.36-6.30 (m, 1H), 6.23 (s, 1H), 4.94 (s, 2H), 3.86 (s, 3H), 2.40- 2.35 (m, 2H), 2.00-1.96 (m, 2H), 1.44 (2H, t, J = 6.7 Hz), 0.94 (s, 6H).
460		H	Me	1H-NMR (400 MHz, DMSO-d6) δ: 10.57 (s, 1H) 8.40 (d, J = 7.3 Hz, 1H), 7.85 (s, 1H), 7.75 (d, J = 7.3 Hz, 2H), 7.39 (s, 1H), 6.92 (dd, J = 7.3, 1.8 Hz, 1H), 6.41 (s, 1H), 4.83 (s, 2H), 2.28 (s, 2H), 2.04 (s, 3H), 1.95 (s, 2H), 1.38-1.34 (m, 2H), 0.85 (s, 6H).
461		Me	H	1H-NMR (400 MHz, CDCl3) δ: 10.10 (s, 1H), 7.98-7.93 (m, 2H), 7.50-7.43 (m, 2H), 7.16-7.08 (s, 1H), 6.83 (s, 1H), 5.78 (s, 1H), 5.03 (s, 2H), 2.30-2.23 (m, 5H), 1.98 (s, 2H), 1.51-1.48 (m, 2H), 0.98 (s, 6H).
462		H	OMe	1H-NMR (400 MHz, DMSO-d6) δ: 10.55 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 7.91 (s, 1H), 7.83 (s, 1H), 7.46 (s, 1H), 6.95 (d, J = 7.3 Hz, 1H), 6.37 (s, 2H), 4.86 (s, 2H), 3.85 (s, 3H), 2.67-2.53 (m, 2H), 2.46-2.16 (m, 3H), 2.05-1.99 (m, 1H), 1.57-1.45 (m, 1H).
463		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 9.39 (br s, 1H), 7.97 (d, J = 7.3 Hz, 1H), 7.82 (s, 1H), 7.55 (s, 1H), 7.46 (s, 1H), 7.06-7.04 (br m, 1H), 6.38-6.37 (br m, 1H), 6.25 (s, 1H), 4.94 (s, 2H), 3.86 (s, 3H), 2.47-2.28 (m, 3H), 1.85- 1.78 (m, 2H), 1.37-1.24 (m, 2H), 1.00 (d, J = 6.1 Hz, 3H).
464		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 10.58 (s, 1H), 8.46 (dd, J = 7.3, 1.2 Hz, 1H), 7.95-7.90 (m, 2H), 7.83-7.82 (m, 1H), 7.46 (d, J = 1.2 Hz, 1H), 7.00 (d, J = 9.8 Hz, 1H), 6.96 (dd, J = 7.3, 2.4 Hz, 1H), 6.46 (s, 1H), 4.92 (s, 2H), 2.83-2.75 (m, 2H), 2.66-2.60 (m, 2H), 2.19-2.09
				(m, 2H).
465		H	H	LC-MS: [M + H]+/Rt (min) 364.3/0.582 (Method D)
466		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 9.86 (s, 1H), 7.90 (s, 1H), 7.78 (s, 1H), 7.62 (s, 1H), 7.52 (d, J = 6.7 Hz, 1H), 7.39 (s, 1H), 7.18 (s, 1H), 7.11 (d, J = 6.7 Hz, 1H), 6.34 (s, 1H), 5.02 (s, 2H), 3.99 (s, 3H).
467		H	H	1H-NMR (400 MHz, CD3OD) δ: 8.38 (d, J = 7.3 Hz, 1H), 8.01 (d, J = 9.8 Hz, 2H), 7.75 (s, 1H), 7.57 (d, J = 1.2 Hz, 1H), 7.48 (dd, J = 8.8, 1.5 Hz, 1H), 7.40 (d, J = 1.2 Hz, 1H), 7.10 (t, J = 4.9 Hz, 2H), 5.05 (s, 2H).

Examples 468-481

According to the method of Example 1, 37, 38, or 50, and common reaction conditions, the compounds of Examples 468 to 481 were obtained by using each corresponding material compounds.

Example	M1	R1	R2	Analytical data
468		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 8.0 Hz, 1H), 7.15 (t, J = 8.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 6.27 (s, 1H), 6.19 (s, 1H), 4.98 (s, 2H), 4.16 (t, J = 8.0 Hz, 2H), 3.90-3.78 (m, 7H), 3.17 (t, J = 8.0 Hz, 2H), 2.98 (m, 4H), 2.36 (s, 2H), 1.98 (m, 2H), 1.45 (t, J = 6.4 Hz, 2H),
				0.95 (6H, s).
469		H	H	LC-MS: [M + H]+/Rt (min) 457.4/0.824 (Method D)
470		OMe	H	1H-NMR (400 MHz, CDCl3) δ: 7.89 (d, J = 8.0 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 6.25 (s, 1H), 6.17 (s, 1H), 4.97 (s, 2H), 4.14 (t, J = 8.0 Hz, 2H), 3.90-3.78 (m, 7H), 3.15 (t, J = 8.0 Hz, 2H), 2.96 (m, 4H), 2.34 (s, 2H), 1.96 (m, 2H), 1.43 (t, J = 6.4 Hz, 2H),
				0.93 (6H, s).
471		H	H	1H-NMR (400 MHz, CDCl3) δ: 7.84 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 9.8 Hz, 1H), 7.12 (t, J = 8.2 Hz, 1H), 6.92 (d, J = 9.8 Hz, 1H), 6.78 (d, J = 7.9 Hz, 1H), 6.30- 6.28 (m, 1H), 5.20 (s, 2H), 5.01 (s, 2H), 4.21 (t, J = 8.5 Hz, 2H), 3.49 (s, 3H), 3.23 (t, J = 8.5 Hz, 2H), 2.42 (br s, 2H), 2.03-
				2.01 (m, 2H), 1.46 (t, J = 6.4
				Hz, 2H), 0.94 (s, 6H).
472		H	H	1H-NMR (400 MHz, CDCl3) δ: 7.91 (d, J = 7.3 Hz, 1H), 7.24-7.13 (m, 2H), 6.93 (dd, J = 9.1, 1.2 Hz, 1H), 6.69 (d, J = 7.9 Hz, 1H), 5.00 (d, J = 5.5 Hz, 2H), 4.18 (t, J = 8.2 Hz, 2H), 3.86-3.83 (m, 4H), 3.19 (t, J = 8.2 Hz, 2H), 2.99-2.97 (br m, 4H), 2.67-2.44 (m, 1H), 1.93-1.90 (br m, 1H),
				1.82-1.61 (m, 4H), 1.48-0.99 (m,
				4H), 0.96-0.91 (m, 3H).
473		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 7.91 (br m, 1H), 7.15 (br m, 1H), 6.68 (br m, 1H), 6.28 (s, 1H), 6.19 (s, 1H), 4.98 (s, 2H), 4.18-4.14 (m, 2H), 3.85-3.81 (m, 7H), 3.19- 3.15 (m, 2H), 2.99-2.97 (m, 4H), 2.44-2.25 (m, 3H), 1.84-1.73 (m, 3H), 1.35-1.24 (m, 1H), 0.99 (d, J = 6.7 Hz, 3H).
474		H	OMe	1H-NMR (400 MHz, DMSO-d6) δ: 7.67 (d, J = 7.9 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 6.37-6.34 (m, 2H), 5.00 (s, 2H), 4.20 (t, J = 8.2 Hz, 2H), 3.85 (s, 3H), 3.73 (t, J = 4.3 Hz, 4H), 3.12 (t, J = 8.2 Hz, 2H), 2.93 (t, J = 4.6 Hz, 4H), 2.68- 2.52 (m, 2H), 2.47-2.30 (m, 2H), 2.24-2.15 (m, 1H), 2.04-1.98 (m,
				1H), 1.55-1.44 (m, 1H).
475		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 7.90 (d, J = 9.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 8.0 Hz, 1H), 6.95 (d, J = 9.6 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 6.46 (s, 1H), 5.00 (s, 2H), 4.20 (t, J = 8.0 Hz, 2H), 3.74-3.70 (m, 4H), 3.11 (t, J = 8.0 Hz, 2H),
				2.94-2.90 (m, 4H), 2.44-2.41 (m,
				2H), 2.35-2.31 (m, 2H), 1.09 (s, 6H).
476		OMe	H	1H-NMR (400 MHz, CDCl3) δ: 7.90 (d, J = 7.9 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 6.69 (d, J = 7.3 Hz, 1H), 6.35 (br s, 1H), 6.21 (s, 1H), 4.98 (s, 2H), 4.17 (t, J = 8.2 Hz, 2H), 3.85-3.83 (m, 4H), 3.83 (s, 3H), 3.18 (t, J = 8.2 Hz, 2H), 2.99-2.97 (m, 4H), 2.61-2.56 (m, 1H), 2.48-2.25 (m, 4H), 2.12-2.06 (m, 1H), 1.67-1.56
				(m, 1H).
477		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 7.90 (d, J = 9.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 8.0 Hz, 1H), 6.95 (d, J = 10.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 6.51-6.49 (m, 1H), 5.01 (s, 2H), 4.20 (t, J = 8.0 Hz, 3H), 3.73- 3.71 (m, 4H), 3.15-3.10 (m, 2H),
				2.94-2.90 (m, 4H), 2.67-2.63 (m,
				1H), 2.54-2.52 (m, 1H), 2.24-
				2.16 (m, 1H), 2.15-2.06 (m, 1H),
				1.03 (d, J = 6.8 Hz, 3H).
478		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 7.91 (d, J = 9.8 Hz, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.97 (d, J = 9.8 Hz, 1H), 6.69 (d, J = 7.9 Hz, 1H), 6.61- 6.58 (m, 1H), 5.04 (s, 2H), 4.22 (t, J = 8.2 Hz, 2H), 3.74-3.71 (m, 4H), 3.13 (t, J = 8.2 Hz, 2H), 2.95-2.91 (m, 4H), 2.49-2.41 (m, 3H), 2.34-2.22 (m, 1H), 1.77-1.70 (m, 2H), 1.38-1.23 (m, 2H).
479		H	OMe	LC-MS: [M + H]+/Rt (min) 487.3/0.982 (Method A)
480		H	H	LC-MS: [M + H]+/Rt (min) 421.4/1.72 (Method C)
481		H	H	LC-MS: [M + H]+/Rt (min) 407.3/1.65 (Method C)

Examples 482-490

According to the method of Example 1, 37, or 50, and common reaction conditions, the compounds of Examples 482 to 490 were obtained by using each corresponding material compounds.

Example	M1	R1	R2	Analytical data
482		H	OMe	1H-NMR (400 MHz, DMSO-d6) δ: 8.21-8.20 (m, 1H), 7.95 (d, J = 2.4 Hz, 1H), 7.29 (dt, J = 2.4, 6.4 Hz, 1H), 6.32-6.29 (m, 2H), 4.96 (s, 2H), 3.82 (s, 3H), 3.67-3.64 (m, 2H), 3.59-3.57 (m, 2H), 3.38-3.34 (m, 2H), 3.28- 3.26 (m, 2H), 2.61-2.51 (m, 1H), 2.48-2.41 (m, 1H), 2.41-2.29 (m,
				2H), 2.23-2.13 (m, 1H), 2.03-
				1.96 (m, 1H), 1.53-1.43 (m, 1H).
483		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 8.21 (s, 1H), 7.96 (s, 1H), 7.89-7.85 (m, 1H), 7.32-7.26 (m, 1H), 6.94-6.90 (m, 1H), 6.43 (s, 1H), 4.97 (s, 2H), 3.69-3.57 (m, 4H), 3.40-3.34 (m, 3H), 2.67-2.63 (m, 1H), 2.43-2.40 (m, 1H), 2.34- 2.31 (m, 3H), 1.08 (s, 6H).
484		H	H	1H-NMR (400 MHz, DMSO-d6) δ: 8.21 (s, 1H), 7.96-7.95 (m, 1H), 7.87 (d, J = 10.0 Hz, 1H), 7.31-7.26 (m, 1H), 6.91 (d, J = 9.6 Hz, 1H), 6.48-6.46 (s, 1H), 4.98- 4.97 (m, 2H), 3.69-3.65 (m, 2H), 3.61-3.57 (m, 2H), 3.39-3.35 (m, 2H), 3.29-3.26 (m, 2H), 2.81-
				2.64 (m, 2H), 2.46-2.39 (m, 1H),
				2.22-2.15 (m, 1H), 2.14-2.05 (m,
				1H), 1.03 (d, J = 7.2 Hz, 3H).
485		H	OMe	LC-MS: [M + H]+/Rt (min) 428.3/0.866 (Method A)
486		OMe	H	1H-NMR (400 MHz, CDCl3) δ: 8.14- 8.13 (m, 1H), 8.01 (d, J = 2.4 Hz, 1H), 6.88 (dt, J = 11.6, 2.4 Hz, 1H), 6.33-6.32 (br m, 1H), 6.18 (s, 1H), 4.97 (s, 2H), 3.83 (s, 3H), 3.81-3.70 (br m, 4H), 3.34-3.25 (m, 4H), 2.60-2.54 (m, 1H), 2.48-2.24 (m, 4H), 2.12- 2.06 (m, 1H), 1.67-1.58 (m, 1H).
487		H	H	1H-NMR (400 MHz, CDCl3) δ: 8.14- 8.13 (br m, 1H), 8.01 (d, J = 2.1 Hz, 1H), 7.53 (d, J = 10.1 Hz, 1H), 6.93 (d, J = 10.1 Hz, 1H), 6.89 (dt, J = 11.0, 2.1 Hz, 1H), 6.32-6.30 (br m, 1H), 5.02 (d, J = 15.2 Hz, 1H), 4.98 (d, J = 15.2 Hz, 1H), 3.84-3.71 (m, 4H), 3.36-3.26 (m, 4H), 2.80- 2.75 (m, 1H), 2.52-2.45 (m, 1H),
				2.37-2.29 (m, 3H), 2.15-2.11 (m,
				1H), 1.64-1.55 (m, 1H).
488		H	OMe	1H-NMR (400 MHz, CDCl3) δ: 8.13- 8.12 (br m, 1H), 8.00 (d, J = 2.4 Hz, 1H), 6.88 (dt, J = 11.6, 2.4 Hz, 1H), 6.26 (d, J = 4.9 Hz, 1H), 6.16 (s, 1H), 4.97 (s, 2H), 3.81 (s, 3H), 3.81-3.68 (m, 4H), 3.33-3.24 (m, 4H), 2.44- 2.24 (m, 3H), 1.85-1.71 (m, 3H), 1.35-1.25 (m, 1H), 0.99 (d, J =
				6.7 Hz, 3H).
489		H	H	LC-MS: [M + H]+/Rt (min) 434.3/0.662 (Method A)
490		OMe	H	1H-NMR (400 MHz, CDCl3) δ: 8.13 (t, J = 1.8 Hz, 1H), 8.01 (d, J = 2.4 Hz, 1H), 6.88 (dt, J = 11.0, 2.4 Hz, 1H), 6.26-6.24 (m, 1H), 6.17 (s, 1H), 4.97 (s, 2H), 3.82 (s, 3H), 3.70 (s, 2H), 3.36-3.22 (m, 4H), 2.40-2.30 (m, 2H), 1.99-1.94 (m, 2H), 1.47- 1.43 (m, 2H), 0.95 (s, 6H),
				0.90-0.85 (m, 2H).

Examples 491-534

According to the method of Example 1, 37, or 50, and common reaction conditions, the compounds of Examples 491 to 534 were obtained by using corresponding material compounds.

Example	Chemical structure	Analytical data
491		1H-NMR (400 MHz, CDCl3) δ: 9.02 (s, 1H), 7.78 (s, 1H), 7.24-7.22 (m, 2H), 6.37 (s, 1H), 6.25 (s, 1H), 4.95 (s, 2H), 4.22 (s, 3H), 3.87 (s, 3H), 2.43-2.37 (m, 2H), 2.04- 1.99 (m, 2H), 1.49 (t, J = 6.4 Hz, 2H), 0.98 (s, 6H).
492		1H-NMR (400 MHz, CDCl3) δ: 9.07 (s, 1H), 7.87 (s, 1H), 7.45-7.30 (m, 2H), 6.40-6.31 (m, 1H), 6.27- 6.21 (m, 1H), 4.94 (s, 2H), 3.85 (s, 3H), 2.62 (s, 3H), 2.39 (s, 2H), 2.00 (s, 2H), 1.53-1.45 (m, 2H), 0.97 (s, 6H).
493		1H-NMR (400 MHz, CDCl3) δ: 9.38 (s, 1H), 8.16 (s, 1H), 7.52 (s, 1H), 6.79 (t, J = 57.4 Hz, 1H), 6.38 (s, 1H), 6.27 (s, 1H), 4.98 (s, 2H), 3.88 (s, 3H), 2.42-2.39 (m, 2H), 2.04-2.00 (m, 2H), 1.50 (t, J = 6.4 Hz, 2H), 0.98 (s, 6H).
494		1H-NMR (400 MHz, CDCl3) δ: 9.34 (s, 1H), 7.39 (d, J = 1.5 Hz, 1H), 7.29 (dd, J = 11.6, 1.5 Hz, 1H), 6.35- 6.33 (m, 1H), 6.23 (s, 1H), 4.93 (s, 2H), 4.21 (s, 3H), 3.85 (s, 3H), 2.42-2.35 (m, 2H), 2.02- 1.98 (m, 2H), 1.47 (t, J = 6.5 Hz, 2H), 0.95 (s, 6H).
495		1H-NMR (400 MHz, CDCl3) δ: 9.70 (s, 1H), 8.43 (d, J = 7.3 Hz, 1H), 8.26 (s, 1H), 8.09 (s, 1H), 7.66 (d, J = 9.8 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.03 (d, J = 9.1 Hz, 1H), 6.45 (s, 1H), 5.03 (s, 2H), 2.49-2.43 (m, 2H), 2.33-2.23 (m, 2H), 1.82-1.63 (m, 4H).
496		1H-NMR (400 MHz, CDCl3) δ: 10.13 (s, 1H), 8.30 (d, J = 7.3 Hz, 1H), 8.20 (d, J = 5.5 Hz, 1H), 7.99 (s, 1H), 7.60 (d, J = 10.7 Hz, 1H), 7.14 (dt, J = 16.9, 6.9 Hz, 1H), 7.03-6.95 (m, 1H), 6.26 (s, 1H), 5.04 (s, 2H), 2.54 (s, 2H), 2.39 (s, 2H), 1.18 (s, 6H).
497		1H-NMR (400 MHz, DMSO-d6) δ: 10.97 (s, 1H), 8.86 (d, J = 7.9 Hz, 1H), 8.37 (s, 1H), 8.13 (dd, J = 8.8, 5.8 Hz, 2H), 7.82 (d, J = 1.2 Hz, 1H), 7.69 (d, J = 1.2 Hz, 1H), 7.21 (dd, J = 7.3, 1.8 Hz, 1H), 7.14 (d, J = 9.8 Hz, 1H), 4.98 (s, 2H).
498		1H-NMR (400 MHz, CDCl3) δ: 9.25 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.28 (s, 1H), 8.18 (d, J = 9.8 Hz, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.50 (d, J = 5.5 Hz, 1H), 7.36 (d, J = 4.9 Hz, 1H), 7.25-7.18 (m, 2H), 5.12 (s, 2H).
499		1H-NMR (400 MHz, CDCl3) δ: 10.20 (s, 1H), 8.27-8.22 (m, 1H), 8.15 (s, 1H), 8.00-7.93 (m, 1H), 7.09- 7.02 (m, 1H), 6.30 (s, 1H), 6.21 (s, 1H), 4.98 (s, 2H), 3.83 (s, 3H), 2.34 (s, 2H), 1.95 (s, 2H), 1.50-1.38 (m, 2H), 0.94 (s, 6H).
500		1H-NMR (400 MHz, CD3OD) δ: 8.89 (s, 1H), 7.49-7.41 (m, 1H), 7.19-7.12 (m, 1H), 7.12-7.03 (m, 1H), 6.30 (s, 1H), 6.18 (s, 1H), 4.88 (s, 2H), 3.77 (s, 3H), 3.14 (s, 6H), 2.33 (s, 2H), 1.99-1.92 (m, 2H), 1.49-1.38 (m, 2H), 0.93 (s, 6H).
501		1H-NMR (400 MHz, CDCl3) δ: 10.00 (s, 1H), 9.31-9.20 (m, 1H), 8.08 (s, 1H), 7.45-7.35 (m, 1H), 7.23- 7.15 (m, 1H), 6.75 (s, 1H), 5.75 (s, 1H), 4.96 (s, 2H), 2.34-2.14 (m, 6H), 1.86-1.61 (m, 3H), 1.38-1.23 (m, 1H), 0.95 (d, J = 8.0 Hz, 3H),
502		1H-NMR (400 MHz, CDCl3) δ: 10.10 (s, 1H), 8.25-8.22 (m, 1H), 8.11 (s, 1H), 7.96-7.90 (m, 1H), 7.06- 7.00 (m, 1H), 6.76 (s, 1H), 5.76 (s, 1H), 4.95 (s, 2H), 2.30-2.14 (m, 6H), 1.79-1.64 (m, 3H), 1.35-1.23 (m, 1H), 0.96 (d, J = 8.0 Hz, 3H),
503		1H-NMR (400 MHz, CDCl3) δ: 8.71-8.66 (m, 1H), 8.31 (s, 1H), 8.23-8.20 (m, 1H), 7.32-7.26 (m, 1H), 6.85 (s, 1H), 5.86-5.81 (m, 1H), 5.00 (s, 2H), 2.36-2.29 (m, 2H), 2.26 (s, 3H), 2.03-1.97 (m, 2H), 1.55-1.48 (m, 2H), 0.99 (s, 6H).
504		1H-NMR (400 MHz, CDCl3) δ: 7.59-7.55 (m, 1H), 7.24-7.20 (m, 1H), 7.19- 7.15 (m, 1H), 6.82 (s, 1H), 5.84-5.79 (m, 1H), 4.93 (s, 2H), 3.16 (s, 6H), 2.35-2.28 (m, 2H), 2.23 (s, 3H), 2.01-1.96 (m, 2H), 1.53-1.47 (m, 2H), 0.99 (s, 6H).
505		1H-NMR (400 MHz, CD3OD) δ: 9.05 (s, 1H), 8.46-8.39 (m, 1H), 8.26-8.15 (m, 1H), 7.16-7.02 (m, 1H), 6.91-6.80 (m, 1H), 4.98 (s, 2H), 2.36-2.29 (m, 2H), 2.27 (s, 3H), 2.02- 1.98 (m, 2H), 1.55-1.48 (m, 2H), 0.99 (s, 6H).
506		1H-NMR (400 MHz, CDCl3) δ: 9.33 (s, 1H), 7.58-7.51 (m, 3H), 7.49-7.45 (m, 2H), 6.99-6.93 (m, 1H), 6.96 (s, 1H), 4.92 (s, 2H), 3.88-3.77 (m, 2H), 2.44-2.36 (m, 2H), 1.37 (s, 6H).
507		1H-NMR (400 MHz, CDCl3) δ: 9.55 (s, 1H), 7.61-7.57 (m, 1H), 7.50-7.46 (m, 2H), 7.45-7.39 (m, 2H), 6.99-6.95 (m, 1H), 6.32 (s, 1H), 4.94 (s, 2H), 4.33-4.28 (m, 2H), 2.38- 2.32 (m, 2H), 1.21 (s, 6H).
508		LC-MS: [M + H]+/Rt (min) 394.4/0.690 (Method A)
509		LC-MS: [M + H]+/Rt (min) 510.3/0.944 (Method A)
510		LC-MS: [M + H]+/Rt (min) 476.3/0.876 (Method A)
511		1H-NMR (400 MHz, DMSO-d6) δ: 7.86 (d, J = 10.0 Hz, 1H), 7.82 (d, J = 6.0 Hz, 1H), 6.93 (d, J = 10.0 Hz, 1H), 6.59-6.57 (m, 1H), 6.54-6.51 (m, 1H), 6.14- 6.13 (m, 1H), 4.98 (s, 2H), 3.77 (s, 3H), 3.66- 3.61 (m, 2H), 3.57-3.52 (m, 2H), 3.42-3.38 (m, 2H), 3.34-3.31 (m, 2H), 2.67-2.63 (m, 1H), 2.63- 2.59 (m, 1H), 2.47-2.42 (m, 1H), 2.33-2.18 (m, 2H), 2.06-2.00 (m, 1H), 1.54-1.43 (m, 1H).
512		1H-NMR (400 MHz, DMSO-d6) δ: 10.92 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.37 (d, J = 9.8 Hz, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.91 (d, J = 9.8 Hz, 1H), 7.21 (dd, J = 7.3, 1.8 Hz, 1H), 6.97 (d, J = 9.8 Hz, 1H), 6.61 (d, J = 3.7 Hz, 1H), 4.94 (s, 2H), 2.45-2.42 (m, 2H), 2.13-2.12 (m, 2H), 1.46 (t, J = 6.4 Hz, 2H), 0.36-0.31 (m, 4H).
513		LC-MS: [M + H]+/Rt (min) 422.4/0.776 (Method A)
514		LC-MS: [M + H]+/Rt (min) 420.1/0.914 (Method A)
515		LC-MS: [M + H]+/Rt (min) 416.3/0.671 (Method A)
516		1H-NMR (400 MHz, DMSO-d6) δ: 8.23 (d, J = 9.8 Hz, 1H), 7.98 (d, J = 7.9 Hz, 1H), 7.93 (d, J = 7.9 Hz, 2H), 7.44 (d, J = 7.9 Hz, 2H), 7.30 (t, J = 7.9 Hz, 1H), 7.25-7.19 (m, 2H), 5.29 (s, 2H), 4.70 (t, J = 6.7 Hz, 2H), 4.51 (t, J = 5.8 Hz, 2H), 4.39 (t, J = 8.5 Hz, 2H), 3.89-3.80 (m, 4H), 3.34-3.28 (m, 2H), 3.26-3.21 (m, 2H), 2.49 (s, 3H).
517		LC-MS: [M + H]+/Rt (min) 414.0/0.781 (Method A)
518		1H-NMR (400 MHz, DMSO-d6) δ: 8.85 (s, 2H), 8.05 (d, J = 7.9 Hz, 1H), 7.86 (d, J = 9.8 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.15 (d, J = 7.3 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.56-6.53 (m, 1H), 5.04 (s, 2H), 4.22 (t, J = 8.2 Hz, 2H), 3.33-3.27 (m, 2H), 2.66 (s, 3H), 2.33-2.28 (m, 2H), 2.22-2.17 (m, 2H), 1.66-1.53 (m, 4H).
519		1H-NMR (400 MHz, DMSO-d6) δ: 7.85 (d, J = 9.8 Hz, 2H), 7.09 (t, J = 7.6 Hz, 1H), 6.93 (t, J = 9.2 Hz, 2H), 6.55-6.53 (m, 1H), 5.00 (s, 2H), 4.21 (t, J = 8.5 Hz, 2H), 3.55-3.52 (m, 4H), 3.40 (s, 2H), 3.21 (t, J = 8.5 Hz, 2H), 2.34- 2.27 (m, 6H), 2.21-2.16 (m, 2H), 1.66-1.53 (m, 4H).
520		1H-NMR (400 MHz, DMSO-d6) δ: 8.10 (d, J = 9.8 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 7.21 (t, J = 7.9 Hz, 1H), 7.14-7.10 (m, 2H), 5.16 (s, 2H), 4.49 (t, J = 8.2 Hz, 1H), 4.30-4.18 (m, 4H), 3.94-3.85 (m, 2H), 3.14 (t, J = 8.5 Hz, 2H), 2.35 (s, 3H), 1.80 (s, 3H).
521		1H-NMR (400 MHz, DMSO-d6) δ: 9.05 (d, J = 1.8 Hz, 1H), 8.74 (t, J = 2.1 Hz, 1H), 8.62 (d, J = 2.4 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.86 (d, J = 9.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.56-6.54 (m, 1H), 5.04 (s, 2H), 4.25 (t, J = 8.5 Hz, 2H), 3.49 (t, J = 8.4 Hz, 2H), 2.33-2.28 (m, 2H), 2.23-2.16 (m, 2H), 1.67-1.53 (m, 4H).
522		1H-NMR (400 MHz, DMSO-d6) δ: 9.20 (s, 1H), 8.98 (s, 2H), 8.07 (d, J = 7.9 Hz, 1H), 7.86 (d, J = 9.8 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 6.7 Hz, 1H), 6.93 (d, J = 9.8 Hz, 1H), 6.56-6.53 (m, 1H), 5.05 (s, 2H), 4.23 (t, J = 8.2 Hz, 2H), 3.34-3.26 (m, 2H), 2.33-2.28 (m, 2H), 2.21-2.18 (m, 2H), 1.66- 1.55 (m, 4H).
523		1H-NMR (400 MHz, DMSO-d6) δ: 9.47-9.45 (m, 1H), 9.33-9.31 (m, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 9.8 Hz, 1H), 7.89- 7.87 (m, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.28 (d, J = 6.7 Hz, 1H), 6.98 (d, J = 9.8 Hz, 1H), 6.62-6.59 (m, 1H), 5.08 (s, 2H), 4.27 (t, J = 8.2 Hz, 2H), 3.38 (t, J = 8.2 Hz, 2H), 3.32- 3.29 (m, 2H), 2.63-2.58 (m, 2H), 1.97-1.89 (m, 2H).
524		1H-NMR (400 MHz, DMSO-d6) δ: 8.70-8.69 (m, 1H), 8.58 (dd, J = 4.9, 1.8 Hz, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.94-7.90 (m, 2H), 7.48 (dd, J = 8.2, 5.2 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 6.7 Hz, 1H), 6.96 (d, J = 9.8 Hz, 1H), 6.59-6.56 (m, 1H), 5.03 (s, 2H), 4.22 (t, J = 8.2 Hz, 2H), 3.28-3.25 (m, 2H), 2.66-2.56 (m, 4H), 1.95-1.87 (m, 2H).
525		LC-MS: [M + H]+/Rt (min) 416.3/0.740 (Method A)
526		1H-NMR (400 MHz, DMSO-d6) δ: 9.44 (dd, J = 2.4, 1.2 Hz, 1H), 9.29 (dd, J = 5.5, 1.2 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.88 (d, J = 9.8 Hz, 1H), 7.85 (dd, J = 5.5, 2.4 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 7.25 (d, J = 6.7 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 6.58- 6.56 (m, 1H), 5.06 (s, 2H), 4.25 (t, J = 8.2 Hz, 2H), 3.36 (t, J = 8.5 Hz, 2H), 3.28-3.26 (m, 2H), 2.12-2.09 (m, 2H), 1.43 (t, J = 6.4 Hz, 2H), 0.31 (d, J = 6.1 Hz, 4H).
527		LC-MS: [M + H]+/Rt (min) 450.3/0.773 (Method A)
528		1H-NMR (400 MHz, DMSO-d6) δ: 7.93-7.87 (m, 2H), 7.17 (t, J = 7.9 Hz, 1H), 6.98- 6.94 (m, 2H), 6.58-6.55 (m, 1H), 5.92-5.90 (m, 1H), 5.04 (s, 2H), 4.24- 4.19 (m, 4H), 3.81 (t, J = 5.2 Hz, 2H), 3.25 (t, J = 8.2 Hz, 2H), 2.39-2.21 (m, 6H), 1.67-1.58 (m, 4H).
529		1H-NMR (400 MHz, DMSO- d6) δ: 9.44 (dd, J = 2.4, 1.2 Hz, 1H), 9.32-9.30 (m, 1H), 8.13 (d, J = 7.9 Hz, 1H), 7.86 (dd, J = 5.5, 2.4 Hz, 1H), 7.47 (d, J = 9.8 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.28-7.25 (m, 1H), 7.19 (d, J = 7.9 Hz, 2H), 7.14 (d, J = 9.8 Hz, 1H), 7.09-7.05 (m, 2H), 4.89 (s, 2H), 4.19 (t, J = 8.5 Hz, 2H), 3.34-3.30 (m, 2H), 2.27 (s, 3H).
530		1H-NMR (400 MHz, DMSO-d6) δ: 10.79 (s, 1H), 8.82 (d, J = 7.3 Hz, 1H), 8.35 (s, 1H), 8.07 (d, J = 1.8 Hz, 1H), 7.44 (d, J = 9.8 Hz, 1H), 7.18-7.04 (m, 6H), 4.72 (s, 2H), 2.24 (s, 3H).
531		1H-NMR (400 MHz, DMSO-d6) δ: 10.49 (s, 1H), 8.71- 8.70 (m, 1H), 8.11-8.10 (m, 1H), 7.90-7.87 (m, 1H), 7.73-7.70 (m, 1H), 7.53-7.49 (m, 1H), 6.95- 6.92 (m, 1H), 6.51-6.49 (m, 1H), 4.89-4.86 (m, 2H), 2.37-2.31 (m, 2H), 2.03-1.99 (m, 2H), 1.44- 1.40 (m, 2H), 0.93-0.89 (m, 6H).
532		1H-NMR (400 MHz, DMSO-d6) δ: 10.53 (s, 1H), 8.46- 8.44 (m, 1H), 7.88 (d, J = 9.6 Hz, 2H), 7.82 (s, 1H), 7.45-7.44 (m, 1H), 6.96- 6.93 (m, 2H), 6.55-6.51 (m, 1H), 4.88 (s, 2H), 2.56-2.52 (m, 1H), 2.36- 2.18 (m, 2H), 1.86-1.74 (m, 2H), 1.70-1.61 (m, 1H), 1.28-1.18 (m, 1H), 0.96 (d, J = 6.8 Hz, 3H).
533		1H-NMR (400 MHz, CDCl3) δ: 7.55 (d, J = 9.8 Hz, 1H), 7.00-6.98 (m, 1H), 6.88 (d, J = 9.8 Hz, 1H), 6.83- 6.79 (m, 2H), 6.34 (s, 1H), 4.83-4.74 (m, 2H), 4.42-4.38 (m, 1H), 4.09- 3.96 (m, 2H), 3.24-3.17 (m, 1H), 2.82-2.75 (m, 1H), 2.61-2.54 (m, 1H), 2.35-2.07 (m, 4H), 1.87- 1.81 (m, 3H), 1.33-1.24 (m, 2H), 1.01 (d, J = 6.7 Hz, 3H).
534		1H-NMR (400 MHz, CDCl3) δ: 7.57 (d, J = 9.8 Hz, 1H), 6.98 (d, J = 1.2 Hz, 1H), 6.89 (d, J = 9.8 Hz, 1H), 6.80 (d, J = 1.2 Hz, 1H), 6.78 (d, J = 7.3 Hz, 1H), 6.32-6.30 (m, 1H), 4.83- 4.74 (m, 2H), 4.44-4.36 (m, 1H), 4.09-3.96 (m, 2H), 3.23-3.17 (m, 1H), 2.81-2.74 (m, 1H), 2.44- 2.40 (m, 2H), 2.26-2.19 (m, 1H), 2.16-2.06 (m, 1H), 2.04-2.02 (m, 2H), 1.48 (t, J = 6.4 Hz, 2H),
		0.95 (s, 6H).

Examples 535 and 536 cis-trans isomers of the compound (35.5 mg) obtained in

Example 472 were resolved by chiral column chromatography to obtained the following compounds (Example 535 and 536):

[Resolution Conditions]

Detection apparatus: SPD-M20A (Shimadzu Corporation)

HPLC: LC-20AT (Shimadzu Corporation)

Column: CHIRALPAK IA (Daicel Corporation) (S—5 μm, 20×250 mm)

Elution condition: 0.0-60.0 (min): A/B=55:45Solvent A: hexane with 0.1% diethylamineSolvent B: (isopropylalcohol:methanol=2:1) with 0.1% diethylamineFlow rate: 10 ml/min

UV: 220 nm

Column temperature: 40° C.

		Retention	Yield
	Example	time (min.)	(mg)	Purity
	Former	535	31.5	13.5	99.9%
	peak
	Latter	536	41.5	14.0	99.8%
	peak

Examples 537 and 538

Optical isomers of the compound (14.1 mg) obtained in Example 330 were resolved by chiral column chromatography to obtain the following compounds (Examples 537 and 538):

[Resolution Conditions]

Detection apparatus: SPD-M20A (Shimadzu Corporation)

HPLC: LC-20AT (Shimadzu Corporation)

Column: CHIRALPAK AY-H (Daicel Corporation) (S—5 μm, 20×250 mm)

Elution condition: 0.0-80.0 (min): A/B=65:35Solvent A: hexaneSolvent B: isopropylalcoholFlow rate: 10 ml/min

UV: 220 nm

Column temperature: 40° C.

		Retention	Yield	Optical
	Example	time (min)	(mg)	purity
	Former	537	43.5	4.5	87.8% ee
	peak
	Latter	538	56	4.8	98.6% ee
	peak

Examples 539 and 540

Optical isomers of the compound (13.7 mg) obtained in Example 339 were resolved by chiral column chromatography to obtain the following compounds (Examples 539 and 540):

[Resolution Conditions]

Detection apparatus: SPD-M20A (Shimadzu Corporation)

HPLC: LC-20AT (Shimadzu Corporation)

Column: CHIRALPAK AY-H (Daicel Corporation) (S—5 μm, 20×250 mm)

Elution condition: 0.0-80.0 (min): A/B=50:50Solvent A: hexaneSolvent B: isopropylalcoholFlow rate: 10 ml/min

UV: 220 nm

Column temperature: 40° C.

		Retention	Yield	Optical
	Example	time (min.)	(mg)	purity
	Former	539	39.8	4.5	99% ee
	peak
	Latter	540	52.5	7.6	98.2% ee
	peak

Examples 541 to 571

According to the method of Example 50 and common reaction conditions, the compounds of Examples 541 to 571 were obtained by using each corresponding material compound.

Example	Chemical structure	Analytical data
541		LC-MS: [M + H]+/Rt (min) 420.1/0.914 (Method A)
542		LC-MS: [M + H]+/Rt (min) 391.3/0.761 (Method A)
543		LC-MS: [M + H]+/Rt (min) 375.1/0.661 (Method B)
544		LC-MS: [M + H]+/Rt (min) 375.0/0.745 (Method A)
545		LC-MS: [M + H]+/Rt (min) 375.0/0.725 (Method A)
546		LC-MS: [M + H]+/Rt (min) 375.0/0.784 (Method A)
547		1H-NMR (400 MHz, CDCl3) δ: 9.36 (s, 1H), 8.52 (t, J = 8.2 Hz, 1H), 7.61 (d, J = 10.4 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.37 (dd, J = 10.4, 2.0 Hz), 7.00 (d, J = 9.8 Hz, 1H), 6.38 (s, 1H), 4.99 (s, 2H), 2.66- 2.57 (m, 1H), 2.39-2.27 (m, 2H), 1.91-1.80 (m, 2H), 1.77-1.65 (m, 1H), 1.42- 1.23 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H).
548		LC-MS: [M + H]+/Rt (min) 376.0/0.995 (Method A)
549		LC-MS: [M + H]+/Rt (min) 409.1/0.958 (Method A)
550		LC-MS: [M + H]+/Rt (min) 392.0/0.791 (Method A)
551		LC-MS: [M + H]+/Rt (min) 376.1/0.964 (Method A)
552		LC-MS: [M + H]+/Rt (min) 383.0/0.838 (Method A)
553		LC-MS: [M + H]+/Rt (min) 405.0/0.834 (Method A)
554		1H-NMR (400 MHz, CDCl3) δ: 9.95 (s, 1H), 8.36 (d, J = 7.3 Hz, 1H), 8.23 (s, 1H), 8.05 (d, J = 1.8 Hz, 1H), 7.66 (d, J = 9.8 Hz, 1H), 7.13 (dd, J = 7.3, 1.8 Hz, 1H), 7.01 (d, J = 9.8 Hz, 1H), 6.42 (s, 1H), 5.04 (s, 2H), 2.72-2.59 (m, 1H), 2.47-2.26 (m, 2H), 1.98- 1.83 (m, 2H), 1.58-1.45 (m, 1H), 1.43-1.25 (m, 3H), 0.93 (t, J = 7.2 Hz, 3H).
555		1H-NMR (400 MHz, CDCl3) δ: 9.77 (s, 1H), 9.37 (s, 1H), 8.22 (s, 1H), 7.66 (d, J = 9.6 Hz, 1H), 7.56 (d, J = 9.6 Hz, 1H), 7.30-7.25 (m, 1H), 7.02 (t, J = 10.1 Hz, 1H), 6.41 (s, 1H), 5.05 (s, 2H), 2.70-2.59 (m, 1H), 2.45-2.23 (m, 2H), 1.97- 1.80 (m, 2H), 1.59-1.42 (s, 1H), 1.41-1.24 (m, 3H), 0.95 (t, J = 7.2 Hz, 3H).
556		LC-MS: [M + H]+/Rt (min) 368.2/0.693 (Method A)
557		LC-MS: [M + H]+/Rt (min) 416.2/0.710 (Method A)
558		LC-MS: [M + H]+/Rt (min) 340.1/0.609 (Method A)
559		LC-MS: [M + H]+/Rt (min) 354.2/0.651 (Method A)
560		LC-MS: [M + H]+/Rt (min) 401.1/0.804 (Method A)
561		LC-MS: [M + H]+/Rt (min) 353.2/0.834 (Method A)
562		LC-MS: [M + H]+/Rt (min) 431.3/0.822 (Method A)
563		1H-NMR (400 MHz, CDCl3) δ: 9.85 (s, 1H), 9.10 (s, 1H), 8.43 (d, J = 6.1 Hz, 1H), 8.24 (s, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.54-7.51 (m, 2H), 7.23 (d, J = 10.4 Hz, 1H), 6.96 (d, J = 9.8 Hz, 1H), 4.90 (s, 2H), 4.37- 4.29 (m, 1H), 2.82 (s, 3H), 1.91-1.79 (m, 2H), 1.76- 1.65 (m, 2H), 1.40-1.21 (m, 2H), 0.94-0.80 (m, 2H).
564		LC-MS: [M + H]+/Rt (min) 379.3/0.749 (Method A)
565		1H-NMR (400 MHz, CDCl3) δ: 7.94 (d, J = 7.9 Hz, 1H), 7.20-7.13 (m, 2H), 6.88 (d, J = 9.8 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.89 (s, 2H), 4.30-4.20 (m, 1H), 3.88-3.82 (m, 4H), 3.16 (t, J = 8.2 Hz, 2H), 3.02-2.93 (m, 4H), 2.77 (s, 3H), 1.90-1.77 (m, 2H), 1.75- 1.63 (m, 2H), 1.63-1.50 (m, 6H).
566		LC-MS: [M + H]+/Rt (min) 379.3/0.721 (Method A)
567		1H-NMR (400 MHz, CDCl3) δ: 9.71 (s, 1H), 9.09 (s, 1H), 8.43 (d, J = 5.5 Hz, 1H), 8.19 (d, J = 1.8 Hz, 1H), 7.83 (d, J = 9.2 Hz, 1H), 7.57-7.50 (m, 2H), 7.21 (d, J = 9.6 Hz, 1H), 6.95 (d, J = 9.6 Hz, 1H), 4.90 (s, 2H), 3.25 (s, 2H), 3.00 (s, 3H), 1.03 (s, 3H), 0.45-
		0.42 (m, 2H), 0.39-0.36 (m,
		2H).
568		1H-NMR (400 MHz, CDCl3) δ: 7.92 (s, 1H), 7.17-7.13 (m, 2H), 6.85 (d, J = 9.8 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.90 (s, 2H), 3.90- 3.79 (m, 4H), 3.25-3.07 (m, 2H), 3.18 (s, 2H), 3.05- 2.95 (m, 4H), 2.98 (s, 3H), 1.70-1.55 (m, 2H), 1.03 (s, 3H), 0.45-0.38 (m, 2H), 0.367-0.32 (m, 2H).
569		1H-NMR (400 MHz, CDCl3) δ: 9.91 (s, 1H), 9.04 (s, 1H), 8.38 (d, J = 5.5 Hz, 1H), 8.18 (s, 1H), 7.79 (d, J = 8.6 Hz, 1H), 7.48 (dd, J = 8.4, 2.0 Hz, 1H), 7.43 (d, J = 6.0 Hz, 1H), 7.21 (d, J = 10.4 Hz, 1H), 6.96 (d, J = 10.0 Hz, 1H), 4.93 (s, 2H), 4.50-4.40 (m, 1H), 2.93 (s, 3H), 2.44-2.39 (m, 2H), 2.23-2.18 (m, 2H), 0.55-0.51 (m, 2H), 0.45-
		0.39 (m, 2H).
570		1H-NMR (400 MHz, CDCl3) δ: 7.95-7.91 (m, 1H), 7.18- 7.10 (m, 2H), 6.87 (d, J = 10.1 Hz, 1H), 6.67 (d, J = 8.2 Hz, 1H), 4.88 (s, 2H), 4.40-4.30 (m, 1H), 3.85- 3.80 (m, 4H), 3.18-3.10 (m, 2H), 2.98-2.93 (m, 4H), 2.85 (s, 3H), 2.85-2.77 (m, 2H), 2.40-2.32 (m, 1H), 2.17-2.10 (m, 1H), 2.05- 2.00 (m, 1H), 1.85-1.70 (m, 1H), 0.50-0.45 (m, 2H), 0.40-0.35 (m, 2H).
571		LC-MS: [M + H]+/Rt (min) 409.4/0.714 (Method A)

Example 572

2-[6-(4-Methylpiperidin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide

To a solution of the compound of Reference example 33 (50.0 mg) in dichloromethane (2 mL) were added imidazo[1,2-A]pyridine-7-amine hydrochloride (66.4 mg), WSC (61.5 mg), and 4-dimethylaminopyridine (118.0 mg), and the mixture was stirred at room temperature for 2 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by amino silica gel column chromatography (solvent; ethyl acetate, and then ethyl acetate:methanol=90:10) to obtain the titled compound (14.0 mg).

¹H-NMR (400 MHz, DMSO-d₆) δ: 10.96 (s, 1H), 8.86 (d, J=7.3 Hz, 1H), 8.42 (s, 1H), 8.37 (s, 1H), 8.13-8.06 (m, 2H), 7.22 (dd, dd, J=7.6, 2.1 Hz, 1H), 5.18 (s, 2H), 4.51-4.44 (m, 2H), 3.00-2.87 (m, 2H), 1.72-1.59 (m, 3H), 1.16-1.02 (m, 2H), 0.88 (d, J=6.1 Hz, 3H).

Example 573

2-{6-[Methyl(2-methylpropyl)amino]-1H-pyrazolo[3,4-b]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl) acetamide

To a solution of the compound of Reference example 35 (15.0 mg) in dimethylformamide (2 mL) were added N,2-dimethylpropane-1-amine hydrochloride (6.8 mg) and potassium carbonate (18.9 mg), and the mixture was stirred at 50° C. for 2 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate, and then ethyl acetate:methanol=98:2) to obtain the titled compound (5.0 mg).

¹H-NMR (400 MHz, DMSO-d₆) δ: 10.96 (s, 1H), 8.87 (d, J=7.3 Hz, 1H), 8.38 (s, 1H), 8.26 (s, 1H), 8.12 (d, J=1.8 Hz, 1H), 8.08 (s, 1H), 7.23 (dd, J=7.6, 1.8 Hz, 1H), 5.18 (s, 2H), 3.44 (d, J=7.3 Hz, 2H), 3.15 (s, 3H), 2.08-1.98 (m, 1H), 0.87-0.80 (m, 6H).

Example 574

2-[6-(2-Fluoro-4-methylphenyl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide

To a solution of the compound of Reference example 35 (25.0 mg) in 1,4-dioxane (2 mL) were added (2-fluoro-4-methylphenyl)boronic acid (15.2 mg) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl) [2-(2′-amino-1,1′-biphenyl)]palladium(II) (6.0 mg), and the mixture was stirred at 80° C. for 7 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate, and then ethyl acetate:methanol=98:2) to obtain the titled compound (5.0 mg).

¹H-NMR (400 MHz, DMSO-d₆) δ: 11.14 (s, 1H), 9.03 (d, J=2.4 Hz, 1H), 8.86 (d, J=7.3 Hz, 1H), 8.59 (s, 1H), 8.40 (s, 1H), 8.09 (d, J=2.4 Hz, 1H), 7.88 (t, J=7.9 Hz, 1H), 7.26-7.19 (m, 3H), 5.51 (s, 2H), 2.38 (s, 3H).

Example 575

2-[6-(5-Methyl-1,3-thiazol-2-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide

To a solution of the compound of Reference example 35 (15.0 mg) in 1,2-dimethoxyethane (1 mL) were 5-methyl-2-(tributylstannyl)thiazole (39.0 mg) and tetrakis(triphenylphosphine)palladium(0) (5.3 mg), and the mixture was subjected to microwave irradiation, and stirred at 150° C. for 20 minutes. Water was added thereto, and the mixture was extracted with chloroform. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform:methanol=98:2, and then chloroform:methanol=90:10) to obtain the titled compound (5.8 mg).

LC-MS: [M+H]⁺/Rt (min) 391.9/0.650 (Method A)

Example 576

2-(6-Cyclobutyl-1H-pyrazolo[3,4-b]pyrazin-1-yl)-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide

To a solution of the compound of Reference example 35 (60.0 mg) in tetrahydrofuran (2 mL) were added 0.5 mol/L cyclobutylzinc bromide (0.548 mL) and bis(tri-tert-butylphosphine)palladium(0) (18.7 mg), and the mixture was stirred at room temperature for 3 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; ethyl acetate, and then ethyl acetate:methanol=90:10) to obtain the titled compound (27.0 mg).

¹H-NMR (400 MHz, DMSO-d₆) δ: 11.10 (s, 1H), 8.88 (d, J=7.3 Hz, 1H), 8.63 (s, 1H), 8.48 (s, 1H), 8.38 (s, 1H), 8.11 (d, J=2.1 Hz, 1H), 7.24 (dd, J=7.6, 2.1 Hz, 1H), 5.46 (s, 2H), 3.97-3.89 (m, 1H), 2.41-2.31 (m, 4H), 2.11-1.99 (m, 1H), 1.92-1.83 (m, 1H).

Examples 577-640

According to the methods of Reference examples 32-36 or Examples 572-576, and common reaction conditions, the compounds of Examples 577-640 were obtained by using each corresponding material compound.

Example	M1	Analytical data
577		1H-NMR (400 MHz, DMSO-d6) δ: 11.02 (s, 1H), 8.89 (s, 1H), 8.78 (d, J = 7.3 Hz, 1H), 8.37 (s, 1H), 8.29 (s, 1H), 8.01 (d, J = 1.2 Hz, 1H), 7.16-
		7.13 (m, 1H), 6.93-6.91 (m, 1H),
		5.36-5.34 (m, 2H), 2.69-2.64 (m,
		1H), 2.34-2.27 (m, 2H), 1.84-1.72
		(m, 2H), 1.67-1.60 (m, 1H), 1.27-
		1.17 (m, 1H), 0.90 (d, J = 6.7 Hz,
		3H).
578		1H-NMR (400 MHz, CDCl3) δ: 9.05 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.27 (d, J = 4.3 Hz, 2H), 8.17 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.13 (dd, J = 7.3, 1.8 Hz, 1H), 5.15 (s, 2H),
		3.71-3.68 (m, 4H), 2.01-1.93 (m,
		2H), 1.87-1.82 (m, 4H), 1.72-1.68
		(m, 4H).
579		1H-NMR (400 MHz, DMSO-d6) δ: 10.35 (s, 1H), 8.24-8.22 (m, 1H), 7.73 (s, 1H), 7.48 (dd, J = 2.3, 0.9 Hz, 1H), 7.45 (s, 1H), 7.41 (s, 1H),
		6.60 (dd, J = 7.5, 2.3 Hz, 1H), 4.54
		(s, 2H), 2.92-2.87 (m, 4H), 1.39-
		1.19 (m, 8H).
580		1H-NMR (400 MHz, DMSO-d6) δ: 11.08 (s, 1H), 8.99 (s, 1H), 8.87 (d, J = 7.3 Hz, 1H), 8.47 (s, 1H), 8.37 (s, 1H), 8.09 (d, J = 1.8 Hz, 1H), 7.23 (dd, J = 7.3, 1.8 Hz, 1H), 7.05-
		7.03 (m, 1H), 5.44 (s, 2H), 2.67-
		2.64 (m, 2H), 2.19-2.18 (m, 2H),
		1.51 (t, J = 6.1 Hz, 2H), 0.38-0.32
		(m, 4H).
581		1H-NMR (400 MHz, DMSO-d6) δ: 11.10 (s, 1H), 8.99 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.46 (s, 1H), 8.37 (s, 1H), 8.09 (d, J = 2.1 Hz, 1H), 7.23 (dd, J = 7.3, 2.1 Hz, 1H), 7.00-
		6.98 (m, 1H), 5.43 (s, 2H), 2.60-
		2.57 (m, 2H), 2.09-2.08 (m, 2H),
		1.49 (t, J = 6.4 Hz, 2H), 0.94 (s,
		6H).
582		1H-NMR (400 MHz, DMSO-d6) δ: 11.06 (s, 1H), 9.05-9.02 (m, 1H), 8.87 (d, J = 6.7 Hz, 1H), 8.51 (s, 1H), 8.37 (s, 1H), 8.09 (d, J = 1.8 Hz, 1H), 7.23 (dd, J = 7.6, 2.1 Hz, 1H),
		6.88 (s, 1H), 5.45 (s, 2H) , 2.90-
		2.82 (m, 4H), 2.25-2.15 (m, 2H).
583		1H-NMR (400 MHz, DMSO-d6) δ: 11.07 (s, 1H), 9.30 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.53 (s, 1H), 8.36 (s, 1H), 8.16 (d, J = 7.3 Hz, 2H), 8.09
		(s, 1H), 7.36 (d, J = 6.7 Hz, 2H),
		7.23 (d, J = 6.7 Hz, 1H), 5.51 (s,
		2H), 2.37 (s, 3H).
584		1H-NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 8.95 (s, 1H), 8.85 (d, J = 7.9 Hz, 1H), 8.44 (s, 1H), 8.36 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.21
		(dd, J = 7.3, 1.8 Hz, 1H), 6.99 (s,
		1H), 5.41 (s, 2H), 2.74 (d, J = 14.6
		Hz, 1H), 2.44-2.36 (m, 2H), 1.90-
		1.86 (m, 2H), 1.47 (s, 1H), 1.35-
		1.25 (m, 3H), 0.92-0.86 (m, 3H).
585		1H-NMR (400 MHz, DMSO-d6) δ: 11.03 (s, 1H), 8.95 (s, 1H), 8.85 (d, J = 7.3 Hz, 1H), 8.44 (s, 1H), 8.36 (s, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.21
		(dd, J = 7.3, 2.4 Hz, 1H), 7.01 (s,
		1H), 5.41 (s, 2H), 2.54 (s, 2H),
		2.26 (s, 2H), 1.71-1.60 (m, 4H).
586		LC-MS: [M + H]+/Rt (min) 391.0/0.830, 0.854 (Method A) (cis-trans mixture)
587		1H-NMR (400 MHz, DMSO-d6) δ: 11.13 (s, 1H), 9.30 (s, 1H), 8.88 (d, J = 7.3 Hz, 1H), 8.52 (s, 1H), 8.38 (s, 1H), 8.27-8.23 (m, 2H), 8.11 (d, J = 2.4 Hz, 1H), 7.26 (dd, J = 7.6,
		2.4 Hz, 1H), 7.13-7.09 (m, 2H),
		5.52 (s, 2H), 3.84 (s, 3H).
588		1H-NMR (400 MHz, DMSO-d6) δ: 10.99 (s, 1H), 8.87 (d, J = 8.5 Hz, 1H), 8.43 (s, 1H), 8.38 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 8.09 (s, 1H), 7.23 (dd, J = 7.6, 1.8 Hz, 1H), 5.19
		(s, 2H), 3.73-3.69 (m, 4H), 1.38-
		1.35 (m, 4H), 0.95 (s, 6H).
589		1H-NMR (400 MHz, DMSO-d6) δ: 10.97 (s, 1H), 8.87 (d, J = 6.7 Hz, 1H), 8.38 (s, 1H), 8.25 (s, 1H), 8.12 (d, J = 2.4 Hz, 1H), 8.08 (s, 1H), 7.23 (dd, J = 7.3, 2.4 Hz, 1H), 5.18
		(s, 2H), 3.67 (t, J = 7.3 Hz, 2H),
		3.15 (s, 3H), 1.44 (q, J = 7.1 Hz,
		2H), 0.65-0.58 (m, 1H), 0.30-0.25
		(m, 2H), −0.01--0.05 (m, 2H).
590		1H-NMR (400 MHz, DMSO-d6) δ: 11.13 (s, 1H), 9.35 (s, 1H), 8.88 (d, J = 7.3 Hz, 1H), 8.58 (s, 1H), 8.37 (s, 1H), 8.29-8.26 (m, 2H), 8.11 (d, J =
		2.4 Hz, 1H), 7.60-7.53 (m, 3H),
		7.25 (dd, J = 7.6, 2.4 Hz, 1H), 5.54
		(s, 2H).
591		LC-MS: [M + H]+/Rt (min) 392.0/0.724 (Method A)
592		1H-NMR (400 MHz, DMSO-d6) δ: 10.97 (s, 1H), 8.87 (d, J = 7.3 Hz, 1H), 8.12 (d, J = 2.4 Hz, 1H), 7.99 (s,
		1H), 7.96 (s, 1H), 7.74 (t, J = 5.5
		Hz, 1H), 7.23 (dd, J = 7.3, 2.4 Hz,
		1H), 5.14 (s, 2H), 3.27-3.21 (m,
		2H), 3.12-3.06 (m, 1H), 1.68-1.56
		(m, 1H), 1.44-1.26 (m, 1H), 1.16-
		1.02 (m, 1H), 0.88-0.75 (m, 6H).
593		1H-NMR (400 MHz, CDCl3) δ: 9.15 (s, 1H), 8.45 (d, J = 7.3 Hz, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 8.16 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.14 (dd, J = 7.3, 2.3 Hz, 1H), 5.17 (s, 2H), 5.02-4.93 (m, 1H), 3.07 (s, 3H),
		2.01-1.93 (m, 2H), 1.76-1.67 (m,
		6H).
594		1H-NMR (400 MHz, CDCl3) δ: 9.12 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.27 (s, 1H), 8.16 (s, 1H), 8.15 (s, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.15 (dd, J = 7.3, 2.4 Hz, 1H), 5.14 (s, 2H), 3.62-3.58 (m, 2H), 3.52 (d, J = 6.7
		Hz, 2H), 1.77-1.69 (m, 2H), 1.16-
		1.07 (m, 1H), 0.98 (t, J = 7.3 Hz,
		3H), 0.60-0.55 (m, 2H), 0.35-0.31
		(m, 2H).
595		1H-NMR (400 MHz, DMSO-d6) δ: 10.97 (s, 1H), 8.87 (d, J = 7.3 Hz, 1H), 8.38 (s, 1H), 8.21 (s, 1H), 8.12 (d, J = 2.4 Hz, 1H), 8.07 (s, 1H),
		7.23 (dd, J = 7.3, 2.4 Hz, 1H), 5.17
		(s, 2H), 3.60 (q, J = 7.3 Hz, 2H),
		3.49 (t, J = 7.3 Hz, 2H), 1.63-1.53
		(m, 2H), 1.12 (t, J = 7.3 Hz, 3H),
		0.83 (t, J = 7.3 Hz, 3H).
596		LC-MS: [M + H]+/Rt (min) 400.0/0.616 (Method A)
597		LC-MS: [M + H]+/Rt (min) 396.1/0.602 (Method A)
598		LC-MS: [M + H]+/Rt (min) 414.1/0.635 (Method A)
599		LC-MS: [M + H]+/Rt (min) 382.0/0.556 (Method A)
600		LC-MS: [M + H]+/Rt (min) 428.0/0.703 (Method A)
601		1H-NMR (400 MHz, CDCl3) δ: 9.26 (br s, 1H), 8.44 (d, J = 7.3 Hz, 1H), 8.25 (s, 1H), 8.14 (s, 2H), 8.07 (d, J = 2.4 Hz, 1H), 7.15 (dd, J = 7.3, 2.4 Hz, 1H), 5.15 (s, 2H), 4.36 (br s, 1H), 3.06 (s, 3H), 1.95-1.72
		(m, 6H), 1.59-1.39 (m, 4H).
602		1H-NMR (400 MHz, DMSO-d6) δ: 11.05 (s, 1H), 8.87-8.83 (m, 2H), 8.36- 8.35 (m, 2H), 8.08 (d, J = 1.8 Hz, 1H), 7.92 (s, 1H), 7.21 (dd, J = 7.3, 1.8 Hz, 1H), 5.36 (s, 2H), 4.06
		(t, J = 5.2 Hz, 2H), 2.51-2.48 (m,
		2H), 1.93-1.87 (m, 2H).
603		LC-MS: [M + H]+/Rt (min) 407.9/0.675 (Method A)
604		LC-MS: [M + H]+/Rt (min) 390.0/0.568 (Method A)
605		LC-MS: [M + H]+/Rt (min) 390.0/0.587 (Method A)
606		LC-MS: [M + H]+/Rt (min) 404.0/0.638 (Method A)
607		LC-MS: [M + H]+/Rt (min) 389.9/0.545 (Method A)
608		LC-MS: [M + H]+/Rt (min) 391.9/0.651 (Method A)
609		1H-NMR (400 MHz, CDCl3) δ: 8.97 (s, 1H), 8.45 (d, J = 7.3 Hz, 1H), 8.31 (s, 1H), 8.26 (s, 1H), 8.21 (s, 1H), 8.06 (d, J = 1.8 Hz, 1H), 7.13 (dd, J = 7.8, 2.3 Hz, 1H), 5.17 (s, 2H), 4.05 (t, J = 10.7 Hz, 2H), 3.91 (t,
		J = 5.5 Hz, 2H), 1.76 (t, J = 5.5
		Hz, 2H), 1.01 (t, J = 5.5 Hz, 2H),
		0.55-0.53 (m, 2H).
610		1H-NMR (400 MHz, DMSO-d6) δ: 10.94 (s, 1H), 8.85 (d, J = 7.3 Hz, 1H), 8.35 (s, 1H), 8.23 (s, 1H), 8.10- 8.05 (m, 2H), 7.21 (dd, J = 7.3, 2.4 Hz, 1H), 5.17 (s, 2H), 4.80-
		4.72 (m, 1H), 3.07 (s, 3H), 2.20-
		2.11 (m, 4H), 1.73-1.51 (m, 2H).
611		1H-NMR (400 MHz, DMSO-d6) δ: 11.09 (s, 1H), 9.02 (s, 1H), 8.87 (d, J = 7.3 Hz, 1H), 8.49 (s, 1H), 8.38 (s, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.23 (dd, J = 7.3, 2.4 Hz, 1H), 7.06- 7.04 (m, 1H), 5.45 (s, 2H), 2.72- 2.67 (m, 2H), 2.55-2.51 (m, 1H),
		2.36-2.31 (m, 1H), 1.86-1.75 (m,
		2H), 1.41-1.30 (m, 2H).
612		LC-MS: [M + H]+/Rt (min) 390.0/0.571 (Method A)
613		LC-MS: [M + H]+/Rt (min) 386.0/0.450 (Method A)
614		LC-MS: [M + H]+/Rt (min) 386.0/0.629 (Method A)
615		LC-MS: [M + H]+/Rt (min) 408.2/0.631 (Method A)
616		LC-MS: [M + H]+/Rt (min) 404.0/0.636 (Method A)
617		LC-MS: [M + H]+/Rt (min) 420.0/0.719 (Method A)
618		1H-NMR (400 MHz, DMSO-d6) δ: 11.01 (s, 1H), 8.88-8.86 (m, 1H), 8.37 (s, 1H), 8.29 (s, 1H), 8.12 (d, J =
		1.8 Hz, 1H), 8.09 (s, 1H), 7.24 (dd,
		J = 7.3, 2.4 Hz, 1H), 5.19 (s, 2H),
		3.53 (d, J = 6.7 Hz, 2H), 3.19 (s,
		3H), 1.12-1.02 (m, 1H), 0.40-0.36
		(m, 2H), 0.29-0.25 (m, 2H).
619		1H-NMR (400 MHz, DMSO-d6) δ: 11.01 (s, 1H), 8.88-8.86 (m, 1H), 8.37 (s, 1H), 8.29 (s, 1H), 8.12 (d, J = 1.8 Hz, 1H), 8.09 (s, 1H), 7.24 (dd, J = 7.3, 2.4 Hz, 1H), 5.19 (s, 2H),
		3.53 (d, J = 6.7 Hz, 2H), 3.19 (s,
		3H), 1.12-1.02 (m, 1H), 0.40-0.36
		(m, 2H), 0.29-0.25 (m, 2H).
620		1H-NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.27 (s, 1H), 8.17 (s, 1H), 8.16 (s, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 7.3, 2.4 Hz, 1H), 5.16 (s, 2H),
		4.98-4.90 (m, 1H), 3.04 (s, 3H),
		1.26 (d, J = 6.7 Hz, 6H).
621		LC-MS: [M + H]+/Rt (min) 457.9/0.809 (Method A)
622		LC-MS: [M + H]+/Rt (min) 378.0/0.699 (Method A)
623		1H-NMR (400 MHz, DMSO-d6) δ: 10.98 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.37 (s, 1H), 8.24 (s, 1H), 8.11 (d, J = 1.8 Hz, 1H), 8.08 (s, 1H),
		7.23 (dd, J = 7.3, 1.8 Hz, 1H), 5.17
		(s, 2H), 3.65 (q, J = 7.1 Hz, 2H),
		3.12 (s, 3H), 1.10 (t, J = 7.1 Hz,
		3H).
624		1H-NMR (400 MHz, DMSO-d6) δ: 10.98 (s, 1H), 8.85 (d, J = 7.3 Hz, 1H), 8.36 (s, 1H), 8.27 (s, 1H), 8.10- 8.09 (m, 2H), 7.22 (dd, J = 7.3, 2.4 Hz, 1H), 5.19 (s, 2H), 3.77 (d,
		J = 6.1 Hz, 2H), 3.17 (s, 3H), 2.61-
		2.50 (m, 3H), 2.47-2.31 (m, 2H).
625		1H-NMR (400 MHz, DMSO-d6) δ: 10.98 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.36 (s, 1H), 8.24 (s, 1H), 8.12
		(d, J = 2.4 Hz, 1H), 8.07 (s, 1H),
		7.23 (dd, J = 7.3, 2.4 Hz, 1H), 5.18
		(s, 2H), 3.65 (d, J = 7.3 Hz, 2H),
		3.12 (s, 3H), 2.67-2.59 (m, 1H),
		1.92-1.82 (m, 2H), 1.75-1.65 (m,
		4H).
626		1H-NMR (400 MHz, DMSO-d6) δ: 10.98 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.36 (s, 1H), 8.23 (s, 1H), 8.12 (d, J = 2.4 Hz, 1H), 8.07 (s, 1H),
		7.22 (dd, J = 7.3, 2.4 Hz, 1H), 5.17
		(s, 2H), 3.56 (d, J = 7.3 Hz, 2H),
		3.14 (s, 3H), 2.28-2.16 (m, 1H),
		1.62-1.50 (m, 2H), 1.50-1.42 (m,
		2H), 1.35-1.23 (m, 2H), 1.19-1.09
		(m, 2H).
627		1H-NMR (400 MHz, DMSO-d6) δ: 10.96 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.37 (s, 1H), 8.36 (s, 1H), 8.16 (s, 1H), 8.10 (d, J = 2.4 Hz, 1H),
		7.22 (dd, J = 7.3, 2.4 Hz, 1H),
		6.42-6.12 (m, 1H), 5.22 (s, 2H),
		4.12-4.03 (m, 2H), 3.24 (s, 3H).
628		1H-NMR (400 MHz, CDCl3) δ: 9.08 (s, 1H), 8.47 (d, J = 7.3 Hz, 1H), 8.28 (s, 1H), 8.22 (s, 1H), 8.19 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.16 (dd, J = 7.3, 1.8 Hz, 1H), 5.46-5.37 (m, 1H), 5.23-5.14 (m, 2H), 3.12 (s,
		3H), 2.58-2.45 (m, 1H), 2.39-2.26
		(m, 1H), 2.24-2.08 (m, 3H), 2.04-
		1.90 (m, 1H).
629		1H-NMR (400 MHz, CDCl3) δ: 9.04 (s, 1H), 8.61 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.27 (s, 1H), 8.20 (s, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.13 (dd, J = 7.3, 2.4 Hz, 1H), 5.17 (s, 2H),
		3.52 (s, 2H), 3.30 (s, 3H), 3.24
		(s, 3H), 1.25 (s, 2H), 1.04 (s, 2H).
630		1H-NMR (400 MHz, DMSO-d6) δ: 10.99 (s, 1H), 8.85 (d, J = 7.3 Hz, 1H), 8.35 (s, 1H),8.25 (s, 1H), 8.09- 8.08 (m, 2H), 7.21 (dd, J = 7.3, 2.4 Hz, 1H), 5.18 (s, 2H), 5.03- 4.94 (m, 1H), 3.13 (s, 3H), 2.45- 2.40 (m, 2H), 2.22-2.17 (m, 2H),
		0.41-0.29 (m, 4H).
631		1H-NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 8.20 (s, 1H), 8.07 (d, J = 1.8 Hz, 1H), 7.15 (dd, J = 7.3, 1.8 Hz, 1H), 5.19 (s, 2H),
		3.19 (s, 3H), 2.63-2.60 (m, 1H),
		1.60 (d, J = 7.3 Hz, 2H), 1.00 (s,
		3H), 0.95-0.86 (m, 2H), 0.70 (t,
		J = 4.9 Hz, 1H).
632		1H-NMR (400 MHz, CDCl3) δ: 9.08 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.27 (s, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.14 (dd, J = 7.3, 2.4 Hz, 1H), 5.17 (s, 2H), 4.75-4.67 (m, 1H), 3.16 (s, 3H), 2.27-2.21 (m, 2H), 2.04-1.97 (m,
		2H), 1.27 (s, 3H), 1.17 (s, 3H).
633		1H-NMR (400 MHz, CDCl3) δ: 9.16 (s, 1H), 8.49 (d, J = 7.3 Hz, 1H), 8.30 (s, 1H), 8.19 (s, 1H), 8.16 (s, 1H), 8.11 (d, J = 2.1 Hz, 1H), 7.16 (dd, J = 7.3, 2.1 Hz, 1H), 5.16 (s, 2H),
		4.11-4.06 (m, 1H), 3.19 (s, 3H),
		1.32 (d, J = 6.7 Hz, 3H), 1.11-1.02
		(m, 1H), 0.74-0.67 (m, 1H), 0.54-
		0.41 (m, 2H), 0.29-0.22 (m, 1H).
634		1H-NMR (400 MHz, CDCl3) δ: 9.18 (s, 1H), 8.49 (d, J = 7.3 Hz, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 8.21 (s, 1H), 8.13 (d, J = 2.4 Hz, 1H), 7.17 (dd, J = 7.3, 2.4 Hz, 1H), 5.21 (s, 2H),
		3.00 (s, 3H), 2.63-2.53 (m, 1H),
		2.21-2.14 (m, 1H), 1.95-1.83 (m,
		4H), 1.35-1.27 (m, 2H), 1.15 (d,
		J = 6.7 Hz, 3H).
635		LC-MS: [M + H]+/Rt (min) 392.2/0.756 (Method A)
636		1H-NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.26 (d, J = 7.9 Hz, 1H), 8.16 (s, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.87 (s, 1H), 7.14 (dd, J = 7.3, 2.4 Hz, 1H),
		5.17 (s, 2H), 5.09 (d, J = 6.7 Hz,
		1H), 4.35-4.32 (m, 1H), 2.18-2.12
		(m, 2H), 1.81-1.48 (m, 6H).
637		1H-NMR (400 MHz, CDCl3) δ: 9.16 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.27 (s, 1H), 8.15 (d, J = 2.3 Hz, 1H), 8.09-8.08 (m, 2H), 7.14 (dd, J = 7.5, 2.1 Hz, 1H), 5.15 (s, 2H), 4.71
		(br s, 2H), 2.32-2.26 (m, 1H),
		2.13-2.03 (m, 2H), 1.99-1.95 (m,
		1H), 1.90-1.86 (m, 1H), 1.73-1.67
		(m, 2H), 1.43-1.38 (m, 2H), 1.18
		(d, J = 7.3 Hz, 1H), 0.82 (d, J =
		6.9 Hz, 2H).
638		1H-NMR (400 MHz, DMSO-d6) δ: 10.95 (s, 1H), 8.86 (d, J = 7.9 Hz, 1H), 8.37 (s, 1H), 8.10 (s, 2H), 7.86 (s, 1H), 7.22 (dd, J = 7.6, 2.1 Hz, 1H), 5.17 (s, 2H), 4.14 (s, 2H),
		4.05 (s, 2H), 2.34-2.31 (m, 2H),
		2.24-2.17 (m, 1H), 1.80-1.75 (m,
		2H), 1.01 (d, J = 6.7 Hz, 3H).
639		1H-NMR (400 MHz, DMSO-d6) δ: 11.06 (s, 1H), 8.97 (d, J = 7.3 Hz, 1H), 8.48 (s, 1H), 8.41 (s, 1H), 8.22
		(d, J = 1.8 Hz, 1H), 8.19 (s, 1H),
		7.34 (dd, J = 7.5, 2.1 Hz, 1H), 5.29
		(s, 2H), 3.70 (s, 2H), 3.28 (s, 3H),
		1.01 (s, 3H), 0.56 (dd, J = 5.3,
		4.3 Hz, 2H), 0.33 (dd, J = 5.7, 4.3
		Hz, 2H).
640		1H-NMR (400 MHz, DMSO-d6) δ: 10.94 (s, 1H), 8.86 (d, J = 7.3 Hz, 1H), 8.36 (d, J = 7.2 Hz, 2H), 8.11 (s,
		1 H), 8.11 (d, J = 3.2 Hz, 1H), 7.22
		(dd, J = 7.3, 1.8 Hz, 1H), 5.18 (s,
		2H), 4.12 (d, J = 21.4 Hz, 2H), 3.25
		(s, 3H), 0.98-0.88 (m, 2H), 0.86-
		0.78 (m, 2H).

Examples 641-648

According to the methods of Reference examples 32-36 or Examples 572 to 576, and common reaction conditions, the compounds of Examples 641-648 were obtained by using each corresponding material compound.

Ex-
ample	M1	Analytical data
641		1H-NMR (400 MHz, DMSO-d6) δ: 11.08 (s, 1H), 9.44 (d, J = 1.2 Hz, 1H), 9.17 (d, J = 2.4 Hz, 1H), 8.96 (d, J = 1.8 Hz, 1H), 8.45 (d, J = 1.8
		Hz, 1H), 8.32 (s, 1H), 8.11 (dd,
		J = 8.5, 1.8 Hz, 1H), 7.80 (dd, J =
		6.7, 1.8 Hz, 1H), 7.02-6.94 (m,
		1H), 5.45 (d, J = 1.2 Hz, 2H),
		2.80-2.61 (m, 1H), 2.46-2.27 (m,
		2H), 1.93-1.76 (m, 2H), 1.76-1.62
		(m, 1H), 1.35-1.22 (m, 1H), 0.99-
		0.94 (m, 3H).
642		LC-MS: [M + H]+/Rt (min) 403.3/1.70 (Method B)
643		1H-NMR (400 MHz, CDCl3) δ: 9.26 (d, J = 4.9 Hz, 2H), 9.07 (s, 1H), 8.26-8.18 (m, 3H), 7.87 (d, J = 9.2 Hz, 1H), 7.81-7.78 (m, 1H), 5.19 (s, 2H), 3.71-3.68 (m, 4H),
		2.01-1.92 (m, 2H), 1.87-1.83 (m,
		4H), 1.72-1.68 (m, 4H).
644		1H-NMR (400 MHz, DMSO-d6) δ: 11.02 (s, 1H), 9.44 (s, 1H), 9.18 (s, 1H), 8.35 (d, J = 1.8 Hz, 1H), 8.12 (d, J = 8.7 Hz, 1H), 8.08 (s,
		1H), 8.04 (s, 1H), 7.82 (dd, J =
		8.7, 1.8 Hz, 1H), 5.20 (s, 2H),
		3.55-3.50 (m, 4H), 2.00-1.80 (m,
		8H).
645		1H-NMR (400 MHz, DMSO-d6) δ: 11.11 (s, 1H), 9.45 (s, 1H), 9.18 (s, 1H), 8.99 (s, 1H), 8.51-8.47 (m, 1H), 8.34 (d, J = 1.8 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 7.82
		(dd, J = 8.5, 1.8 Hz, 1H), 7.06-
		7.03 (m, 1H), 5.49-5.45 (m, 2H),
		2.67-2.63 (m, 2H), 2.19-2.17 (m,
		2H), 1.51 (t, J = 6.1 Hz, 2H),
		0.37-0.32 (m, 4H).
646		1H-NMR (400 MHz, DMSO-d6) δ: 11.13 (s, 1H), 9.45 (s, 1H), 9.18 (s, 1H), 9.04 (s, 1H), 8.51 (s, 1H), 8.34 (d, J = 1.8 Hz, 1H), 8.13 (d, J = 9.2 Hz, 1H), 7.82 (dd, J =
		9.2, 1.8 Hz, 1H), 6.89 (s, 1H),
		5.48 (s, 2H), 2.86-2.81 (m, 4H),
		2.25-2.14 (m, 2H).
647		1H-NMR (400 MHz, DMSO-d6) δ: 11.00 (s, 1H), 9.42 (s, 1H), 9.16 (s, 1H), 8.33 (d, J = 1.8 Hz, 1H), 8.23 (s, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.06 (s, 1H), 7.79 (dd, J =
		8.5, 1.8 Hz, 1H), 5.19 (s, 2H),
		3.65 (t, J = 7.1 Hz, 2H), 3.12 (s,
		3H), 1.41 (q, J = 7.1 Hz, 2H),
		0.62-0.53 (m, 1H), 0.26-0.21 (m,
		2H), −0.05--0.09 (m, 2H).
648		1H-NMR (400 MHz, DMSO-d6) δ: 11.08 (s, 1H), 9.43 (s, 1H), 9.16 (s, 1H), 8.86 (s, 1H), 8.36 (s, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.11 (d, J = 8.6 Hz, 1H), 7.92 (s, 1H),
		7.80 (s, 1H), 5.40 (s, 2H), 4.06
		(t, J = 5.2 Hz, 2H), 2.51-2.49 (m,
		2H), 1.92-1.86 (m, 2H).

Examples 649-668

According to the methods of Reference examples 32-36 or Examples 572-576, and common reaction conditions, the compounds of Examples 649-668 were obtained by using each corresponding material compound.

Ex-
ample	M1	Analytical data
649		1H-NMR (400 MHz, DMSO-d6) δ: 10.91 (s, 1H), 9.35-9.34 (m, 1H), 8.98 (s, 1H), 8.45 (s, 1H), 8.43 (s, 1H), 7.87 (d, J = 9.8 Hz, 1H), 7.64 (dd, J = 9.8, 2.1 Hz, 1H), 7.00-6.98 (m,
		1H), 5.41 (s, 2H), 2.60-2.56 (m,
		2H), 2.09-2.08 (m, 2H), 1.49 (t, J =
		6.4 Hz, 2H), 0.94 (s, 6H).
650		1H-NMR (400 MHz, DMSO-d6) δ: 10.84 (s, 1H), 9.27-9.26 (m, 1H), 8.89 (s, 1H), 8.37 (s, 1H), 8.35 (s, 1H), 7.78 (d, J = 9.8 Hz, 1H), 7.56 (dd,
		J = 9.8, 2.1 Hz, 1H), 6.93 (s, 1H),
		5.33 (s, 2H), 2.68 (d, J = 16.5 Hz,
		1H), 2.38-2.31 (m, 2H), 1.84-1.80
		(m, 2H), 1.40 (s, 1H), 1.28-1.14
		(m, 3H), 0.85-0.78 (m, 3H).
651		1H-NMR (400 MHz, DMSO-d6) δ: 10.74 (s, 1H), 9.29 (d, J = 1.8 Hz, 1H), 8.35 (s, 1H), 8.00 (s, 1H), 7.96 (s, 1H), 7.79 (d, J = 9.2 Hz, 1H),
		7.56 (dd, J = 9.8, 1.8 Hz, 1H), 5.08
		(s, 2H), 3.48-3.42 (m, 4H), 1.94-
		1.73 (m, 8H).
652		LC-MS: [M + H]+/Rt (min) 375.0/0.901 (Method A)
653		1H-NMR (400 MHz, DMSO-d6) δ: 10.84 (s, 1H), 9.27-9.26 (m, 1H), 8.89 (s, 1H), 8.37 (s, 1H), 8.35 (s, 1H), 7.79 (d, J = 9.8 Hz, 1H), 7.55 (dd,
		J = 9.8, 1.8 Hz, 1H), 6.93-6.91 (m,
		1H), 5.33 (s, 2H), 2.70-2.64 (m,
		1H), 2.46-2.43 (m, 1H), 2.35-2.27
		(m, 1H), 1.85-1.74 (m, 2H), 1.68-
		1.59 (m, 1H), 1.28-1.17 (m, 1H),
		0.91 (d, J = 6.1 Hz, 3H).
654		1H-NMR (400 MHz, DMSO-d6) δ: 10.86 (s, 1H), 9.38-9.37 (m, 1H), 8.43 (d, J = 1.8 Hz, 2H), 8.09 (s, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.64 (dd, J = 9.2, 1.8 Hz, 1H), 5.17 (s, 2H),
		3.73-3.69 (m, 4H), 1.38-1.35 (m,
		4H), 0.95 (s, 6H).
655		LC-MS: [M + H]+/Rt (min) 403.0/0.789 (Method A)
656		LC-MS: [M + H]+/Rt (min) 401.0/0.836 (Method A)
657		1H-NMR (400 MHz, DMSO-d6) δ: 10.84 (s, 1H), 9.39-9.38 (m, 1H), 8.43 (s, 1H), 8.24 (s, 1H), 8.08 (s, 1H), 7.87 (d, J = 9.8 Hz, 1H), 7.64 (dd,
		J = 9.8, 2.1 Hz, 1H), 5.17 (s, 2H),
		3.57 (d, J = 7.3 Hz, 2H), 3.15 (s,
		3H), 2.29-2.17 (m, 1H), 1.59-1.52
		(m, 2H), 1.50-1.40 (m, 2H), 1.34-
		1.25 (m, 2H), 1.18-1.09 (m, 2H).
658		LC-MS: [M + H]+/Rt (min) 428.0/0.708 (Method A)
659		1H-NMR (400 MHz, CDCl3) δ: 9.46 (s, 1H), 8.78 (s, 1H), 8.31 (s, 1H), 8.30 (s, 1H), 8.20 (s, 1H), 7.66 (d, J = 10.1 Hz, 1H), 7.25-7.23 (m, 1H), 5.17 (s, 2H), 4.05 (t, J = 10.7 Hz, 2H), 3.91 (t, J = 5.5 Hz, 2H),
		1.76 (t, J = 5.5 Hz, 2H), 1.00 (t,
		J = 5.5 Hz, 2H), 0.55-0.03 (m, 2H).
660		1H-NMR (400 MHz, DMSO-d6) δ: 10.94 (s, 1H), 9.35 (dd, J = 1.8, 0.9 Hz, 1H), 9.01 (s, 1H), 8.49 (s, 1H), 8.43 (s, 1H), 7.87 (dd, J = 9.6, 0.9 Hz, 1H), 7.64 (dd, J = 9.6, 1.8 Hz, 1H), 7.06-7.04 (m, 1H), 5.43 (s, 2H), 2.72-2.68
661		1H-NMR (400 MHz, CDCl3) δ: 9.49 (d, J = 1.8 Hz, 1H), 8.90 (s, 1H), 8.31 (s, 1H), 8.16 (s, 1H), 8.15 (s, 1H),
		7.67 (d, J = 9.8 Hz, 1H), 7.27-7.24
		(m, 1H), 5.16 (s, 2H), 3.46 (d, J =
		7.3 Hz, 2H), 3.23 (s, 3H), 2.20-
		2.07 (m, 1H), 0.96 (d, J = 6.1 Hz,
		6H).
662		1H-NMR (400 MHz, CDCl3) δ: 9.50 (d, J = 1.2 Hz, 1H), 8.82 (s, 1H), 8.34 (s, 1H), 8.27 (s, 1H), 8.25 (s, 1H),
		7.70 (d, J = 8.5 Hz, 1H), 7.29 (dd,
		J = 9.8, 1.8 Hz, 1H), 5.23 (s, 2H),
		4.50 (d, J = 2.4 Hz, 2H), 3.34 (s,
		3H), 2.26 (t, J = 2.4 Hz, 1H).
663		1H-NMR (400 MHz, DMSO-d6) δ: 10.83 (s, 1H), 9.37 (d, J = 1.8 Hz, 1H), 8.43 (s, 1H), 8.29 (s, 1H), 8.09
		(s, 1H), 7.87 (d, J = 9.8 Hz, 1H),
		7.64 (dd, J = 9.8, 1.8 Hz, 1H), 5.17
		(s, 2H), 3.53 (d, J = 6.7 Hz, 2H),
		3.19 (s, 3H), 1.12-1.03 (m, 1H),
		0.40-0.35 (m, 2H), 0.31-0.25 (m,
		2H).
664		1H-NMR (400 MHz, DMSO-d6) δ: 10.84 (s, 1H), 9.37-9.36 (m, 1H), 8.56 (s, 1H), 8.43 (s, 1H), 8.14 (s, 1H), 7.87 (d, J = 9.8 Hz, 1H), 7.64 (dd, J = 9.8, 1.8 Hz, 1H), 5.20 (s, 2H),
		3.11 (s, 3H), 2.87-2.81 (m, 1H),
		1.02-0.97 (m, 2H), 0.76-0.72 (m,
		2H).
665		LC-MS: [M + H]+/Rt (min) 366.0/0.658 (Method A)
666		1H-NMR (400 MHz, DMSO-d6) δ: 10.94 (s, 1H), 9.48 (s, 1H), 8.54 (s, 1H), 8.38 (s, 1H), 8.21 (s, 1H), 7.98 (d, J = 9.8 Hz, 1H), 7.74 (dd, J = 9.5, 2.1 Hz, 1 H), 5.29 (s, 2H), 5.15-5.09 (m, 1H), 3.26 (s, 3H),
		2.56-2.53 (m, 2H), 2.35-2.30 (m,
		2H), 0.54-0.50 (m, 2H), 0.46-0.42
		(m, 2H).
667		1H-NMR (400 MHz, DMSO-d6) δ: 10.92 (s, 1H), 9.47 (d, J = 1.4 Hz, 1H), 8.53 (s, 1H), 8.41 (s, 1H), 8.19
		(s, 1H), 7.97 (d, J = 9.6 Hz, 1H),
		7.74 (dd, J = 9.6, 2.3 Hz, 1H), 5.27
		(s, 2H), 3.70 (s, 2H), 3.28 (s, 3H),
		1.01 (s, 3H), 0.56 (dd, J = 5.3,
		4.3 Hz, 2H), 0.33 (dd, J = 5.7, 4.3
		Hz, 2H).
668		1H-NMR (400 MHz, DMSO-d6) δ: 10.84 (s, 1H), 9.38 (s, 1H), 8.43 (s, 1H), 8.24 (s, 1H), 8.09 (s, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.64 (dd, J = 9.8, 1.8 Hz, 1H), 5.17 (s, 2H), 4.77-4.68 (m, 1H), 3.06 (s, 3H),
		2.09-2.04 (m, 2H), 1.92 (dd, J =
		11.6, 9.2 Hz, 2H), 1.07 (s, 3H),
		1.02 (s, 3H).

Examples 669-684

According to the methods of Reference examples 32-36 or Examples 572-576, and common reaction conditions, the compounds of Examples 669-684 were obtained by using each corresponding material compound.

Example	M2	Analytical data
669		1H-NMR (400 MHz, DMSO-d6) δ: 10.86 (s, 1H), 9.40-9.37 (m, 1H), 8.44 (s, 1H), 8.31 (s, 1H), 8.08 (s, 1H), 7.87 (d, J = 10.4 Hz, 1H), 7.65 (dd, J = 9.5, 2.1 Hz, 1H), 5.17 (s, 2H), 4.98-4.90 (m, 1H), 3.00 (s, 3H),
		1.82-1.78 (m, 2H), 1.71-1.48 (m, 6H).
670		LC-MS: [M + H]+/Rt (min) 391.2/0.546 (Method A)
671		1H-NMR (400 MHz, CDCl3) δ: 8.63 (s, 1H), 8.20-8.18 (m, 2H), 7.98-7.94 (m, 1H), 7.07-7.02 (m, 1H), 6.72- 6.68 (m, 1H), 5.19 (s, 2H), 5.05- 4.96 (m, 1H), 3.88-3.84 (m, 4H), (40 3.08 (s, 3H), 3.07-3.03 (m, 4H), 2.02-1.98 (m, 2H), 1.86-1.61 (m, 6H).
672		1H-NMR (400 MHz, CDCl3) δ: 8.96 (s, 1H), 8.28 (s, 1H), 8.19 (d, J = 4.3 Hz, 2H), 7.97-7.93 (m, 1H), 6.98- 6.94 (m, 1H), 5.16 (s, 2H), 5.02- 4.97 (m, 1H), 3.09 (s, 3H), 2.75 (s, 3H), 2.01-1.92 (m, 2H), 1.82- 1.63 (m, 6H).
673		LC-MS: [M + H]+/Rt (min) 421.1/0.607 (Method A)
674		LC-MS: [M + H]+/Rt (min) 435.3/0.860 (Method A)
675		1H-NMR (400 MHz, CDCl3) δ: 8.51 (s, 1H), 8.17 (d, J = 8.6 Hz, 2H), 7.84 (s, 1H), 7.38-7.30 (m, 2H), 5.16 (s, 2H), 5.03-4.97 (m, 1H), 3.07 (s, 3H), 2.61 (s, 3H), 2.03-1.94 (m, 2H), 1.85-1.63 (m, 6H).
676		LC-MS: [M + H]+/Rt (min) 423.0/0.838 (Method A)
677		1H-NMR (400 MHz, CDCl3) δ: 9.33 (s, 1H), 8.76 (s, 1H), 8.28 (s, 1H), 8.19 (d, J = 5.5 Hz, 2H), 7.01 (d, 6.7 Hz, 1H), 5.17 (s, 2H), 5.02- 4.98 (m, 1H), 3.08 (s, 3H), 2.61 (s, 3H), 2.00-1.92 (m, 2H), 1.85- 1.64 (m, 6H).
678		LC-MS: [M + H]+/Rt (min) 441.9/0.948 (Method A)
679		LC-MS: [M + H]+/Rt (min) 392.0/0.797 (Method A)
680		LC-MS: [M + H]+/Rt (min) 403.0/0.835 (Method A)
681		LC-MS: [M + H]+/Rt (min) 431.0/0.657 (Method A)
682		LC-MS: [M + H]+/Rt (min) 418.0/0.645 (Method A)
683		1H-NMR (400 MHz, CDCl3) δ: 9.17 (s, 1H), 8.57 (d, J = 3.2 Hz, 1H), 8.32 (dd, J = 8.5, 2.5 Hz, 1H), 8.18 (s, 1H), 8.16 (s, 1H), 7.64 (d, J = 8.7 Hz, 1H), 5.14 (s, 2H), 5.00-4.92 (m, 1H), 3.06 (s, 3H), 1.98-1.91 (m, 2H), 1.81-1.76 (m, 2H), 1.73-
		1.62 (m, 4H).
684		1H-NMR (400 MHz, CDCl3) δ: 8.99- 8.90 (m, 1H), 8.14 (d, J = 9.1 Hz, 2H), 7.69 (s, 1H), 7.60 (s, 1H), 7.36 (s, 1H), 6.91 (s, 1H), 5.14 (s, 2H), 4.99-4.93 (m, 1H), 3.04 (s, 3H), 2.52 (s, 3H), 1.99-1.90 (m, 2H), 1.78-1.66 (m, 6H).

Examples 685-698

According to the methods of Reference examples 32-36 or Examples 572-576, and common reaction conditions, the compounds of Examples 685-698 were obtained by using each corresponding material compound.

Example	M2	Analytical data
685		1H-NMR (400 MHz, DMSO-d6) δ: 10.61 (s, 1H), 8.44 (d, J = 7.3 Hz, 1H), 8.23 (s, 1H), 8.07 (s, 1H), 7.88 (d, J = 1.8 Hz, 1H), 7.81 (s, 1H), 7.43 (d, J = 1.2 Hz, 1H), 6.96 (dd, J = 7.3, 2.4 Hz, 1H), 5.13
		(s, 2H), 4.81-4.73 (m, 1H), 3.08
		(s, 3H), 2.20-2.13 (m, 4H), 1.67-
		1.52 (m, 2H).
686		1H-NMR (400 MHz, CDCl3) δ: 8.66 (s, 1H), 8.16 (s, 1H), 8.14 (s, 1H), 7.91 (d, J = 7.3 Hz, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.24 (s, 1H), 6.96 (dd, J = 7.3, 2.4 Hz, 1H), 5.15 (s, 2H), 4.81-4.72
		(m, 1H), 3.17 (s, 3H), 2.41 (s,
		3H), 2.38-2.30 (m, 2H), 2.28-2.17
		(m, 2H), 1.83-1.72 (m, 2H).
687		1H-NMR (400 MHz, CDCl3) δ: 9.03 (s, 1H), 8.27 (s, 1H), 8.17 (d, J = 1.2 Hz, 1H), 8.13 (d, J = 1.8 Hz, 1H), 7.92 (d, J = 1.2 Hz, 1H), 6.99 (s, 1H), 5.16 (s, 2H), 4.80- 4.71 (m, 1H), 3.16 (s, 3H), 2.74 (s, 3H), 2.37-2.30 (m, 2H), 2.27- 2.17 (m, 2H), 1.82-1.71 (m, 2H).
688		1H-NMR (400 MHz, DMSO-d6) δ: 8.22 (s, 1H), 8.06 (s, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.94 (d, J = 7.3 Hz, 1H), 5.90-5.88 (m, 1H), 5.30 (s, 2H), 4.81-4.73 (m, 1H), 4.27 (t, J = 7.9 Hz, 2H), 4.21-4.18 (m, 2H), 3.79 (t, J = 5.5 Hz, 2H), 3.27- 3.22 (m, 2H), 3.07 (s, 3H), 2.38-
		2.34 (m, 2H), 2.20-2.12 (m, 4H),
		1.69-1.53 (m, 2H).
689		1H-NMR (400 MHz, DMSO-d6) δ: 8.68- 8.66 (m, 2H), 8.25 (s, 1H), 8.10 (s, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.55-7.54 (m, 2H), 7.32 (t, J = 7.9 Hz, 1H), 7.16 (d, J = 6.7 Hz, 1H), 5.36 (s, 2H), 4.84-4.76 (m, 1H), 4.33 (t, J = 8.5 Hz, 2H), 3.36-3.32 (m, 2H), 3.10 (s, 3H), 2.24-2.15 (m, 4H), 1.72-1.59 (m, 2H).
690		LC-MS: [M + H]+/Rt (min) 406.0/0.878 (Method A)
691		1H-NMR (400 MHz, DMSO-d6) δ: 8.22 (s, 1H), 8.07 (s, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.71-7.70 (m, 1H), 7.63-7.60 (m, 1H), 5.35 (s, 2H), 4.81-4.72 (m, 1H), 4.35 (t, J = 8.5 Hz, 2H), 3.25 (t, J = 8.5 Hz, 2H), 3.07 (s, 3H), 2.21-2.12 (m, 4H), 1.69-1.54 (m, 2H).
692		LC-MS: [M + H]+/Rt (min) 415.9/1.000 (Method A)
693		1H-NMR (400 MHz, CDCl3) δ: 8.29 (d, J = 7.9 Hz, 1H), 8.12-8.11 (m, 2H), 7.58 (d, J = 1.8 Hz, 1H), 7.36-7.31 (m, 1H), 7.04-7.02 (m, 1H), 6.28 (d, J = 1.8 Hz, 1H), 5.27 (s, 2H), 4.77-4.69 (m, 1H), 4.24 (t, J = 8.5 Hz, 2H), 3.81 (s, 3H), 3.20 (t, J = 8.5 Hz, 2H), 3.16 (s, 3H), 2.38-2.31 (m, 2H),
		2.31-2.18 (m, 2H), 1.85-1.72 (m, 2H).
694		1H-NMR (400 MHz, CDCl3) δ: 8.15- 8.10 (m, 3H), 7.73 (s, 1H), 7.58 (s, 1H), 7.24-7.17 (m, 2H), 5.27 (s, 2H), 4.77-4.68 (m, 1H), 4.27 (t, J = 8.2 Hz, 2H), 4.00 (s, 3H), 3.39 (t, J = 8.5 Hz, 2H), 3.15 (s, 3H), 2.37-2.30 (m, 2H), 2.29- 2.18 (m, 2H), 1.83-1.69 (m, 2H).
695		1H-NMR (400 MHz, CDCl3) δ: 8.12 (d, J = 7.9 Hz, 1H), 8.07 (d, J = 4.3 Hz, 2H), 7.23 (d, J = 7.9 Hz, 1H), 7.08 (d, J = 7.9 Hz, 1H), 5.22 (s, 2H), 4.73-4.64 (m, 1H), 4.50 (t, J = 8.5 Hz, 1H), 4.39 (t, J = 9.5 Hz, 1H), 4.23-4.18 3H), 4.13-4.07 (m, 1H), 3.88- 3.80 (m, 1H), 3.17 (t, J = 8.5 Hz, 2H), 3.11 (s, 3H), 2.34-2.25 (m, 2H), 2.23-2.15 (m, 2H), 1.92
		(s, 3H), 1.80-1.70 (m, 2H).
696		LC-MS: [M + H]+/Rt (min) 476.3/0.738 (Method A)
697		1H-NMR (400 MHz, CDCl3) δ: 8.10 (s, 1H), 8.09 (s, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 6.73 (d, J = 7.9 Hz, 1H), 5.24 (s, 2H), 4.76-4.67 (m, 1H), 4.20 (t, J = 7.9 Hz, 2H), 3.21 (t, J = 7.9 Hz, 2H), 3.14 (s, 3H), 3.06-3.03 (m, 4H), 2.60 (s, 4H), 2.39 (s, 3H), 2.36-2.27 (m, 2H), 2.25-2.17 (m, 2H), 1.83-1.71 (m, 2H).
698		1H-NMR (400 MHz, CDCl3) δ: 8.10- 8.07 (m, 3H), 7.21 (t, J = 7.9 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 5.24 (s, 2H), 4.76-4.67 (m, 1H), 4.21 (t, J = 8.5 Hz, 2H), 3.84- (m, 3H), 3.18-3.12 (m, 7H), 2.39 (s, 3H), 2.36-2.27 (m, 2H), 2.25-2.17 (m, 2H), 1.83-1.76 (m, 2H).

Examples 699-734

According to the methods of Reference examples 32-36 or Examples 572-576, and common reaction conditions, the compounds of Examples 699-734 were obtained by using each corresponding material compound.

Example	M2	Analytical data
699		1H-NMR (400 MHz, DMSO-d6) δ: 9.45-9.44 (m, 1H), 9.31 (dd, J = 5.5, 1.2 Hz, 1H), 8.55 (s, 1H), 8.13 (s, 1H), 8.09 (d, J 7.9 Hz, 1H), 7.87 (dd, J = 5.5, 2.4 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.27-7.25 (m, 1H), 5.38 (s, 2H), 4.34 (t, J = 8.2 Hz, 2H), 3.38 (t, J = 7.9 Hz,
		2H), 3.10 (s, 3H), 2.85-2.80
		(m, 1H), 1.01-0.94 (m, 2H),
		0.75-0.71 (m, 2H).
700		LC-MS: [M + H]+/Rt (min) 390.0/0.551 (Method A)
701		1H-NMR (400 MHz, CDCl3) δ: 8.56 (s, 1H), 8.10 (s, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 7.04-6.95 (m, 1H), 5.23 (s, 2H), 4.19 (t, J = 8.5 Hz, 2H), 3.94-3.89 (m, 1H), 3.59-3.52 (m, 2H), 3.32-3.26
		(m, 5H), 3.16 (s, 3H), 2.80-
		2.62 (m, 3H), 2.54-2.43 (m,
		2H), 2.11-2.02 (m, 1H), 1.82-
		1.74 (m, H), 1.03-0.98 (m,
		2H), 0.79-0.71 (m, 2H).
702		1H-NMR (400 MHz, DMSO-d6) δ: 10.62 (s, 1H), 8.53 (s, 1H), 8.44 (d, J = 7.3 Hz, 1H), 8.11 (s, 1H), .87-7.86 (m, 1H), 7.80 (d, J = 1.2 Hz, 1H), 7.43 (d, J = 1.2 Hz, 1H), 6.95 (dd,
		J = 7.3, 2.4 Hz, 1H), 5.14 (s,
		2H), 3.09 (s, 3H), 2.84-2.79
		(m, 1H), 0.99-0.94 (m, 2H),
		0.73-0.70 (m, 2H).
703		1H-NMR (400 MHz, CDCl3) δ: 8.68 (s, 1H), 8.61 (s, 1H), 8.19 (s, 1H), 7.90 (d, J = 7.3 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.23 (s, 1H), 6.97 (dd, J = 7.3, 2.4 Hz, 1H), 5.15 (s, 2H), 3.22 (s,
		3H), 2.82-2.77 (m, 1H), 2.40
		(s, 3H), 1.08-1.03 (m, 2H),
		0.83-0.79 (m, 2H).
704		1H-NMR (400 MHz, CDCl3) δ: 8.93 (s, 1H), 8.62 (s, 1H), 8.28 (s, 1H), 8.21 (s, 1H), 7.92 (d, J 2.4 Hz, 1H), 6.98 (d, J = 1.2 Hz, 1H), 5.17 (s, 2H), 3.22 (s, 3H), 2.83-2.78 (m, 1H), 2.75 (s, 3H), 1.08-1.03 (m, 2H), 0.83-0.79 (m, 2H).
705		1H-NMR (400 MHz, DMSO-d6) δ: 8.52 (s, 1H), 8.09 (s, 1H), 7.75 (d, J = 9.2 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.68 (dd, J = 9.2, 2.4 Hz, 1H), 5.26 (s, 2H), 4.24 (t, J = 8.5 Hz, 2H), 3.70-3.67 (m, 4H), 3.15 (t, J = 8.5 Hz, 2H), 3.08 (s, 3H),
		3.02-2.99 (m, 4H), 2.83-2.78
		(m, 1H), 0.99-0.94 (m, 2H),
		0.73-0.69 (m, 2H).
706		1H-NMR (400 MHz, CDCl3) δ: 9.13 (s, 1H), 8.72 (s, 1H), 8.62 (s, 1H), 8.47 (d, J = 6.1 Hz, 1H), 8.22-8.17 (m, 2H), 7.87 (d, J = 8.6 Hz, 1H), 7.57 (d, J = 5.5 Hz, 1H), 7.48 (dd, J = 8.9, 2.1
		Hz, 1H), 5.19 (s, 2H), 3.24 (s,
		3H), 2.83-2.78 (m, 1H), 1.06
		(t, J = 5.8 Hz, 2H), 0.85-0.79
		(m, 2H).
707		LC-MS: [M + H]+/Rt (min) 364.0/0.787 (Method A)
708		LC-MS: [M + H]+/Rt (min) 366.0/0.796 (Method A)
709		LC-MS: [M + H]+/Rt (min) 348.9/0.994 (Method A)
710		LC-MS: [M + H]+/Rt (min) 347.9/1.076 (Method A)
711		1H-NMR (400 MHz, CDCl3) δ: 8.86 (dd, J = 4.3, 1.6 Hz, 1H), 8.76 (s, 1H), 8.61 (s, 1H), 8.21 (s, 1H), 8.14-8.12 (m, 1H), 8.07 (dd, J = 8.2, 0.9 Hz, 1H), 7.80-7.72 (m, 2H), 7.31 (dd, J =
		8.2, 4.1 Hz, 1H), 5.2 (s,
		2H), 3.22 (s, 3H), 2.82-2.77
		(m, 1H), 1.07-1.00 (m, 2H),
		0.83-0.78 (m, 2H).
712		LC-MS: [M + H]+/Rt (min) 375.2/0.647 (Method A)
713		1H-NMR (400 MHz, CDCl3) δ: 9.03 (s, 1H), 8.95 (d, J = 4.1 Hz, 1H), 8.91 (d, J = 1.4 Hz, 1H), 8.77 (s, 1H), 8.63 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.24 (s, 1H), 7.55 (dd, J = 8.2, 4.1
		Hz, 1H), 5.24 (s, 2H), 3.23 (s,
		3H), 2.85-2.77 (m, 1H), 1.06
		(q, J = 6.4 Hz, 2H), 0.82 (d,
		J = 7.3 Hz, 2H).
714		1H-NMR (400 MHz, CDCl3) δ: 8.56 (s, 1H), 8.08 (s, 1H), 7.24- 7.18 (m, 1H), 6.68-6.65 (m, 1H), 6.61-6.56 (m, 2H), 5.21 (s, 2H), 3.79-3.72 (m, 4H), 3.21-3.18 (m, 7H), 2.78-2.73 (m, 1H), 1.04-0.99 (m, 2H), 0.80-0.76 (m, 2H).
715		1H-NMR (400 MHz, CDCl3) δ: 8.60 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.14 (s, 1H), 7.33-7.30 (m, 2H), 5.27 (s, 2H), 4.33 (t, J = 8.5 Hz, 2H), 3.50 (t, J = 8.5 Hz, 2H), 3.20 (s, 3H), 2.81-2.76 (m, 1H), 1.07-1.02
		(m, 2H), 0.83-0.79 (m, 2H).
716		1H-NMR (400 MHz, CDCl3) δ: 8.60 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.14 (s, 1H), 7.33-7.30 (m, 2H), 5.27 (s, 2H), 4.33 (t, J = 8.5 Hz, 2H), 3.50 (t, J = 8.5 Hz, 2H), 3.20 (s, 3H), 2.81-2.76 (m, 1H), 1.07-1.02 (m, 2H), 0.83-0.79 (m, 2H).
717		LC-MS: [M + H]+/Rt (min) 374.2/0.900 (Method A)
718		LC-MS: [M + H]+/Rt (min) 374.2/0.917 (Method A)
719		1H-NMR (400 MHz, CDCl3) δ: 8.81 (s, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.67-8.63 (m, 2H), 8.24 (s, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.65-7.60 (m, 1H), 7.55-7.51
		(m, 1H), 5.22 (s, 2H), 3.24 (s,
		3H), 2.85-2.77 (m, 1H), 1.08-
		1.03 (m, 2H), 0.84-0.78 (m, 2H).
720		LC-MS: [M + H]+/Rt (min) 0.599 (Method A)
721		LC-MS: [M + H]+/Rt (min) 375.2/0.584 (Method A)
722		1H-NMR (400 MHz, CDCl3) δ: 8.71 (s, 1H), 8.62 (s, 1H), 8.32 (d, J = 3.1 Hz, 1H), 8.20 (s, 1H), 8.08 (dd, J = 8.5, 3.1 Hz, 1H), 7.28-7.26 (m, 1H), 5.15 (s, 2H), 3.22 (s, 3H), 2.83-2.78
		(m, 1H), 1.07-1.05 (m, 2H),
		0.83-0.79 (m, 2H).
723		1H-NMR (400 MHz, CDCl3) δ: 9.33 (s, 1H), 9.05-9.01 (m, 1H), 8.88 (d, J = 3.2 Hz, 1H), 8.86- 8.82 (m, 1H), 8.61 (s, 1H), 8.22 (s, 1H), 8.17 (d, J = 7.3 Hz, 1H), 7.48 (dd, J = 8.2, 4.1
		Hz, 1H), 5.25 (s, 2H), 3.21 (s,
		3H), 2.82-2.78 (m, 1H), 1.04-
		1.01 (m, 2H), 0.90-0.84 (m, 2H).
724		LC-MS: [M + H]+/Rt (min) 375.2/0.685 (Method A)
725		LC-MS: [M + H]+/Rt (min) 375.2/0.734 (Method A)
726		1H-NMR (400 MHz, CDCl3) δ: 8.64 (s, 1H), 8.60 (s, 1H), 8.50 (d, J = 2.7 Hz, 1H), 8.33 (dd, J = 4.6, 1.4 Hz, 1H), 8.18 (s, 1H), 8.10-8.08 (m, 1H), 7.23 (dd, J = 4.3, 2.2 Hz, 1H), 5.16 (s,
		2H), 3.21 (s, 3H), 2.82-2.77
		(m, 1H), 1.06-1.04 (m, 2H),
		0.81-0.79 (m, 2H).
727		LC-MS: [M + H]+/Rt (min) 375.2/0.816 (Method A)
728		1H-NMR (400 MHz, CDCl3) δ: 9.35 (s, 1H), 9.25 (s, 1H), 8.94 (s, 1H), 8.62 (s, 1H), 8.45 (d, J = 2.7 Hz, 1H), 8.22 (d, J = 4.6 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.70 (dd, J = 9.1, 2.7 Hz,
		1H), 5.22 (s, 2H), 3.22 (s,
		3H), 2.83-2.78 (m, 1H), 1.10-
		1.04 (m, 2H), 0.83-0.75 (m, 2H).
729		LC-MS: [M + H]+/Rt (min) 375.2/0.752 (Method A)
730		1H-NMR (400 MHz, CDCl3) δ: 8.55 (s, 1H), 8.10 (s, 1H), 7.98 (d, J = 7.9 Hz, 1H), 7.07 (t, J = 7.9 Hz, 1H), 6.58 (d, J = 7.9 Hz, 1H), 5.23 (s, 2H) 4.30- 4.15 (m, 2H), 3.33 (t, J = 8.2 Hz, 2H), 3.15 (s, 3H) 2.76- 2.71 (m, 1H), 1.85-1.70 (m,
		1H), 1.03-0.97 (m, 2H), 0.96-
		0.91 (m, 2H), 0.79-0.75 (m,
		2H), 0.71-0.66 (m, 2H).
731		LC-MS: [M + H]+/Rt (min) 417.2/1.054 (Method A)
732		1H-NMR (400 MHz, CDCl3) δ: 9.16 (s, 1H), 8.86 (s, 1H), 8.60 (s, 1H), 8.44-8.42 (m, 1H), 8.33 (s, 1H), 8.21 (s, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.61-7.53 (m, 2H), 5.20 (s, 2H), 3.21 (s,
		3H), 2.83-2.75 (m, 1H), 1.06-
		1.00 (m, 2H), 0.85-0.75 (m, 2H).
733		1H-NMR (400 MHz, CDCl3) δ: 9.49 (s, 1H), 9.41 (s, 1H), 9.18 (s, 1H), 8.63 (s, 1H), 8.43-8.41 (d, 1H), 8.23 (s, 1H), 7.89 (d, J = 8.6 Hz, 1H), 7.77 (dd, J = 8.6, 1.8 Hz, 1H), 5.22 (s, 2H),
		3.22 (s, 3H), 2.84-2.77 (m,
		1H), 1.08-1.02 (m, 2H), 0.83-
		0.76 (m, 2H).
734		1H-NMR (400 MHz, CDCl3) δ: 8.51 (s, 1H), 8.12 (d, J = 7.9 Hz, 1H), 8.07 (s, 1H), 7.13-7.02 (m, 2H), 5.11 (s, 2H), 4.10- 4.00 (m, 2H), 3.55-3.45 (m, 2H), 3.13 (s, 3H), 2.75-2.69 (m, 1H), 2.01 (d, J = 10.4 Hz, 1H), 1.58 (s, 6H), 1.00-0.93
		(m, 2H), 0.77-0.73 (m, 2H).

Examples 735-761

According to the methods of Reference examples 32-36 or Examples 572-576, and common reaction conditions, the compounds of Examples 735-761 were obtained by using each corresponding material compound.

Example	Chemical structure	Analytical data
735		1H-NMR (400 MHz, CDCl3) δ: 10.64 (s, 1H), 8.96 (d, J = 1.8 Hz, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.44 (d, J = 2.4 Hz, 1H), 8.08 (s, 1H), 7.73 (dd, J = 8.8, 2.1 Hz, 1H), 7.55-
		7.49 (m, 1H), 7.03-
		6.95 (m, 1H), 5.36
		(d, J = 1.2 Hz, 2H),
		2.82-2.62 (m, 1H),
		2.47-2.28 (m, 2H),
		1.96-1.79 (m, 2H),
		1.79-1.65 (m, 1H),
		1.38-1.22 (m, 1H),
		0.99 (d, J = 15.2
		Hz, 3H).
736		1H-NMR (400 MHz, CDCl3) δ: 8.31 (s, 1H), 8.20-8.15 (m, 2H), 8.03 (s, 1H), 7.20-7.18 (m, 2H), 5.19 (s, 2H), 3.80- 3.75 (m, 4H), 3.65- 3.62 (m, 4H), 3.21 (s, 4H), 1.98-1.90 (m, 2H), 1.84-1.81 (m, 4H), 1.69-1.66 (m, 4H).
737		1H-NMR (400 MHz, DMSO-d6) δ: 10.72 (s, 1H), 8.91-8.89 (m, 1H), 8.39-8.37 (m, 1H), 8.36 (s, 1H), 7.80 (d, J = 1.8 Hz, 1H), 7.75 (d, J = 1.2 Hz, 1H), 7.37 (d, J = 1.2 Hz,
		1H), 6.92-6.89 (m,
		2H), 5.31 (s, 2H),
		2.52-2.50 (m, 2H),
		2.02-1.99 (m, 2H),
		1.41 (t, J = 6.4 Hz,
		2H), 0.88-0.81 (m,
		6H).
738		1H-NMR (400 MHz, DMSO-d6) δ: 10.94 (s, 1H), 8.87 (d, J = 7.3 Hz, 1H), 8.37 (s, 1H), 8.12 (d, J = 2.3 Hz, 1H), 7.97 (s, 1H), 7.24 (dd, J = 7.3, 2.3 Hz, 1H), 5.09 (s, 2H), 3.55-3.51 (m, 4H), 2.41 (s, 3H), 2.04-
		1.85 (m, 8H).
739		1H-NMR (400 MHz, DMSO-d6) δ: 10.79 (s, 1H), 9.38 (d, J = 1.8 Hz, 1H), 8.43 (s, 1H), 7.96 (s, 1H), 7.87 (d, J = 9.6 Hz, 1H), 7.65 (dd, J = 9.6, 1.8 Hz, 1H), 5.08 (s, 2H), 3.55-3.52 (m,
		4H), 2.41 (s, 3H),
		2.02-1.82 (m, 8H).
740		1H-NMR (400 MHz, DMSO-d6) δ: 8.92 (s, 1H), 8.39 (s, 1H), 8.34 (d, J = 2.4 Hz, 1H), 8.03 (dd, J = 4.9, 1.2 Hz, 1H), 7.39-7.35 (m, 1H), 7.26-7.22 (m, 1H), 6.96-6.95 (m, 1H), 5.53-5.51 (m, 2H), 3.80 (t, J = 4.9 Hz, 2H), 3.60 (t, J =
		4.9 Hz, 2H), 3.34
		(t, J = 4.9 Hz, 2H),
		3.20 (t, J = 4.9 Hz,
		2H), 2.75-2.70 (m,
		1H), 2.48-2.33 (m,
		2H), 1.92-1.66 (m,
		3H), 1.34-1.23 (m,
		1H), 0.99-0.91 (m,
		3H).
741		LC-MS: [M + H]+/Rt (min) 454.0 /0.809 (Method A)
742		1H-NMR (400 MHz, DMSO-d6) δ: 9.00 (d, J = 2.4 Hz, 1H), 8.54 (s, 1H), 8.34 (d, J = 2.4 Hz, 1H), 8.03 (dd, J = 4.3, 1.2 Hz, 1H), 7.86 (t, J = 7.9 Hz, 1H), 7.38-7.34 (m, 1H), 7.28-7.19 (m, 3H), 5.62 (s, 2H), 3.80 (t, J = 4.9 Hz, 2H),
		3.59 (t, J = 4.9 Hz,
		2H), 3.35 (t, J =
		4.9 Hz, 2H), 3.20
		(t, J = 4.9 Hz, 2H),
		2.40 (s, 3H).
743		1H-NMR (400 MHz, DMSO-d6) δ: 9.00 (d, J = 2.4 Hz, 1H), 8.54 (s, 1H), 8.19- 8.17 (m, 2H), 7.86 (t, J = 8.2 Hz, 1H), 7.27-7.19 (m, 2H), 6.85-6.84 (m, 2H), 5.62 (s, 2H), 3.79 (t, J = 4.9 Hz, 2H), 3.56 (t, J = 4.9 Hz, 2H), 3.50 (t, J =
		4.9 Hz, 2H), 3.36
		(t, J = 4.9 Hz, 2H),
		2.40 (s, 3H).
744		LC-MS: [M + H]+/Rt (min) 439.0/0.622 (Method A)
745		1H-NMR (400 MHz, CDCl3) δ: 8.96 (s, 1H), 8.31 (s, 1H), 8.23 (s, 1H), 8.22 (s, 1H), 7.96 (d, J = 1.8 Hz, 1H), 7.01 (d, J = 1.2 Hz, 1H), 5.19 (s, 2H), 3.59 (d, J = 6.7 Hz, 2H),
		3.31 (s, 3H), 2.78
		(s, 3H), 1.18-1.08
		(m, 1H), 0.63-0.58
		(m, 2H), 0.38-0.34
		(m, 2H).
746		1H-NMR (400 MHz, CDCl3) δ: 9.10 (s, 1H), 8.60 (d, J = 2.3 Hz, 1H), 8.35- 8.32 (m, 2H), 8.22 (s, 1H), 7.66 (d, J = 8.7 Hz, 1H), 5.18 (s, 2H), 4.07 (dd, J = 11.0, 5.5 Hz, 2H), 3.93-3.91 (m,
		2H), 1.78 (dd, J =
		5.5, 2.7 Hz, 2H),
		1.03-1.02 (m, 2H),
		0.56-0.54 (m, 2H).
747		1H-NMR (400 MHz, CDCl3) δ: 8.80 (s, 1H), 8.44 (d, J = 2.4 Hz, 1H), 8.33 (s, 1H), 8.26-8.23 (m, 3H), 7.58 (dd, J = 1.2, 0.6 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.18 (s, 1H), 5.19 (s,
		2H), 4.08 (dd, J =
		11.0, 5.5 Hz, 2H),
		3.93 (dd, J = 5.5,
		2.8 Hz, 2H), 1.78
		(dd, J = 5.5, 2.8
		Hz, 2H), 1.04-1.02
		(m, 2H), 0.56-0.54
		(m, 2H).
748		1H-NMR (400 MHz, CDCl3) δ: 9.19 (s, 1H), 8.59 (d, J = 2.3 Hz, 1H), 8.34 (dd, J = 8.7, 2.7 Hz, 1H), 8.18 (d, J = 9.6 Hz, 2H), 7.65 (d, J = 8.7 Hz, 1H), 5.16 (s, 2H), 3.56
		(d, J = 6.4 Hz, 2H),
		3.27 (s, 3H), 1.15-
		1.04 (m, 1H), 0.64-
		0.52 (m, 2H), 0.33-
		0.32 (m, 2H).
749		1H-NMR (400 MHz, CDCl3) δ: 9.14 (s, 1H), 8.57 (d, J = 2.4 Hz, 1H), 8.34 (dd, J = 8.5, 2.4 Hz, 1H), 8.16 (s, 1H), 7.77 (s, 1H), 7.65 (d, J = 8.5 Hz, 1H), 5.14 (s,
		2H), 4.22 (s, 2H),
		4.12 (s, 2H), 2.40-
		2.31 (m, 3H), 1.86
		(dd, J = 11.3, 8.2
		Hz, 2H), 1.09 (d, J =
		6.7 Hz, 3H).
750		1H-NMR (400 MHz, DMSO-d6) δ: 8.25 (s, 1H), 8.20 (t, J = 5.5 Hz, 1 H), 8.06 (s, 1H), 7.42- 7.40 (m, 1H), 7.32- 7.23 (m, 3H), 5.07 (quintet, J = 8.1 Hz, 1H), 4.85 (s,
		2H), 3.17 (s, 3H),
		2.85 (t, J = 7.3
		Hz, 2 H), 2.51-2.47
		(m, 4 H), 2.31-2.26
		(m, 2H), 0.56-0.52
		(m, 2H), 0.46-0.42
		(m, 2H).
751		1H-NMR (400 MHz, DMSO-d6) δ: 8.25 (s, 1H), 8.07 (s, 1H), 7.62 (s, 1H), 7.54-7.51 (m, 1H), 7.36 (d, J = 8.2 Hz, 1H), 5.24 (d, J = 2.3 Hz, 2H), 5.08 (s, 1H), 5.06-5.02 (m, 2H), 4.65 (d, J =
		18.3 Hz, 2H),
		3.16 (s, 3H), 2.51-
		2.45 (m, 2H), 2.27-
		2.22 (m, 2H), 0.48-
		0.44 (m, 2H), 0.42-
		0.38 (m, 2H).
752		1H-NMR (400 MHz, CDCl3) δ: 9.05 (s, 1H), 8.95 (dd, J = 4.3, 1.2 Hz, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.84 (s, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.33 (dd, J = 8.6, 1.8 Hz, 1H),
		8.02 (s, 1H), 7.56
		(dd, J = 8.6, 4.3
		Hz, 1H), 5.65-5.60
		(m, 1H), 5.21 (s,
		2H), 3.29 (s, 3H),
		2.58-2.53 (m, 2H),
		2.29-2.24 (m, 2H),
		0.60-0.52 (m, 2H),
		0.49-0.42 (m, 2H).
753		1H-NMR (400 MHz, DMSO-d6) δ: 11.10 (s, 1H), 8.87 (d, J = 2.7 Hz, 1H), 8.27 (s, 1H), 8.24 (dd, J = 8.7, 2.3 Hz, 1H), 8.10 (s, 1H), 8.00 (d, J = 8.7 Hz, 1H), 5.20 (s, 2H),
		5.05-4.96 (m, 1H),
		3.15 (s, 3H), 2.48-
		2.43 (m, 2H), 2.25-
		2.20 (m, 2H), 0.47-
		0.43 (m, 2H), 0.39-
		0.35 (m, 2H).
754		1H-NMR (400 MHz, DMSO-d6) δ: 11.82 (s, 1H), 9.32 (d, J = 1.2 Hz, 1H), 9.00 (d, J = 1.8 Hz, 1H), 8.57 (s, 1H), 8.15 (s, 1H), 5.33 (s, 2H), 4.14 (dd, J = 11.3, 5.6 Hz, 2H), 3.88 (dd, J = 5.2,
		2.6 Hz, 2H), 1.67
		(dd, J = 5.5, 2.7
		Hz, 2H), 0.83 (dd,
		J = 6.4, 4.6 Hz,
		2H), 0.57 (d, J =
		4.9 Hz, 2H).
755		1H-NMR (400 MHz, DMSO-d6) δ: 11.09 (s, 1H), 9.07 (d, J = 2.7 Hz, 1H), 8.94 (dd, J = 4.3, 1.6 Hz, 1H), 8.73 (d, J 1.8 Hz, 1H), 8.37 (dd, J = 6.9, 0.9 Hz, 1H), 8.26 (s,
		1H), 8.11 (s, 1H),
		7.68 (dd, J = 8.5,
		4.3 Hz, 1H), 5.24
		(s, 2H), 4.78-4.69
		(m, 1H), 3.07 (s,
		3H), 2.10-2.05 (m,
		2H), 1.95-1.89 (m,
		2H), 1.06 (s, 3H),
		1.01 (s, 3H).
756		1H-NMR (400 MHz, DMSO-d6) δ: 11.12 (s, 1H), 8.86 (d, J = 1.8 Hz, 1H), 8.25-8.22 (m, 2H), 8.08 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 5.18 (s, 2H), 4.72 (tt, J = 8.4, 8.4
		Hz, 1H), 3.06 (s,
		3H), 2.09-2.04 (m,
		2H), 1.98-1.90 (m,
		2H), 1.10 (s, 3H),
		1.06 (s, 3H).
757		1H-NMR (400 MHz, DMSO-d6) δ: 11.44 (s, 1H), 8.82 (d, J = 1.2 Hz, 1H), 8.56 (s, 1H), 8.24 (dd, J = 8.9, 2.1 Hz, 1H), 8.11 (dd, J = 8.9, 4.4 Hz, 2H), 5.28 (s, 2H), 4.14 (dd, J = 11.3, 5.6
		Hz, 2H), 3.87 (dd,
		J = 5.2, 2.6 Hz,
		2H), 1.66 (dd, J =
		5.2, 2.6 Hz, 2H),
		0.83 (dd, J = 5.2,
		2.6 Hz, 2H), 0.57
		(s, 2H).
758		1H-NMR (400 MHz, DMSO-d6) δ: 10.92 (s, 1H), 9.51 (s, 1H), 9.19 (s, 1H), 8.51 (d, J = 1.8 Hz, 1H), 8.24 (s, 1H), 8.09 (s, 1H), 8.06- 7.99 (m, 2H), 5.20 (s, 2H), 4.77-4.68
		(m, 1H), 3.06 (s,
		3H), 2.09-2.04 (m,
		2H), 1.94-1.89 (m,
		2H), 1.06 (s, 3H),
		1.01 (s, 3H).
759		1H-NMR (400 MHz, DMSO-d6) δ: 11.04 (s, 1H), 9.62 (s, 1H), 9.30 (s, 1H), 8.62 (d, J = 1.8 Hz, 1H), 8.37 (s, 1H), 8.21 (s, 1H), 8.17- 8.11 (m, 2H), 5.32 (s, 2H), 5.15-5.07
		(m, 1H), 3.25 (s,
		3H), 2.57-2.52 (m,
		2H), 2.35-2.30 (m,
		2H), 0.51-0.47 (m,
		2H), 0.43-0.39 (m,
		2H).
760		1H-NMR (400 MHz, DMSO-d6) δ: 11.17 (s, 1H), 9.17 (d, J = 2.7 Hz, 1H), 9.04 (dd, J = 4.1, 1.8 Hz, 1H), 8.81 (d, J = 1.8 Hz, 1H), 8.47 (d, J = 9.1 Hz, 1H), 8.42 (s, 1H), 8.20
		(s, 1H), 7.78 (dd,
		J = 8.2, 4.1 Hz,
		1H), 5.34 (s, 2H),
		3.70 (s, 2H), 3.28
		(s, 3H), 1.00 (s,
		3H), 0.57-0.55 (m,
		2H), 0.33-0.30 (m, 2H).
761		LC-MS: [M + H]+/Rt (min) 392.4/0.914 (Method A)

Example 762

2-[6-(2-Cyclopropylethoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide

To a solution of 2-cyclopropylethanol (18.6 mg) in dimethylformamide (0.54 mL) was added 55% sodium hydride (11.7 mg), and the solution was stirred at room temperature for 10 minutes. To the reaction solution was added the compound of Reference example 38 (20.0 mg), and the solution was stirred at 60° C. for 2 hours. The reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform, and then chloroform:methanol=90:10) to obtain the titled compound (10.3 mg).

¹H-NMR (400 MHz, CDCl₃) δ: 9.18 (s, 1H), 9.02 (s, 1H), 8.48 (d, J=7.4 Hz, 1H), 8.29 (s, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 7.31 (d, J=7.4 Hz, 1H), 5.28 (s, 2H), 4.54 (t, J=6.7 Hz, 2H), 1.85-1.73 (m, 1H), 0.89-0.86 (m, 2H), 0.52-0.47 (m, 2H), 0.18-0.12 (m, 2H).

Examples 763-804

According to the methods of Reference examples 38-41 or Examples 572-576 and 762, and common reaction conditions, the compounds of Examples 763-804 were obtained by using each corresponding material compound.

Example	M1	Analytical data
763		1H-NMR (400 MHz, DMSO-d6) δ: 10.95 (s, 1H), 8.88 (s, 1H), 8.87-8.85 (m, 1H), 8.37 (s, 1H), 8.11 (d, J = 1.2 Hz, 1H), 8.02 (s, 1H), 7.22
		(dd, J = 7.3, 2.4 Hz, 1H), 5.15
		(s, 2H), 4.80-4.69 (m, 2H), 2.94-
		2.83 (m, 2H), 1.70-1.57 (m, 3H),
		1.09-0.94 (m, 2H), 0.88 (d, J =
		6.1 Hz, 3H).
764		1H-NMR (400 MHz, CDCl3) δ: 9.19 (s, 1H), 8.94 (br s, 1H), 8.47 (d, J = 7.3 Hz, 1H), 8.28 (s, 1H), 8.25 (s, 1H), 7.99 (d, J = 1.8 Hz,
		1H), 7.54-7.49 (m, 1H), 7.20
		(dd, J = 7.3, 2.4 Hz, 1H), 5.35 (s,
		2H), 2.95-2.84 (m, 1H), 2.62-2.41
		(m, 2H), 2.02-1.88 (m, 2H), 1.88-
		1.71 (m, 1H), 1.47-1.32 (m, 1H),
		1.05 (d, J = 6.1 Hz, 3H).
765		1H-NMR (400 MHz, CDCl3) δ: 8.97 (s, 1H), 8.76 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.21 (s, 1H), 7.94 (s, 2H), 7.14-7.11 (m, 1H), 5.08
		(s, 2H), 3.63-3.54 (m, 4H), 2.01-
		1.88 (m, 8H).
766		1H-NMR (400 MHz, CDCl3) δ: 8.98 (s, 1H), 8.72 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.21 (s, 1H), 7.94 (d, J = 1.8 Hz, 1H), 7.91 (s, 1H), 7.12 (dd, J = 7.3, 2.4 Hz, 1H), 5.06 (s, 2H), 3.80-3.77 (m, 4H),
		1.88-1.84 (m, 2H), 1.79-1.75 (m,
		4H), 1.59-1.52 (m, 4H).
767		1H-NMR (400 MHz, CDCl3) δ: 8.88 (s, 1H), 8.76 (s, 1H), 8.41 (d, J = 7.3 Hz, 1H), 8.21 (s, 1H), 7.97 (s, 1H), 7.95 (d, J = 1.8 Hz, 1H), 7.13 (dd, J = 7.3, 2.4 Hz, 1H),
		5.07 (s, 2H), 4.21 (t, J = 5.2 Hz,
		4H), 2.62 (t, J = 5.2 Hz, 4H).
768		1H-NMR (400 MHz, CDCl3) δ: 8.89 (s, 1H), 8.83 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.26 (s, 1H), 8.04 (s, 1H), 7.99 (d, J = 1.8 Hz, 1H), 7.18 (dd, J = 7.3, 2.4 Hz, 1H), 5.13 (s, 2H), 4.10-4.07 (m, 4H),
		2.06-1.99 (m, 4H).
769		LC-MS: [M + H]+/Rt (min) 411.0/0.713 (Method A)
770		1H-NMR (400 MHz, CDCl3) δ: 9.12 (s, 1H), 9.01 (s, 1H), 8.39 (d, J = 6.7 Hz, 1H), 8.20 (s, 1H), 8.18 (s, 1H), 7.95 (d, J = 1.2 Hz, 1H), 7.90 (d, J = 1.2 Hz, 1H), 7.17 (d,
		J = 2.4 Hz, 1H), 7.08 (s, 1H),
		5.30 (s, 2H), 2.27 (s, 3H).
771		LC-MS: [M + H]+/Rt (min) 391.0/0.744 (Method A)
772		1H-NMR (400 MHz, DMSO-d6) δ: 11.09 (s, 1H), 9.33 (s, 1H), 8.87 (d, J = 7.3 Hz, 1H), 8.38 (d, J = 7.9 Hz, 2H), 8.11-8.10 (m, 1H), 7.33 (d, J = 3.1 Hz, 1H), 7.25- 7.22 (m, 1H), 6.36-6.34 (m,
		1H), 5.44 (s, 2H), 2.39 (s, 3H).
773		1H-NMR (400 MHz, CDCl3) δ: 9.79 (s, 1H), 9.38-9.32 (m, 1H), 9.08- 9.01 (m, 2H), 8.88-8.82 (m, 2H), 8.58-8.54 (m, 2H), 7.88 (s, 1H), 5.95 (s, 2H).
774		LC-MS: [M + H]+/Rt (min) 411.0/0.832 (Method A)
775		1H-NMR (400 MHz, CDCl3) δ: 9.01 (s, 1H), 8.82 (s, 1H), 8.37 (d, J = 7.3 Hz, 1H), 8.21 (s, 1H), 8.01 (s, 1H), 7.87 (s, 1H), 7.14-7.7.10 (m, 1H), 7.04-7.02 (m, 2H), 6.98- 6.94 (m, 1H), 5.02 (s, 2H), 2.26
		(s, 3H).
776		1H-NMR (400 MHz, CDCl3) δ: 9.09 (s, 1H), 8.84 (s, 1H), 8.35 (d, J = 7.3 Hz, 1H), 8.18-8.17 (m, 2H), 8.03 (s, 1H), 7.92 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 2.4 Hz, 1H),
		7.07 (dd, J = 7.3, 2.4 Hz, 1H),
		6.94 (dd, J = 11.0, 7.9 Hz, 1H),
		6.76 (t, J = 5.5 Hz, 1H), 5.14 (s,
		2H), 2.30 (s, 3H).
777		LC-MS: [M + H]+/Rt (min) 391.8/0.560 (Method A)
778		LC-MS: [M + H]+/Rt (min) 401.9/0.689 (Method A)
779		LC-MS: [M + H]+/Rt (min) 444.9/0.851 (Method A)
780		LC-MS: [M + H]+/Rt (min) 381.0/0.722 (Method A)
781		1H-NMR (400 MHz, DMSO-d6) δ: 11.02 (s, 1H), 9.22 (s, 1H), 8.79 (d, J = 7.3 Hz, 1H), 8.29 (d, J = 1.8 Hz, 2H), 8.02 (d, J = 1.8 Hz, 1H), 7.17-7.14 (m, 2H), 5.34 (s, 2H), 2.22 (s, 3H), 1.91-1.90 (m, 3H).
782		1H-NMR (400 MHz, CDCl3) δ: 9.60 (s, 1H), 9.38 (s, 1H), 9.03 (d, J = 7.3 Hz, 1H), 8.84 (s, 1H), 8.58 (s, 1H), 8.55 (d, J = 2.3 Hz, 1H), 7.76 (dd, J = 7.6, 2.3 Hz, 1H), 5.70 (s, 2H), 4.83 (t, J = 8.7 Hz,
		2H), 4.49-4.45 (m, 2H), 3.03-2.93
		(m, 1H), 1.69-1.60 (m, 1H), 1.12-
		1.10 (m, 2H), 0.80-0.76 (m, 2H).
783		1H-NMR (400 MHz, CDCl3) δ: 9.46 (s, 1H), 9.06 (s, 1H), 8.48 (d, J = 7.3 Hz, 1H), 8.30-8.24 (m, 2H), 8.00 (s, 1H), 7.31-7.27 (m, 1H), F 7.21-7.15 (m, 1H), 7.12-7.02 (m, 2H), 5.28 (s, 2H),
		2.28 (s, 3H).
784		1H-NMR (400 MHz, DMSO-d6) δ: 10.87 (s, 1H), 8.83 (s, 1H), 8.79 (d, J = 7.3 Hz, 1H), 8.29 (s, 1H), 8.03 (d, J = 1.8 Hz, 1H), 7.97 (s, 1H), 7.14 (dd, J = 7.3, 1.8 Hz, 1H),
		5.39 (s, 1H), 5.09 (s, 2H), 4.10
		(s, 2H), 3.86 (t, J = 5.8 Hz, 2H),
		1.97 (s, 2H), 1.59 (s, 3H).
785		1H-NMR (400 MHz, CDCl3) δ: 9.00 (s, 1H), 8.97 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.21 (s, 1H), 8.15 (s, 1H), 8.12 (s, 1H), 8.04 (s, 1H), 7.14 (dd, J = 7.6, 2.1 Hz,
		1H), 5.24 (s, 2H), 4.11-4.09 (m,
		2H), 2.59-2.56 (m, 2H), 1.98-
		1.95 (m, 2H).
786		1H-NMR (400 MHz, CDCl3) δ: 9.12 (s, 1H), 8.99 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 7.92 (d, J = 1.8 Hz, 1H),
		7.48 (d, J = 4.3 Hz, 1H), 7.15
		(dd, J = 7.3, 2.4 Hz, 1H), 5.29
		(s, 2H), 2.59-2.61 (m, 2H), 2.28-
		2.30 (m, 2H), 1.77-1.74 (m, 2H),
		1.66-1.64 (m, 2H).
787		1H-NMR (400 MHz, CDCl3) δ: 11.21 (s, 1H), 9.44 (s, 1H), 8.90 (d, J = 7.3 Hz, 1H), 8.44 (s, 2H), 8.41 (s, 1H), 8.14 (s, 1H), 7.35 (s,
		1H), 7.33 (s, 1H), 7.29 (d, J =
		10.1 Hz, 1H), 5.51 (s, 2H), 2.37
		(s, 3H).
788		1H-NMR (400 MHz, CDCl3) δ: 8.91 (s, 1H), 8.76 (d, J = 6.4 Hz, 1H), 8.40 (d, J = 8.2 Hz, 1H), 8.21 (s, 1H), 7.97 (s, 1H), 7.95 (d, J = 1.4 Hz, 1H), 7.13 (dd, J = 7.3, 2.3 Hz, 1H), 5.09-5.06 (m, 3H),
		4.79 (d, J = 13.2 Hz, 1H), 3.24-
		3.02 (m, 2H), 2.02-1.98 (m, 1H),
		1.79-1.76 (m, 1H), 1.55-1.53 (m,
		1H), 1.04 (d, J = 6.9 Hz, 3H).
789		1H-NMR (400 MHz, CDCl3) δ: 9.04 (s, 1H), 8.72 (s, 1H), 8.39 (d, J = 4.1 Hz, 1H), 8.20 (s, 1H), 7.97-7.91 (m, 2H), 7.13 (dd, J = 7.3, 2.3 Hz, 1H), 5.07 (d, J = 11.0 Hz, 2H), 4.13-4.04
		(m, 2H), 3.61-3.54 (m, 2H),
		1.43-1.26 (m, 6H), 0.90 (s,
		3H), 0.79 (t, J = 7.5 Hz, 3H).
790		1H-NMR (400 MHz, CDCl3) δ: 8.99 (s, 1H), 8.74 (s, 1H), 8.39 (d, J = 7.3 Hz, 1H), 8.20 (s, 1H), 7.93- 7.91 (m, 2H), 7.13 (dd, J = 7.6, 2.1 Hz, 1H), 5.06 (s, 2H), 3.73 (s, 2H), 3.18 (s, 3H), 1.50-1.45
		(m, 2H), 0.62-0.59 (m, 1H), 0.39-
		0.34 (m, 2H), 0.01-0.02 (m, 2H).
791		1H-NMR (400 MHz, CDCl3) δ: 9.32 (s, 1H), 9.20 (s, 1H), 8.35 (d, J = 8.2 Hz, 1H), 8.27 (s, 1H), 8.18 (s, 1H), 7.84 (d, J = 1.8 Hz, 1H), 7.37-7.31 (m, 1H), 7.13 (dd, J = 7.5, 2.1 Hz, 1H), 6.80-6.76 (m, 2H), 5.32 (s, 2H), 3.70 (s, 3H).
792		LC-MS: [M + H]+/Rt (min) 440.2/0.810 (Method A)
793		LC-MS: [M + H]+/Rt (min) 428.1/0.530 (Method A)
794		1H-NMR (400 MHz, CDCl3) δ: 8.99 (s, 1H), 8.82 (s, 1H), 8.40 (d, J = 7.3 Hz, 1H), 8.21 (s, 1H), 7.97 (s, 1H), 7.92 (d, J = 1.4 Hz, 1H), 7.14 (dd, J = 7.5, 2.1 Hz, 1H),
		5.10 (s, 2H), 3.19 (s, 3H), 2.85-
		2.81 (m, 1H), 0.91-0.86 (m, 2H),
		0.68-0.64 (m, 2H).
795		1H-NMR (400 MHz, CDCl3) δ: 9.00 (s, 1H), 8.79 (s, 1H), 8.45 (d, J = 7.8 Hz, 1H), 8.25 (s, 1H), 7.99 (d, J = 1.8 Hz, 1H), 7.98 (s, 1H), 7.17 (dd, J = 7.8, 2.3 Hz, 1H), 5.33-5.31 (m, 1H), 5.12 (s, 2H),
		3.07 (s, 3H), 1.89-1.87 (m, 2H),
		1.76-1.74 (m, 2H), 1.65-1.63 (m,
		2H), 1.24-1.22 (m, 2H).
796		LC-MS: [M + H]+/Rt (min) 428.1/0.816 (Method A)
797		LC-MS: [M + H]+/Rt (min) 378.1/0.778 (Method A)
798		1H-NMR (400 MHz, CDCl3) δ: 9.01 (s, 1H), 8.45 (t, J = 8.2 Hz, 1H), 8.25 (s, 1H), 7.99-7.97 (m, 2H),
		7.17 (dd, J = 7.8, 2.3 Hz, 1H),
		5.12 (s, 2H), 3.77 (d, J = 6.4 Hz,
		2H), 3.20 (s, 3H), 2.72-2.68 (m,
		1H), 2.05-1.99 (m, 2H), 1.88-
		1.76 (m, 4H).
799		LC-MS: [M + H]+/Rt (min) 428.1/0.956 (Method A)
800		LC-MS: [M + H]+/Rt (min) 378.1/0.700 (Method A)
801		LC-MS: [M + H]+/Rt (min) 428.1/0.792 (Method A)
802		1H-NMR (400 MHz, CDCl3) δ: 9.04 (s, 1H), 8.84 (s, 1H), 8.47 (d, J 7.3 Hz, 1H), 8.28 (s, 1H), 8.02- 7.99 (m, 2H), 7.20 (dd, J = 7.3, 2.4 Hz, 1H), 5.57 (br s, 1H), 5.16 (s, 2H), 3.29 (s, 3H), 2.58-2.54
		(m, 2H), 2.29-2.25 (m, 2H), 0.60-
		0.56 (m, 2H), 0.49-0.45 (m, 2H).
803		1H-NMR (400 MHz, DMSO-d6) δ: 10.83 (s, 1H), 8.88 (s, 1H), 8.83 (d, J 7.3 Hz, 1H), 8.34 (s, 1H), 8.09
		(d, J = 1.8 Hz, 1H), 8.01 (s, 1H),
		7.25 (dd, J = 7.3, 2.4 Hz, 1H),
		5.12 (dd, J = 11.6, 5.8 Hz, 3H),
		3.10 (s, 3H), 2.03-1.90 (m, 4H),
		1.11 (s, 3H), 1.07 (s, 3H).
804		1H-NMR (400 MHz, DMSO-d6) δ: 10.50 (s, 1H), 8.41 (dd, J = 11.9, 4.6 Hz, 2H), 7.92 (s, 1H), 7.66 (d,
		J = 1.2 Hz, 1H), 7.57 (s, 1H),
		6.78 (dd, J = 7.3, 2.4 Hz, 1H),
		4.71 (s, 2H), 3.20 (br s, 2H),
		2.73 (br s, 3H), 0.81-0.79
		(m, 2H), 0.43- 0.39 (m, 5H).

Examples 805-810

According to the methods of Reference examples 38-41 or Examples 572-576 and 762, and common reaction conditions, the compounds of Examples 805-810 were obtained by using each corresponding material compound.

Example	M1	Analytical data
805		1H-NMR (400 MHz, DMSO-d6) δ: 11.08 (br s, 1H), 9.44 (s, 1H), 9.29 (s, 1H) , 9.18 (s, 1H), 8.36 (s, 1H), 8.34 (d, J = 1.8 Hz, 1H), 8.12 (d, J = 9.2 Hz, 1H), 7.81 (dd, J = 8.9,
		2.1 Hz, 1H), 7.39-7.35 (m, 1H),
		5.42 (s, 2H), 2.85-2.73 (m, 1H),
		2.45-2.29 (m, 2H), 1.93-1.76 (m,
		2H), 1.75-1.63 (m, 1H), 1.34-1.20
		(m, 1H), 0.97 (d, J = 6.7 Hz, 3H).
806		1H-NMR (400 MHz, CDCl3) δ: 9.26 (s, 1H), 9.24 (s, 1H), 9.03 (s, 1H), 8.78 (s, 1H), 8.14 (s, 1H), 7.98 (s, 1H), 7.84 (s, 2H), 5.14 (s, 2H), 4.89-4.86 (m, 2H), 2.98-2.92
		(m, 2H), 1.76-1.73 (m, 2H), 1.26-
		1.15 (m, 2H), 0.96 (d, J = 6.1 Hz,
		3H), 0.86-0.83 (m, 1H).
807		LC-MS: [M + H]+/Rt (min) 415.1/0.802 (Method A)
808		1H-NMR (400 MHz, CDCl3) δ: 9.21 (s, 1H), 9.19 (s, 1H), 8.98 (s, 1H), 8.73 (s, 1H), 8.09 (s, 1H), 7.93 (s, 1H), 7.79-7.76 (m, 2H), 5.09 (s, 2H), 3.80-3.77 (m, 4H), 1.90- 1.85 (m, 2H), 1.79-1.75 (m, 4H), 1.59-1.56 (m, 4H).
809		1H-NMR (400 MHz, CDCl3) δ: 9.38 (s, 1H), 9.18 (s, 1H), 9.17 (s, 1H), 8.88 (s, 1H), 8.18 (s, 1H), 7.79- 7.75 (m, 2H), 7.62 (s, 1H), 4.79 (s, 2H), 3.79-3.70 (m, 4H), 1.62- 1.60 (m, 4H), 1.04 (s, 6H).
810		1H-NMR (400 MHz, CDCl3) δ: 9.22 (s, 1H), 9.20 (s, 1H), 9.15 (s, 1H), 8.83 (s, 1H), 8.23 (s, 1H), 8.08 (s, 1H), 7.83-7.81 (m, 2H), 7.29 (s, 1H), 5.33 (s, 2H), 2.96-2.90 (m, 2H), 2.81-2.75 (m, 2H), 2.19- 2.10 (m, 2H).

Examples 811-822

According to the methods of Reference examples 38-41 or Examples 572-576 and 762, and common reaction conditions, the compounds of Examples 811-822 were obtained by using each corresponding material compound.

Example	M1	Analytical data
811		1H-NMR (400 MHz, CDCl3) δ: 9.40 (s, 1H), 8.80 (s, 1H), 8.71 (s, 1H), 8.24 (s, 1H), 7.90 (s, 1H), 7.59 (d, J = 9.8 Hz, 1H), 7.19 (s, 1H), 5.07 (s, 2H), 3.78 (t, J = 5.8 Hz, 4H), 1.87 (d, J = 9.1 Hz, 2H), 1.77
		(t, J = 7.0 Hz, 4H), 1.57 (t, J =
		5.5 Hz, 4H).
812		1H-NMR (400 MHz, CDCl3) δ: 9.44 (s, 1H), 9.20 (s, 1H), 8.52 (s, 1H), 8.31 (s, 1H), 8.28 (s, 1H), 7.67 (d, J = 9.2 Hz, 1H), 7.37 (d, J = 14.7 Hz, 1H), 5.35 (s, 2H), 3.00- 2.97 (m, 2H), 2.88-2.81 (m, 2H), 2.25-2.18 (m, 2H).
813		LC-MS: [M + H]+/Rt (min) 439.9/0.801 (Method A)
814		LC-MS: [M + H]+/Rt (min) 392.0/0.773 (Method A)
815		LC-MS: [M + H]+/Rt (min) 428.0/0.777 (Method A)
816		LC-MS: [M + H]+/Rt (min) 426.1/0.722 (Method A)
817		LC-MS: [M + H]+/Rt (min) 378.0/0.725 (Method A)
818		1H-NMR (400 MHz, CDCl3) δ: 9.39 (s, 1H), 8.82 (s, 2H), 8.26-8.24 (m, 1H), 7.97 (s, 1H), 7.61 (s, 1H), 7.20 (br s, 1H), 5.11 (s, 2H), 3.18 (s, 3H), 2.83-2.81 (m, 1H), 0.90- 0.88 (m, 2H), 0.68-0. 66 (m, 2H).
819		1H-NMR (400 MHz, DMSO-d6) δ: 10.81 (s, 1H), 9.38 (s, 1H), 8.87 (s, 1H), 8.43 (s, 1H), 8.01 (s, 1H), 7.86 (d, J = 9.6 Hz, 1H), 7.63 (d,
		J = 9.6 Hz, 1H), 5.14 (s, 2H), 3.71
		(br s, 2H), 3.12 (s, 3H), 2.63 (br
		s, 1H), 1.60-1.90 (m, 6H).
820		LC-MS: [M + H]+/Rt (min) 404.1/0.895 (Method A)
821		1H-NMR (400 MHz, CDCl3) δ: 9.44 (s, J = 1.8 Hz, 1H), 8.85 (s, 1H), 8.78 (s, 1H), 8.29 (s, 1H), 7.96 (s, 1H), 7.64 (d, J = 8.5 Hz, 1H) , 7.24-7.22 (m, 1H), 5.28-5.18 (m, 1H), 5.13 (s, 2H), 3.16 (s, 3H), 2.13-2.08 (m, 2H), 2.04-1.97 (m, 2H), 1.23 (s, 3H), 1.14 (s, 3H).
822		LC-MS: [M + H]+/Rt (min) 392.3/0.770 (Method A)

Examples 823-830

According to the methods of Reference examples 38-41 or Examples 572-576 and 762, and common reaction conditions, the compounds of Examples 823-830 were obtained by using each corresponding material compound.

Ex-
ample	M2	Analytical data
823		1H-NMR (400 MHz, CDCl3) δ: 8.98 (s, 1H), 8.85 (s, 1H), 8.56 (d, J = 1.8 Hz, 1H), 8.36 (dd, J = 8.5, 2.4 Hz, 1H), 8.05 (s, 1H), 7.66 (d, J = 8.5 Hz, 1H), 5.15 (s, 2H), 4.27 (dd, J = 11.0, 5.5 Hz, 2H), 4.09-4.07 (m,
		2H), 1.71 (dd, J = 5.5, 2.7 Hz,
		2H), 1.00 (dd, J = 5.2, 2.6 Hz,
		2H), 0.52 (s, 2H).
824		1H-NMR (400 MHz, CDCl3) δ: 9.03 (s, 1H), 8.82 (s, 1H), 8.42 (d, J = 2.3 Hz, 1H), 8.28-8.25 (m, 2H), 8.03 (s, 1H), 7.57 (dd, J = 1.4, 0.7 Hz, 1H), 7.31 (d, J = 8.7 Hz, 1H), 7.17-7.17 (m, 1H), 5.16 (s, 2H), 4.26 (dd, J = 11.2, 5.6 Hz, 2H),
		4.08-4.07 (m, 2H), 1.71-1.70 (m,
		2H), 1.00-0.98 (m, 2H), 0.52-0.50
		(m, 2H).
825		1H-NMR (400 MHz, CDCl3) δ: 8.84 (s, 1H), 8.19 (s, 1H), 8.12 (d, J = 2.3 Hz, 1H), 8.02 (s, 1H), 7.82 (dd, J = 9.1, 2.7 Hz, 1H), 6.71 (d, J = 9.1 Hz, 1H), 5.12 (s, 2H), 4.27
		(dd, J = 11.2, 5.6 Hz, 2H), 4.08
		(dd, J = 5.5, 2.7 Hz, 2H), 3.90 (br
		s, 3H), 1.71 (dd, J = 5.3, 2.6 Hz,
		2H), 1.00 (dd, J = 6.2, 4.8 Hz,
		2H), 0.51 (s, 2H).
826		1H-NMR (400 MHz, CDCl3) δ: 8.83 (s, 1H), 8.57 (s, 1H), 8.50 (d, J = 2.7 Hz, 1H), 8.34 (dd, J = 4.6, 1.4 Hz, 1H), 8.12-8.10 (m, 1H), 8.02 (s, 1H), 7.26-7.25 (m, 2H), 5.13 (s, 2H), 4.27 (dd, J = 11.2, 5.6 Hz,
		2H), 4.07 (dd, J = 5.5, 2.7 Hz,
		2H), 1.70 (dd, J = 5.5, 2.7 Hz,
		1H), 0.99 (dd, J = 6.2, 4.8 Hz,
		2H), 0.52 (d, J = 5.9 Hz, 2H).
827		1H-NMR (400 MHz, DMSO-d6) δ: 11.30 (s, 1H), 9.13 (s, 2H), 8.95 (s, 1H), 8.10 (s, 1H), 5.23 (s, 2H), 4.24 (dd, J = 11.4, 5.7 Hz, 2H), 3.99 (dd, J = 5.3, 2.6 Hz, 2H),
		1.62 (dd, J = 5.5, 2.7 Hz, 2H),
		0.83 (dd, J = 5.7, 4.8 Hz, 2H),
		0.56 (s, 2H).
828		1H-NMR (400 MHz, DMSO-d6) δ: 11.82 (s, 1H), 9.32 (d, J = 1.4 Hz, 1H), 9.00 (d, J = 1.4 Hz, 1H), 8.95 (s, 1H), 8.09 (s, 1H), 5.30 (s, 2H), 4.23 (dd, J = 11.4, 5.7 Hz, 2H),
		3.98 (d, J = 5.5 Hz, 2H), 1.62 (dd,
		J = 5.3, 2.6 Hz, 2H), 0.82 (dd, J =
		5.3, 2.6 Hz, 2H), 0.56 (s, 2H).
829		1H-NMR (400 MHz, DMSO-d6) δ: 10.64 (s, 1H), 8.88 (s, 1H), 8.56 (d, J = 2.3 Hz, 1H), 8.02 (s, 1H), 7.85 (dd, J = 8.5, 2.5 Hz, 1H), 7.16 (d, J = 8.7 Hz, 1H), 5.06 (s, 2H), 4.18 (dd, J = 11.4, 5.7 Hz, 2H), 3.93
		(s, 2H), 2.94-2.87 (m, 1H), 1.56
		(dd, J = 5.0, 2.5 Hz, 2H), 1.14 (s,
		3H), 1.12 (s, 3H), 0.77 (dd, J =
		5.3, 2.6 Hz, 2H), 0.50 (s, 2H).
830		1H-NMR (400 MHz, DMSO-d6) δ: 11.45 (s, 1H), 8.94 (s, 1H), 8.82 (s, 1H), 8.25 (dd, J = 8.9, 2.1 Hz, 1H), 8.09 (dd, J = 7.5, 3.8 Hz, 2H), 5.25 (s, 2H), 4.23 (dd, J =
		11.2, 5.6 Hz, 2H), 4.00-3.96 (m,
		2H), 1.62-1.60 (br m, 2H), 0.83-
		0.81 (br m, 2H), 0.57-0.55 (br m,
		2H) .

Examples 831-851

According to the methods of Reference examples 38-41 or Examples 572-576 and 762, and common reaction conditions, the compounds of Examples 831-851 were obtained by using each corresponding material compound.

Example	Chemical structure	Analytical data
831		1H-NMR (400 MHz, CDCl3) δ: 9.86 (s, 1H), 8.74 (s, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.92 (s, 1H), 7.84 (s, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.51 (s, 1H), 7.46 (d, J = 4.3 Hz, 1H), 5.20 (s, 2H), 4.84 (d, J = 13.4 Hz, 2H), 2.90 (dd, J = 18.3, 7.3 Hz, 2H), 2.63 (s, 3H), 1.72-1.63 (m, 3H), 1.14 (td, J = 14.3, 6.5 Hz, 2H), 0.93 (d, J = 6.7 Hz, 3H).
832		1H-NMR (400 MHz, CDCl3) δ: 9.13 (s, 1H), 8.18 (s, 1H), 8.02 (d, J = 7.3 Hz, 1H), 7.78 (br s, 1H), 7.57 (s, 1H), 7.50 (s, 1H), 7.47-7.41 (m, 1H), 7.41-7.30 (m, 1H), 5.39 (s, 2H), 2.92- 2.81 (m, 1H), 2.58-2.36 (m, 2H), 2.12- 1.85 (m, 2H), 1.83-1.69 (m, 1H), 1.41- 1.28 (m, 1H), 1.01 (d, J = 6.1 Hz, 3H).
833		1H-NMR (400 MHz, DMSO-d6) δ: 10.63 (br s, 1H), 9.27 (s, 1H), 8.70 (s, 1H), 8.34 (s, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.73 (d, J = 9.2 Hz, 1H), 7.52 (dd, J = 8.5, 1.8 Hz, 1H), 7.37 (br s, 1H), 5.33 (s, 2H), 2.86-2.74 (m, 1H), 2.44-2.33 (m, 2H), 1.95-1.78 (m, 2H), 1.78-1.64 (m, 1H), 1.35-1.23 (m, 1H), 0.98 (d, J = 6.1 Hz, 3H).
834		1H-NMR (400 MHz, CDCl3) δ: 8.84 (s, 1H), 8.72 (s, 1H), 7.95-7.91 (m, 2H), 7.62 (s, 1H), 7.49 (s, 1H), 7.41 (s, 1H), 7.05 (dd, J = 7.3, 2.4 Hz, 1H), 5.06 (s, 2H), 3.59 (4H, br s), 1.98- 1.71 (m, 8H).
835		1H-NMR (400 MHz, CDCl3) δ: 8.67 (s, 1H), 8.25 (s, 1H), 8.10 (s, 1H), 7.81 (s, 1H), 7.16-7.14 (m, 2H), 5.09 (s, 2H), 4.79-4.76 (m, 2H), 3.76-3.68 (m, 4H), 2.88-2.81 (m, 2H), 1.74-1.55 (m, 7H), 1.19-1.05 (m, 2H), 0.91-0.89 (m, 3H).
836		1H-NMR (400 MHz, CDCl3) δ: 8.85 (s, 1H), 8.31 (s, 1H), 8.06 (s, 1H), 8.02 (s, 1H), 7.12 (s, 1H), 5.21 (s, 2H), 3.20 (s, 3H), 2.83-2.78 (m, 1H), 2.73 (s, 3H), 0.89-0.85 (m, 2H), 0.69-0.64 (m, 2H).
837		LC-MS: [M + H]+/Rt (min) 406.1/0.877 (Method A)
838		LC-MS: [M + H]+/Rt (min) 427.1/0.776 (Method A)
839		1H-NMR (400 MHz, CDCl3) δ: 8.77 (br s, 2H), 8.21 (s, 1H), 7.97 (s, 1H), 7.83 (d, J = 2.3 Hz, 1H), 6.93 (d, J = 0.9 Hz, 1H), 5.08 (br s, 2H), 4.04 (br s, 1H), 3.13 (s, 3H), 2.68 (s, 3H), 2.24-1.97 (m, 4H), 1.92-1.74 (m, 2H).
840		LC-MS: [M + H]+/Rt (min) 377.2/0.938 (Method A)
841		LC-MS: [M + H]+/Rt (min) 375.1/0.588 (Method A)
842		1H-NMR (400 MHz, CDCl3) δ: 9.05 (s, 1H), 8.97-8.92 (m, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.84 (s, 1H), 8.77-8.75 (m, 1H), 8.35-8.31 (m, 1H), 8.04 (s, 1H), 7 .56 (dd, J = 8.6, 4.3 Hz, 1H), 5.65-5.54 (m, 1H), 5.23 (s, 2H), 3.29 (s, 3H), 2.58-2.53 (m, 2H), 2.29-2.24 (m, 2H), 0.88 (t, J = 6.7 Hz, 2H), 0.60-0.54 (m, 2H), 0.48-0.42 (m, 2H).
843		1H-NMR (400 MHz, CDCl3) δ: 8.98 (s, 1H), 8.84 (s, 1H), 8.55 (d, J = 2.4 Hz, 1H), 8.36 (dd, J = 8.5, 2.4 Hz, 1H), 8.04 (s, 1H), 7.66 (d, J = 8.5 Hz, 1H), 5.16-5.13 (m, 3H), 4.86 (d, J = 13.4 Hz, 1H), 3.26 (dd, J = 29.0, 13.7 Hz, 1H), 3.15-3.08 (m, 1H), 2.13- 2.09 (m, 1H), 1.85-1.83 (m, 1H), 1.62- 1.55 (m, 1H), 1.12 (d, J = 6.7 Hz, 3H).
844		LC-MS: [M + H]+/Rt (min) 417.1/0.869 (Method A)
845		LC-MS: [M + H]+/Rt (min) 389.2/0.939 (Method A)
846		LC-MS: [M + H]+/Rt (min) 403.1/0.798 (Method A)
847		1H-NMR (400 MHz, DMSO-d6) δ: 11.82 (s, 1H), 9.32 (d, J = 1.2 Hz, 1H), 9.00 (d, J = 1.2 Hz, 1H), 8.93 (s, 1H), 8.08 (s, 1H), 5.29 (s, 2H), 4.94 (s, 1H), 4.67 (d, J = 12.8 Hz, 1H), 3.41 (dd, J = 25.6, 11.6 Hz, 1H), 3.12 (dd, J = 11.3, 5.6 Hz, 1H), 2.20-2.17 (m, 1H), 1.79 (d, J = 13.4 Hz, 1H), 1.36 (dd, J = 21.4, 12.2 Hz, 1H), 0.99 (d, J = 6.7 Hz, 3H).
848		LC-MS: [M + H]+/Rt (min) 415.2/0.861 (Method A)
849		LC-MS: [M + H]+/Rt (min) 403.4/0.787 (Method A)
850		1H-NMR (400 MHz, DMSO-d6) δ: 11.45 (s, 1H), 8.92 (s, 1H), 8.83 (dd, J = 2.3, 0.9 Hz, 1H), 8.25 (dd, J = 8.7, 2.3 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 8.07 (s, 1H), 5.25 (s, 2H), 4.98- 4.91 (m, 1H), 4.70-4.63 (m, 1H), 3.43 (dd, J = 10.5, 5.3 Hz, 1H), 3.36-3.28 (m, 1H), 3.12 (s, 1H), 1.81-1.74 (m, 1H), 1.39-1.35 (m, 1H), 0.99 (d, J = 6.9 Hz, 3H).
851		1H-NMR (400 MHz, DMSO-d6) δ: 11.07 (s, 1H), 9.07 (d, J = 2.4 Hz, 1H), 8.94 (dd, J = 4.3, 1.2 Hz, 1H), 8.90 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.39- 8.35 (m, 1H), 8.04 (s, 1H), 7.68 (dd, J = 8.6, 4.3 Hz, 1H), 5.21 (s, 2H), 3.66 (s, 2H), 3.19 (s, 3H), 0.89 (d, J = 7.9 Hz, 3H), 0.45 (s, 2H) , 0.22 (s, 2H).

Examples 852-863

According to the methods of Reference examples 42-44 or Examples 572-576, and common reaction conditions, the compounds of Examples 852-863 were obtained by using each corresponding material compound.

Example	M1	Analytical data
852		LC-MS: [M + H]+/Rt (min) 388.0/0.968 (Method A)
853		1H-NMR (400 MHz, CDCl3) δ: 9.24 (s, 1H), 8.45 (d, J = 7.3 Hz, 1H), 8.26 (s, 1H), 7.98 (d, J = 1.8 Hz, 1H), 7.91 (s, 1H), 7.78 (d, J = 9.2 Hz, 1H), 7.19 (dd, J = 7.3,
		1.8 Hz, 1H), 6.67 (d, J = 9.2 Hz,
		1H), 5.20 (s, 2H), 4.48 (d, J =
		12.8 Hz, 2H), 2.96 (td, J = 12.8,
		2.2 Hz, 2H), 1.78-1.65 (m, 3H),
		1.31-1.16 (m, 2H), 0.97 (d, J =
		6.1 Hz, 3H).
854		1H-NMR (400 MHz, CDCl3) δ: 9.30 (s, 1H) , 8.45 (d, J = 7.3 Hz, 1H), 8.26 (s, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.91 (s, 1H), 7.77 (d, J = 9.1 Hz, 1H), 7.20 (dd, J = 7.6, 2.1 Hz, 1H), 6.67 (d, J = 9.1 Hz,
		1H), 5.21 (s, 2H), 3.67-3.60 (m,
		4H), 1.99-1.89 (m, 2H), 1.89-1.78
		(m, 6H), 1.70-1.63 (m, 2H).
855		LC-MS: [M + H]+/Rt (min) 403.1/0.853 (Method A)
856		LC-MS: [M + H]+/Rt (min) 405.1/0.892 (Method A)
857		LC-MS: [M + H]+/Rt (min) 391.0/0.735 (Method A)
858		LC-MS: [M + H]+/Rt (min) 395.0/0.699 (Method A)
859		LC-MS: [M + H]+/Rt (min) 377.0/0.764 (Method A)
860		LC-MS: [M + H]+/Rt (min) 410.0/0.780 (Method A)
861		1H-NMR (400 MHz, CDCl3) δ: 9.21 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.27 (s, 1H), 8.00-7.98 (m, 1H), 7.92 (s, 1H), 7.78 (d, J = 9.2 Hz,
		1H), 7.20 (dd, J = 7.3, 1.8 Hz,
		1H), 6.55 (d, J = 8.5 Hz, 1H),
		5.21 (s, 2H), 3.43 (d, J = 7.9 Hz,
		2H), 3.20 (s, 3H), 2.02 (s, 1H),
		0.96 (d, J = 7.6 Hz, 6H).
862		1H-NMR (400 MHz, CDCl3) δ: 9.30 (s, 1H), 8.42 (d, J = 7.3 Hz, 1H), 8.24 (s, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.89 (s, 1H), 7.77-7.74 (m, 1H), 7.17 (dd, J = 7.3, 2.4 Hz, 1H), 6.56 (d, J = 8.6 Hz, 1H),
		5.20 (s, 2H), 5.06-4.98 (m, 1H),
		2.98 (s, 3H), 1.98-1.93 (m, 2H),
		1.80-1.73 (m, 2H), 1.72-1.55 (m,
		4H).
863		1H-NMR (400 MHz, CDCl3) δ: 9.11 (s, 1H), 8.44 (d, J = 7.3 Hz, 1H), 8.26 (s, 1H), 8.01 (d, J = 1.8 Hz, 1H), 7.95 (s, 1H), 7.85 (d, J = 9.2 Hz, 1H), 7.18 (dd, J = 7.3, 2.4 Hz, 1H), 6.71 (d, J = 9.2 Hz, 1H), 5.22 (s, 2H), 4.02 (dd, J =
		5.5, 5.5 Hz, 2H), 3.90-3.84 (m,
		2H), 1.76-1.68 (m, 2H), 0.91-0.98
		(m, 2H), 0.53-0.49 (m, 2H).

Examples 864-870

According to the methods of Reference examples 42-44 or Examples 572-576, and common reaction conditions, the compounds of Examples 864-870 were obtained by using each corresponding material compound.

Example	M1	Analytical data
864		1H-NMR (400 MHz, CDCl3) δ: 8.92 (br s, 1H), 8.09 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.98 (d, J = 7.3 Hz, 1H), 7.65-7.62 (m, 1H), 7.56-7.53 (m, 1H), 7.46 (s, 1H), 7.41-7.37 (m,
		1H), 7.09 (dd, J = 7.6, 2.1 Hz, 1H),
		6.87-6.82 (m, 1H), 5.34 (s, 2H),
		2.85-2.76 (m, 1H), 2.58-2.50 (m,
		1H), 2.45-2.35 (m, 1H), 1.96-1.84
		(m, 2H), 1.82-1.73 (m, 1H), 1.45-
		1.32 (m, 1H), 1.03 (d, J = 6.1 Hz, 3H).
865		LC-MS: [M + H]+/Rt (min) 405.3/0.859 (Method A)
866		LC-MS: [M + H]+/Rt (min) 387.3/0.782 (Method A)
867		LC-MS: [M + H]+/Rt (min) 409.3/0.827 (Method A)
868		LC-MS: [M + H]+/Rt (min) 375.3/0.707 (Method A)
869		LC-MS: [M + H]+/Rt (min) 375.3/0.686 (Method A)
870		1H-NMR (400 MHz, DMSO-d6) δ: 10.58 (s, 1H), 8.45 (d, J = 7.3 Hz, 1H), 7.88-7.83 (m, 4H), 7.44 (s, 1H), 6.98 (dd, J = 7.3, 1.8 Hz, 1H), 6.79 (d, J = 9.1 Hz, 1H), 5.12 (s, 2H),
		4.44-4.36 (m, 2H), 2.89-2.79 (m,
		2H), 1.66-1.50 (m, 3H), 1.13-0.99
		(m, 2H), 0.86 (d, J = 6.1 Hz, 3H).

Examples 871-875

According to the methods of Reference examples 42-44 or Examples 572-576, and common reaction conditions, the compounds of Examples 871-875 were obtained by using each corresponding material compound.

Example	M1	Analytical data
871		1H-NMR (400 MHz, DMSO-d6) δ: 10.90 (s, 1H), 9.37-9.33 (m, 1H), 8.42 (s, 1H), 8.40 (d, J = 8 .6 Hz, 1H), 8.29 (s, 1H), 8.08-8.00 (m, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.67-7.62 (m, 2H),
		7.46-7.39 (m, 1H), 7.28-7.21 (m,
		1H), 5.46 (s, 2H).
872		1H-NMR (400 MHz, CDCl3) δ: 9.58- 9.47 (m, 2H), 8.32 (s, 1H), 7.90 (s, 1H), 7.80 (d, J = 9.1 Hz, 1H), 7.68 (d, J = 9.8 Hz, 1H), 7.39-7.34 (m, 1H), 6.68 (d, J = 9.1 Hz, 1H), 5.33 (s,
		2H), 4.51-4.41 (m, 2H), 3.08-2.96
		(m, 2H), 1.83-1.62 (m, 3H), 1.31-
		1.16 (m, 2H), 0.96 (d, J = 6.7 Hz, 3H).
873		LC-MS: [M + H]+/Rt (min) 391.3/0.843 (Method A)
874		LC-MS: [M + H]+/Rt (min) 404.3/0.869 (Method A)
875		1H-NMR (400 MHz, CDCl3) δ: 9.47 (s, 1H), 9.04 (s, 1H), 8.30 (s, 1H), 7.90 (s, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.64 (d, J = 9.2 Hz, 1H),7.24- 7.21 (m, 1H), 6.56 (t, J = 8.6 Hz, 1H), 5.21 (s, 2H), 5.08-4.97 (m,
		1H), 3.00 (s, 3H), 1.98-1.88 (m,
		2H), 1.81-1.72 (m, 2H), 1.71-1.56
		(m, 4H).

Examples 876-880

According to the methods of Reference examples 42-44 or Examples 572-576, and common reaction conditions, the compounds of Examples 876-880 were obtained by using each corresponding material compound.

Ex-
ample	M2	Analytical data
876		1H-NMR (400 MHz, CDCl3) δ: 8.95 (s, 1H), 8.04 (s, 1H), 8.01- 7.99 (m, 1H), 7.90 (s, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.45 (s, 2H), 6.68 (d, J = 9.1 Hz, 1H), 5.28
		(s, 2H), 4.49-4.40 (m, 2H),
		3.05-2.94 (m, 2H),
		1.81-1.59 (m, 3H), 1.32-1.17 (m,
		2H), 0.95 (d, J = 6.1 Hz, 3H).
877		1H-NMR (400 MHz, CDCl3) δ: 9.37-9.16 (m, 3H), 8.16-8.09 (m, 1H), 7.95-7.89 (m, 1H), 7.89-7.82 (m, 2H), 7.78 (dd, J = 9.1, 1.2 Hz, 1H),
		6.71-6.62 (m, 1H), 5.25-5.21 (m,
		2H), 4.53-4.43 (m, 2H), 3.02-2.87
		(m, 2H), 1.83-1.62 (m, 3H), 1.31-
		1.15 (m, 2H), 0.99-0.94 (m, 3H).
878		LC-MS: [M + H]+/Rt (min) 391.0/0.874 (Method A)
879		LC-MS: [M + H]+/Rt (min) 419.1/1.066 (Method A)
880		LC-MS: [M + H]+/Rt (min) 391.0/0.807 (Method A)

Examples 881-894

According to the methods of Reference examples 42-45 or Examples 572-576, and common reaction conditions, the compounds of Examples 881-894 were obtained by using each corresponding material compound.

Example	Chemical Structure	Analytical data
881		1H-NMR (400 MHz, DMSO-d6) δ: 8.34 (d, J = 2.4 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.08 (s, 1H), 8.03 (dd, J = 4.9, 1.2 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.39-7.34 (m, 1H), 7.24 (dd, J = 8.5, 4.9 Hz, 1H), 6.79-6.75 (m, 1H), 5.44 (s, 2H), 3.83- 3.76 (m, 2H), 3.65-3.56 (m, 2H), 3.36- 3.26 (m, 2H), 3.24-3.16 (m, 2H), 2.77- 2.66 (m, 1H), 2.48-2.28 (m, 2H), 1.89- 1.73 (m, 2H), 1.73-1.62 (m, 1H), 1.32- 1.20 (m, 1H), 0.97 (d, J = 6.7 Hz 3H).
882		1H-NMR (400 MHz, DMSO-d6) δ: 8.16 (d, J = 7.9 Hz, 1H), 8.12 (s, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.09 (t, J = 8.2 Hz, 1H), 6.82-6.77 (m, 1H), 6.67 (d, J = 7.9 Hz, 1H), 5.48 (s, 2H), 4.32 (t, J = 7.9 Hz, 2H), 3.76-3.68 (m, 4H), 3.15 (t, J = 8.2 Hz, 2H), 2.98-2.88 (m, 4H), 2.79-2.68 (m, 1H), 2.47-2.27 (m, 2H), 1.91-1.76 (m, 2H), 1.76-1.63 (m, 1H), 1.35-1.22 (m, 1H) , 0.97 (d, J = 6.7 Hz, 3H).
883		1H-NMR (400 MHz, DMSO-d6) δ: 10.61 (s, 1H), 8.70 (s, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.12 (s, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 9.1 Hz, 1H), 7.53 (dd, J = 8.8, 2.1 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 6.84-6.78 (m, 1H), 5.32 (s, 2H), 2.79-2.70 (m, 1H), 2.47-2.28 (m, 2H), 1.91-1.76 (m, 2H), 1.76-1.63 (m, 1H), 1.34-1.21 (m, 1H), 0.97 (d, J = 6.1 Hz, 3H).
884		1H-NMR (400 MHz, DMSO-d6) δ: 10.64 (br s, 1H), 8.70 (s, 1H), 8.39 (d, J = 7.9 Hz, 1H), 8.28 (s, 1H), 8.10 (d, J = 1.8 Hz, 1H), 8.08-8.00 (m, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.53 (dd, J = 8.6, 1.8 Hz, 1H), 7.46- 7.39 (m, 1H), 7.28-7.21 (m, 1H), 5.42 (s, 2H).
885		1H-NMR (400 MHz, CDCl3) δ: 9.28-9.18 (m, 3H), 8.13 (s, 1H), 7.91 (s, 1H), 7.87-7.84 (m, 2H), 7.77 (d, J = 9.1 Hz, 1H), 6.66 (d, J = 9.1 Hz, 1H), 5.22 (s, 2H), 3.67-3.61 (m, 4H), 1.98-1.89 (m, 2H), 1.86-1.78 (m, 4H), 1.68-1.62 (m, 4H).
886		1H-NMR (400 MHz, CDCl3) δ: 9.07 (s, 1H), 8.27 (s,1H), 7.95 (s, 1H), 7.83 (s, 1H), 7.81-7.79 (m, 1H), 7.07-7.03 (m, 1H), 7.02 (m, 1H), 5.21 (s, 2H), 3.24 (s, 3H), 2.74 (s, 3H), 2.70-2.65 (m, 1H), 0.99-0.94 (m, 2H), 0.78-0.72 (m, 2H).
887		1H-NMR (400 MHz, CDCl3) δ: 8.02 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H), 7.77 (d, J = 9.1 Hz, 1H), 7.08 (t, J = 8.0 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 6.58 (d, J = 7.8 Hz, 1H), 5.27 (s, 2H), 4.19 (t, J = 8.5 Hz, 2H), 3.30 (t, J = 8.5 Hz, 2H), 3.17 (s, 3H), 2.63-2.57 (m, 1H), 1.81-1.77 (m, 1H), 0.98-0.85 (m, 4H), 0.73-0.65 (m, 4H).
888		1H-NMR (400 MHz, CDCl3) δ: 9.63 (s, 1H), 9.19-9.16 (m, 1H), 9.07 (d, J = 3.1 Hz, 1H), 8.86 (s, 1H), 8.59 (d, J = 8.5 Hz, 1H), 7.98 (s, 1H), 7.83 (d, J = 9.2 Hz, 1H), 7.72 (dd, J = 8.2, 4.6 Hz, 1H), 7.06 (d, J = 9.2 Hz, 1H), 5.31 (s, 2H), 3.26 (s, 3H), 2.70-2.65 (m, 1H), 1.00- 0.95 (m, 2H), 0.79-0.74 (m, 2H).
889		LC-MS: [M + H]+/Rt (min) 402.2/0.864 (Method A)
890		1H-NMR (400 MHz, CDCl3) δ: 9.18 (s, 1H), 8.53 (d, J = 2.4 Hz, 1H), 8.36 (dd, J = 8.5, 2.4 Hz, 1H), 7.96 (s, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 5.21 (s, 2H), 4.03 (dd, J = 5.6 Hz, 5.6, 2H), 3.88-3.84 (m, 2H), 1.78-1.71 (m, 2H), 1.02-0.98 (m, 2H), 0.53-0.49 (m, 2H).
891		1H-NMR (400 MHz, CDCl3) δ: 9.29 (s, 1H), 8.92 (dd, J = 4.0, 1.5 Hz, 1H), 8.89 (d, J = 4.3 Hz, 1H) , 8.74 (d, J = 1.8 Hz, 1H), 8.30 (dd, J = 8.6, 1.8 Hz, 1H), 7.91 (s, 1H), 7.75 (d, J = 7.9, 1H), 7.52 (dd, J = 9.0, 4.9 Hz, 1H), 6.56 (d, J = 9.2 Hz, 1H), 5.25 (s, 2H), 5.08-4.97 (m, 1H), 2.98 (s, 3H), 1.97-1.87 (m, 2H), 1.79-1.72 (m, 2H), 1.71-1.55 (m,
		4H), 1.26 (tt, J = 12.5, 4.4 Hz, 3H),
		0.88 (q, J = 7.3 Hz, 1H).
892		LC-MS: [M + H]+/Rt (min) 402.3/0.899 (Method A)
893		1H-NMR (400 MHz, DMSO-d6) δ: 8.34 (d, J = 3.0 Hz, 1H), 8.05-8.01 (m, 1H), 7.99 (s, 1H), 7.64 (d, J = 8.5 Hz, 1H), 7.53 (s, 1H), 7.39-7.34 (m, 1H), 7.26- 7.21 (m, 2H), 6.22-6.17 (m, 1H), 5.49 (s, 2H), 3.80-3.70 (m, 2H), 3.63-3.56 (m, 2H), 3.37-3.28 (m, 2H), 3.23-3.16 (m, 2H), 2.54-2.41 (m, 2H), 2.34-2.25 (m, 1H), 1.88-1.75 (m, 2H), 1.74-1.64 (m, 1H), 1.40-1.27 (m, 1H) , 0.98 (d, J = 6.1 Hz, 3H).
894		1H-NMR (400 MHz, DMSO-d6) δ: 10.64 (s, 1H), 8.46 (d, J = 7.3 Hz, 1H), 8.03 (s, 1H), 7.91-7.88 (m, 1H), 7.82 (s, 1H), 7.69-7.64 (m, 2H), 7.44 (d, J = 1.2 Hz, 1H), 7.29-7.25 (m, 1H), 6.99 (dd, J = 7.3, 2.4 Hz, 1H), 6.26-6.20 (m, 1H), 5.37 (s, 2H), 2.54-2.42 (m, 2H), 2.36- 2.25 (m, 1H), 1.88-1.76 (m, 2H), 1.76- 1.64 (m, 1H), 1.40-1.28 (m, 1H), 0.98 (d, J = 6.1 Hz, 3H).

Examples 895 and 896

The compound obtained in Example 577 (4.6 mg) was resolved by chiral column chromatography to obtain the following optically-active compounds.

[Resolution Conditions]

Detection apparatus: SPD-M20A (Shimadzu Corporation)

HPLC: LC-20AT (Shimadzu Corporation)

Column: CHIRALPAK IG (DAICEL) (20×250 mm)

Elution condition: 0.0-30.0 (min): A/B=40:60Solvent A: hexaneSolvent B: isopropylalcoholFlow rate: 1.0 ml/min

UV: 220 nm

Column temperature: 40° C.

		Retention	Yield	Optical
	Example	time (min)	(mg)	purity
	Former	895	20.244	0.8	>95% ee
	peak
	Latter	896	22.450	0.8	>95% ee
	peak

Tests

Hereinafter, the results of pharmacological tests for representative compounds herein are described, and the pharmacologic effects of each compound are explained, but the present invention is not limited to the following Tests.

Test 1: Evaluation of the Amplification of Nav1.1-Derived Voltage-Gated Sodium Current (Nav1.1 Current) by Using a Cell Line Stably Expressing Human Nav1.1

(1) Preparation of Test Compound Solution

Test compounds were prepared by dissolving in DMSO at 200 times of the concentration at evaluation, and diluting the obtained solution to twice the concentration of evaluation with an extracellular fluid (135 mmol/L NaCl, 4 mmol/L KCl, 1 mmol/L MgCl₂, 5 mmol/L CaCl₂, 5 mmol/L Glucose, 10 mmol/L HEPES).

(2) Induction and Measurement of Nav1.1 Current

A HEK293 cell line stably expressing human Nav1.1 (cat #CYL3009, Eurofins DiscoverX Products, LLC, Human Embryonic Kidney 293) was purchased, and used in the present test. Nav1.1 current was induced by stimulating Ramp wave voltage. Detection of current which accompanied with the stimulation of voltage was carried out by a patch-clamp voltage-clamp method using HTS automated patch clamp system (SynchroPatch 768PE, Nanion Technologies GmbH, Germany). Only cells with more than 500 pA of voltage-gated sodium channel current were used for the evaluation of the activity of compounds on Nav1.1 current because there was the possibility that currents derived from endogenous voltage-gated sodium channels accounted for large proportion in cells with less than 500 pA of voltage-gated sodium channel current which was induced by stimulating Ramp wave voltage.

(3) Pharmacological Effect on Nav1.1 Current

The effect of test compounds on the amplification of Nav1.1-derived voltage-gated sodium current was evaluated by using a cell line stably expressing human Nav1.1 and HTS automated patch clamp system. In other words, test compounds were added in an extracellular fluid containing 1% DMSO, and evaluated as a change of the peak value of Nav1.1 current and the area under the curve (AUC).

(4) Method for Pharmacological Evaluation

The Nav1.1 current amplification rates of test compounds were calculated by the following formula:

Nav1.1 current amplification rate (%)=100×[the peak value of Nav1.1 current or the area under the curve after the addition of test compounds]/[the peak value of Nav1.1 current or the area under the curve before the addition of test compounds]−100

Test Result

The Nav1.1 current amplification rates (%) of the representative compounds of the present invention are shown in the following table.

	Concentration	Nav1.1
	for	current
	evaluation	amplification
Example	(μM)	rate (%)
1	10	246
2	10	148
3	10	40
4	10	3
5	10	6
6	10	35
7	10	3
8	10	4
9	10	11
10	10	124
11	10	205
12	10	241
13	10	76
14	10	9
15	10	10
16	10	59
17	10	212
18	10	11
19	10	98
20	10	152
21	10	130
22	10	110
23	10	28
24	10	286
25	10	163
26	10	364
27	10	5
28	10	158
29	10	20
30	10	77
31	10	220
32	10	60
33	10	220
34	10	311
35	10	301
36	10	312
37	10	93
38	10	174
39	10	125
40	10	20
41	10	324
42	10	216
43	10	174
44	10	59
45	10	202
46	10	85
47	10	11
48	10	33
49	10	2
50	10	155
51	10	196
52	10	248
53	10	161
54	10	20
55	10	111
56	10	10
57	10	48
58	10	26
59	10	180
60	10	57
61	10	77
62	10	13
63	10	49
64	10	11
65	10	17
66	10	49
67	10	177
68	10	42
69	10	137
70	10	68
71	10	131
72	10	119
73	10	92
74	10	70
75	10	15
76	—	—
77	10	93
78	10	78
79	10	165
80	10	131
81	10	69
82	10	121
83	10	45
84	10	315
85	10	15
86	10	73
87	10	255
88	10	183
89	10	187
90	10	31
91	10	93
92	10	88
93	10	65
94	10	198
95	10	221
96	10	105
97	10	296
98	10	15
99	10	103
100	10	197
101	—	—
102	10	8
103	10	58
104	10	11
105	—	—
106	—	—
107	10	37
108	10	5
109	10	57
110	10	12
111	—	—
112	10	46
113	10	30
114	10	83
115	10	56
116	10	12
117	—	—
118	10	7
119	10	120
120	10	176
121	10	184
122	10	173
123	10	246
124	10	205
125	10	220
126	10	167
127	10	229
128	10	240
129	10	314
130	10	181
131	10	227
132	10	108
133	10	285
134	10	44
135	10	195
136	10	63
137	10	58
138	10	58
139	10	166
140	10	93
141	10	46
142	10	34
143	10	74
144	10	48
145	10	113
146	10	148
147	10	127
148	10	97
149	10	126
150	10	157
151	10	104
152	10	50
153	10	77
154	10	75
155	10	99
156	10	33
157	50	29
158	10	122
159	10	32
160	10	324
161	10	21
162	10	6
163	10	118
164	10	187
165	10	146
166	10	150
167	10	129
168	10	205
169	10	155
170	10	107
171	3	2
172	10	117
173	10	112
174	10	75
175	10	44
176	10	66
177	10	169
178	10	44
179	10	27
180	10	22
181	10	118
182	10	32
183	10	95
184	10	35
185	10	22
186	10	51
187	10	37
188	10	30
189	10	3
190	10	100
191	3	52
192	10	137
193	10	219
194	10	252
195	10	209
196	10	225
197	10	318
198	10	36
199	10	36
200	10	103
201	10	139
202	10	131
203	10	267
204	10	189
205	10	235
206	10	154
207	1	89
208	10	200
209	10	179
210	10	178
211	10	212
212	10	74
213	10	136
214	10	64
215	10	183
216	10	121
217	10	25
218	1	155
219	10	97
220	10	50
221	10	281
222	1	137
223	10	46
224	10	118
225	10	146
226	10	319
227	3	303
228	1	29
229	1	34
230	1	33
231	1	50
232	10	37
233	50	47
234	1	240
235	1	198
236	1	214
237	50	27
238	50	128
239	10	310
240	10	241
241	10	260
242	10	97
243	10	276
244	3	263
245	1	393
246	10	136
247	10	53
248	3	392
249	3	584
250	3	564
251	3	307
252	3	254
253	3	455
254	3	309
255	10	32
256	10	36
257	3	45
258	3	79
259	10	71
260	10	13
261	10	60
262	10	124
263	10	342
264	3	597
265	3	110
266	3	108
267	3	231
268	3	55
269	3	127
270	3	481
271	3	48
272	1	127
273	1	77
274	1	60
275	1	46
276	1	207
277	1	210
278	1	204
279	1	123
280	1	10
281	10	40
282	1	26
283	1	15
284	1	91
285	1	113
286	1	848
287	1	73
288	1	115
289	50	51
290	3	94
291	50	212
292	1	46
293	50	55
294	1	271
295	1	95
296	1	87
297	1	151
298	1	51
299	3	6
300	3	140
301	3	410
302	3	104
303	3	67
304	10	167
305	3	314
306	3	532
307	3	320
308	50	9
309	1	71
310	1	87
311	1	265
312	1	80
313	1	84
314	1	9
315	1	19
316	1	81
317	1	41
318	3	77
319	1	134
320	1	10
321	3	478
322	3	115
323	3	154
324	3	50
325	3	233
326	3	132
327	3	124
328	3	58
329	3	100
330	1	191
331	3	64
332	3	15
333	3	25
334	3	255
335	3	187
336	1	68
337	1	52
338	1	241
339	1	127
340	50	41
341	50	202
342	1	109
343	1	44
344	1	69
345	1	232
346	1	96
347	1	37
348	1	57
349	1	101
350	1	31
351	50	98
352	1	155
353	50	32
354	1	123
355	1	130
356	1	378
357	50	43
358	1	71
359	10	26
360	1	200
361	1	101
362	1	133
363	1	174
364	1	25
365	50	32
366	50	37
367	1	38
368	10	18
369	50	10
370	10	35
371	50	64
372	10	52
373	10	35
374	10	18
375	10	173
376	10	44
377	1	134
378	1	37
379	10	147
380	1	82
381	1	153
382	1	13
383	1	84
384	1	15
385	50	42
386	50	126
387	1	19
388	10	37
389	10	53
390	10	50
391	10	30
392	10	53
393	10	19
394	10	98
395	10	343
396	10	136
397	10	273
398	10	175
399	10	102
400	10	238
401	10	286
402	10	323
403	10	270
404	10	42
405	3	268
406	50	68
407	3	113
408	50	80
409	3	244
410	3	66
411	50	18
412	50	36
413	3	27
414	10	40
415	10	93
416	10	383
417	3	23
418	3	105
419	1	66
420	10	39
421	10	199
422	10	287
423	10	11
424	10	40
425	10	283
426	10	244
427	10	172
428	1	109
429	1	101
430	10	28
431	10	11
432	1	280
433	10	192
434	10	232
435	10	262
436	10	226
437	3	582
438	3	404
439	10	87
440	10	196
441	10	30
442	10	414
443	10	114
444	10	292
445	10	320
446	10	333
447	10	148
448	10	236
449	10	250
450	10	187
451	10	365
452	10	10
453	10	15
454	10	157
455	10	131
456	10	224
457	50	29
458	10	24
459	10	118
460	10	221
461	10	337
462	10	124
463	10	218
464	10	18
465	10	186
466	10	233
467	1	80
468	1	275
469	10	243
470	10	522
471	1	142
472	10	387
473	10	487
474	10	235
475	10	633
476	10	343
477	10	398
478	3	345
479	10	420
480	1	110
481	10	128
482	10	219
483	10	175
484	10	224
485	10	264
486	10	148
487	10	190
488	10	376
489	10	29
490	10	469
491	3	157
492	3	222
493	3	317
494	3	255
495	1	28
496	1	37
497	1	43
498	10	24
499	1	50
500	1	14
501	1	33
502	1	49
503	1	58
504	1	27
505	50	255
506	50	10
507	10	10
508	10	24
509	3	238
510	3	50
511	3	37
512	1	103
513	10	262
514	1	325
515	1	255
516	1	130
517	1	359
518	1	344
519	1	135
520	1	253
521	1	358
522	1	367
523	1	129
524	1	143
525	10	18
526	1	499
527	1	324
528	1	198
529	1	43
530	50	9
531	1	183
532	10	239
533	10	22
534	10	7
535	10	277
536	10	345
537	1	99
538	1	135
539	1	80
540	1	112
541	1	325
542	1	214
543	1	154
544	1	208
545	1	223
546	1	59
547	1	70
548	1	41
549	1	33
550	1	31
551	10	16
552	1	24
553	1	155
554	1	115
555	1	80
556	1	13
557	1	17
558	10	11
559	10	34
560	1	12
561	1	17
562	1	247
563	1	50
564	10	73
565	1	62
566	1	98
567	50	281
568	1	42
569	50	393
570	1	99
571	10	24
572	1	49
573	1	44
574	1	303
575	1	84
576	3	14
577	1	249
578	1	57
579	1	59
580	1	134
581	1	138
582	1	68
583	1	155
584	1	53
585	1	126
586	1	25
587	1	22
588	1	60
589	1	44
590	1	32
591	1	22
592	50	13
593	1	78
594	10	11
595	3	14
596	3	11
597	3	32
598	1	13
599	50	26
600	1	75
601	1	10
602	1	14
603	1	11
604	50	15
605	50	109
606	1	75
607	50	37
608	1	98
609	1	84
610	1	60
611	1	113
612	3	12
613	3	20
614	3	95
615	3	20
616	3	23
617	1	41
618	1	41
619	1	107
620	3	21
621	3	69
622	3	14
623	10	25
624	1	61
625	1	255
626	1	200
627	50	60
628	1	14
629	3	15
630	1	120
631	1	49
632	1	164
633	1	15
634	1	13
635	1	76
636	10	13
637	3	13
638	10	58
639	1	100
640	1	38
641	1	361
642	1	252
643	1	199
644	1	197
645	1	351
646	1	148
647	1	165
648	1	53
649	1	91
650	1	26
651	1	26
652	1	53
653	1	173
654	1	23
655	1	172
656	1	70
657	1	44
658	1	33
659	1	25
660	1	64
661	1	12
662	50	47
663	1	13
664	1	34
665	50	63
666	1	64
667	1	45
668	1	72
669	1	30
670	1	77
671	1	34
672	1	56
673	3	20
674	1	62
675	1	36
676	1	36
677	1	35
678	1	132
679	1	63
680	1	50
681	1	26
682	1	53
683	1	63
684	1	39
685	1	41
686	1	13
687	1	67
688	1	201
689	1	286
690	1	66
691	3	11
692	1	33
693	1	13
694	1	448
695	1	219
696	1	306
697	1	21
698	1	18
699	1	366
700	3	13
701	1	38
702	1	60
703	1	27
704	1	109
705	1	54
706	1	195
707	1	62
708	3	25
709	1	44
710	1	62
711	1	100
712	50	78
713	1	112
714	3	11
715	1	13
716	1	45
717	3	23
718	50	34
719	1	78
720	1	230
721	1	17
722	1	35
723	1	95
724	1	28
725	10	51
726	10	31
727	10	71
728	1	71
729	10	55
730	1	133
731	10	102
732	1	152
733	1	76
734	1	107
735	1	321
736	1	13
737	1	249
738	3	22
739	3	10
740	1	91
741	1	61
742	1	32
743	50	39
744	1	147
745	1	43
746	1	102
747	1	73
748	1	17
749	10	63
750	10	27
751	10	121
752	1	135
753	1	106
754	1	14
755	1	245
756	1	104
757	1	10
758	1	61
759	1	57
760	1	104
761	1	43
762	50	37
763	1	98
764	1	164
765	1	25
766	1	41
767	10	60
768	1	18
769	1	23
770	1	35
771	1	40
772	50	35
773	1	69
774	1	50
775	50	12
776	50	17
777	1	13
778	50	13
779	1	44
780	1	10
781	50	15
782	50	64
783	3	11
784	1	45
785	3	17
786	1	34
787	1	50
788	1	174
789	1	36
790	1	31
791	50	14
792	1	161
793	50	55
794	1	27
795	1	111
796	1	66
797	1	66
798	1	193
799	1	35
800	1	55
801	1	122
802	1	111
803	1	222
804	1	93
805	1	373
806	1	262
807	1	86
808	1	226
809	10	64
810	1	86
811	1	23
812	1	13
813	1	105
814	1	87
815	1	86
816	1	13
817	1	21
818	50	195
819	1	88
820	1	50
821	1	116
822	1	42
823	1	226
824	1	240
825	1	30
826	1	31
827	1	29
828	1	108
829	1	54
830	1	54
831	1	128
832	1	204
833	1	283
834	1	26
835	50	118
836	1	19
837	1	103
838	0.3	122
839	1	143
840	1	164
841	1	28
842	1	87
843	1	171
844	1	221
845	1	76
846	1	158
847	1	132
848	0.3	22
849	0.3	57
850	1	79
851	1	89
852	1	111
853	1	82
854	1	45
855	1	93
856	1	50
857	1	18
858	1	11
859	50	39
860	1	50
861	1	78
862	1	97
863	1	49
864	1	160
865	1	14
866	1	16
867	1	65
868	1	19
869	1	17
870	1	120
871	1	10
872	1	38
873	1	89
874	1	74
875	1	43
876	1	98
877	1	263
878	1	42
879	50	16
880	50	42
881	1	446
882	1	88
883	1	164
884	1	34
885	1	209
886	1	125
887	0.3	173
888	1	101
889	1	151
890	1	68
891	1	81
892	1	39
893	10	31
894	10	151
895	1	244
896	1	241

Test 2: Evaluation of the Amplification in Nav1.5-Derived Voltage-Gated Sodium Current (Nav1.5 Current) by Using a Cell Line Stably Expressing Human Nav1.5

A CHO-K1 cell line (Chinese hamster ovary) stably expressing human Nav1.5 (Gene Bank Accession No: P_000326.2) is obtained by using purchased T-Rex System (ThermoFisher Scientific, USA), and used for the present test. The effect of test compounds on the amplification of Nav1.5 current is evaluated by using a cell line stably expressing human Nav1.5 and HTS automated patch clamp system, similarly in the method using Nav1.1. In other words, test compounds are added in an extracellular fluid which contained 1% DMSO and 500 nmol/L Tetrodotoxin (TTX), and evaluated as a change of the peak value of Nav1.5 current and the area under the curve (AUC). The induction and the measurement of Nav1.5 current, the pharmacological effect on Nav1.5 current, and a method for pharmacological evaluation are carried out by the same method as in Nav1.1.

Test 3: Evaluation of the Cognitive Function by Novel Object Recognition Test (Hereinafter, Also Referred to as “NORT”)

The present test is for evaluating the improvement of cognitive function with the test compounds. When an APP-Tg mouse which is an AD (Alzheimer's disease) model mouse is evaluated by NORT, the memory for a familiar object decreases depending on the time interval between the first trial run (training) and the second trial run (test). For example, if the first trial run is done and 3 hours later the second one is done, there is no difference in the searching times between novel object and known object for the APP-Tg mouse, compared with a healthy mouse. Thus, the APP-Tg mouse suffers from significant amnesia.

The APP-Tg mouse used herein was prepared by constructing an expression cassette linked to human APP₇₅₁ isoform to which Swedish (K670N/M671L) and Indiana (V717F) mutation were introduced at downstream of mouse Thy-1 promoter, then injecting the expression cassette into a mouse fertilized egg, and transplanting it to a host mouse. The prepared mouse presents with intracerebral AB accumulation and cognitive dysfunction from early on, and thus the mouse can be used for the evaluation of cognitive function. APP-Tg mouse has been also reported in Non-patent literature 6.

To the prepared APP-Tg mouse, the test compound was administered, and then the first trial run was done for the mouse 30 minutes after the intraperitoneal administration or after 10 days of mixed diet administration. The second trial run was done 3 hours after the first trial run, and the searching times between novel object and known object in the second trial were evaluated. The discrimination index was calculated from the searching time for novel object and known object in the second trial run, and the improvement of cognitive function of the test compound was confirmed by comparing the discrimination index with the test compound-unadministered group as an index of the cognitive function. The discrimination index was calculated by the following formula.

Discrimination index={(Searching time for novel object)−(Searching time for known object)}/{(Searching time for novel object)+(Searching time for known object)}

According to the above method, the compound of Example 1 was intraperitoneally administered to the APP-Tg mouse at doses of 3, 10 and 30 mg/kg 30 minutes before the first trial run, and the improvement of cognitive function was evaluated. The result is shown in the following table. Here, the significant difference from the vehicle-administered group was determined using the parametric Dunnett multiple comparison test. The compound of Example 1 showed a dose-dependent improvement of cognitive function, and was confirmed to be statistically significant at doses of 10 and 30 mg/kg.

				p value vs.
	Dose	Discrimination		vehicle
Example	(mg/g i.p.)	index	SEM	#: p < 0.05
1	vehicle	−0.05	0.09
	3	0.12	0.06	—
	10	0.22	0.07	#
	30	0.25	0.09	#

The present test can be also done with a combination with Elacridar (Tokyo Chemical Industry Co., Ltd.). Elacridar can inhibit P-gp and BCRP which are excretion transporters expressed in the blood-brain barrier and thereby Elacridar has the effect of improving the transferability of the test compound to the brain. Eracridal was orally administered to APP-Tg mice at 100 mg/kg 2 hours before the first trial run, and then the test compound was intraperitoneally administered to the mice 30 minutes before the first trial run according to the above method. And, the improvement of cognitive function was evaluated. The significant difference from the vehicle-administered group was determined using the parametric Dunnett multiple comparison test. The results are shown in the following table. The compounds of Examples 577, 593, and 609 showed some improvement of cognitive function, and especially the compounds of Examples 577 and 609 showed strong improvement of cognitive function.

				p value vs.
	Dose	Discrimination		vehicle
Example	(mg/g i.p.)	index	SEM	#: p < 0.05
577	vehicle	−0.03	0.05
	10	0.13	0.10	—
	30	0.21	0.06	#
593	vehicle	−0.03	0.10
	30	0.11	0.11	—
	60	0.20	0.06	—
609	vehicle	−0.03	0.10
	30	0.29	0.07	#
	60	0.29	0.04	#

And, the present test can be also done with a combination with ABT (1-aminobenzotriazole) (Tokyo Chemical Industry Co., Ltd.). ABT has the effect of improving the blood concentration of the test compound by inhibiting CYP and suppressing metabolism. The test compound and ABT (1 mg/g-food) were administered with food to APP-Tg mice for 10 days, and then the improvement of cognitive function was evaluated according to the above method. The significant difference from the vehicle-administered group was determined using the parametric Dunnett multiple comparison test. The results are shown in the following table. The compounds of Examples 630, 746, 795, 819, and 821 showed some improvement of cognitive function, and especially the compounds of Examples 819 and 821 showed strong improvement of cognitive function.

	Dose	Discrimination		p value vs.
Example	(mg/g-food)	index	SEM	vehicle
630	vehicle	0.06	0.10
	0.2	0.04	0.19	—
	2	0.45	0.09	—
746	vehicle	0.06	0.10
	0.2	0.28	0.20	—
	2	0.38	0.23	—
753	vehicle	0.25	0.13
	0.1	0.21	0.15	—
	4	0.28	0.14	—
795	vehicle	0.15	0.08
	0.2	0.30	0.07	—
	2	0.27	0.06	—
819	vehicle	0.25	0.13
	0.2	0.47	0.10	p = 0.057
	2	0.52	0.10	p = 0.094
821	vehicle	0.15	0.08
	0.2	0.30	0.03	—
	2	0.37	0.02	p = 0.074

The above results showed that the compounds of Examples 1, 577, 593, 609, 630, 746, 795, 819, and 821 have some improvement of cognitive function. In addition, the improvement of cognitive function of the compounds described in the other Examples can be evaluated by the same method as described above.

Test 4: Evaluation of Phosphorylated Tau Oligomers Using APP-Tg Mice

This test is a test to quantify the oligomer of phosphorylated tau in the brain to evaluate the action of a compound. Although APP-Tg mice do not show neurofibrillary tangles or neuronal cell death, month-age-dependent increases in brain phosphorylated tau and its oligomers are observed compared to wild-type mice. The APP-Tg mice used herein were prepared by the method described in Test 3.

The test compound administered with food to APP-Tg mice for 7-10 days. At this time, in order to increase the blood concentration of the test compound, ABT was used in combination with a mixed diet of 1 mg/g-food depending on the compound. After the administration, the brain was collected, and the protein is extracted from the collected brain using TBS (Tris Buffered Saline) or sarcosyl, and then SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) of the soluble or insoluble fraction was performed. After that, Western blotting was performed using an anti-oligomerized tau antibody (Anti-Tau, oligomeric, clone TOMA-1), and the effect of the test compound was evaluated by quantifying the band amount of the phosphorylated tau oligomer.

The reducing effect of phosphorylated tau oligomer was calculated by the following formula, and from the calculated values, the results were defined as follows: 0-25%: +, 25-50%: ++, 50-75%: +++, and 75-100%: ++++. The significant difference from the vehicle-administered group was determined using the Student t-test. For the band amount, the value corrected by the β-actin band amount was used.

Reducing effect of phosphorylated tau oligomer={(band amount of oligomerized tau in vehicle-administered group−band amount of oligomerized tau in test compound-administered group)/band amount of oligomerized tau in vehicle-administered group}×100

The results are shown in the following table. It has clarified that Examples 1, 410, 560, 565, 577, 630, 746, 753, 795, and 819 have some reducing effect of tau oligomer, and especially Examples 1, 410, 560, 565, 577, and 795 have strong reducing effect of tau oligomer.

		Reducing
		effect of	p value vs.
	Dose	phosphorylated	vehicle	with ABT
Example	(mg/g-food)	tau oligomer	#: p < 0.05	1 mg/g-food
1	1.9	+ + +	—	—
	5.8	+ + + +	#
364	0.6	+	—	with ABT
	2	+	—
410	0.6	+++	p = 0.08	with ABT
	2	+	—
560	0.5	++	—	with ABT
	4.5	++++	#
565	0.5	+++	—	with ABT
	4.5	++	—
577	2.2	+	—	—
	6.6	+++	p = 0.07
630	0.2	++	—	with ABT
	2	++	—
746	0.2	++	—	with ABT
	2	++	—
753	0.1	++	—	with ABT
	4	++	—
795	0.2	+	—	with ABT
	2	+++	#
819	0.2	++	—	with ABT
	2	+	—
821	0.2	+	—	with ABT
	2	+	—

The oligomer of phosphorylated tau of the compounds described in the other Examples can be evaluated by the same method as described above.

Test 5: Evaluation of Intracerebral Tau Aggregate Accumulation and Cerebral Atrophy Using rTg4510 Mice

This test is a test to evaluate the effects of the compounds on intracerebral tau aggregate accumulation and cerebral atrophy. The rTg4510 mice overexpress the human-type FTDP-17 mutant tau in the forebrain, and month-age-dependent intracerebral tau aggregate accumulation and cerebral atrophy are observed. The rTg4510 mice used herein were produced by mating Tg (tauP301L) 4510 mice (Stock No. 015815) and CaMKII-tTA mice (Stock No. 007004) purchased from The Jackson Laboratory and breeding them.

The test compound was administered as a mixed diet to rTg4510 mice from the age of 4 months, and PET scan and MRI were performed at the ages of 4, 6 and 8 months to quantitatively evaluate the amount of the intracerebral tau aggregate accumulated and cerebral atrophy. The PET scan was performed using MicroPET Focus 220 of Siemens Medical Solutions (0.851 mm thick (intercenter) 95 slices, 19.0 cm axial field of view (FOV), and 7.6 cm intra-section FOV). The administration of radioactive compound [¹⁸F] PM-PBB3 (precursor obtained from Aprinoia) and the PET scan were performed in dimly lit after the mice was treated with 1.5% isoflurane anesthesia to avoid photoracemization of the radioactive compound. The emission scan was performed for 60 minutes immediately after the intravenous administration of [¹⁸F] PM-PBB3 (1 mCi) (3D list mode, energy window: 350-750 keV). Then, the list mode data sorted into 3D synograms were converted into 2D synograms by Fourier-rebinding (frames: 4×1, 8×2 and 8×5 minutes). The dynamic image for 60 minutes after the administration of [¹⁸F] PM-PBB3 was reconstructed by a filter-corrected back projection with a 0.5 mm Hanning filter. Regions of interest (ROI) were set in multiple brain regions using PMOD image analysis software (PMOD Technology) with reference to the MRI templates and the PET reconstructed images. Tau aggregate accumulation was evaluated by calculating SUVR (Standardized uptake value ratio) with the cerebellum as a reference region, based on the added average of dynamic images from 40 minutes to 60 minutes.

The evaluation of cerebral atrophy was performed with horizontal superconducting magnet type MRI (7T, inner diameter 400 mm, self-shielding type, zero boil-off type). The imaging was performed under isoflurane anesthesia while maintaining the rectal temperature at 36.5±0.5° C. After Tripilot acquisition, the brain images were acquired by TurboRARE T2 emphasis sequence (TR: 4200 ms, TE: 36 ms, Fat-Sup: on, NA: 4, RARE factor: 8, scan time: 14 min) (FOV read: 25.6 mm, FOV P1: 14.5 mm, Slice thickness: 0.5 mm, number of slices: 28). The ROI of each brain region was set in each of the acquired slices, and the volume of the brain region was calculated by summing the ROI areas of all the slices to evaluate the effect of the test compound.

According to the above method, rTg4510 mice were fed a diet containing 5.8 mg/g-food of the compound of Example 1 from the age of 4 months, and the effect of PET/MR on tau aggregate accumulation and cerebral atrophy was evaluated. The results are shown in FIGS. 1-3 and the table below.

In FIG. 1, the SUVR average images of tau PET in Example 1-administration and non-administration groups with rTg4510 mice at the ages of 4, 6 and 8 months are shown in the upper row, and typical T2-weighted images of the corresponding positions are shown in the lower row. It was clarified that, at the age of 4 months, there was no difference in the degree of tau PET tracer accumulation between the two administration groups and no difference in the brain volume, but in the non-administration group, an increase in the PET tracer accumulation was observed in each region with aging, and similarly, the cerebral atrophy and the enlargement of the lateral ventricle were observed, whereas they were significantly suppressed in the Example 1-administration group.

FIG. 2 shows the quantitative results of volume changes in each brain region. The result showed that the cerebellar volume which is the reference region did not change with aging, but the age-dependent cerebral atrophy observed in the cerebral neocortex and hippocampus was statistically significantly suppressed in the Example 1-administration group. And, it was shown that the age-dependent increase in the lateral ventricular volume was statistically significantly suppressed in the Example 1-administration group. The results are also shown in the table below.

	volume (mm3)
	* p < 0.05, ** p < 0.01 vs. control
month	administration		cerebral		lateral
old	group	cerebellum	neocortex	hippocampus	ventricle
4	control	33.9 ± 0.20	58.2 ± 0.38	12.4 ± 0.19	1.04 ± 0.046
	Example 1	34.3 ± 0.19	60.1 ± 0.49	14.0 ± 0.13	0.79 ± 0.014
6	control	33.7 ± 0.34	41.1 ± 0.77	9.98 ± 0.21	8.21 ± 0.179
	Example 1	33.9 ± 0.18	50.9 ± 0.98	12.6 ± 0.22	1.70 ± 0.312
8	control	33.7 ± 0.19	33.3 ± 0.53	9.51 ± 0.20	8.41 ± 0.516
	Example 1	33.4 ± 0.33	45.3 ± 1.13	12.7 ± 0.12	0.61 ± 0.036

FIG. 3 shows SUVR in each brain region. It was shown that the age-dependent increase in SUVR observed in the cerebral neocortex and hippocampus was statistically significantly suppressed in the Example 1-administration group. The results are also shown in the table below.

	SUVR (cerebellum ratio)
	* p < 0.05, ** p < 0.01 vs. control
month	administration	cerebral
old	group	neocortex	hippocampus
4	control	1.020 ± 0.009	1.082 ± 0.008
	Example 1	0.986 ± 0.009	1.078 ± 0.009
6	control	1.196 ± 0.012	1.337 ± 0.012
	Example 1	1.098 ± 0.013	1.182 ± 0.016
8	control	1.378 ± 0.011	1.472 ± 0.012
	Example 1	1.184 ± 0.017	1.284 ± 0.024

In the same manner as described above, the compound of Example 577 was administered to the mice as a mixed diet at 0.7 and 6.6 mg/g-food and evaluated. In the non-administration group, the SUVR of the tau PET tracer increased monotonically with ages at 4, 6 and 8 months, but in the compound-administration group of Example 577, 3 out of 5 individuals in the 0.7 mg/g-hood administration group and 3 out of 6 in the 6.6 mg/g-hood administration group did not show any increase in the SUVR in the transition from the age of 6 months to the age of 8 months, which suggested that the accumulation of tau aggregates was suppressed. And, no suppression of cerebral atrophy was observed in the Example 577-administration group.

The compound of Example 795 was administered to the mice as a mixed diet at 3 mg/g-food in the same manner as described above, and evaluated. ABT was used in combination with a mixed diet of 1 mg/g-food. The results of the compound administration group of Example 795 at 3 mg/g-food are shown in FIGS. 4 and 5 and the table below.

FIG. 4 shows average SUVR images of tau PET in the administration group of the compound of Example 795 at 3 mg/g-food and non-administration group of rTg4510 mice at the age of 4, 6 and 8 months. It was shown that in the non-administration group, an increase in PET tracer accumulation was observed in each brain region with aging, whereas in the compound administration group of Example 795 at 3 mg/g-food, they were suppressed. FIG. 5 shows the SUVR in each brain region. It was shown that the age-dependent increase in SUVR observed in the cerebral neocortex and hippocampus tended to be suppressed in the compound administration group of Example 795 at 3 mg/g-food. The results are also shown in the table below.

	SUVR(cerebellum ratio)
month	administration	cerebral
old	group	neocortex	hippocampus
4	control	1.034 ± 0.049	1.139 ± 0.061
	Example 795 3 mg/g-food	1.023 ± 0.009	1.134 ± 0.042
6	control	1.200 ± 0.070	1.374 ± 0.080
	Example 795 3 mg/g-food	1.149 ± 0.031	1.308 ± 0.044
8	control	1.410 ± 0.117	1.583 ± 0.152
	Example 795 3 mg/g-food	1.268 ± 0.036	1.419 ± 0.048

Although the age-dependent increase in lateral ventricular volume was not different in the compound administration group of Example 795 at 3 mg/g-food from the non-administration group at the age of 8 months, a tendency to suppress was observed at the age of 6 months, which suggests that cerebral atrophy was delayed.

The compound of Example 560 was administered to the mice as a mixed diet at 4.5 mg/g-hood in the same manner as described above, and evaluated. ABT was used in combination with a mixed diet of 1 mg/g-food. The results of the compound administration group of Example 560 at 4.5 mg/g-food are shown in FIGS. 6 and 7 and the table below.

FIG. 6 shows average SUVR images of tau PET in the administration group of the compound of Example 560 at 4.5 mg/g-food and non-administration group of rTg4510 mice at the ages of 4, 6 and 8 months. It was shown that in the non-administration group, an increase in PET tracer accumulation was observed in each brain region with aging, whereas in the compound administration group of Example 560 at 4.5 mg/g-food, they were suppressed. FIG. 7 shows the SUVR in each brain region. It was shown that the age-dependent increase in SUVR observed in the cerebral neocortex and hippocampus tended to be suppressed in the compound administration group of Example 560 at 4.5 mg/g-food. The results are also shown in the table below.

	SUVR(cerebellum ratio)
month	administration	cerebral
old	group	neocortex	hippocampus
4	control	1.019 ± 0.020	1.089 ± 0.014
	Example 560 4.5 mg/g-food	1.026 ± 0.037	1.103 ± 0.036
6	control	1.242 ± 0.026	1.377 ± 0.040
	Example 560 4.5 mg/g-food	1.224 ± 0.060	1.328 ± 0.078
8	control	1.456 ± 0.035	1.559 ± 0.049
	Example 560 4.5 mg/g-food	1.351 ± 0.049	1.468 ± 0.056

And, the age-dependent increase in lateral ventricular volume was suppressed in the compound administration group of Example 560 at 4.5 mg/g-food, which suggests that cerebral atrophy was suppressed. The results are shown in the table below.

		lateral
month	administration	ventricular
old	group	volume (mm3)
4	control	0.50 ± 0.05
	Example 560 4.5 mg/g-food	0.47 ± 0.06
6	control	3.11 ± 0.82
	Example 560 4.5 mg/g-food	0.34 ± 0.10
8	control	3.68 ± 0.77
	Example 560 4.5 mg/g-food	0.71 ± 0.35

By the same method as described above, the evaluation of tau aggregate accumulation and cerebral atrophy in the brain can be carried out for the compounds described in other examples.

INDUSTRIAL APPLICABILITY

Nav activator may become a useful medicament for treating and/or preventing tauopathy.

Claims

1. A medicament for treating and/or preventing tauopathy, comprising a Nav activator.

2. The medicament of claim 1, wherein the Nav activator is an activator for at least one Nav subtype selected from the group consisting of Nav1.1, Nav1.2, Nav1.3, and Nav1.6.

3. The medicament of claim 1, wherein the Nav activator is Nav1.1 activator.

4. The medicament of claim 3, wherein the Nav1.1 activator is a small molecule compound.

5. The medicament of Item 3, wherein the Nav1.1 activator is a compound of formula (1):

6. The medicament of claim 5, wherein Ring Cy is a group of formula (a):

7. The medicament of claim 5 or 6, wherein M2 is (1) a group of any one of the following formulae (2a-1)-(2a-23) and (2b-1)-(2b-11):

8. The medicament of claim 5 or 6, wherein M2 is a group of (1) a group of the following formulae (2a-1), (2a-2), (2a-12), (2a-20), (2a-21), (2b-3), (2b-4), (2b-7), or (2b-10):

9. The medicament of any one of claims 5 to 8, wherein M1 is (1) saturated or partially-unsaturated C4-2 carbocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom; and C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,(2) 4- to 12-membered saturated or partially-unsaturated heterocyclyl which may be optionally substituted with the same or different 1 to 4 substituents selected from the group consisting of halogen atom; and C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy, or(3) —NReRf, wherein Re and Rf are independently(a) hydrogen atom,(b) C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,(c) C3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl,(d) C3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl,(e) C6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C1-6 alkyl, and C1-6 alkoxy, or(f) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C1-6 alkyl, and C1-6 alkoxy.

10. The medicament of any one of claims 5 to 9, wherein M2 is a group of the following formula (2a-20), (2a-21), (2b-3), (2b-4), or (2b-7):

11. The medicament of any one of claims 5 to 9, wherein M2 is a group of the following formula (2a′-20), (2a′-21), (2b′-3), (2b′-4), or (2b′-7):

12. The medicament of any one of claims 5 to 9, wherein M2 is a group of the following formula (2d) or (2f):

13. The medicament of claim 12, wherein R8, R9, and R10 are independently(a) hydrogen atom,(b) halogen atom,(c) cyano,(d) C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom; hydroxy; C1-6 alkoxy which may be optionally substituted with hydroxy or C1-6 alkoxy; and amino (which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy; and C2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,(e) C1-6 alkoxy which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy, or(f) amino which may be optionally substituted with the same or different 1 to 2 substituents selected from the group consisting of C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms; saturated or partially-unsaturated C3-7 carbocyclyl; and C2-7 alkylcarbonyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy.

14. The medicament of any one of claims 5 to 13, wherein M1 is a group of the following formula (3):

15. The medicament of claim 14, wherein X16 is C, and the bond having a broken line is a double bond.

16. The medicament of claim 14, wherein X16 is CH, and the bond having a broken line is a single bond.

17. The medicament of claim 14, wherein X16 is N, and the bond having a broken line is a single bond.

18. The medicament of any one of claims 5 to 13, wherein M1 is —NReRf, wherein Re and Rf are independently (a) hydrogen atom,(b) C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,(c) C3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl,(d) C3-10 cycloalkyl-C1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl,(e) C6-10 aryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C1-6 alkyl, and C1-6 alkoxy, or(f) 5- to 10-membered heteroaryl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, cyano, C1-6 alkyl, and C1-6 alkoxy.

19. The medicament of any one of claims 5 to 13, wherein M1 is —NReRf, wherein Re and Rf are independently (a) hydrogen atom,(b) C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,(c) C3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl, or(d) C3-10 cycloalkyl-C1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl.

20. The medicament of any one of claims 5 to 13, wherein M1 is —NReRf, wherein Re is methyl, andRf is(a) C1-6 alkyl which may be optionally substituted with the same or different 1 to 3 halogen atoms,(b) C3-10 cycloalkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl, or(c) C3-10 cycloalkyl-C1-4 alkyl which may be optionally substituted with the same or different 1 to 3 substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C3-6 cycloalkyl.

21. The medicament of any one of claims 5 to 13, wherein M1 is a group of any one of the following formulae (3a-1)-(3a-4):

22. The medicament of any one of claims 5 to 13, wherein M1 is a group of any one of the following formulae (3c-1)-(3c-6):

23. The medicament of any one of claims 5 to 13, wherein M is a group of any one of the following formulae (3d-1)-(3d-12):

24. The medicament of any one of claims 6 to 23, wherein Ring Cy is formula (a).

25. The medicament of claim 24, wherein R1a and R2a are independently hydrogen atom, halogen atom, cyano, methyl, or methoxy.

26. The medicament of claim 24, wherein R1a and R2a are hydrogen atom.

27. The medicament of any one of claims 6 to 23, wherein Ring Cy is formula (b).

28. The medicament of claim 27, wherein Y1 is N, and Y2 and Y3 are independently CR2b.

29. The medicament of claim 27, wherein Y1 and Y2 are N, and Y3 is CR2b.

30. The medicament of claim 27, wherein Y1 and Y3 are N, and Y2 is CR2b.

31. The medicament of any one of claims 27 to 30, wherein R1b and R2b are independently hydrogen atom, halogen atom, cyano, C1-6 alkyl, C3-6 cycloalkyl, or C1-6 alkoxy, provided that when there are plural R2b, each R2b may be the same or different.

32. The medicament of any one of claims 27 to 30, wherein R1b and R2b are hydrogen atom.

33. The medicament of claim 5, wherein the Nav1.1 activator is any one compound selected from the group consisting of the following compounds: N-(4-cyanophenyl)-2-[3-(4-methylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide,N-(1,3-benzoxazol-5-yl)-2-[3-(4-methylpiperidin-1-yl)-6-oxopyridazin-1(6H)-yl] acetamide,2-[3-(6-azaspiro[3.4] octan-6-yl)-6-oxopyridazin-1(6H)-yl]-N-(quinazolin-7-yl)acetamide,N-[2-(dimethylamino)-1,3-benzoxazol-5-yl]-2-[3-(4-methylcyclohex-1-ene)-6-oxopyridazin-1(6H)-yl]acetamide,N-(2,6-dimethylpyridin-4-yl)-2-[3-(4-methylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide,6-(4-methylcyclohex-1-en-1-yl)-2-{2-[4-(2-methylpyridin-3-yl) piperazin-1-yl]-2-oxoethyl}pyridazin-3(2H)-one,2-[3-(4,4-dimethylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide,2-[3-(4,4-dimethylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,N-(1,3-benzoxazol-5-yl)-2-[3-(4,4-dimethylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide,2-[6-oxo-3-(spiro[2.5]oct-5-en-6-yl)pyridazin-1(6H)-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-{2-oxo-2-[4-(pyridazin-4-yl)-2,3-dihydro-1H-indol-1-yl]ethyl}-6-(spiro[2.5]oct-5-en-6-yl) pyridazin-3(2H)-one,N-(1,3-benzoxazol-5-yl)-2-[3-(4-methylcyclohex-1-en-1-yl)-6-oxopyridazin-1(6H)-yl]acetamide,2-{3-[(4S)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-{3-[(4R)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-{3-[(4S)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide,2-{3-[(4R)-4-methylcyclohex-1-en-1-yl]-6-oxopyridazin-1(6H)-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide,N-(6-cyanopyridin-3-yl)-2-[3-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-6-oxopyridazin-1(6H)-yl]acetamide, and6-[cyclopentyl(methyl)amino]-2-{2-[4-(morpholin-4-yl)-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}pyridazin-3(2H)-one.

34. The medicament of claim 5, wherein the Nav1.1 activator is any one compound selected from the group consisting of the following compounds: 2-{6-[cyclopentyl(methyl)amino]-1H-pyrazolo[3,4-b]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-[6-(4-methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-[6-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-{6-[methyl(spiro[2.3]hexan-5-yl)amino]-1H-pyrazolo[3,4-b]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-{6-[(3,3-dimethylcyclobutyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-{6-[(3,3-dimethylcyclobutyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrazin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide,N-(6-cyanopyridin-3-yl)-2-[6-(4,4-difluoro-6-azaspiro[2.5]octan-6-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]acetamide,N-(6-cyanopyridin-3-yl)-2-{6-[methyl(spiro[2.3]hexan-5-yl)amino]-1H-pyrazolo[3,4-b]pyrazin-1-yl}acetamide,2-{6-[cyclopentyl(methyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide,2-{6-[(cyclobutylmethyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide,2-{6-[(3,3-dimethylcyclobutyl)(methyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide, andan optically active form of 2-[6-(4-methylcyclohex-1-en-1-yl)-1H-pyrazolo[3,4-b]pyrazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide.

35. The medicament of any one of claims 1 to 34, wherein the tauopathy is Alzheimer's disease, Alzheimer-type dementia, diffuse neurofibrillary tangles with calcification, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam island, amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, frontotemporal lobar degeneration (including Pick's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, globular glial tauopathy, and frontotemporal dementia and parkinsonism linked to chromosome 17), senile dementia of the neurofibrillary tangle type, Down syndrome, chronic traumatic encephalopathy, myotonic dystrophy, Niemann-Pick disease type C, static encephalopathy of childhood with neurodegeneration in adulthood, PLA2G6-associated neurodegeneration, Gerstmann-Straussler-Scheinker disease, familial British dementia, familial Danish dementia, post-encephalitic Parkinsonism, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, or a combination of any two or more of these diseases.

36. The medicament of any one of claims 1 to 34, wherein the tauopathy is diffuse neurofibrillary tangles with calcification, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam island, amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, frontotemporal lobar degeneration (including Pick's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain dementia, globular glial tauopathy, and frontotemporal dementia and parkinsonism linked to chromosome 17), senile dementia of the neurofibrillary tangle type, Down syndrome, chronic traumatic encephalopathy, myotonic dystrophy, Niemann-Pick disease type C, static encephalopathy of childhood with neurodegeneration in adulthood, PLA2G6-associated neurodegeneration, Gerstmann-Straussler-Scheinker disease, familial British dementia, familial Danish dementia, post-encephalitic Parkinsonism, subacute sclerosing panencephalitis, SLC9A6-related mental retardation, or a combination of any two or more of these diseases.

37. The medicament of any one of claims 1 to 36, which can decrease phosphorylated tau aggregation and/or inhibit cerebral atrophy.

38. A method for decreasing phosphorylated tau aggregation and/or inhibiting cerebral atrophy, comprising administering a Nav activator.

39. A method for treating and/or preventing tauopathy, comprising administering a therapeutically effective amount of a Nav activator to a patient in need thereof.

40. Use of a Nav activator in the manufacture of a medicament for treating and/or preventing tauopathy.

41. A Nav activator in use for treating and/or preventing tauopathy.

42. A combination of the medicament of any one of claims 1 to 37, and at least one medicament selected from another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, antiparkinsonian agent, antihypertensive drug, anti-inflammatory agent, antidiabetic drug, antihyperlipidemic drug, anti-obesity agent, antiemetic drug, a medicament for treating dysphagia, a medicament for treating dysuria, and cathartic drug.

43. The medicament of any one of claims 1 to 37, which is used in combination with at least one medicament selected from another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, antiparkinsonian agent, antihypertensive drug, anti-inflammatory agent, antidiabetic drug, antihyperlipidemic drug, anti-obesity agent, antiemetic drug, a medicament for treating dysphagia, a medicament for treating dysuria, and cathartic drug.

44. A method for treating and/or preventing tauopathy, comprising administering a therapeutically effective amount of the medicament of any one of claims 1 to 37 in combination with at least one medicament selected from another medicament for treating tauopathy, a medicament for treating Alzheimer-type dementia, antiepileptic agent, antipsychotic agent, antidepressive agent, anti-anxiety agent, Chinese herbal drug, sleep-inducing drug, antiparkinsonian agent, antihypertensive drug, anti-inflammatory agent, antidiabetic drug, antihyperlipidemic drug, anti-obesity agent, antiemetic drug, a medicament for treating dysphagia, a medicament for treating dysuria, and cathartic drug, to a patient in need thereof.